[
  {
    "id": "11eaf82f-6192-4c0b-804d-a9023e977d57",
    "code": "FOLFOX",
    "tumourGroup": "Colorectal",
    "tumourSupergroup": "Colorectal",
    "treatmentIntent": "Curative",
    "summary": "FOLFOX is a standard adjuvant and palliative regimen for colorectal cancer combining 5-FU, leucovorin, and oxaliplatin. Primary concerns include peripheral neuropathy and myelosuppression.",
    "eligibility": {
      "summary": [
        "Metastatic or adjuvant colorectal cancer"
      ],
      "criteria": {
        "Age": "18–75 years",
        "ECOG": "0–2",
        "Creatinine": "< 1.5x ULN"
      }
    },
    "precautions": [
      "Oxaliplatin causes cumulative peripheral neuropathy",
      "Cold sensitivity during infusion",
      "Monitor for hypersensitivity reactions"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "85 mg/m²",
          "name": "Oxaliplatin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "400 mg/m²",
          "name": "Leucovorin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "400 mg/m² bolus + 2400 mg/m² CI",
          "name": "5-Fluorouracil",
          "route": "IV",
          "schedule": "Day 1-2"
        }
      ],
      "cycles": "12 cycles every 14 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Renal function tests",
      "Neuropathy assessment"
    ],
    "doseModifications": {
      "diarrhea": "Dose reduce 5-FU by 25% for grade 3+ diarrhea",
      "neuropathy": "Reduce oxaliplatin 25% for grade 2, hold for grade 3+",
      "neutropenia": "Hold treatment if ANC < 1.0"
    },
    "referenceList": [
      "NCCN Colorectal Guidelines",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "14 days",
      "total_cycles": "12",
      "administration_time": "4-6 hours"
    },
    "preMedications": {
      "standard": [
        "Dexamethasone 8mg IV",
        "Ondansetron 8mg IV",
        "Ranitidine 50mg IV"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron 8mg TDS PRN",
      "diarrhea": "Loperamide PRN",
      "mucositis": "Magic mouthwash PRN"
    },
    "supportiveCare": {
      "growth_factors": "G-CSF if indicated",
      "neuropathy_prevention": "Avoid cold exposure during infusion"
    },
    "rescueAgents": {
      "severe_diarrhea": "IV fluids, electrolyte replacement",
      "hypersensitivity": "Epinephrine, steroids, antihistamines"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "Neuropathy assessment"
      ],
      "before_each_cycle": [
        "FBC",
        "U&E",
        "LFTs",
        "ECOG performance status"
      ]
    },
    "toxicityMonitoring": {
      "diarrhea": "Monitor for dehydration",
      "neuropathy": "Grade with oxaliplatin-specific scale",
      "myelosuppression": "Weekly monitoring if grade 3+ toxicity"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation effect",
      "phenytoin": "Reduced phenytoin levels"
    },
    "contraindications": [
      "Severe peripheral neuropathy",
      "Severe renal impairment",
      "Known hypersensitivity to platinum compounds"
    ],
    "version": "3.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "22eaf82f-6192-4c0b-804d-a9023e977d58",
    "code": "Carboplatin-Paclitaxel",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Curative",
    "summary": "Standard first-line chemotherapy for advanced non-small cell lung cancer. Combines carboplatin with paclitaxel for optimal efficacy with manageable toxicity profile.",
    "eligibility": {
      "summary": [
        "Advanced NSCLC",
        "Adjuvant therapy eligible"
      ],
      "criteria": {
        "Age": "18-75 years",
        "ECOG": "0-2",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Paclitaxel hypersensitivity reactions",
      "Carboplatin-induced thrombocytopenia",
      "Peripheral neuropathy risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "AUC 5-6",
          "name": "Carboplatin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "200 mg/m²",
          "name": "Paclitaxel",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "4-6 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Renal function tests",
      "Performance status"
    ],
    "doseModifications": {
      "neuropathy": "Reduce paclitaxel 25% for grade 2+",
      "neutropenia": "Hold if ANC < 1.0",
      "thrombocytopenia": "Hold if platelets < 100,000"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "4-6",
      "administration_time": "4-5 hours"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron 8mg IV"
      ],
      "hypersensitivity_prevention": [
        "Dexamethasone 20mg IV",
        "Diphenhydramine 50mg IV",
        "Ranitidine 50mg IV"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron 8mg TDS PRN",
      "neuropathy": "Gabapentin if symptomatic",
      "constipation": "Docusate 100mg BD"
    },
    "supportiveCare": {
      "growth_factors": "G-CSF if febrile neutropenia history",
      "neuropathy_monitoring": "Before each cycle"
    },
    "rescueAgents": {
      "hypersensitivity": "Epinephrine 1:1000, steroids, antihistamines",
      "febrile_neutropenia": "Immediate broad-spectrum antibiotics"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "CrCl",
        "ECOG PS"
      ],
      "before_each_cycle": [
        "FBC",
        "U&E",
        "LFTs",
        "Neuropathy assessment"
      ]
    },
    "toxicityMonitoring": {
      "neuropathy": "Grade with CTCAE v5.0",
      "ototoxicity": "Audiometry if indicated",
      "myelosuppression": "Weekly monitoring during treatment"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "phenytoin": "Altered metabolism"
    },
    "contraindications": [
      "Severe hypersensitivity to taxanes",
      "Severe bone marrow suppression",
      "Pregnancy"
    ],
    "version": "2.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "44eaf82f-6192-4c0b-804d-a9023e977d60",
    "code": "R-CHOP",
    "tumourGroup": "Lymphoma",
    "tumourSupergroup": "Lymphoma",
    "treatmentIntent": "Curative",
    "summary": "Standard first-line treatment for diffuse large B-cell lymphoma combining rituximab with CHOP chemotherapy. Highly effective immunochemotherapy regimen.",
    "eligibility": {
      "summary": [
        "DLBCL",
        "Aggressive B-cell lymphomas"
      ],
      "criteria": {
        "Age": "18-80 years",
        "ECOG": "0-3",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Rituximab infusion reactions",
      "Anthracycline cardiotoxicity",
      "Tumor lysis syndrome risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "375 mg/m²",
          "name": "Rituximab",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "750 mg/m²",
          "name": "Cyclophosphamide",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "50 mg/m²",
          "name": "Doxorubicin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "1.4 mg/m² (max 2mg)",
          "name": "Vincristine",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "100mg",
          "name": "Prednisolone",
          "route": "PO",
          "schedule": "Days 1-5"
        }
      ],
      "cycles": "6-8 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "LVEF assessment",
      "LDH",
      "Beta-2 microglobulin"
    ],
    "doseModifications": {
      "neuropathy": "Reduce vincristine for grade 2+ neuropathy",
      "neutropenia": "G-CSF support if indicated",
      "cardiotoxicity": "Monitor LVEF, reduce doxorubicin if LVEF drops"
    },
    "referenceList": [
      "NCCN Lymphoma Guidelines",
      "ESMO Guidelines",
      "British Committee for Standards in Haematology"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "6-8",
      "administration_time": "6-8 hours"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV"
      ],
      "rituximab_premedication": [
        "Paracetamol 1g PO",
        "Chlorpheniramine 10mg IV",
        "Hydrocortisone 100mg IV"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron 8mg TDS PRN",
      "constipation": "Docusate 100mg BD",
      "infection_prevention": "Co-trimoxazole prophylaxis"
    },
    "supportiveCare": {
      "growth_factors": "G-CSF if neutropenia history",
      "cardiac_monitoring": "LVEF every 4 cycles",
      "infection_prevention": "PCP prophylaxis"
    },
    "rescueAgents": {
      "tumor_lysis": "Allopurinol, hydration, electrolyte monitoring",
      "infusion_reaction": "Stop infusion, antihistamines, steroids",
      "febrile_neutropenia": "Immediate antibiotics"
    },
    "monitoring": {
      "imaging": "CT every 3 cycles",
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "LVEF",
        "LDH",
        "HIV/HBV screening"
      ],
      "before_each_cycle": [
        "FBC",
        "U&E",
        "LFTs",
        "Performance status"
      ]
    },
    "toxicityMonitoring": {
      "neuropathy": "Assess before each cycle",
      "cardiotoxicity": "Serial LVEF monitoring",
      "infusion_reactions": "Monitor during rituximab infusion"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "live_vaccines": "Avoid during treatment"
    },
    "contraindications": [
      "Active infection",
      "Severe heart failure",
      "Pregnancy"
    ],
    "version": "2.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "55eaf82f-6192-4c0b-804d-a9023e977d61",
    "code": "Cisplatin-Gemcitabine",
    "tumourGroup": "Bladder",
    "tumourSupergroup": "Bladder",
    "treatmentIntent": "Curative",
    "summary": "Standard neoadjuvant or adjuvant chemotherapy for muscle-invasive bladder cancer. Combines cisplatin with gemcitabine for optimal efficacy.",
    "eligibility": {
      "summary": [
        "Muscle-invasive bladder cancer",
        "Neoadjuvant or adjuvant setting"
      ],
      "criteria": {
        "Age": "18-75 years",
        "CrCl": "> 60 mL/min",
        "ECOG": "0-2"
      }
    },
    "precautions": [
      "Cisplatin nephrotoxicity and ototoxicity",
      "Gemcitabine myelosuppression",
      "Adequate hydration essential"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "70 mg/m²",
          "name": "Cisplatin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "1000 mg/m²",
          "name": "Gemcitabine",
          "route": "IV",
          "schedule": "Days 1 and 8"
        }
      ],
      "cycles": "4 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Hearing assessment",
      "Liver function tests"
    ],
    "doseModifications": {
      "neutropenia": "Hold if ANC < 1.0",
      "ototoxicity": "Audiometry if hearing loss",
      "nephrotoxicity": "Hold if creatinine >1.5x baseline"
    },
    "referenceList": [
      "EAU Guidelines",
      "NCCN Bladder Cancer Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "4",
      "administration_time": "4-5 hours"
    },
    "preMedications": {
      "hydration": [
        "Normal saline 1L pre and post cisplatin",
        "Magnesium and potassium supplementation"
      ],
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron 8mg TDS PRN",
      "neuropathy": "Gabapentin if symptomatic",
      "constipation": "Docusate 100mg BD"
    },
    "supportiveCare": {
      "growth_factors": "G-CSF if indicated",
      "renal_protection": "Pre and post hydration",
      "electrolyte_monitoring": "Mg, K supplementation"
    },
    "rescueAgents": {
      "ototoxicity": "Hearing aids if permanent loss",
      "nephrotoxicity": "Stop cisplatin, consider carboplatin",
      "febrile_neutropenia": "Broad-spectrum antibiotics"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "CrCl",
        "LFTs",
        "Audiometry",
        "Mg, K"
      ],
      "before_each_cycle": [
        "FBC",
        "U&E",
        "CrCl",
        "Hearing assessment"
      ]
    },
    "toxicityMonitoring": {
      "neuropathy": "Clinical assessment",
      "ototoxicity": "Audiometry every 2 cycles",
      "nephrotoxicity": "Monitor creatinine weekly"
    },
    "interactions": {
      "loop_diuretics": "Increased ototoxicity",
      "aminoglycosides": "Increased nephrotoxicity"
    },
    "contraindications": [
      "Severe renal impairment",
      "Significant hearing loss",
      "Pregnancy"
    ],
    "version": "1.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "66eaf82f-6192-4c0b-804d-a9023e977d62",
    "code": "BEP",
    "tumourGroup": "Testicular",
    "tumourSupergroup": "Testicular",
    "treatmentIntent": "Curative",
    "summary": "Bleomycin, Etoposide, and Cisplatin regimen for testicular cancer. Gold standard treatment with excellent cure rates for good and intermediate risk disease.",
    "eligibility": {
      "summary": [
        "Testicular germ cell tumors",
        "Good to intermediate risk"
      ],
      "criteria": {
        "Age": "16-50 years",
        "ECOG": "0-2",
        "Pulmonary_function": "Normal"
      }
    },
    "precautions": [
      "Bleomycin pulmonary toxicity",
      "Cisplatin nephrotoxicity and ototoxicity",
      "Raynaud syndrome risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "30 units",
          "name": "Bleomycin",
          "route": "IV",
          "schedule": "Days 2, 9, 16"
        },
        {
          "dose": "100 mg/m²",
          "name": "Etoposide",
          "route": "IV",
          "schedule": "Days 1-5"
        },
        {
          "dose": "20 mg/m²",
          "name": "Cisplatin",
          "route": "IV",
          "schedule": "Days 1-5"
        }
      ],
      "cycles": "3 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Pulmonary function tests",
      "Hearing assessment",
      "Tumor markers"
    ],
    "doseModifications": {
      "neutropenia": "G-CSF support if indicated",
      "nephrotoxicity": "Reduce cisplatin if creatinine rises",
      "pulmonary_toxicity": "Stop bleomycin if DLCO drops >20%"
    },
    "referenceList": [
      "EAU Testicular Cancer Guidelines",
      "NCCN Guidelines",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "3",
      "administration_time": "Daily x 5 days"
    },
    "preMedications": {
      "hydration": [
        "Normal saline 1-2L with Mg/K supplementation"
      ],
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV",
        "Aprepitant 125mg PO"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron 8mg TDS PRN",
      "pulmonary": "Monitor for dyspnea and cough",
      "neuropathy": "Gabapentin if symptomatic"
    },
    "supportiveCare": {
      "renal_protection": "Adequate hydration",
      "pulmonary_monitoring": "PFTs every cycle",
      "fertility_preservation": "Sperm banking pre-treatment"
    },
    "rescueAgents": {
      "ototoxicity": "Hearing aids if needed",
      "nephrotoxicity": "Reduce/stop cisplatin",
      "pulmonary_toxicity": "Stop bleomycin, steroids if pneumonitis"
    },
    "monitoring": {
      "weekly": [
        "FBC",
        "U&E",
        "Tumor markers"
      ],
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "PFTs",
        "Audiometry",
        "AFP",
        "HCG",
        "LDH"
      ],
      "each_cycle": [
        "PFTs",
        "Clinical assessment"
      ]
    },
    "toxicityMonitoring": {
      "ototoxicity": "Audiometry each cycle",
      "nephrotoxicity": "Weekly creatinine",
      "pulmonary_toxicity": "PFTs and DLCO monitoring"
    },
    "interactions": {
      "oxygen": "Avoid high concentrations with bleomycin",
      "aminoglycosides": "Increased nephrotoxicity"
    },
    "contraindications": [
      "Significant pulmonary disease",
      "Severe renal impairment",
      "Previous bleomycin exposure >400 units"
    ],
    "version": "3.2",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "99eaf82f-6192-4c0b-804d-a9023e977d65",
    "code": "Cisplatin-Etoposide",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Curative",
    "summary": "Standard regimen for extensive stage small cell lung cancer and limited stage disease with concurrent radiotherapy.",
    "eligibility": {
      "summary": [
        "Small cell lung cancer",
        "Extensive or limited stage"
      ],
      "criteria": {
        "Age": "18-75 years",
        "CrCl": "> 50 mL/min",
        "ECOG": "0-2"
      }
    },
    "precautions": [
      "Cisplatin nephrotoxicity and ototoxicity",
      "Etoposide myelosuppression",
      "Tumor lysis syndrome risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "25 mg/m²",
          "name": "Cisplatin",
          "route": "IV",
          "schedule": "Days 1-3"
        },
        {
          "dose": "100 mg/m²",
          "name": "Etoposide",
          "route": "IV",
          "schedule": "Days 1-3"
        }
      ],
      "cycles": "4-6 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Hearing assessment",
      "LDH",
      "Electrolytes"
    ],
    "doseModifications": {
      "neutropenia": "G-CSF support",
      "ototoxicity": "Audiometry if hearing loss",
      "nephrotoxicity": "Hold if creatinine >1.5x baseline"
    },
    "referenceList": [
      "NCCN SCLC Guidelines",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "4-6",
      "administration_time": "3 days consecutive"
    },
    "preMedications": {
      "hydration": [
        "Normal saline 1-2L with Mg/K"
      ],
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron TDS PRN",
      "neuropathy": "Gabapentin if needed",
      "constipation": "Docusate 100mg BD"
    },
    "supportiveCare": {
      "growth_factors": "G-CSF PRN",
      "renal_protection": "Pre/post hydration",
      "electrolyte_monitoring": "Daily during treatment"
    },
    "rescueAgents": {
      "tumor_lysis": "Allopurinol, hydration",
      "nephrotoxicity": "Stop cisplatin, hydration",
      "febrile_neutropenia": "Immediate antibiotics"
    },
    "monitoring": {
      "daily": [
        "U&E during treatment"
      ],
      "baseline": [
        "FBC",
        "U&E",
        "CrCl",
        "LFTs",
        "Audiometry",
        "LDH"
      ],
      "each_cycle": [
        "FBC",
        "Renal function"
      ]
    },
    "toxicityMonitoring": {
      "neuropathy": "Clinical assessment",
      "ototoxicity": "Audiometry each cycle",
      "nephrotoxicity": "Daily creatinine during treatment"
    },
    "interactions": {
      "phenytoin": "Altered metabolism",
      "aminoglycosides": "Increased nephrotoxicity"
    },
    "contraindications": [
      "Severe renal impairment",
      "Significant hearing loss",
      "Pregnancy"
    ],
    "version": "2.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "77eaf82f-6192-4c0b-804d-a9023e977d63",
    "code": "FEC-D",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Curative",
    "summary": "FEC-D (5-Fluorouracil, Epirubicin, Cyclophosphamide followed by Docetaxel) is a NCCN Category 1 sequential regimen for early-stage breast cancer. This European-developed protocol offers an alternative to AC-T with different toxicity profile.",
    "eligibility": {
      "summary": [
        "Early-stage or locally advanced breast cancer",
        "Alternative to AC-T regimen",
        "HER2-negative disease"
      ],
      "criteria": {
        "Age": "18–70 years",
        "ECOG": "0–2",
        "Other": "Adequate organ function, no active infections",
        "Cardiac": "LVEF ≥50% or within institutional normal limits",
        "Biomarkers": "HER2-negative"
      },
      "nccn_category": "1",
      "line_of_therapy": "Adjuvant",
      "treatment_setting": "Early-stage",
      "biomarker_requirements": {
        "HER2": "Negative",
        "ER_PR": "Any status"
      }
    },
    "precautions": [
      "5-FU mucositis and diarrhea",
      "Epirubicin cardiotoxicity",
      "Docetaxel fluid retention"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "500 mg/m²",
          "name": "5-Fluorouracil",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "100 mg/m²",
          "name": "Epirubicin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "500 mg/m²",
          "name": "Cyclophosphamide",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "3 cycles FEC, then 3 cycles Docetaxel 100mg/m²"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "LVEF assessment",
      "Renal function"
    ],
    "doseModifications": {
      "mucositis": "Hold for grade 3+ mucositis, resume with dose reduction",
      "neuropathy": "Reduce docetaxel by 25% for grade 2, discontinue for grade 3+",
      "neutropenia": "Hold treatment if ANC <1.0, resume with growth factor support",
      "cardiotoxicity": "Discontinue if LVEF drops >10% from baseline or <50%",
      "dose_reductions": {
        "level_1": "25% dose reduction for grade 3 toxicity",
        "level_2": "50% dose reduction for recurrent toxicity"
      },
      "alternate_options": {
        "severe_neuropathy": "Complete FEC portion only",
        "docetaxel_intolerance": "Switch to paclitaxel 175 mg/m² q3weeks",
        "anthracycline_contraindication": "Consider TC regimen instead"
      }
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "St Gallen Consensus"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "6",
      "administration_time": "3-4 hours"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV"
      ],
      "docetaxel_premedication": [
        "Dexamethasone 8mg PO x3 days"
      ]
    },
    "postMedications": {
      "diarrhea": "Loperamide PRN",
      "mucositis": "Oral care, magic mouthwash",
      "neuropathy": "Gabapentin if needed"
    },
    "supportiveCare": {
      "mouth_care": "Regular oral hygiene",
      "fluid_management": "Monitor weight",
      "cardiac_monitoring": "LVEF every 3 cycles"
    },
    "rescueAgents": {
      "cardiotoxicity": "ACE inhibitors",
      "severe_mucositis": "IV hydration, parenteral nutrition",
      "febrile_neutropenia": "G-CSF, antibiotics"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "LVEF"
      ],
      "each_cycle": [
        "FBC",
        "U&E",
        "LFTs",
        "Mucositis assessment"
      ]
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "CBC with differential",
        "ECHO or MUGA scan",
        "Neurological assessment",
        "Oral examination",
        "Weight monitoring"
      ],
      "primary_toxicities": [
        "Myelosuppression",
        "Cardiotoxicity (epirubicin)",
        "Peripheral neuropathy (docetaxel)",
        "Mucositis",
        "Alopecia",
        "Fluid retention"
      ],
      "monitoring_schedule": {
        "baseline": [
          "CBC",
          "Comprehensive metabolic panel",
          "LVEF assessment",
          "Neurologic exam"
        ],
        "post_treatment": [
          "LVEF assessment 3-6 months post completion"
        ],
        "during_treatment": [
          "LVEF assessment every 3 months",
          "Neuropathy assessment during docetaxel phase"
        ],
        "before_each_cycle": [
          "CBC",
          "Basic metabolic panel",
          "Performance status",
          "Toxicity assessment"
        ]
      }
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "phenytoin": "Altered metabolism"
    },
    "contraindications": [
      "Severe heart failure (LVEF <40%)",
      "Active severe infection",
      "Pregnancy or breastfeeding",
      "Known hypersensitivity to anthracyclines or taxanes",
      "Prior cumulative anthracycline dose >300 mg/m² doxorubicin equivalent",
      "Severe hepatic impairment",
      "Severe renal impairment",
      "Uncontrolled cardiac arrhythmias"
    ],
    "version": "2.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "aaeaf82f-6192-4c0b-804d-a9023e977d66",
    "code": "Gemcitabine-Cisplatin",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Curative",
    "summary": "Alternative first-line regimen for advanced NSCLC, particularly in patients with contraindications to taxanes.",
    "eligibility": {
      "summary": [
        "Advanced NSCLC",
        "Squamous cell histology preferred"
      ],
      "criteria": {
        "Age": "18-75 years",
        "CrCl": "> 60 mL/min",
        "ECOG": "0-2"
      }
    },
    "precautions": [
      "Gemcitabine thrombocytopenia and flu-like symptoms",
      "Cisplatin nephrotoxicity",
      "Pulmonary toxicity rare but serious"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "1250 mg/m²",
          "name": "Gemcitabine",
          "route": "IV",
          "schedule": "Days 1 and 8"
        },
        {
          "dose": "75 mg/m²",
          "name": "Cisplatin",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "4 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Liver function tests",
      "Hearing assessment"
    ],
    "doseModifications": {
      "flu_syndrome": "Supportive care",
      "nephrotoxicity": "Dose reduce cisplatin 25%",
      "thrombocytopenia": "Hold if platelets <100,000"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "4",
      "administration_time": "2 days per cycle"
    },
    "preMedications": {
      "hydration": [
        "Normal saline 1L pre/post cisplatin"
      ],
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "fatigue": "Energy conservation",
      "flu_syndrome": "Paracetamol, rest"
    },
    "supportiveCare": {
      "renal_protection": "Adequate hydration",
      "symptom_management": "Supportive care",
      "platelet_monitoring": "Weekly FBC"
    },
    "rescueAgents": {
      "nephrotoxicity": "IV hydration, stop cisplatin",
      "pulmonary_toxicity": "Steroids",
      "severe_thrombocytopenia": "Platelet transfusion"
    },
    "monitoring": {
      "weekly": [
        "FBC",
        "U&E"
      ],
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "CrCl",
        "Audiometry"
      ],
      "each_cycle": [
        "Comprehensive assessment"
      ]
    },
    "toxicityMonitoring": {
      "pulmonary": "Dyspnea assessment",
      "nephrotoxicity": "Creatinine monitoring",
      "thrombocytopenia": "Weekly platelet monitoring"
    },
    "interactions": {
      "warfarin": "Monitor INR closely",
      "live_vaccines": "Avoid during treatment"
    },
    "contraindications": [
      "Severe renal impairment",
      "Active pulmonary fibrosis",
      "Pregnancy"
    ],
    "version": "1.9",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "bbeaf82f-6192-4c0b-804d-a9023e977d67",
    "code": "CAPOX",
    "tumourGroup": "Colorectal",
    "tumourSupergroup": "Colorectal",
    "treatmentIntent": "Curative",
    "summary": "Capecitabine and Oxaliplatin combination for adjuvant colorectal cancer treatment. Oral convenience with IV oxaliplatin.",
    "eligibility": {
      "summary": [
        "Stage III colorectal cancer",
        "Adjuvant setting"
      ],
      "criteria": {
        "Age": "18-75 years",
        "CrCl": "> 50 mL/min",
        "ECOG": "0-2"
      }
    },
    "precautions": [
      "Oxaliplatin peripheral neuropathy",
      "Capecitabine hand-foot syndrome",
      "Cold-induced neuropathy"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "130 mg/m²",
          "name": "Oxaliplatin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "1000 mg/m² BD",
          "name": "Capecitabine",
          "route": "PO",
          "schedule": "Days 1-14"
        }
      ],
      "cycles": "8 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Renal function",
      "Neuropathy assessment"
    ],
    "doseModifications": {
      "diarrhea": "Reduce capecitabine dose",
      "neuropathy": "Reduce oxaliplatin 25% for grade 2+",
      "hand_foot_syndrome": "Interrupt capecitabine"
    },
    "referenceList": [
      "NCCN Colorectal Guidelines",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "8",
      "administration_time": "2 hours IV + 14 days oral"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV"
      ],
      "neuropathy_prevention": [
        "Avoid cold exposure"
      ]
    },
    "postMedications": {
      "diarrhea": "Loperamide PRN",
      "neuropathy": "Gabapentin if symptomatic",
      "hand_foot_care": "Moisturizers, avoid friction"
    },
    "supportiveCare": {
      "skin_care": "Hand and foot inspection",
      "GI_support": "Antidiarrheal agents",
      "neuropathy_monitoring": "Before each cycle"
    },
    "rescueAgents": {
      "severe_HFS": "Topical treatments",
      "severe_diarrhea": "IV hydration, electrolytes",
      "severe_neuropathy": "Stop oxaliplatin"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "CrCl",
        "Neuropathy score"
      ],
      "each_cycle": [
        "FBC",
        "U&E",
        "LFTs",
        "Neuropathy assessment"
      ]
    },
    "toxicityMonitoring": {
      "diarrhea": "Frequency and grade",
      "neuropathy": "Oxaliplatin-specific neuropathy scale",
      "hand_foot_syndrome": "CTCAE grading"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "phenytoin": "Monitor levels"
    },
    "contraindications": [
      "Severe neuropathy",
      "Severe renal impairment",
      "Pregnancy"
    ],
    "version": "2.3",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "cceaf82f-6192-4c0b-804d-a9023e977d68",
    "code": "FOLFIRI",
    "tumourGroup": "Colorectal",
    "tumourSupergroup": "Colorectal",
    "treatmentIntent": "Palliative",
    "summary": "Second-line treatment for metastatic colorectal cancer with irinotecan, 5-FU, and leucovorin.",
    "eligibility": {
      "summary": [
        "Metastatic colorectal cancer",
        "Second-line after oxaliplatin"
      ],
      "criteria": {
        "Age": "18-75 years",
        "ECOG": "0-2",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Irinotecan diarrhea (early and late)",
      "Myelosuppression",
      "UGT1A1 polymorphism considerations"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "180 mg/m²",
          "name": "Irinotecan",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "400 mg/m²",
          "name": "Leucovorin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "400 mg/m² bolus + 2400 mg/m² infusion",
          "name": "5-Fluorouracil",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "Every 14 days until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "UGT1A1 genotyping",
      "Performance status"
    ],
    "doseModifications": {
      "diarrhea": "Reduce irinotecan 25% for grade 3+",
      "UGT1A1_poor": "Reduce irinotecan 25%",
      "neutropenia": "Delay treatment if ANC <1.0"
    },
    "referenceList": [
      "NCCN Colorectal Guidelines",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "14 days",
      "total_cycles": "Until progression",
      "administration_time": "46 hours"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV"
      ],
      "diarrhea_prevention": [
        "Atropine 0.25mg SC for early diarrhea"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "mucositis": "Oral care",
      "delayed_diarrhea": "Loperamide 4mg then 2mg q2h"
    },
    "supportiveCare": {
      "hydration": "Monitor fluid balance",
      "growth_factors": "G-CSF if indicated",
      "diarrhea_management": "Loperamide protocol"
    },
    "rescueAgents": {
      "severe_diarrhea": "IV hydration, electrolyte replacement",
      "severe_mucositis": "IV nutrition",
      "febrile_neutropenia": "G-CSF, antibiotics"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "UGT1A1",
        "ECOG"
      ],
      "each_cycle": [
        "FBC",
        "U&E",
        "LFTs",
        "Diarrhea assessment"
      ]
    },
    "toxicityMonitoring": {
      "diarrhea": "Early vs delayed onset",
      "mucositis": "WHO grading",
      "neutropenia": "Weekly FBC monitoring"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "St_Johns_wort": "Avoid interaction"
    },
    "contraindications": [
      "Chronic diarrhea",
      "Severe liver dysfunction",
      "Pregnancy"
    ],
    "version": "1.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "ddeaf82f-6192-4c0b-804d-a9023e977d69",
    "code": "Carboplatin-Paclitaxel-Ovarian",
    "tumourGroup": "Ovarian",
    "tumourSupergroup": "Ovarian",
    "treatmentIntent": "Curative",
    "summary": "Standard first-line treatment for epithelial ovarian cancer following optimal debulking surgery.",
    "eligibility": {
      "summary": [
        "Epithelial ovarian cancer",
        "Post-surgical first-line"
      ],
      "criteria": {
        "Age": "18-75 years",
        "ECOG": "0-2",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Paclitaxel hypersensitivity reactions",
      "Carboplatin hypersensitivity",
      "Peripheral neuropathy development"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "AUC 5-6",
          "name": "Carboplatin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "175 mg/m²",
          "name": "Paclitaxel",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "6 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "CA-125",
      "Liver function tests",
      "Renal function"
    ],
    "doseModifications": {
      "neuropathy": "Reduce paclitaxel 25% for grade 2+",
      "hypersensitivity": "Premedication protocol",
      "thrombocytopenia": "Hold if platelets <100,000"
    },
    "referenceList": [
      "NCCN Ovarian Guidelines",
      "ESMO Guidelines",
      "SGO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "6",
      "administration_time": "4-5 hours"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron 8mg IV"
      ],
      "hypersensitivity_prevention": [
        "Dexamethasone 20mg IV",
        "Diphenhydramine 50mg IV",
        "Ranitidine 50mg IV"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "neuropathy": "Gabapentin if symptomatic",
      "constipation": "Docusate 100mg BD"
    },
    "supportiveCare": {
      "tumor_markers": "CA-125 monitoring",
      "growth_factors": "G-CSF if indicated",
      "neuropathy_prevention": "Dose modifications"
    },
    "rescueAgents": {
      "hypersensitivity": "Epinephrine, steroids, antihistamines",
      "severe_neuropathy": "Dose reduction/discontinuation",
      "febrile_neutropenia": "Immediate antibiotics"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "CA-125",
        "ECOG"
      ],
      "each_cycle": [
        "FBC",
        "U&E",
        "CA-125",
        "Neuropathy assessment"
      ]
    },
    "toxicityMonitoring": {
      "neuropathy": "CTCAE grading",
      "tumor_response": "CA-125 and imaging",
      "hypersensitivity": "During infusion monitoring"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "phenytoin": "Altered metabolism"
    },
    "contraindications": [
      "Severe hypersensitivity to taxanes",
      "Severe neuropathy",
      "Pregnancy"
    ],
    "version": "2.4",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "eeeaf82f-6192-4c0b-804d-a9023e977d70",
    "code": "Cisplatin-5FU-Cervical",
    "tumourGroup": "Cervical",
    "tumourSupergroup": "Cervical",
    "treatmentIntent": "Curative",
    "summary": "Concurrent chemoradiotherapy regimen for locally advanced cervical cancer with weekly cisplatin.",
    "eligibility": {
      "summary": [
        "Locally advanced cervical cancer",
        "Concurrent with radiotherapy"
      ],
      "criteria": {
        "Age": "18-70 years",
        "CrCl": "> 60 mL/min",
        "ECOG": "0-2"
      }
    },
    "precautions": [
      "Cisplatin nephrotoxicity during radiotherapy",
      "Enhanced mucositis with concurrent treatment",
      "Pelvic radiation toxicity"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "40 mg/m²",
          "name": "Cisplatin",
          "route": "IV",
          "schedule": "Weekly x 6"
        },
        {
          "dose": "1000 mg/m²/day",
          "name": "5-Fluorouracil",
          "route": "IV",
          "schedule": "Days 1-4, cycles 1 and 5"
        }
      ],
      "cycles": "6 weeks concurrent with radiotherapy"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Hearing assessment",
      "Pelvic examination"
    ],
    "doseModifications": {
      "nephrotoxicity": "Hold if creatinine >1.5x baseline",
      "severe_diarrhea": "Supportive care",
      "severe_mucositis": "Treatment break"
    },
    "referenceList": [
      "NCCN Cervical Guidelines",
      "FIGO Guidelines",
      "NCI Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Weekly cisplatin",
      "total_cycles": "6 weeks",
      "administration_time": "Concurrent with RT"
    },
    "preMedications": {
      "hydration": [
        "Normal saline 1L pre/post cisplatin"
      ],
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV"
      ]
    },
    "postMedications": {
      "diarrhea": "Loperamide PRN",
      "mucositis": "Magic mouthwash",
      "pelvic_care": "Sitz baths, barrier creams"
    },
    "supportiveCare": {
      "pelvic_care": "Skin care during RT",
      "renal_protection": "Pre/post hydration",
      "nutritional_support": "Dietitian involvement"
    },
    "rescueAgents": {
      "nephrotoxicity": "IV hydration, stop cisplatin",
      "severe_mucositis": "Treatment break, supportive care",
      "radiation_dermatitis": "Topical treatments"
    },
    "monitoring": {
      "weekly": [
        "FBC",
        "U&E",
        "CrCl",
        "Clinical assessment"
      ],
      "baseline": [
        "FBC",
        "U&E",
        "CrCl",
        "Audiometry",
        "Pelvic exam"
      ]
    },
    "toxicityMonitoring": {
      "mucositis": "Daily assessment during RT",
      "nephrotoxicity": "Weekly creatinine monitoring",
      "pelvic_toxicity": "Weekly examination"
    },
    "interactions": {
      "loop_diuretics": "Increased ototoxicity",
      "aminoglycosides": "Increased nephrotoxicity"
    },
    "contraindications": [
      "Severe renal impairment",
      "Previous pelvic radiotherapy",
      "Pregnancy"
    ],
    "version": "1.7",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "ffeaf82f-6192-4c0b-804d-a9023e977d71",
    "code": "ABVD",
    "tumourGroup": "Lymphoma",
    "tumourSupergroup": "Lymphoma",
    "treatmentIntent": "Curative",
    "summary": "Standard first-line treatment for classical Hodgkin lymphoma with excellent cure rates and manageable toxicity.",
    "eligibility": {
      "summary": [
        "Classical Hodgkin lymphoma",
        "First-line treatment"
      ],
      "criteria": {
        "Age": "16-65 years",
        "ECOG": "0-2",
        "Normal_cardiac_function": "Required"
      }
    },
    "precautions": [
      "Doxorubicin cardiotoxicity",
      "Bleomycin pulmonary toxicity",
      "Dacarbazine hepatotoxicity"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "25 mg/m²",
          "name": "Doxorubicin",
          "route": "IV",
          "schedule": "Days 1 and 15"
        },
        {
          "dose": "10 units/m²",
          "name": "Bleomycin",
          "route": "IV",
          "schedule": "Days 1 and 15"
        },
        {
          "dose": "6 mg/m²",
          "name": "Vinblastine",
          "route": "IV",
          "schedule": "Days 1 and 15"
        },
        {
          "dose": "375 mg/m²",
          "name": "Dacarbazine",
          "route": "IV",
          "schedule": "Days 1 and 15"
        }
      ],
      "cycles": "2-6 cycles every 28 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "LVEF assessment",
      "Pulmonary function tests"
    ],
    "doseModifications": {
      "cardiotoxicity": "Monitor LVEF every 4 cycles",
      "hepatotoxicity": "Monitor LFTs",
      "pulmonary_toxicity": "Stop bleomycin if DLCO drops >20%"
    },
    "referenceList": [
      "NCCN Hodgkin Guidelines",
      "ESMO Guidelines",
      "EORTC Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "2-6 depending on stage",
      "administration_time": "Days 1 and 15"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV"
      ],
      "cardiac_protection": [
        "Consider dexrazoxane if cumulative dose high"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "fatigue": "Energy conservation techniques",
      "pulmonary": "Monitor for dyspnea"
    },
    "supportiveCare": {
      "cardiac_monitoring": "LVEF every 4 cycles",
      "pulmonary_monitoring": "PFTs every 2 cycles",
      "fertility_preservation": "Discuss before treatment"
    },
    "rescueAgents": {
      "cardiotoxicity": "Cardio-oncology referral",
      "pulmonary_toxicity": "Stop bleomycin, steroids",
      "severe_myelosuppression": "G-CSF support"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "LVEF",
        "PFTs",
        "Staging studies"
      ],
      "every_2_cycles": [
        "PFTs"
      ],
      "every_4_cycles": [
        "LVEF"
      ]
    },
    "toxicityMonitoring": {
      "neuropathy": "Clinical assessment",
      "cardiotoxicity": "Serial LVEF monitoring",
      "pulmonary_toxicity": "PFTs and DLCO monitoring"
    },
    "interactions": {
      "oxygen": "Avoid high concentrations with bleomycin",
      "live_vaccines": "Avoid during treatment"
    },
    "contraindications": [
      "Significant pulmonary disease",
      "Severe cardiac dysfunction",
      "Pregnancy"
    ],
    "version": "2.6",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "00faf82f-6192-4c0b-804d-a9023e977d72",
    "code": "ALL-Protocol",
    "tumourGroup": "Leukemia",
    "tumourSupergroup": "Leukemia",
    "treatmentIntent": "Curative",
    "summary": "Pediatric-inspired acute lymphoblastic leukemia protocol for adults with intensive induction and consolidation.",
    "eligibility": {
      "summary": [
        "Adult acute lymphoblastic leukemia",
        "Pediatric-inspired protocol"
      ],
      "criteria": {
        "Age": "18-60 years",
        "ECOG": "0-2",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "CNS prophylaxis required",
      "Tumor lysis syndrome risk",
      "Intensive myelosuppression"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "60 mg/m²",
          "name": "Daunorubicin",
          "route": "IV",
          "schedule": "Days 1, 8, 15, 22"
        },
        {
          "dose": "1.4 mg/m² (max 2mg)",
          "name": "Vincristine",
          "route": "IV",
          "schedule": "Weekly x 4"
        },
        {
          "dose": "10000 units/m²",
          "name": "PEG-Asparaginase",
          "route": "IM",
          "schedule": "Day 5"
        },
        {
          "dose": "60mg/m²",
          "name": "Prednisolone",
          "route": "PO",
          "schedule": "Days 1-28"
        }
      ],
      "cycles": "Complex multi-phase protocol"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Coagulation studies",
      "CNS examination",
      "Cytogenetics"
    ],
    "doseModifications": {
      "CNS_disease": "Intrathecal chemotherapy",
      "coagulopathy": "Hold asparaginase if fibrinogen low",
      "hepatotoxicity": "Monitor LFTs closely with asparaginase"
    },
    "referenceList": [
      "NCCN ALL Guidelines",
      "CALGB Studies",
      "Pediatric Protocols"
    ],
    "cycleInfo": {
      "cycle_length": "Multi-phase protocol",
      "total_cycles": "Induction, consolidation, maintenance",
      "administration_time": "Varies by phase"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron 8mg IV"
      ],
      "tumor_lysis_prevention": [
        "Allopurinol 300mg daily",
        "Aggressive hydration"
      ]
    },
    "postMedications": {
      "CNS_prophylaxis": "Intrathecal methotrexate",
      "steroid_effects": "Monitor glucose, mood",
      "infection_prevention": "Antimicrobial prophylaxis"
    },
    "supportiveCare": {
      "CNS_monitoring": "Lumbar punctures",
      "TLS_prevention": "Hydration, allopurinol",
      "infection_prevention": "Isolation if neutropenic"
    },
    "rescueAgents": {
      "CNS_disease": "High-dose methotrexate",
      "tumor_lysis": "Rasburicase, dialysis if severe",
      "severe_hepatotoxicity": "Stop asparaginase"
    },
    "monitoring": {
      "daily": [
        "FBC during induction"
      ],
      "weekly": [
        "LFTs",
        "Coags"
      ],
      "baseline": [
        "FBC",
        "LFTs",
        "Coags",
        "LP",
        "Cytogenetics",
        "Flow cytometry"
      ]
    },
    "toxicityMonitoring": {
      "CNS_status": "Serial LPs",
      "coagulopathy": "Fibrinogen monitoring",
      "hepatotoxicity": "Daily LFTs during asparaginase"
    },
    "interactions": {
      "warfarin": "Contraindicated with asparaginase",
      "live_vaccines": "Contraindicated"
    },
    "contraindications": [
      "Severe liver disease",
      "Active bleeding",
      "Previous asparaginase allergy"
    ],
    "version": "3.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "11faf82f-6192-4c0b-804d-a9023e977d73",
    "code": "AIM",
    "tumourGroup": "Sarcoma",
    "tumourSupergroup": "Sarcoma",
    "treatmentIntent": "Curative",
    "summary": "Doxorubicin, Ifosfamide, and Mesna regimen for high-grade soft tissue sarcomas with curative intent.",
    "eligibility": {
      "summary": [
        "High-grade soft tissue sarcoma",
        "Adjuvant or neoadjuvant"
      ],
      "criteria": {
        "Age": "16-65 years",
        "ECOG": "0-2",
        "Normal_cardiac_function": "Required"
      }
    },
    "precautions": [
      "Doxorubicin cardiotoxicity",
      "Ifosfamide hemorrhagic cystitis",
      "Mesna protection essential"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "75 mg/m²",
          "name": "Doxorubicin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "10 g/m²",
          "name": "Ifosfamide",
          "route": "IV",
          "schedule": "Days 1-5"
        },
        {
          "dose": "10 g/m²",
          "name": "Mesna",
          "route": "IV",
          "schedule": "Days 1-5"
        }
      ],
      "cycles": "4-6 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "LVEF assessment",
      "Renal function",
      "Urinalysis"
    ],
    "doseModifications": {
      "cardiotoxicity": "Monitor LVEF, stop if drops >10%",
      "nephrotoxicity": "Monitor creatinine",
      "hemorrhagic_cystitis": "Ensure adequate mesna"
    },
    "referenceList": [
      "NCCN Sarcoma Guidelines",
      "ESMO Guidelines",
      "SSG Protocols"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "4-6",
      "administration_time": "5 days continuous infusion"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV"
      ],
      "bladder_protection": [
        "Mesna protocol"
      ],
      "cardiac_protection": [
        "Consider dexrazoxane"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "fatigue": "Energy conservation",
      "bladder_care": "Adequate hydration, frequent voiding"
    },
    "supportiveCare": {
      "renal_function": "Daily monitoring during treatment",
      "bladder_protection": "Continuous mesna",
      "cardiac_monitoring": "LVEF every 2 cycles"
    },
    "rescueAgents": {
      "cardiotoxicity": "Cardio-oncology referral",
      "hemorrhagic_cystitis": "Bladder irrigation, cystoscopy",
      "severe_myelosuppression": "G-CSF support"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "LVEF",
        "Urinalysis"
      ],
      "every_2_cycles": [
        "LVEF"
      ],
      "daily_during_treatment": [
        "U&E",
        "Urinalysis"
      ]
    },
    "toxicityMonitoring": {
      "urotoxicity": "Daily urinalysis during cycles",
      "cardiotoxicity": "Serial LVEF monitoring",
      "nephrotoxicity": "Creatinine monitoring"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "live_vaccines": "Avoid during treatment"
    },
    "contraindications": [
      "Severe cardiac dysfunction",
      "Active urinary tract disease",
      "Pregnancy"
    ],
    "version": "2.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "22faf82f-6192-4c0b-804d-a9023e977d74",
    "code": "Temozolomide",
    "tumourGroup": "CNS",
    "tumourSupergroup": "CNS",
    "treatmentIntent": "Curative",
    "summary": "Standard adjuvant treatment for glioblastoma following surgery and radiotherapy with concurrent and adjuvant temozolomide.",
    "eligibility": {
      "summary": [
        "Glioblastoma multiforme",
        "Post-surgery and radiotherapy"
      ],
      "criteria": {
        "Age": "18-70 years",
        "ECOG": "0-2",
        "MGMT_status": "Preferably methylated"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Lymphopenia and PCP risk",
      "Potential secondary malignancies"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "75 mg/m²",
          "name": "Temozolomide",
          "route": "PO",
          "schedule": "Daily during RT, then 150-200 mg/m² days 1-5 q28d"
        }
      ],
      "cycles": "Concurrent phase + 6 adjuvant cycles"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "MRI brain",
      "Performance status"
    ],
    "doseModifications": {
      "lymphopenia": "PCP prophylaxis if CD4 <200",
      "myelosuppression": "Reduce dose if ANC <1.5 or platelets <100k"
    },
    "referenceList": [
      "NCCN CNS Guidelines",
      "EORTC 26981 Study",
      "Stupp Protocol"
    ],
    "cycleInfo": {
      "cycle_length": "28 days adjuvant",
      "total_cycles": "6 adjuvant cycles",
      "administration_time": "Daily oral"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron 4mg PO PRN"
      ],
      "PCP_prophylaxis": [
        "Co-trimoxazole if lymphopenic"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron PRN, take with food",
      "fatigue": "Rest periods",
      "seizure_prevention": "Continue antiepileptics"
    },
    "supportiveCare": {
      "blood_monitoring": "Weekly FBC during concurrent phase",
      "tumor_monitoring": "MRI every 2 cycles",
      "infection_prevention": "PCP prophylaxis if indicated"
    },
    "rescueAgents": {
      "PCP_pneumonia": "High-dose co-trimoxazole",
      "tumor_progression": "Salvage therapy",
      "severe_myelosuppression": "Treatment delay, G-CSF"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "MRI brain",
        "MGMT status"
      ],
      "every_cycle": [
        "FBC",
        "Clinical assessment"
      ],
      "every_2_cycles": [
        "MRI brain"
      ],
      "weekly_during_RT": [
        "FBC"
      ]
    },
    "toxicityMonitoring": {
      "lymphopenia": "CD4 monitoring if available",
      "tumor_response": "Serial MRI imaging",
      "myelosuppression": "Weekly FBC monitoring"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "valproic_acid": "Potential interaction"
    },
    "contraindications": [
      "Severe myelosuppression",
      "Active infection",
      "Pregnancy"
    ],
    "version": "1.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "33faf82f-6192-4c0b-804d-a9023e977d75",
    "code": "Docetaxel-Prostate",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "Standard first-line chemotherapy for metastatic castration-resistant prostate cancer with proven survival benefit.",
    "eligibility": {
      "summary": [
        "Metastatic castration-resistant prostate cancer",
        "First-line chemotherapy"
      ],
      "criteria": {
        "Age": "18-80 years",
        "ECOG": "0-2",
        "Castrate_testosterone": "< 1.7 nmol/L"
      }
    },
    "precautions": [
      "Docetaxel hypersensitivity reactions",
      "Fluid retention and edema",
      "Peripheral neuropathy development"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "75 mg/m²",
          "name": "Docetaxel",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "5mg BD",
          "name": "Prednisolone",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Every 21 days for up to 10 cycles"
    },
    "tests": [
      "Full blood count",
      "PSA",
      "Liver function tests",
      "Performance status"
    ],
    "doseModifications": {
      "neuropathy": "Reduce docetaxel 25% for grade 2+",
      "neutropenia": "G-CSF support if indicated",
      "fluid_retention": "Dexamethasone premedication"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "EAU Guidelines",
      "TAX 327 Study"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Up to 10",
      "administration_time": "1 hour"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron 8mg IV"
      ],
      "hypersensitivity_prevention": [
        "Dexamethasone 8mg PO x3 days"
      ]
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "neuropathy": "Gabapentin if symptomatic",
      "fluid_retention": "Monitor weight, diuretics if needed"
    },
    "supportiveCare": {
      "PSA_monitoring": "Every cycle",
      "fluid_management": "Daily weights",
      "neuropathy_prevention": "Dose modifications"
    },
    "rescueAgents": {
      "febrile_neutropenia": "G-CSF, antibiotics",
      "severe_fluid_retention": "Diuretics, dose reduction",
      "severe_hypersensitivity": "Epinephrine, steroids"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "PSA",
        "Testosterone",
        "ECOG"
      ],
      "each_cycle": [
        "FBC",
        "LFTs",
        "PSA",
        "Weight",
        "Neuropathy assessment"
      ]
    },
    "toxicityMonitoring": {
      "neuropathy": "Clinical grading each cycle",
      "PSA_response": "Serial PSA measurements",
      "fluid_retention": "Weight monitoring"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "CYP3A4_inhibitors": "Potential interaction"
    },
    "contraindications": [
      "Severe liver impairment",
      "Active infection",
      "Severe heart failure"
    ],
    "version": "2.2",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "44faf82f-6192-4c0b-804d-a9023e977d76",
    "code": "MVAC",
    "tumourGroup": "Bladder",
    "tumourSupergroup": "Bladder",
    "treatmentIntent": "Curative",
    "summary": "Methotrexate, Vinblastine, Doxorubicin, Cisplatin for muscle-invasive bladder cancer with curative intent.",
    "eligibility": {
      "summary": [
        "Muscle-invasive bladder cancer",
        "Neoadjuvant or metastatic setting"
      ],
      "criteria": {
        "Age": "18-70 years",
        "CrCl": "> 60 mL/min",
        "ECOG": "0-1"
      }
    },
    "precautions": [
      "Cisplatin nephrotoxicity and ototoxicity",
      "Doxorubicin cardiotoxicity",
      "Methotrexate mucositis and pneumonitis"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "30 mg/m²",
          "name": "Methotrexate",
          "route": "IV",
          "schedule": "Days 1, 15, 22"
        },
        {
          "dose": "3 mg/m²",
          "name": "Vinblastine",
          "route": "IV",
          "schedule": "Days 2, 15, 22"
        },
        {
          "dose": "30 mg/m²",
          "name": "Doxorubicin",
          "route": "IV",
          "schedule": "Day 2"
        },
        {
          "dose": "70 mg/m²",
          "name": "Cisplatin",
          "route": "IV",
          "schedule": "Day 2"
        }
      ],
      "cycles": "4 cycles every 28 days"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "LVEF assessment",
      "Hearing assessment",
      "Liver function tests"
    ],
    "doseModifications": {
      "mucositis": "Reduce MTX for grade 3+",
      "cardiotoxicity": "Monitor LVEF every 2 cycles",
      "nephrotoxicity": "Hold if creatinine >1.5x baseline"
    },
    "referenceList": [
      "NCCN Bladder Guidelines",
      "EAU Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "4",
      "administration_time": "3 days per cycle"
    },
    "preMedications": {
      "hydration": [
        "Normal saline 1-2L with Mg/K supplementation"
      ],
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV"
      ],
      "leucovorin_rescue": [
        "24h post MTX"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "mucositis": "Oral care, magic mouthwash",
      "neuropathy": "Gabapentin if needed"
    },
    "supportiveCare": {
      "folate_rescue": "Leucovorin after MTX",
      "renal_protection": "Pre/post hydration",
      "cardiac_monitoring": "LVEF every 2 cycles"
    },
    "rescueAgents": {
      "cardiotoxicity": "Cardio-oncology referral",
      "nephrotoxicity": "IV hydration, reduce/stop cisplatin",
      "severe_mucositis": "IV nutrition, treatment delay"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "LVEF",
        "Audiometry",
        "CrCl"
      ],
      "each_cycle": [
        "FBC",
        "U&E",
        "LFTs"
      ],
      "every_2_cycles": [
        "LVEF",
        "Audiometry"
      ]
    },
    "toxicityMonitoring": {
      "mucositis": "Daily oral assessment",
      "cardiotoxicity": "Serial LVEF monitoring",
      "nephrotoxicity": "Daily creatinine during treatment"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "aminoglycosides": "Increased nephrotoxicity"
    },
    "contraindications": [
      "Severe renal impairment",
      "Severe cardiac dysfunction",
      "Active pulmonary disease"
    ],
    "version": "2.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "55faf82f-6192-4c0b-804d-a9023e977d77",
    "code": "TPF",
    "tumourGroup": "Head-Neck",
    "tumourSupergroup": "Head-Neck",
    "treatmentIntent": "Curative",
    "summary": "Docetaxel, Cisplatin, 5-FU induction chemotherapy for locally advanced head and neck squamous cell carcinoma.",
    "eligibility": {
      "summary": [
        "Locally advanced HNSCC",
        "Induction prior to chemoradiotherapy"
      ],
      "criteria": {
        "Age": "18-70 years",
        "ECOG": "0-2",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Docetaxel hypersensitivity and fluid retention",
      "Cisplatin nephrotoxicity and ototoxicity",
      "5-FU mucositis"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "75 mg/m²",
          "name": "Docetaxel",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "75 mg/m²",
          "name": "Cisplatin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "750 mg/m²/day",
          "name": "5-Fluorouracil",
          "route": "IV",
          "schedule": "Days 1-5"
        }
      ],
      "cycles": "3 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Hearing assessment",
      "Liver function tests",
      "Swallowing assessment"
    ],
    "doseModifications": {
      "mucositis": "Reduce 5-FU for grade 3+",
      "neuropathy": "Reduce docetaxel 25%",
      "nephrotoxicity": "Hold if creatinine >1.5x baseline"
    },
    "referenceList": [
      "NCCN Head-Neck Guidelines",
      "ESMO Guidelines",
      "TAX 323/324 Studies"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "3",
      "administration_time": "5 days"
    },
    "preMedications": {
      "hydration": [
        "Normal saline 1-2L with Mg/K"
      ],
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV"
      ],
      "docetaxel_premedication": [
        "Dexamethasone 8mg PO x3 days"
      ]
    },
    "postMedications": {
      "dysphagia": "Nutritional support",
      "mucositis": "Oral care, magic mouthwash",
      "neuropathy": "Gabapentin if symptomatic"
    },
    "supportiveCare": {
      "oral_care": "Regular hygiene",
      "nutritional_support": "Dietitian involvement",
      "swallowing_assessment": "Speech therapy"
    },
    "rescueAgents": {
      "nephrotoxicity": "IV hydration",
      "severe_mucositis": "PEG tube feeding",
      "severe_neuropathy": "Dose reduction"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "CrCl",
        "Audiometry",
        "Swallowing study"
      ],
      "each_cycle": [
        "FBC",
        "U&E",
        "LFTs",
        "Oral assessment"
      ]
    },
    "toxicityMonitoring": {
      "mucositis": "Daily oral examination",
      "ototoxicity": "Audiometry each cycle",
      "nephrotoxicity": "Creatinine monitoring"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "phenytoin": "Monitor levels"
    },
    "contraindications": [
      "Severe renal impairment",
      "Active oral infection",
      "Severe malnutrition"
    ],
    "version": "2.7",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "66faf82f-6192-4c0b-804d-a9023e977d78",
    "code": "OEPA",
    "tumourGroup": "Pediatric",
    "tumourSupergroup": "Pediatric",
    "treatmentIntent": "Curative",
    "summary": "Vincristine, Etoposide, Prednisolone, Doxorubicin for pediatric Hodgkin lymphoma with reduced late effects.",
    "eligibility": {
      "summary": [
        "Pediatric Hodgkin lymphoma",
        "Intermediate risk"
      ],
      "criteria": {
        "Age": "5-18 years",
        "Stage": "IIA with risk factors",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Growth and development considerations",
      "Late cardiac effects",
      "Secondary malignancy risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "1.5 mg/m² (max 2mg)",
          "name": "Vincristine",
          "route": "IV",
          "schedule": "Days 1, 8"
        },
        {
          "dose": "125 mg/m²",
          "name": "Etoposide",
          "route": "IV",
          "schedule": "Days 1-3"
        },
        {
          "dose": "40 mg/m²",
          "name": "Prednisolone",
          "route": "PO",
          "schedule": "Days 1-15"
        },
        {
          "dose": "40 mg/m²",
          "name": "Doxorubicin",
          "route": "IV",
          "schedule": "Days 1, 15"
        }
      ],
      "cycles": "2 cycles every 28 days"
    },
    "tests": [
      "Full blood count",
      "LVEF assessment",
      "Growth parameters",
      "Liver function tests",
      "Thyroid function"
    ],
    "doseModifications": {
      "neuropathy": "Reduce vincristine",
      "growth_delay": "Endocrine monitoring",
      "cardiotoxicity": "Monitor LVEF closely"
    },
    "referenceList": [
      "GPOH Guidelines",
      "COG Protocols",
      "EuroNet-PHL Studies"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "2",
      "administration_time": "Varies by drug"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron age-appropriate dosing"
      ],
      "growth_monitoring": [
        "Regular height/weight"
      ],
      "psychosocial_support": [
        "Child life specialist"
      ]
    },
    "postMedications": {
      "nausea": "Age-appropriate antiemetics",
      "fatigue": "School accommodation",
      "neuropathy": "Monitor motor function"
    },
    "supportiveCare": {
      "growth_monitoring": "Regular endocrine assessment",
      "psychological_support": "Family support",
      "fertility_preservation": "Age-appropriate counseling"
    },
    "rescueAgents": {
      "cardiotoxicity": "Pediatric cardiology",
      "severe_neuropathy": "Physical therapy",
      "severe_myelosuppression": "G-CSF support"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "LVEF",
        "Growth parameters",
        "Staging"
      ],
      "each_cycle": [
        "FBC",
        "LFTs",
        "Growth assessment"
      ],
      "post_treatment": [
        "Long-term follow-up"
      ]
    },
    "toxicityMonitoring": {
      "growth": "Height/weight velocity",
      "neuropathy": "Neurological examination",
      "cardiotoxicity": "Serial echocardiograms"
    },
    "interactions": {
      "live_vaccines": "Delayed post-treatment",
      "school_exposures": "Infection precautions"
    },
    "contraindications": [
      "Severe cardiac dysfunction",
      "Active infection",
      "Previous anthracycline exposure"
    ],
    "version": "1.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "77faf82f-6192-4c0b-804d-a9023e977d79",
    "code": "Pembrolizumab",
    "tumourGroup": "Melanoma",
    "tumourSupergroup": "Melanoma",
    "treatmentIntent": "Curative",
    "summary": "Anti-PD-1 immunotherapy for advanced melanoma with durable responses and manageable immune-related adverse events.",
    "eligibility": {
      "summary": [
        "Advanced melanoma",
        "PD-L1 positive or negative"
      ],
      "criteria": {
        "Age": "18+ years",
        "ECOG": "0-2",
        "No_active_autoimmune": "Required"
      }
    },
    "precautions": [
      "Immune-related adverse events",
      "Pneumonitis risk",
      "Endocrinopathies possible"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "200mg",
          "name": "Pembrolizumab",
          "route": "IV",
          "schedule": "Every 3 weeks"
        }
      ],
      "cycles": "Continue until progression or unacceptable toxicity"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Thyroid function",
      "Chest imaging",
      "ECOG performance status"
    ],
    "doseModifications": {
      "irAEs": "Hold for grade 2+, steroids for grade 3+",
      "pneumonitis": "Permanent discontinuation for grade 3+",
      "endocrinopathy": "Hormone replacement as needed"
    },
    "referenceList": [
      "NCCN Melanoma Guidelines",
      "ESMO Guidelines",
      "KEYNOTE Studies"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "30 minutes"
    },
    "preMedications": {
      "antihistamine": [
        "Diphenhydramine 25mg IV PRN"
      ],
      "corticosteroids": [
        "Available for irAE management"
      ]
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "skin_care": "Moisturizers, sun protection",
      "irAE_monitoring": "Patient education on symptoms"
    },
    "supportiveCare": {
      "irAE_management": "Corticosteroids for grade 2+",
      "endocrine_support": "Hormone replacement",
      "patient_education": "Symptom recognition"
    },
    "rescueAgents": {
      "pneumonitis": "High-dose steroids, permanent discontinuation",
      "endocrinopathy": "Hormone replacement",
      "severe_colitis": "Steroids, infliximab"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "TFTs",
        "CXR",
        "ECOG"
      ],
      "each_cycle": [
        "FBC",
        "LFTs",
        "TFTs",
        "Clinical assessment"
      ],
      "every_3_cycles": [
        "CT imaging"
      ]
    },
    "toxicityMonitoring": {
      "colitis": "Stool frequency monitoring",
      "endocrine": "Regular hormone levels",
      "pneumonitis": "Serial chest imaging"
    },
    "interactions": [
      "Live vaccines contraindicated",
      "Immunosuppressants may reduce efficacy"
    ],
    "contraindications": [
      "Active autoimmune disease",
      "Organ transplant recipient",
      "Pregnancy"
    ],
    "version": "1.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "88faf82f-6192-4c0b-804d-a9023e977d80",
    "code": "Dacarbazine",
    "tumourGroup": "Melanoma",
    "tumourSupergroup": "Melanoma",
    "treatmentIntent": "Palliative",
    "summary": "Traditional chemotherapy for metastatic melanoma with modest response rates but established safety profile.",
    "eligibility": {
      "summary": [
        "Metastatic melanoma",
        "When immunotherapy contraindicated"
      ],
      "criteria": {
        "Age": "18-75 years",
        "ECOG": "0-2",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Flu-like syndrome",
      "Hepatotoxicity potential"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "250 mg/m²",
          "name": "Dacarbazine",
          "route": "IV",
          "schedule": "Days 1-5"
        }
      ],
      "cycles": "Every 21 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Performance status",
      "Lactate dehydrogenase"
    ],
    "doseModifications": {
      "flu_syndrome": "Supportive care",
      "hepatotoxicity": "Monitor LFTs closely",
      "myelosuppression": "Hold if ANC <1.0 or platelets <100k"
    },
    "referenceList": [
      "NCCN Melanoma Guidelines",
      "Historical Studies"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "5 days"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV"
      ],
      "flu_prevention": [
        "Paracetamol prophylaxis"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "fatigue": "Energy conservation",
      "flu_syndrome": "Paracetamol, rest"
    },
    "supportiveCare": {
      "LDH_monitoring": "Tumor marker",
      "symptom_management": "Supportive care",
      "infection_prevention": "Monitor WBC"
    },
    "rescueAgents": {
      "febrile_neutropenia": "Antibiotics",
      "severe_hepatotoxicity": "Discontinue treatment",
      "severe_myelosuppression": "G-CSF support"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "LDH",
        "ECOG"
      ],
      "each_cycle": [
        "FBC",
        "LFTs",
        "Clinical assessment"
      ],
      "every_2_cycles": [
        "Imaging"
      ]
    },
    "toxicityMonitoring": {
      "hepatotoxicity": "LFT monitoring",
      "tumor_response": "Regular imaging",
      "myelosuppression": "Weekly FBC monitoring"
    },
    "interactions": [
      "Warfarin may be enhanced",
      "Live vaccines contraindicated"
    ],
    "contraindications": [
      "Severe liver disease",
      "Severe myelosuppression",
      "Pregnancy"
    ],
    "version": "1.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "99faf82f-6192-4c0b-804d-a9023e977d81",
    "code": "VRD",
    "tumourGroup": "Myeloma",
    "tumourSupergroup": "Myeloma",
    "treatmentIntent": "Curative",
    "summary": "Bortezomib, Lenalidomide, Dexamethasone induction for newly diagnosed multiple myeloma with excellent response rates.",
    "eligibility": {
      "summary": [
        "Newly diagnosed multiple myeloma",
        "Transplant eligible"
      ],
      "criteria": {
        "Age": "18-70 years",
        "CrCl": "> 30 mL/min",
        "ECOG": "0-2"
      }
    },
    "precautions": [
      "Bortezomib peripheral neuropathy",
      "Lenalidomide thrombosis risk",
      "Dexamethasone hyperglycemia"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "1.3 mg/m²",
          "name": "Bortezomib",
          "route": "SC",
          "schedule": "Days 1, 4, 8, 11"
        },
        {
          "dose": "25mg",
          "name": "Lenalidomide",
          "route": "PO",
          "schedule": "Days 1-14"
        },
        {
          "dose": "20mg",
          "name": "Dexamethasone",
          "route": "PO",
          "schedule": "Days 1, 2, 4, 5, 8, 9, 11, 12"
        }
      ],
      "cycles": "4-6 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Liver function tests",
      "Paraprotein levels",
      "Bone marrow biopsy"
    ],
    "doseModifications": {
      "neuropathy": "Reduce bortezomib dose or change to weekly",
      "thrombosis": "Aspirin prophylaxis",
      "renal_impairment": "Reduce lenalidomide dose"
    },
    "referenceList": [
      "NCCN Myeloma Guidelines",
      "IMWG Guidelines",
      "SWOG S0777 Study"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "4-6",
      "administration_time": "Subcutaneous injection + oral"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron PRN"
      ],
      "PCP_prophylaxis": [
        "Co-trimoxazole"
      ],
      "thromboprophylaxis": [
        "Aspirin 75mg daily or LMWH"
      ]
    },
    "postMedications": {
      "neuropathy": "Gabapentin, dose modification",
      "hyperglycemia": "Monitor glucose, metformin",
      "DVT_prevention": "Mobilization, prophylaxis"
    },
    "supportiveCare": {
      "infection_prevention": "Monitor for infections",
      "neuropathy_monitoring": "Before each cycle",
      "thrombosis_prevention": "Risk assessment"
    },
    "rescueAgents": {
      "thrombosis": "Anticoagulation",
      "severe_infection": "Antibiotics, IVIG if hypogammaglobulinemia",
      "severe_neuropathy": "Dose reduction, neurology referral"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "Paraprotein",
        "BM biopsy",
        "Skeletal survey"
      ],
      "each_cycle": [
        "FBC",
        "U&E",
        "Paraprotein",
        "Neuropathy assessment"
      ]
    },
    "toxicityMonitoring": {
      "response": "Paraprotein and bone marrow",
      "neuropathy": "Clinical neuropathy score",
      "thrombosis": "Clinical assessment for DVT/PE"
    },
    "interactions": [
      "Warfarin interaction with lenalidomide",
      "CYP450 interactions with dexamethasone"
    ],
    "contraindications": [
      "Active infection",
      "Previous thrombosis without anticoagulation",
      "Pregnancy"
    ],
    "version": "2.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "aafaf82f-6192-4c0b-804d-a9023e977d82",
    "code": "Sorafenib",
    "tumourGroup": "Hepatocellular",
    "tumourSupergroup": "Hepatocellular",
    "treatmentIntent": "Palliative",
    "summary": "Multi-kinase inhibitor for advanced hepatocellular carcinoma with proven survival benefit in Child-Pugh A cirrhosis.",
    "eligibility": {
      "summary": [
        "Advanced hepatocellular carcinoma",
        "Child-Pugh A cirrhosis"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Child_Pugh": "A",
        "No_previous_systemic": "Required"
      }
    },
    "precautions": [
      "Hand-foot skin reaction",
      "Diarrhea and fatigue",
      "Hypertension development"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "400mg BD",
          "name": "Sorafenib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "AFP",
      "Blood pressure",
      "Thyroid function"
    ],
    "doseModifications": {
      "HFSR": "Dose reduction or interruption",
      "diarrhea": "Supportive care, dose modification",
      "hypertension": "Antihypertensive therapy"
    },
    "referenceList": [
      "NCCN HCC Guidelines",
      "EASL Guidelines",
      "SHARP Trial"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Twice daily oral"
    },
    "preMedications": {
      "skin_care": [
        "Moisturizers, sun protection"
      ],
      "BP_monitoring": [
        "Regular checks"
      ],
      "antidiarrheal": [
        "Loperamide PRN"
      ]
    },
    "postMedications": {
      "HFSR": "Urea cream, dose modification",
      "fatigue": "Energy conservation",
      "diarrhea": "Loperamide, hydration"
    },
    "supportiveCare": {
      "GI_support": "Dietary modification",
      "BP_management": "Antihypertensives",
      "skin_monitoring": "Regular foot inspection"
    },
    "rescueAgents": {
      "severe_HFSR": "Topical treatments, dose interruption",
      "severe_diarrhea": "IV hydration",
      "uncontrolled_HTN": "Antihypertensive optimization"
    },
    "monitoring": {
      "monthly": [
        "FBC",
        "LFTs",
        "AFP",
        "BP"
      ],
      "baseline": [
        "FBC",
        "LFTs",
        "AFP",
        "BP",
        "TFTs"
      ],
      "every_3_months": [
        "Imaging"
      ]
    },
    "toxicityMonitoring": {
      "HFSR": "Grading and management",
      "diarrhea": "Frequency monitoring",
      "tumor_response": "AFP and imaging"
    },
    "interactions": [
      "Warfarin enhanced effect",
      "CYP3A4 interactions"
    ],
    "contraindications": [
      "Child-Pugh B or C cirrhosis",
      "Severe cardiac disease",
      "Pregnancy"
    ],
    "version": "1.2",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "bbfaf82f-6192-4c0b-804d-a9023e977d83",
    "code": "FOLFIRINOX",
    "tumourGroup": "Pancreatic",
    "tumourSupergroup": "Pancreatic",
    "treatmentIntent": "Palliative",
    "summary": "Intensive chemotherapy for metastatic pancreatic adenocarcinoma in fit patients with excellent performance status.",
    "eligibility": {
      "summary": [
        "Metastatic pancreatic adenocarcinoma",
        "Good performance status only"
      ],
      "criteria": {
        "Age": "18-70 years",
        "ECOG": "0-1",
        "Bilirubin": "< 1.5x ULN"
      }
    },
    "precautions": [
      "Severe diarrhea risk",
      "Significant myelosuppression",
      "Peripheral neuropathy from oxaliplatin"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "85 mg/m²",
          "name": "Oxaliplatin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "180 mg/m²",
          "name": "Irinotecan",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "400 mg/m²",
          "name": "Leucovorin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "400 mg/m² bolus + 2400 mg/m² infusion",
          "name": "5-Fluorouracil",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "Every 14 days until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Renal function",
      "UGT1A1 genotyping",
      "CA 19-9"
    ],
    "doseModifications": {
      "diarrhea": "Reduce irinotecan 25% for grade 3+",
      "neuropathy": "Reduce oxaliplatin 25%",
      "neutropenia": "G-CSF support, dose delay"
    },
    "referenceList": [
      "NCCN Pancreatic Guidelines",
      "PRODIGE 4 Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "14 days",
      "total_cycles": "Until progression",
      "administration_time": "46 hours"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV"
      ],
      "diarrhea_prevention": [
        "Atropine 0.25mg SC"
      ],
      "neuropathy_prevention": [
        "Avoid cold exposure"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "neuropathy": "Gabapentin",
      "delayed_diarrhea": "Loperamide protocol"
    },
    "supportiveCare": {
      "diarrhea_management": "Aggressive loperamide protocol",
      "nutritional_support": "Dietitian involvement",
      "neuropathy_monitoring": "Before each cycle"
    },
    "rescueAgents": {
      "severe_diarrhea": "IV hydration, electrolyte replacement",
      "severe_neuropathy": "Oxaliplatin discontinuation",
      "febrile_neutropenia": "G-CSF, antibiotics"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "UGT1A1",
        "CA19-9",
        "ECOG"
      ],
      "each_cycle": [
        "FBC",
        "U&E",
        "LFTs",
        "Neuropathy assessment"
      ],
      "every_4_cycles": [
        "Imaging"
      ]
    },
    "toxicityMonitoring": {
      "diarrhea": "Early vs delayed, frequency monitoring",
      "neuropathy": "Oxaliplatin-specific scale",
      "myelosuppression": "Weekly FBC"
    },
    "interactions": [
      "Warfarin enhanced effect",
      "St Johns wort interaction"
    ],
    "contraindications": [
      "ECOG ≥ 2",
      "Significant cardiac disease",
      "Chronic diarrhea"
    ],
    "version": "2.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "ccfaf82f-6192-4c0b-804d-a9023e977d84",
    "code": "ECF",
    "tumourGroup": "Gastric",
    "tumourSupergroup": "Gastric",
    "treatmentIntent": "Curative",
    "summary": "Epirubicin, Cisplatin, 5-FU for advanced gastric and esophageal adenocarcinoma with curative or palliative intent.",
    "eligibility": {
      "summary": [
        "Advanced gastroesophageal adenocarcinoma",
        "Perioperative or palliative"
      ],
      "criteria": {
        "Age": "18-75 years",
        "ECOG": "0-2",
        "HER2": "Negative"
      }
    },
    "precautions": [
      "Epirubicin cardiotoxicity",
      "Cisplatin nephrotoxicity and ototoxicity",
      "5-FU mucositis"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "50 mg/m²",
          "name": "Epirubicin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "60 mg/m²",
          "name": "Cisplatin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "200 mg/m²/day",
          "name": "5-Fluorouracil",
          "route": "IV",
          "schedule": "Days 1-21"
        }
      ],
      "cycles": "Every 21 days for 6-8 cycles"
    },
    "tests": [
      "Full blood count",
      "LVEF assessment",
      "Renal function",
      "Hearing assessment",
      "Liver function tests"
    ],
    "doseModifications": {
      "mucositis": "Reduce 5-FU for grade 3+",
      "cardiotoxicity": "Monitor LVEF every 3 cycles",
      "nephrotoxicity": "Hold if creatinine >1.5x"
    },
    "referenceList": [
      "NCCN Gastric Guidelines",
      "ESMO Guidelines",
      "MAGIC Trial"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "6-8",
      "administration_time": "21-day continuous 5-FU"
    },
    "preMedications": {
      "hydration": [
        "Normal saline 1-2L with Mg/K"
      ],
      "antiemetic": [
        "Ondansetron 8mg IV",
        "Dexamethasone 8mg IV"
      ],
      "cardiac_monitoring": [
        "LVEF baseline"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "mucositis": "Oral care, magic mouthwash",
      "neuropathy": "Gabapentin if needed"
    },
    "supportiveCare": {
      "renal_protection": "Pre/post hydration",
      "cardiac_monitoring": "LVEF every 3 cycles",
      "nutritional_support": "Dietitian involvement"
    },
    "rescueAgents": {
      "cardiotoxicity": "Cardio-oncology referral",
      "nephrotoxicity": "IV hydration, discontinue cisplatin",
      "severe_mucositis": "Treatment break"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "LVEF",
        "Audiometry",
        "CrCl"
      ],
      "each_cycle": [
        "FBC",
        "U&E",
        "LFTs"
      ],
      "every_3_cycles": [
        "LVEF"
      ]
    },
    "toxicityMonitoring": {
      "mucositis": "Clinical grading",
      "cardiotoxicity": "Serial LVEF monitoring",
      "nephrotoxicity": "Creatinine monitoring"
    },
    "interactions": [
      "Warfarin enhanced effect",
      "Aminoglycosides increased nephrotoxicity"
    ],
    "contraindications": [
      "Severe cardiac dysfunction",
      "Severe renal impairment",
      "Active GI bleeding"
    ],
    "version": "1.9",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "ddfaf82f-6192-4c0b-804d-a9023e977d85",
    "code": "Sunitinib",
    "tumourGroup": "Renal",
    "tumourSupergroup": "Renal",
    "treatmentIntent": "Palliative",
    "summary": "Multi-targeted tyrosine kinase inhibitor for advanced renal cell carcinoma with proven survival benefit.",
    "eligibility": {
      "summary": [
        "Advanced renal cell carcinoma",
        "Clear cell histology"
      ],
      "criteria": {
        "ECOG": "0-2",
        "No_brain_metastases": "Or treated and stable",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Hand-foot syndrome",
      "Diarrhea and mucositis",
      "Hypertension and cardiac dysfunction"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "50mg daily",
          "name": "Sunitinib",
          "route": "PO",
          "schedule": "4 weeks on, 2 weeks off"
        }
      ],
      "cycles": "6-week cycles until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Thyroid function",
      "LVEF assessment",
      "Blood pressure"
    ],
    "doseModifications": {
      "hypertension": "Antihypertensive therapy",
      "hand_foot_syndrome": "Dose reduction or interruption",
      "cardiac_dysfunction": "LVEF monitoring"
    },
    "referenceList": [
      "NCCN Kidney Cancer Guidelines",
      "ESMO Guidelines",
      "Pivotal Phase III Studies"
    ],
    "cycleInfo": {
      "cycle_length": "42 days",
      "total_cycles": "Until progression",
      "administration_time": "4 weeks on, 2 weeks off"
    },
    "preMedications": {
      "skin_care": [
        "Moisturizers, sun protection"
      ],
      "BP_monitoring": [
        "Regular checks"
      ],
      "cardiac_monitoring": [
        "Baseline LVEF"
      ]
    },
    "postMedications": {
      "diarrhea": "Loperamide",
      "mucositis": "Oral care",
      "hand_foot_syndrome": "Urea cream, dose modification"
    },
    "supportiveCare": {
      "BP_management": "Antihypertensives",
      "skin_monitoring": "Regular inspection",
      "cardiac_protection": "LVEF monitoring"
    },
    "rescueAgents": {
      "severe_HFS": "Topical treatments, dose interruption",
      "uncontrolled_HTN": "Optimize antihypertensives",
      "cardiac_dysfunction": "Cardio-oncology referral"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "TFTs",
        "LVEF",
        "BP"
      ],
      "each_cycle": [
        "FBC",
        "LFTs",
        "TFTs",
        "Clinical assessment"
      ],
      "every_3_cycles": [
        "LVEF",
        "Imaging"
      ]
    },
    "toxicityMonitoring": {
      "tumor_response": "RECIST criteria",
      "cardiac_function": "Serial LVEF",
      "hand_foot_syndrome": "CTCAE grading"
    },
    "interactions": [
      "Warfarin interaction possible",
      "CYP3A4 interactions"
    ],
    "contraindications": [
      "Severe cardiac disease",
      "Uncontrolled hypertension",
      "Pregnancy"
    ],
    "version": "1.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "eefaf82f-6192-4c0b-804d-a9023e977d86",
    "code": "PCV",
    "tumourGroup": "CNS",
    "tumourSupergroup": "CNS",
    "treatmentIntent": "Curative",
    "summary": "Procarbazine, CCNU, Vincristine for oligodendrogliomas and mixed gliomas with 1p/19q codeletion.",
    "eligibility": {
      "summary": [
        "Oligodendroglioma",
        "1p/19q codeleted tumors"
      ],
      "criteria": {
        "Age": "18-70 years",
        "ECOG": "0-2",
        "1p19q": "Codeleted"
      }
    },
    "precautions": [
      "CCNU pulmonary toxicity",
      "Procarbazine MAO inhibition",
      "Vincristine peripheral neuropathy"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "110 mg/m²",
          "name": "CCNU (Lomustine)",
          "route": "PO",
          "schedule": "Day 1 (cycles 1, 3, 5)"
        },
        {
          "dose": "60 mg/m²",
          "name": "Procarbazine",
          "route": "PO",
          "schedule": "Days 8-21"
        },
        {
          "dose": "1.4 mg/m² (max 2mg)",
          "name": "Vincristine",
          "route": "IV",
          "schedule": "Days 8, 29"
        }
      ],
      "cycles": "6 cycles"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Pulmonary function tests",
      "MRI brain",
      "Neurological assessment"
    ],
    "doseModifications": {
      "neuropathy": "Reduce vincristine dose",
      "myelosuppression": "Delay cycles",
      "pulmonary_toxicity": "Monitor PFTs, discontinue CCNU"
    },
    "referenceList": [
      "NCCN CNS Guidelines",
      "RTOG 9402 Study",
      "EORTC 26951 Study"
    ],
    "cycleInfo": {
      "cycle_length": "42 days",
      "total_cycles": "6",
      "administration_time": "Complex schedule"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron 4mg PO"
      ],
      "MAO_precautions": [
        "Dietary restrictions with procarbazine"
      ],
      "neuropathy_monitoring": [
        "Baseline assessment"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "neuropathy": "Gabapentin if symptomatic",
      "MAO_interactions": "Avoid tyramine-rich foods"
    },
    "supportiveCare": {
      "dietary_counseling": "MAO inhibitor precautions",
      "pulmonary_monitoring": "PFTs every 2 cycles",
      "neurological_monitoring": "Regular assessment"
    },
    "rescueAgents": {
      "severe_neuropathy": "Vincristine dose reduction",
      "pulmonary_toxicity": "Discontinue CCNU permanently",
      "hypertensive_crisis": "IV antihypertensives"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "PFTs",
        "MRI brain",
        "Neuro exam"
      ],
      "each_cycle": [
        "FBC",
        "LFTs",
        "Neuro exam"
      ],
      "every_2_cycles": [
        "PFTs",
        "MRI brain"
      ]
    },
    "toxicityMonitoring": {
      "neuropathy": "Clinical grading",
      "tumor_response": "Serial MRI",
      "pulmonary_toxicity": "Serial PFT monitoring"
    },
    "interactions": [
      "Tyramine-rich foods contraindicated",
      "Sympathomimetics contraindicated"
    ],
    "contraindications": [
      "Significant pulmonary disease",
      "Uncontrolled hypertension",
      "Pregnancy"
    ],
    "version": "2.3",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "fffaf82f-6192-4c0b-804d-a9023e977d87",
    "code": "Lenvatinib",
    "tumourGroup": "Thyroid",
    "tumourSupergroup": "Thyroid",
    "treatmentIntent": "Palliative",
    "summary": "Multi-kinase inhibitor for radioactive iodine-refractory differentiated thyroid cancer with significant clinical benefit.",
    "eligibility": {
      "summary": [
        "RAI-refractory differentiated thyroid cancer",
        "Progressive disease"
      ],
      "criteria": {
        "ECOG": "0-2",
        "RAI_refractory": "Confirmed",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Hypertension and proteinuria",
      "Hand-foot syndrome",
      "Hepatotoxicity potential"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "24mg daily",
          "name": "Lenvatinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Thyroid function",
      "Blood pressure",
      "Proteinuria",
      "LVEF"
    ],
    "doseModifications": {
      "proteinuria": "Dose reduction if >2g/24h",
      "hypertension": "Antihypertensive therapy",
      "hepatotoxicity": "Monitor LFTs closely"
    },
    "referenceList": [
      "NCCN Thyroid Guidelines",
      "ATA Guidelines",
      "SELECT Study"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily oral"
    },
    "preMedications": {
      "skin_care": "Moisturizers",
      "BP_monitoring": "Regular checks",
      "thyroid_monitoring": "TSH suppression"
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "diarrhea": "Loperamide",
      "hand_foot_syndrome": "Urea cream, dose modification"
    },
    "supportiveCare": {
      "BP_management": "Antihypertensives",
      "thyroid_replacement": "Levothyroxine optimization",
      "proteinuria_monitoring": "Urine protein"
    },
    "rescueAgents": {
      "severe_proteinuria": "Dose interruption",
      "severe_hypertension": "IV antihypertensives",
      "severe_hepatotoxicity": "Permanent discontinuation"
    },
    "monitoring": {
      "monthly": [
        "FBC",
        "LFTs",
        "BP",
        "Urine protein"
      ],
      "baseline": [
        "FBC",
        "LFTs",
        "TFTs",
        "BP",
        "Urine protein",
        "LVEF"
      ],
      "every_3_months": [
        "Imaging"
      ]
    },
    "toxicityMonitoring": {
      "proteinuria": "24h urine collection",
      "hypertension": "BP monitoring",
      "hepatotoxicity": "LFT monitoring"
    },
    "interactions": {
      "CYP3A4": "Interactions",
      "warfarin": "Interaction possible"
    },
    "contraindications": [
      "Severe cardiac disease",
      "Uncontrolled hypertension",
      "Pregnancy"
    ],
    "version": "1.3",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a0baf82f-6192-4c0b-804d-a9023e977d88",
    "code": "Octreotide-LAR",
    "tumourGroup": "Neuroendocrine",
    "tumourSupergroup": "Neuroendocrine",
    "treatmentIntent": "Palliative",
    "summary": "Long-acting somatostatin analog for symptom control and tumor stabilization in neuroendocrine tumors.",
    "eligibility": {
      "summary": [
        "Functional neuroendocrine tumors",
        "Carcinoid syndrome"
      ],
      "criteria": {
        "ECOG": "0-3",
        "Life_expectancy": "> 3 months",
        "Somatostatin_receptor": "Positive"
      }
    },
    "precautions": [
      "Gallbladder sludge formation",
      "Hyperglycemia potential",
      "Injection site reactions"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "20-30mg",
          "name": "Octreotide LAR",
          "route": "IM",
          "schedule": "Every 28 days"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Chromogranin A",
      "5-HIAA",
      "Gallbladder ultrasound",
      "Blood glucose",
      "Symptom assessment"
    ],
    "doseModifications": {
      "diabetes": "Monitor glucose closely",
      "diarrhea": "Symptomatic relief",
      "gallbladder_monitoring": "Regular ultrasound"
    },
    "referenceList": [
      "NCCN NET Guidelines",
      "ENETS Guidelines",
      "PROMID Study"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "Monthly injection"
    },
    "preMedications": {
      "symptom_diary": "Flushing, diarrhea tracking",
      "injection_technique": "Deep IM injection"
    },
    "postMedications": {
      "diarrhea": "Continue octreotide, symptomatic treatment",
      "flushing": "Document frequency",
      "abdominal_pain": "Antispasmodics"
    },
    "supportiveCare": {
      "glucose_monitoring": "Regular checks",
      "symptom_monitoring": "Daily diary",
      "gallbladder_protection": "Ursodeoxycholic acid if indicated"
    },
    "rescueAgents": {
      "gallbladder_stones": "Ursodeoxycholic acid, surgery if symptomatic",
      "severe_hyperglycemia": "Insulin therapy",
      "injection_site_reaction": "Rotation, warm compress"
    },
    "monitoring": {
      "monthly": [
        "CgA",
        "Symptom assessment"
      ],
      "baseline": [
        "CgA",
        "5-HIAA",
        "Gallbladder US",
        "Glucose",
        "Symptom score"
      ],
      "every_6_months": [
        "Gallbladder US",
        "Imaging"
      ]
    },
    "toxicityMonitoring": {
      "gallbladder": "Regular ultrasound",
      "tumor_markers": "CgA and 5-HIAA levels",
      "symptom_control": "Flushing and diarrhea frequency"
    },
    "interactions": {
      "insulin": "May need adjustment",
      "cyclosporine": "Levels may be affected"
    },
    "contraindications": [
      "Severe liver disease",
      "Pregnancy",
      "Known hypersensitivity"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b1baf82f-6192-4c0b-804d-a9023e977d89",
    "code": "CROSS-Protocol",
    "tumourGroup": "Esophageal",
    "tumourSupergroup": "Esophageal",
    "treatmentIntent": "Curative",
    "summary": "Carboplatin and Paclitaxel with concurrent radiotherapy for locally advanced esophageal cancer per CROSS trial.",
    "eligibility": {
      "summary": [
        "Locally advanced esophageal cancer",
        "Neoadjuvant chemoradiotherapy"
      ],
      "criteria": {
        "ECOG": "0-2",
        "FEV1": "> 1.2L",
        "T3-4 or N+": "Required"
      }
    },
    "precautions": [
      "Radiation esophagitis",
      "Paclitaxel neuropathy",
      "Carboplatin thrombocytopenia"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "AUC 2",
          "name": "Carboplatin",
          "route": "IV",
          "schedule": "Weekly x 5"
        },
        {
          "dose": "50 mg/m²",
          "name": "Paclitaxel",
          "route": "IV",
          "schedule": "Weekly x 5"
        }
      ],
      "cycles": "5 weeks concurrent with RT"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Pulmonary function",
      "Swallowing assessment",
      "Weight monitoring"
    ],
    "doseModifications": {
      "neuropathy": "Reduce paclitaxel 25%",
      "esophagitis": "Treatment break if grade 3+",
      "thrombocytopenia": "Hold if platelets <75,000"
    },
    "referenceList": [
      "NCCN Esophageal Guidelines",
      "CROSS Trial",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Weekly x 5",
      "total_cycles": "5",
      "administration_time": "Concurrent with RT"
    },
    "preMedications": {
      "nutrition": [
        "Dietitian involvement"
      ],
      "antiemetic": [
        "Ondansetron 8mg IV"
      ],
      "mucositis_prevention": [
        "Oral care protocol"
      ]
    },
    "postMedications": {
      "dysphagia": "Nutritional support",
      "neuropathy": "Gabapentin if needed",
      "esophagitis": "Liquid nutrition, proton pump inhibitors"
    },
    "supportiveCare": {
      "mucositis_care": "Magic mouthwash",
      "nutritional_support": "PEG tube if severe dysphagia",
      "radiation_dermatitis": "Topical care"
    },
    "rescueAgents": {
      "aspiration": "NGT or PEG",
      "severe_neuropathy": "Dose reduction",
      "severe_esophagitis": "Treatment break, IV nutrition"
    },
    "monitoring": {
      "weekly": [
        "FBC",
        "Weight",
        "Swallowing assessment"
      ],
      "baseline": [
        "FBC",
        "U&E",
        "PFTs",
        "Swallowing study",
        "Weight"
      ],
      "post_treatment": [
        "Restaging CT"
      ]
    },
    "toxicityMonitoring": {
      "dysphagia": "Weekly swallowing evaluation",
      "neuropathy": "Clinical grading",
      "esophagitis": "Daily assessment during RT"
    },
    "interactions": {
      "antacids": "May affect drug absorption",
      "warfarin": "Enhanced anticoagulation"
    },
    "contraindications": [
      "Severe pulmonary disease",
      "Active esophageal bleeding",
      "Previous chest radiotherapy"
    ],
    "version": "2.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c2baf82f-6192-4c0b-804d-a9023e977d90",
    "code": "Gemcitabine-Cisplatin-Biliary",
    "tumourGroup": "Biliary",
    "tumourSupergroup": "Biliary",
    "treatmentIntent": "Palliative",
    "summary": "Standard chemotherapy for advanced cholangiocarcinoma and gallbladder cancer with proven survival benefit.",
    "eligibility": {
      "summary": [
        "Advanced cholangiocarcinoma",
        "Gallbladder adenocarcinoma"
      ],
      "criteria": {
        "CrCl": "> 60 mL/min",
        "ECOG": "0-2",
        "Biliary_drainage": "If obstructed"
      }
    },
    "precautions": [
      "Cisplatin nephrotoxicity",
      "Gemcitabine thrombocytopenia",
      "Biliary sepsis risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "1000 mg/m²",
          "name": "Gemcitabine",
          "route": "IV",
          "schedule": "Days 1 and 8"
        },
        {
          "dose": "25 mg/m²",
          "name": "Cisplatin",
          "route": "IV",
          "schedule": "Days 1 and 8"
        }
      ],
      "cycles": "Every 21 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Renal function",
      "CA 19-9",
      "Biliary drainage assessment"
    ],
    "doseModifications": {
      "cholangitis": "Antibiotics, drainage",
      "nephrotoxicity": "Hold if creatinine >1.5x baseline",
      "thrombocytopenia": "Hold if platelets <75,000"
    },
    "referenceList": [
      "NCCN Biliary Guidelines",
      "ABC-02 Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "2 days per cycle"
    },
    "preMedications": {
      "hydration": [
        "Normal saline 1L pre/post cisplatin"
      ],
      "antiemetic": [
        "Ondansetron 8mg IV"
      ],
      "biliary_monitoring": [
        "Drainage patency"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "fatigue": "Energy conservation",
      "cholangitis": "Antibiotics at first sign"
    },
    "supportiveCare": {
      "biliary_drainage": "Stent patency monitoring",
      "nutritional_support": "Fat-soluble vitamins",
      "infection_prevention": "Antibiotic prophylaxis"
    },
    "rescueAgents": {
      "cholangitis": "IV antibiotics, drainage intervention",
      "nephrotoxicity": "Hydration, discontinue cisplatin",
      "severe_thrombocytopenia": "Platelet transfusion"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "U&E",
        "CA19-9",
        "MRCP"
      ],
      "each_cycle": [
        "FBC",
        "LFTs",
        "U&E",
        "CA19-9"
      ],
      "every_3_cycles": [
        "Imaging"
      ]
    },
    "toxicityMonitoring": {
      "cholangitis": "Temperature monitoring, WBC",
      "nephrotoxicity": "Creatinine monitoring",
      "tumor_response": "CA19-9 and imaging"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "aminoglycosides": "Increased nephrotoxicity"
    },
    "contraindications": [
      "Active cholangitis",
      "Severe renal impairment",
      "Severe liver dysfunction"
    ],
    "version": "1.7",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d3baf82f-6192-4c0b-804d-a9023e977d91",
    "code": "EPOCH",
    "tumourGroup": "Lymphoma",
    "tumourSupergroup": "Lymphoma",
    "treatmentIntent": "Curative",
    "summary": "Dose-adjusted EPOCH for aggressive B-cell lymphomas including double-hit and CNS lymphomas.",
    "eligibility": {
      "summary": [
        "Aggressive B-cell lymphomas",
        "Double-hit lymphomas"
      ],
      "criteria": {
        "Age": "18-70 years",
        "ECOG": "0-3",
        "No_active_infection": "Required"
      }
    },
    "precautions": [
      "Intensive myelosuppression",
      "Tumor lysis syndrome risk",
      "CNS penetration"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "50 mg/m²/day",
          "name": "Etoposide",
          "route": "IV",
          "schedule": "Days 1-4"
        },
        {
          "dose": "10 mg/m²/day",
          "name": "Vincristine",
          "route": "IV",
          "schedule": "Days 1-4"
        },
        {
          "dose": "50 mg/m²/day",
          "name": "Doxorubicin",
          "route": "IV",
          "schedule": "Days 1-4"
        },
        {
          "dose": "750 mg/m²",
          "name": "Cyclophosphamide",
          "route": "IV",
          "schedule": "Day 5"
        },
        {
          "dose": "60mg/m²",
          "name": "Prednisolone",
          "route": "PO",
          "schedule": "Days 1-5"
        }
      ],
      "cycles": "6 cycles with dose adjustments"
    },
    "tests": [
      "Full blood count",
      "LDH",
      "Beta-2 microglobulin",
      "CNS examination",
      "Bone marrow biopsy"
    ],
    "doseModifications": {
      "neutropenia": "Dose escalation based on nadir ANC",
      "tumor_lysis": "Aggressive prevention protocol",
      "CNS_involvement": "Intrathecal prophylaxis"
    },
    "referenceList": [
      "NCI Guidelines",
      "CALGB Studies"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "6",
      "administration_time": "4-day continuous infusion"
    },
    "preMedications": {
      "growth_factors": [
        "G-CSF per protocol"
      ],
      "CNS_prophylaxis": [
        "Intrathecal methotrexate"
      ],
      "tumor_lysis_prevention": [
        "Allopurinol",
        "Aggressive hydration"
      ]
    },
    "postMedications": {
      "tumor_lysis": "Rasburicase if high risk",
      "CNS_monitoring": "Serial lumbar punctures",
      "infection_prevention": "Prophylactic antibiotics if severe neutropenia"
    },
    "supportiveCare": {
      "CNS_protection": "Intrathecal therapy",
      "TLS_prevention": "Hydration, allopurinol",
      "dose_adjustments": "Based on ANC nadir"
    },
    "rescueAgents": {
      "severe_TLS": "Rasburicase, dialysis",
      "CNS_disease": "High-dose methotrexate",
      "severe_mucositis": "IV nutrition"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LDH",
        "B2M",
        "LP",
        "BM biopsy"
      ],
      "each_cycle": [
        "FBC",
        "LDH",
        "LP if CNS risk"
      ],
      "post_cycle": [
        "ANC nadir for dose adjustment"
      ]
    },
    "toxicityMonitoring": {
      "CNS_status": "Lumbar punctures",
      "tumor_lysis": "LDH, uric acid, electrolytes",
      "dose_escalation": "ANC nadir monitoring"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "allopurinol": "Xanthine oxidase inhibition"
    },
    "contraindications": [
      "Active infection",
      "Severe cardiac dysfunction",
      "Previous CNS bleeding"
    ],
    "version": "2.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e4baf82f-6192-4c0b-804d-a9023e977d92",
    "code": "Nivolumab",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Palliative",
    "summary": "Anti-PD-1 immunotherapy for advanced NSCLC after platinum-based chemotherapy with durable responses.",
    "eligibility": {
      "summary": [
        "Advanced NSCLC",
        "Second-line after platinum"
      ],
      "criteria": {
        "ECOG": "0-2",
        "PD-L1": "Any expression",
        "No_autoimmune_disease": "Required"
      }
    },
    "precautions": [
      "Immune-related adverse events",
      "Pneumonitis risk",
      "Endocrinopathies"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "240mg",
          "name": "Nivolumab",
          "route": "IV",
          "schedule": "Every 2 weeks"
        }
      ],
      "cycles": "Until progression or toxicity"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Thyroid function",
      "Chest imaging"
    ],
    "doseModifications": {
      "colitis": "Steroids grade 2+",
      "pneumonitis": "Permanent discontinuation grade 3+",
      "endocrinopathy": "Hormone replacement"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "CheckMate Studies"
    ],
    "cycleInfo": {
      "cycle_length": "14 days",
      "total_cycles": "Until progression",
      "administration_time": "30 minutes"
    },
    "preMedications": {
      "irAE_education": [
        "Patient symptom recognition"
      ],
      "baseline_imaging": [
        "Chest CT"
      ]
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "diarrhea": "Monitor frequency",
      "skin_reactions": "Topical steroids"
    },
    "supportiveCare": {
      "irAE_monitoring": "Patient education",
      "endocrine_support": "Hormone replacement if needed",
      "pulmonary_monitoring": "Serial imaging"
    },
    "rescueAgents": {
      "pneumonitis": "High-dose steroids",
      "thyroiditis": "Levothyroxine replacement",
      "severe_colitis": "Infliximab"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "TFTs",
        "CXR"
      ],
      "each_cycle": [
        "FBC",
        "LFTs",
        "TFTs"
      ],
      "every_6_weeks": [
        "CT chest"
      ]
    },
    "toxicityMonitoring": {
      "colitis": "Stool frequency",
      "endocrine": "Hormone levels",
      "pneumonitis": "Dyspnea assessment, chest imaging"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "immunosuppressants": "May reduce efficacy"
    },
    "contraindications": [
      "Active autoimmune disease",
      "Organ transplant",
      "Pregnancy"
    ],
    "version": "1.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f5baf82f-6192-4c0b-804d-a9023e977d93",
    "code": "Docetaxel-Cisplatin-5FU",
    "tumourGroup": "Head-Neck",
    "tumourSupergroup": "Head-Neck",
    "treatmentIntent": "Curative",
    "summary": "Intensive induction chemotherapy for locally advanced head and neck cancer with high response rates.",
    "eligibility": {
      "summary": [
        "Locally advanced HNSCC",
        "Induction chemotherapy"
      ],
      "criteria": {
        "ECOG": "0-1",
        "Stage III-IV": "Unresectable",
        "No_distant_metastases": "Required"
      }
    },
    "precautions": [
      "Severe mucositis",
      "Docetaxel fluid retention",
      "Cisplatin ototoxicity"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "75 mg/m²",
          "name": "Docetaxel",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "100 mg/m²",
          "name": "Cisplatin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "1000 mg/m²/day",
          "name": "5-Fluorouracil",
          "route": "IV",
          "schedule": "Days 1-4"
        }
      ],
      "cycles": "3 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Hearing assessment",
      "Nutritional status",
      "Performance status"
    ],
    "doseModifications": {
      "mucositis": "Reduce 5-FU 25% grade 3+",
      "nephrotoxicity": "Hold cisplatin creatinine >1.5x",
      "fluid_retention": "Dexamethasone premedication"
    },
    "referenceList": [
      "NCCN Head-Neck Guidelines",
      "TAX Studies"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "3",
      "administration_time": "4 days"
    },
    "preMedications": {
      "hydration": [
        "2L normal saline with electrolytes"
      ],
      "premedication": [
        "Dexamethasone 8mg x3 days"
      ],
      "nutritional_assessment": [
        "Baseline dietitian"
      ]
    },
    "postMedications": {
      "dysphagia": "Nutritional support",
      "mucositis": "Intensive oral care, PEG feeding",
      "neuropathy": "Gabapentin"
    },
    "supportiveCare": {
      "oral_care": "Intensive hygiene protocol",
      "swallowing_therapy": "Speech pathology",
      "nutritional_support": "PEG tube early if severe mucositis"
    },
    "rescueAgents": {
      "aspiration": "Immediate PEG",
      "nephrotoxicity": "Discontinue cisplatin",
      "severe_mucositis": "PEG tube, IV nutrition"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "Audiometry",
        "Swallowing study"
      ],
      "each_cycle": [
        "FBC",
        "U&E",
        "Oral assessment"
      ],
      "post_induction": [
        "Response assessment"
      ]
    },
    "toxicityMonitoring": {
      "mucositis": "Daily oral examination",
      "swallowing": "Weekly assessment",
      "ototoxicity": "Audiometry each cycle"
    },
    "interactions": {
      "warfarin": "Enhanced effect",
      "phenytoin": "Monitor levels"
    },
    "contraindications": [
      "Severe malnutrition",
      "Active oral infection",
      "Severe renal impairment"
    ],
    "version": "2.3",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a1caf82f-6192-4c0b-804d-a9023e977d94",
    "code": "Pemetrexed-Cisplatin",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Curative",
    "summary": "First-line chemotherapy for non-squamous NSCLC with excellent efficacy and manageable toxicity profile.",
    "eligibility": {
      "summary": [
        "Non-squamous NSCLC",
        "First-line treatment"
      ],
      "criteria": {
        "CrCl": "> 45 mL/min",
        "ECOG": "0-2",
        "Histology": "Non-squamous"
      }
    },
    "precautions": [
      "Pemetrexed requires folate/B12 supplementation",
      "Cisplatin nephrotoxicity",
      "Skin rash common"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "500 mg/m²",
          "name": "Pemetrexed",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "75 mg/m²",
          "name": "Cisplatin",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "4-6 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Vitamin B12/Folate levels",
      "Liver function tests"
    ],
    "doseModifications": {
      "skin_rash": "Dexamethasone premedication",
      "nephrotoxicity": "Hold if creatinine >1.5x",
      "vitamin_deficiency": "Mandatory supplementation"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "PARAMOUNT Study"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "4-6",
      "administration_time": "2-3 hours"
    },
    "preMedications": {
      "hydration": "1-2L normal saline",
      "skin_protection": "Dexamethasone 4mg BD x3days",
      "vitamin_supplementation": "Folic acid 400mcg daily, B12 1000mcg IM q9weeks"
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "fatigue": "Energy conservation",
      "skin_care": "Moisturizers, avoid sun"
    },
    "supportiveCare": {
      "skin_monitoring": "Rash assessment",
      "renal_protection": "Adequate hydration",
      "vitamin_monitoring": "B12/folate levels"
    },
    "rescueAgents": {
      "severe_rash": "Topical steroids, dose reduction",
      "nephrotoxicity": "Discontinue cisplatin",
      "severe_mucositis": "Treatment delay"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "B12",
        "Folate",
        "CrCl"
      ],
      "each_cycle": [
        "FBC",
        "U&E",
        "Skin assessment"
      ],
      "maintenance": "Continue pemetrexed alone"
    },
    "toxicityMonitoring": {
      "hematologic": "Weekly FBC",
      "skin_toxicity": "CTCAE grading",
      "nephrotoxicity": "Creatinine monitoring"
    },
    "interactions": {
      "NSAIDs": "Hold 2 days before pemetrexed",
      "warfarin": "Enhanced effect"
    },
    "contraindications": [
      "Squamous histology",
      "Severe renal impairment",
      "Pregnancy"
    ],
    "version": "2.2",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b2caf82f-6192-4c0b-804d-a9023e977d95",
    "code": "Rituximab-CVP",
    "tumourGroup": "Lymphoma",
    "tumourSupergroup": "Lymphoma",
    "treatmentIntent": "Palliative",
    "summary": "Rituximab with CVP for indolent B-cell lymphomas in elderly or frail patients.",
    "eligibility": {
      "summary": [
        "Indolent B-cell lymphomas",
        "Elderly or frail patients"
      ],
      "criteria": {
        "Age": "> 65 years or frail",
        "CD20": "Positive",
        "ECOG": "0-3"
      }
    },
    "precautions": [
      "Rituximab infusion reactions",
      "CVP myelosuppression",
      "Infection risk in elderly"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "375 mg/m²",
          "name": "Rituximab",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "750 mg/m²",
          "name": "Cyclophosphamide",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "1.4 mg/m² max 2mg",
          "name": "Vincristine",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "40mg/m²",
          "name": "Prednisolone",
          "route": "PO",
          "schedule": "Days 1-5"
        }
      ],
      "cycles": "6-8 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Immunoglobulin levels",
      "Performance status"
    ],
    "doseModifications": {
      "infection": "Prophylaxis if hypogammaglobulinemia",
      "neuropathy": "Reduce vincristine",
      "infusion_reactions": "Slow rituximab infusion"
    },
    "referenceList": [
      "NCCN Lymphoma Guidelines",
      "GLSG Studies"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "6-8",
      "administration_time": "4-6 hours"
    },
    "preMedications": {
      "infection_monitoring": "Regular assessment",
      "rituximab_premedication": "Paracetamol 1g, Chlorpheniramine 10mg, Hydrocortisone 100mg"
    },
    "postMedications": {
      "neuropathy": "Assess each cycle",
      "infusion_reactions": "Stop infusion, supportive care",
      "infection_prevention": "Hygiene measures"
    },
    "supportiveCare": {
      "elderly_support": "Geriatric assessment",
      "infection_prevention": "Monitor for signs",
      "immunoglobulin_monitoring": "Check levels"
    },
    "rescueAgents": {
      "severe_infection": "IV antibiotics, IVIG",
      "severe_neuropathy": "Omit vincristine",
      "severe_infusion_reaction": "Discontinue rituximab"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "Immunoglobulins",
        "Geriatric assessment"
      ],
      "each_cycle": [
        "FBC",
        "Clinical assessment"
      ],
      "post_treatment": "Immunoglobulin monitoring"
    },
    "toxicityMonitoring": {
      "infection": "Temperature, WBC monitoring",
      "neuropathy": "Clinical examination",
      "infusion_reactions": "During rituximab administration"
    },
    "interactions": {
      "warfarin": "Enhanced effect",
      "live_vaccines": "Contraindicated"
    },
    "contraindications": [
      "Active infection",
      "Severe heart failure",
      "Previous severe rituximab reaction"
    ],
    "version": "1.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f1daf82f-6192-4c0b-804d-a9023e977d99",
    "code": "Bevacizumab-FOLFOX",
    "tumourGroup": "Colorectal",
    "tumourSupergroup": "Colorectal",
    "treatmentIntent": "Palliative",
    "summary": "Anti-VEGF therapy combined with FOLFOX for metastatic colorectal cancer with improved progression-free survival.",
    "eligibility": {
      "summary": [
        "Metastatic colorectal cancer",
        "First-line with bevacizumab"
      ],
      "criteria": {
        "ECOG": "0-2",
        "RAS_status": "Wild-type or mutant",
        "No_bleeding_risk": "Required"
      }
    },
    "precautions": [
      "Bevacizumab bleeding and thrombosis risk",
      "Hypertension development",
      "Wound healing complications"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "5 mg/kg",
          "name": "Bevacizumab",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "85 mg/m²",
          "name": "Oxaliplatin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "400 mg/m²",
          "name": "Leucovorin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "400 mg/m² bolus + 2400 mg/m² infusion",
          "name": "5-Fluorouracil",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "Every 14 days until progression"
    },
    "tests": [
      "Full blood count",
      "Blood pressure",
      "Proteinuria",
      "Coagulation studies",
      "Wound assessment"
    ],
    "doseModifications": {
      "bleeding": "Discontinue bevacizumab permanently",
      "proteinuria": "Hold if >2g/24h",
      "hypertension": "Antihypertensive therapy"
    },
    "referenceList": [
      "NCCN Colorectal Guidelines",
      "TREE Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "14 days",
      "total_cycles": "Until progression",
      "administration_time": "46 hours with bevacizumab"
    },
    "preMedications": {
      "BP_monitoring": "Baseline and regular checks",
      "bleeding_assessment": "History and examination",
      "bevacizumab_infusion": "Start slow, monitor for reactions"
    },
    "postMedications": {
      "mucositis": "Oral care",
      "neuropathy": "Gabapentin for oxaliplatin",
      "hypertension": "Antihypertensive medications"
    },
    "supportiveCare": {
      "BP_management": "ACE inhibitors or ARBs preferred",
      "bleeding_prevention": "Avoid unnecessary procedures",
      "neuropathy_monitoring": "Before each cycle"
    },
    "rescueAgents": {
      "thrombosis": "Anticoagulation",
      "severe_bleeding": "Discontinue bevacizumab permanently",
      "hypertensive_crisis": "IV antihypertensives"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "BP",
        "Urine protein",
        "Coagulation"
      ],
      "each_cycle": [
        "FBC",
        "U&E",
        "BP",
        "Bleeding assessment"
      ],
      "every_4_cycles": "Proteinuria"
    },
    "toxicityMonitoring": {
      "bleeding": "Clinical assessment each visit",
      "neuropathy": "Oxaliplatin-specific scale",
      "hypertension": "BP monitoring"
    },
    "interactions": {
      "aspirin": "Caution with bleeding risk",
      "warfarin": "Increased bleeding risk"
    },
    "contraindications": [
      "Active bleeding",
      "Recent surgery <28 days",
      "Severe hypertension"
    ],
    "version": "2.4",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a2daf82f-6192-4c0b-804d-a9023e977e01",
    "code": "Cetuximab-FOLFIRI",
    "tumourGroup": "Colorectal",
    "tumourSupergroup": "Colorectal",
    "treatmentIntent": "Palliative",
    "summary": "Anti-EGFR therapy with FOLFIRI for RAS wild-type metastatic colorectal cancer.",
    "eligibility": {
      "summary": [
        "RAS wild-type metastatic CRC",
        "Second-line or first-line"
      ],
      "criteria": {
        "BRAF": "Wild-type preferred",
        "ECOG": "0-2",
        "RAS_status": "Wild-type"
      }
    },
    "precautions": [
      "Cetuximab skin reactions",
      "Infusion reactions",
      "Hypomagnesemia"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "400 mg/m² loading, then 250 mg/m²",
          "name": "Cetuximab",
          "route": "IV",
          "schedule": "Weekly"
        },
        {
          "dose": "180 mg/m²",
          "name": "Irinotecan",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "400 mg/m²",
          "name": "Leucovorin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "400 mg/m² bolus + 2400 mg/m² infusion",
          "name": "5-Fluorouracil",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "Every 14 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Magnesium levels",
      "Skin assessment",
      "RAS/BRAF status"
    ],
    "doseModifications": {
      "diarrhea": "Irinotecan dose reduction",
      "skin_toxicity": "Dose reduction for grade 3+",
      "hypomagnesemia": "Magnesium supplementation"
    },
    "referenceList": [
      "NCCN Colorectal Guidelines",
      "CRYSTAL Study",
      "FIRE-3 Study"
    ],
    "cycleInfo": {
      "cycle_length": "14 days",
      "total_cycles": "Until progression",
      "administration_time": "Weekly cetuximab + biweekly FOLFIRI"
    },
    "preMedications": {
      "skin_care": "Moisturizers, sun protection",
      "magnesium_monitoring": "Weekly levels",
      "cetuximab_premedication": "Diphenhydramine 50mg IV, Dexamethasone 8mg IV"
    },
    "postMedications": {
      "diarrhea": "Loperamide protocol",
      "skin_care": "Antibiotics for infected rash, moisturizers",
      "paronychia": "Nail care, antibiotics"
    },
    "supportiveCare": {
      "sun_protection": "SPF 30+ sunscreen",
      "skin_monitoring": "Weekly assessment",
      "magnesium_replacement": "Oral or IV supplementation"
    },
    "rescueAgents": {
      "severe_diarrhea": "IV hydration",
      "severe_skin_toxicity": "Dose reduction, topical antibiotics",
      "severe_infusion_reaction": "Discontinue cetuximab"
    },
    "monitoring": {
      "weekly": "Skin assessment, Mg levels",
      "baseline": [
        "FBC",
        "LFTs",
        "Mg",
        "RAS/BRAF testing"
      ],
      "each_cycle": [
        "FBC",
        "LFTs"
      ]
    },
    "toxicityMonitoring": {
      "skin_toxicity": "Weekly grading and photography",
      "hypomagnesemia": "Weekly magnesium levels",
      "infusion_reactions": "During cetuximab infusion"
    },
    "interactions": {
      "warfarin": "Enhanced effect",
      "live_vaccines": "Contraindicated"
    },
    "contraindications": [
      "RAS mutant tumors",
      "Previous severe skin reaction",
      "Active infection"
    ],
    "version": "2.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c4daf82f-6192-4c0b-804d-a9023e977e03",
    "code": "Ipilimumab-Nivolumab",
    "tumourGroup": "Melanoma",
    "tumourSupergroup": "Melanoma",
    "treatmentIntent": "Curative",
    "summary": "Combination immunotherapy for advanced melanoma with enhanced response rates but increased toxicity.",
    "eligibility": {
      "summary": [
        "Advanced melanoma",
        "First-line combination immunotherapy"
      ],
      "criteria": {
        "ECOG": "0-1",
        "No_active_autoimmune": "Required",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Enhanced immune-related adverse events",
      "Colitis and hepatitis risk",
      "Endocrinopathies common"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "3 mg/kg",
          "name": "Ipilimumab",
          "route": "IV",
          "schedule": "Every 3 weeks x 4"
        },
        {
          "dose": "1 mg/kg",
          "name": "Nivolumab",
          "route": "IV",
          "schedule": "Every 3 weeks x 4, then 480mg q4weeks"
        }
      ],
      "cycles": "4 cycles combination, then nivolumab maintenance"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Thyroid function",
      "Chest imaging",
      "Stool assessment"
    ],
    "doseModifications": {
      "colitis": "Steroids grade 2+",
      "hepatitis": "Hold both agents grade 2+",
      "severe_irAEs": "High-dose steroids, permanent discontinuation grade 4"
    },
    "referenceList": [
      "NCCN Melanoma Guidelines",
      "CheckMate Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days induction, then 28 days",
      "total_cycles": "4 + maintenance",
      "administration_time": "60-90 minutes"
    },
    "preMedications": {
      "irAE_education": "Comprehensive patient counseling",
      "monitoring_plan": "Frequent assessment first 12 weeks",
      "steroid_availability": "Prednisolone readily available"
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "diarrhea": "Early intervention, stool monitoring",
      "skin_reactions": "Topical steroids"
    },
    "supportiveCare": {
      "irAE_monitoring": "Weekly contact first 8 weeks",
      "endocrine_support": "Hormone replacement",
      "steroid_protocols": "Prednisolone 1-2mg/kg for grade 2+ irAEs"
    },
    "rescueAgents": {
      "colitis": "Infliximab for steroid-refractory",
      "hepatitis": "Mycophenolate if steroid-refractory",
      "grade_4_irAEs": "Permanent discontinuation, high-dose steroids"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "TFTs",
        "CXR",
        "Stool calprotectin"
      ],
      "each_cycle": "Comprehensive irAE assessment",
      "weekly_first_12_weeks": [
        "FBC",
        "LFTs",
        "TFTs"
      ]
    },
    "toxicityMonitoring": {
      "colitis": "Stool frequency and blood",
      "hepatitis": "LFT monitoring",
      "irAE_monitoring": "Weekly assessment first 12 weeks"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "immunosuppressants": "May reduce efficacy but needed for irAEs"
    },
    "contraindications": [
      "Active autoimmune disease",
      "Organ transplant",
      "Previous grade 4 irAE"
    ],
    "version": "2.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d5daf82f-6192-4c0b-804d-a9023e977e04",
    "code": "Cabazitaxel",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "Second-line chemotherapy for metastatic castration-resistant prostate cancer after docetaxel failure.",
    "eligibility": {
      "summary": [
        "mCRPC after docetaxel",
        "Second-line chemotherapy"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Neutrophil_count": "> 1.5",
        "Previous_docetaxel": "Required"
      }
    },
    "precautions": [
      "Severe neutropenia risk",
      "Diarrhea and dehydration",
      "Hypersensitivity reactions"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "25 mg/m²",
          "name": "Cabazitaxel",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "10mg daily",
          "name": "Prednisolone",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Every 21 days"
    },
    "tests": [
      "Full blood count",
      "PSA",
      "Liver function tests",
      "Performance status"
    ],
    "doseModifications": {
      "diarrhea": "Antidiarrheal agents, dose reduction",
      "neutropenia": "G-CSF support, dose reduction",
      "hypersensitivity": "Premedication protocol"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "TROPIC Study",
      "EAU Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Up to 10",
      "administration_time": "1 hour"
    },
    "preMedications": {
      "G-CSF": "Prophylactic if high risk",
      "premedication": "Antihistamine, corticosteroid, H2 antagonist",
      "diarrhea_prevention": "Patient education"
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "diarrhea": "Early loperamide, hydration",
      "neuropathy": "Gabapentin if develops"
    },
    "supportiveCare": {
      "PSA_monitoring": "Every cycle",
      "diarrhea_management": "Aggressive early intervention",
      "neutropenia_monitoring": "Weekly FBC first 2 cycles"
    },
    "rescueAgents": {
      "severe_diarrhea": "IV hydration, electrolytes",
      "febrile_neutropenia": "G-CSF, antibiotics, hospitalization",
      "severe_hypersensitivity": "Discontinue permanently"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "PSA",
        "ECOG"
      ],
      "each_cycle": [
        "FBC",
        "LFTs",
        "PSA"
      ],
      "weekly_first_2_cycles": "FBC"
    },
    "toxicityMonitoring": {
      "diarrhea": "Daily assessment first month",
      "neutropenia": "Weekly FBC monitoring",
      "PSA_response": "Serial measurements"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "CYP3A4_inhibitors": "Avoid strong inhibitors"
    },
    "contraindications": [
      "Severe liver impairment",
      "Active infection",
      "Previous severe hypersensitivity"
    ],
    "version": "1.9",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e6daf82f-6192-4c0b-804d-a9023e977e05",
    "code": "Abiraterone",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "Androgen biosynthesis inhibitor for metastatic castration-resistant prostate cancer with survival benefit.",
    "eligibility": {
      "summary": [
        "Metastatic castration-resistant prostate cancer",
        "Pre or post chemotherapy"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Castrate_testosterone": "< 1.7 nmol/L",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Mineralocorticoid excess",
      "Hypertension and hypokalemia",
      "Hepatotoxicity potential"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "1000mg daily",
          "name": "Abiraterone acetate",
          "route": "PO",
          "schedule": "Continuous"
        },
        {
          "dose": "10mg daily",
          "name": "Prednisolone",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "PSA",
      "Blood pressure",
      "Electrolytes"
    ],
    "doseModifications": {
      "hypokalemia": "Potassium supplementation",
      "hypertension": "Optimize antihypertensive therapy",
      "hepatotoxicity": "Hold if ALT >5x ULN"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "COU-AA Studies",
      "EAU Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily on empty stomach"
    },
    "preMedications": {
      "BP_monitoring": "Regular checks",
      "hepatic_monitoring": "LFTs monthly initially",
      "electrolyte_monitoring": "K, Na, glucose"
    },
    "postMedications": {
      "edema": "Diuretics if needed",
      "hypokalemia": "Potassium supplements",
      "hypertension": "ACE inhibitors or ARBs"
    },
    "supportiveCare": {
      "PSA_monitoring": "Every 4 weeks",
      "liver_protection": "Avoid hepatotoxins",
      "mineralocorticoid_monitoring": "BP and electrolytes"
    },
    "rescueAgents": {
      "severe_hypokalemia": "IV potassium replacement",
      "hypertensive_crisis": "IV antihypertensives",
      "severe_hepatotoxicity": "Permanent discontinuation"
    },
    "monitoring": {
      "monthly": [
        "LFTs",
        "BP",
        "U&E"
      ],
      "baseline": [
        "FBC",
        "LFTs",
        "PSA",
        "BP",
        "U&E"
      ],
      "every_4_weeks": "PSA"
    },
    "toxicityMonitoring": {
      "PSA_response": "Serial measurements",
      "hepatotoxicity": "LFT monitoring",
      "mineralocorticoid_excess": "BP and electrolyte monitoring"
    },
    "interactions": {
      "warfarin": "Monitor INR",
      "CYP2D6_substrates": "Potential interactions"
    },
    "contraindications": [
      "Severe liver disease",
      "Uncontrolled hypertension",
      "Severe heart failure"
    ],
    "version": "1.4",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f7daf82f-6192-4c0b-804d-a9023e977e06",
    "code": "Enzalutamide",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "Androgen receptor antagonist for metastatic castration-resistant prostate cancer with CNS penetration.",
    "eligibility": {
      "summary": [
        "Metastatic castration-resistant prostate cancer",
        "Pre or post chemotherapy"
      ],
      "criteria": {
        "ECOG": "0-2",
        "No_seizure_history": "Required",
        "Castrate_testosterone": "< 1.7 nmol/L"
      }
    },
    "precautions": [
      "Seizure risk",
      "Fatigue and cognitive effects",
      "Falls risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "160mg daily",
          "name": "Enzalutamide",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "PSA",
      "Testosterone",
      "Performance status",
      "Cognitive assessment",
      "Fall risk assessment"
    ],
    "doseModifications": {
      "seizure": "Permanent discontinuation",
      "severe_fatigue": "Dose reduction to 80mg",
      "cognitive_impairment": "Neuropsychological assessment"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "AFFIRM and PREVAIL Studies",
      "EAU Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily with or without food"
    },
    "preMedications": {
      "fall_prevention": "Assessment and counseling",
      "cognitive_baseline": "Mini-mental state exam",
      "seizure_assessment": "Baseline neurological history"
    },
    "postMedications": {
      "fatigue": "Energy conservation, dose adjustment",
      "fall_prevention": "Home safety assessment",
      "cognitive_effects": "Neuropsychological support"
    },
    "supportiveCare": {
      "PSA_monitoring": "Every 4 weeks",
      "fall_prevention": "Regular assessment",
      "neurological_monitoring": "Seizure precautions"
    },
    "rescueAgents": {
      "seizure": "Discontinue permanently, anticonvulsants",
      "severe_fatigue": "Dose reduction or interruption",
      "cognitive_decline": "Neuropsychological intervention"
    },
    "monitoring": {
      "baseline": [
        "PSA",
        "Testosterone",
        "Neurological exam",
        "Cognitive assessment"
      ],
      "every_4_weeks": "PSA",
      "every_12_weeks": "Cognitive and fall assessment"
    },
    "toxicityMonitoring": {
      "PSA_response": "Serial measurements",
      "cognitive_function": "Regular assessment",
      "seizure_monitoring": "Patient and family education"
    },
    "interactions": {
      "warfarin": "Monitor INR closely",
      "CYP2C8_substrates": "Potential interactions"
    },
    "contraindications": [
      "History of seizures",
      "Severe cognitive impairment",
      "Pregnancy"
    ],
    "version": "1.2",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a8eaf82f-6192-4c0b-804d-a9023e977e07",
    "code": "Gemcitabine-Nab-Paclitaxel",
    "tumourGroup": "Pancreatic",
    "tumourSupergroup": "Pancreatic",
    "treatmentIntent": "Palliative",
    "summary": "Nanoparticle albumin-bound paclitaxel with gemcitabine for metastatic pancreatic adenocarcinoma.",
    "eligibility": {
      "summary": [
        "Metastatic pancreatic adenocarcinoma",
        "First-line treatment"
      ],
      "criteria": {
        "ECOG": "0-1",
        "Bilirubin": "< 1.5x ULN",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Nab-paclitaxel peripheral neuropathy",
      "Gemcitabine myelosuppression",
      "Fatigue and asthenia"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "125 mg/m²",
          "name": "Nab-paclitaxel",
          "route": "IV",
          "schedule": "Days 1, 8, 15"
        },
        {
          "dose": "1000 mg/m²",
          "name": "Gemcitabine",
          "route": "IV",
          "schedule": "Days 1, 8, 15"
        }
      ],
      "cycles": "Every 28 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "CA 19-9",
      "Performance status",
      "Neuropathy assessment"
    ],
    "doseModifications": {
      "neuropathy": "Hold for grade 3+, reduce dose 25%",
      "neutropenia": "Hold if ANC <0.5",
      "thrombocytopenia": "Hold if platelets <75k"
    },
    "referenceList": [
      "NCCN Pancreatic Guidelines",
      "MPACT Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "3 days per cycle"
    },
    "preMedications": {
      "antiemetic": "Ondansetron 8mg IV",
      "nutritional_support": "Dietitian involvement",
      "neuropathy_monitoring": "Baseline assessment"
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "fatigue": "Energy conservation",
      "neuropathy": "Gabapentin or pregabalin"
    },
    "supportiveCare": {
      "tumor_markers": "CA 19-9 monitoring",
      "nutritional_support": "Pancreatic enzymes",
      "neuropathy_prevention": "Dose modifications"
    },
    "rescueAgents": {
      "severe_fatigue": "Treatment delay",
      "severe_neuropathy": "Dose reduction or discontinuation",
      "febrile_neutropenia": "G-CSF, antibiotics"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "CA19-9",
        "Neuropathy score"
      ],
      "each_cycle": [
        "FBC",
        "LFTs",
        "Neuropathy assessment"
      ],
      "every_2_cycles": "CA19-9, imaging"
    },
    "toxicityMonitoring": {
      "neuropathy": "Weekly assessment during treatment",
      "tumor_response": "CA19-9 and imaging",
      "myelosuppression": "Weekly FBC"
    },
    "interactions": {
      "warfarin": "Enhanced effect",
      "CYP2C8_substrates": "Monitor closely"
    },
    "contraindications": [
      "Severe neuropathy",
      "Severe liver dysfunction",
      "ECOG ≥ 2"
    ],
    "version": "1.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b9eaf82f-6192-4c0b-804d-a9023e977e08",
    "code": "Atezolizumab-Bevacizumab",
    "tumourGroup": "Hepatocellular",
    "tumourSupergroup": "Hepatocellular",
    "treatmentIntent": "Palliative",
    "summary": "Combination immunotherapy and anti-angiogenic therapy for advanced hepatocellular carcinoma.",
    "eligibility": {
      "summary": [
        "Advanced hepatocellular carcinoma",
        "First-line treatment"
      ],
      "criteria": {
        "ECOG": "0-1",
        "Child_Pugh": "A",
        "No_autoimmune_disease": "Required"
      }
    },
    "precautions": [
      "Immune-related adverse events",
      "Bevacizumab bleeding risk",
      "Hypertension development"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "1200mg",
          "name": "Atezolizumab",
          "route": "IV",
          "schedule": "Every 3 weeks"
        },
        {
          "dose": "15 mg/kg",
          "name": "Bevacizumab",
          "route": "IV",
          "schedule": "Every 3 weeks"
        }
      ],
      "cycles": "Until progression or toxicity"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "AFP",
      "Blood pressure",
      "Thyroid function"
    ],
    "doseModifications": {
      "irAEs": "Steroids for grade 2+",
      "bleeding": "Discontinue bevacizumab permanently",
      "hypertension": "Antihypertensive therapy"
    },
    "referenceList": [
      "NCCN HCC Guidelines",
      "IMbrave150 Study",
      "EASL Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "60-90 minutes"
    },
    "preMedications": {
      "BP_monitoring": "Baseline and regular checks",
      "irAE_education": "Patient counseling on symptoms",
      "bleeding_assessment": "History and examination"
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "hypertension": "ACE inhibitors preferred",
      "irAE_management": "Early steroid intervention"
    },
    "supportiveCare": {
      "BP_management": "Regular monitoring",
      "liver_function": "Monthly LFTs",
      "irAE_monitoring": "Weekly contact first 8 weeks"
    },
    "rescueAgents": {
      "severe_irAEs": "High-dose steroids",
      "severe_bleeding": "Discontinue bevacizumab",
      "variceal_bleeding": "Urgent endoscopy"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "AFP",
        "BP",
        "TFTs"
      ],
      "each_cycle": [
        "FBC",
        "LFTs",
        "AFP",
        "irAE assessment"
      ],
      "every_6_weeks": "Imaging"
    },
    "toxicityMonitoring": {
      "bleeding": "Clinical assessment",
      "tumor_response": "AFP and imaging",
      "irAE_monitoring": "Weekly assessment first 12 weeks"
    },
    "interactions": {
      "anticoagulants": "Increased bleeding risk",
      "immunosuppressants": "May reduce atezolizumab efficacy"
    },
    "contraindications": [
      "Active autoimmune disease",
      "Active bleeding",
      "Child-Pugh B/C"
    ],
    "version": "2.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c0eaf82f-6192-4c0b-804d-a9023e977e09",
    "code": "Erlotinib",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Palliative",
    "summary": "EGFR tyrosine kinase inhibitor for EGFR-mutated advanced NSCLC with excellent response rates.",
    "eligibility": {
      "summary": [
        "EGFR-mutated advanced NSCLC",
        "First-line targeted therapy"
      ],
      "criteria": {
        "ECOG": "0-3",
        "EGFR_mutation": "Exon 19 deletion or L858R",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Skin rash and diarrhea",
      "Interstitial lung disease",
      "Hepatotoxicity potential"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "150mg daily",
          "name": "Erlotinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "EGFR mutation status",
      "Chest imaging"
    ],
    "doseModifications": {
      "ILD": "Permanent discontinuation",
      "diarrhea": "Dose reduction, antidiarrheal agents",
      "skin_toxicity": "Dose reduction for grade 3+"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "OPTIMAL Study",
      "EURTAC Study"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily on empty stomach"
    },
    "preMedications": {
      "skin_care": "Moisturizers, sun protection",
      "ILD_monitoring": "Baseline chest imaging",
      "patient_education": "Take 1 hour before or 2 hours after food"
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "diarrhea": "Loperamide, hydration",
      "skin_care": "Topical antibiotics for infected rash"
    },
    "supportiveCare": {
      "skin_monitoring": "Weekly assessment first month",
      "tumor_monitoring": "Every 6-8 weeks",
      "pulmonary_monitoring": "Serial chest imaging"
    },
    "rescueAgents": {
      "ILD": "Discontinue permanently, steroids",
      "severe_diarrhea": "IV hydration",
      "severe_skin_toxicity": "Dose interruption, topical treatments"
    },
    "monitoring": {
      "monthly": [
        "FBC",
        "LFTs",
        "Skin assessment"
      ],
      "baseline": [
        "FBC",
        "LFTs",
        "EGFR testing",
        "CXR"
      ],
      "every_6_weeks": "CT chest"
    },
    "toxicityMonitoring": {
      "ILD": "Dyspnea assessment, chest imaging",
      "skin_toxicity": "Weekly grading first month",
      "tumor_response": "RECIST criteria"
    },
    "interactions": {
      "warfarin": "Monitor INR closely",
      "proton_pump_inhibitors": "Reduce erlotinib absorption"
    },
    "contraindications": [
      "EGFR wild-type",
      "Active ILD",
      "Severe liver disease"
    ],
    "version": "1.3",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d1eaf82f-6192-4c0b-804d-a9023e977e10",
    "code": "Osimertinib",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Palliative",
    "summary": "Third-generation EGFR TKI for T790M-positive NSCLC with CNS penetration and improved tolerability.",
    "eligibility": {
      "summary": [
        "T790M-positive NSCLC",
        "First or second-line therapy"
      ],
      "criteria": {
        "ECOG": "0-3",
        "EGFR_T790M": "Positive or treatment-naive EGFR+",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "QT prolongation risk",
      "Interstitial lung disease",
      "Cardiomyopathy potential"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "80mg daily",
          "name": "Osimertinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "ECG",
      "LVEF",
      "EGFR mutation status"
    ],
    "doseModifications": {
      "ILD": "Permanent discontinuation",
      "cardiomyopathy": "Hold if LVEF drops >10%",
      "QT_prolongation": "Hold if QTc >500ms"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "FLAURA Study",
      "AURA Studies"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily with or without food"
    },
    "preMedications": {
      "ILD_monitoring": "Baseline chest imaging",
      "cardiac_monitoring": "Baseline ECG and LVEF",
      "electrolyte_monitoring": "Mg, K, Ca"
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "ILD_symptoms": "Immediate assessment",
      "cardiac_effects": "Electrolyte correction"
    },
    "supportiveCare": {
      "cardiac_monitoring": "ECG and LVEF every 3 months",
      "pulmonary_monitoring": "Serial chest imaging",
      "electrolyte_management": "Regular monitoring"
    },
    "rescueAgents": {
      "ILD": "Discontinue permanently, steroids",
      "cardiomyopathy": "Cardio-oncology referral",
      "QT_prolongation": "Electrolyte correction, dose hold"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "ECG",
        "LVEF",
        "EGFR testing"
      ],
      "every_6_weeks": "CT chest",
      "every_3_months": [
        "ECG",
        "LVEF"
      ]
    },
    "toxicityMonitoring": {
      "ILD": "Dyspnea assessment",
      "tumor_response": "RECIST criteria",
      "cardiac_monitoring": "ECG and LVEF every 3 months"
    },
    "interactions": {
      "QT_prolonging_drugs": "Avoid concurrent use",
      "strong_CYP3A4_inducers": "May reduce efficacy"
    },
    "contraindications": [
      "Long QT syndrome",
      "Active ILD",
      "Severe cardiac dysfunction"
    ],
    "version": "1.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e2eaf82f-6192-4c0b-804d-a9023e977e11",
    "code": "Crizotinib",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Palliative",
    "summary": "ALK inhibitor for ALK-rearranged advanced NSCLC with excellent CNS activity and response rates.",
    "eligibility": {
      "summary": [
        "ALK-rearranged advanced NSCLC",
        "First-line targeted therapy"
      ],
      "criteria": {
        "ECOG": "0-2",
        "ALK_rearrangement": "Positive by FISH or IHC",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Visual disturbances",
      "Hepatotoxicity",
      "QT prolongation"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "250mg BD",
          "name": "Crizotinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "ECG",
      "ALK status",
      "Visual assessment"
    ],
    "doseModifications": {
      "hepatotoxicity": "Hold if ALT >5x ULN",
      "QT_prolongation": "Hold if QTc >500ms",
      "visual_disturbance": "Dose reduction"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "PROFILE Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Twice daily with food"
    },
    "preMedications": {
      "visual_assessment": "Baseline ophthalmology",
      "cardiac_monitoring": "Baseline ECG",
      "hepatic_monitoring": "Weekly LFTs first month"
    },
    "postMedications": {
      "edema": "Diuretics if symptomatic",
      "nausea": "Take with food",
      "visual_effects": "Usually transient, reduce dose if persistent"
    },
    "supportiveCare": {
      "liver_monitoring": "Weekly LFTs first month",
      "visual_monitoring": "Regular assessment",
      "cardiac_monitoring": "ECG monthly"
    },
    "rescueAgents": {
      "severe_edema": "Dose reduction",
      "severe_hepatotoxicity": "Permanent discontinuation",
      "severe_visual_disturbance": "Ophthalmology referral"
    },
    "monitoring": {
      "monthly": "ECG, clinical assessment",
      "baseline": [
        "FBC",
        "LFTs",
        "ECG",
        "ALK testing",
        "Visual assessment"
      ],
      "weekly_first_month": "LFTs"
    },
    "toxicityMonitoring": {
      "hepatotoxicity": "Weekly LFT monitoring first month",
      "tumor_response": "Regular imaging",
      "visual_disturbance": "Patient reporting"
    },
    "interactions": {
      "warfarin": "Monitor INR",
      "strong_CYP3A4_inhibitors": "Reduce crizotinib dose"
    },
    "contraindications": [
      "ALK-negative tumors",
      "Severe liver disease",
      "Long QT syndrome"
    ],
    "version": "1.7",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f3eaf82f-6192-4c0b-804d-a9023e977e12",
    "code": "Carboplatin-Gemcitabine-Ovarian",
    "tumourGroup": "Ovarian",
    "tumourSupergroup": "Ovarian",
    "treatmentIntent": "Curative",
    "summary": "Alternative to cisplatin-based therapy for ovarian cancer in patients with renal impairment or neuropathy.",
    "eligibility": {
      "summary": [
        "Epithelial ovarian cancer",
        "Renal impairment or neuropathy"
      ],
      "criteria": {
        "CrCl": "30-60 mL/min",
        "ECOG": "0-2",
        "Previous_platinum": "Allowed if >6 months"
      }
    },
    "precautions": [
      "Carboplatin hypersensitivity",
      "Gemcitabine thrombocytopenia",
      "Cumulative fatigue"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "AUC 4",
          "name": "Carboplatin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "1000 mg/m²",
          "name": "Gemcitabine",
          "route": "IV",
          "schedule": "Days 1 and 8"
        }
      ],
      "cycles": "6 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "CA-125",
      "Renal function",
      "Liver function tests"
    ],
    "doseModifications": {
      "hypersensitivity": "Premedication protocol",
      "renal_impairment": "Adjust carboplatin AUC",
      "thrombocytopenia": "Hold if platelets <75k"
    },
    "referenceList": [
      "NCCN Ovarian Guidelines",
      "GCIG Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "6",
      "administration_time": "2 days per cycle"
    },
    "preMedications": {
      "antiemetic": "Ondansetron 8mg IV",
      "hypersensitivity_prevention": "Diphenhydramine, dexamethasone"
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "fatigue": "Energy conservation",
      "flu_syndrome": "Paracetamol"
    },
    "supportiveCare": {
      "tumor_markers": "CA-125 every cycle",
      "renal_monitoring": "Creatinine",
      "platelet_monitoring": "Weekly FBC"
    },
    "rescueAgents": {
      "severe_fatigue": "Treatment delay",
      "severe_hypersensitivity": "Discontinue carboplatin",
      "severe_thrombocytopenia": "Platelet transfusion"
    },
    "monitoring": {
      "weekly": "FBC",
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "CA-125"
      ],
      "each_cycle": [
        "U&E",
        "CA-125"
      ]
    },
    "toxicityMonitoring": {
      "tumor_response": "CA-125 and imaging",
      "hypersensitivity": "During carboplatin infusion",
      "thrombocytopenia": "Weekly platelet monitoring"
    },
    "interactions": {
      "warfarin": "Enhanced effect",
      "live_vaccines": "Contraindicated"
    },
    "contraindications": [
      "Severe thrombocytopenia",
      "Previous severe carboplatin reaction",
      "Pregnancy"
    ],
    "version": "1.6",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b5eaf82f-6192-4c0b-804d-a9023e977e14",
    "code": "Rituximab-Bendamustine",
    "tumourGroup": "Lymphoma",
    "tumourSupergroup": "Lymphoma",
    "treatmentIntent": "Curative",
    "summary": "Rituximab with bendamustine for indolent lymphomas with excellent response rates and manageable toxicity.",
    "eligibility": {
      "summary": [
        "Indolent B-cell lymphomas",
        "First-line or relapsed"
      ],
      "criteria": {
        "CD20": "Positive",
        "ECOG": "0-3",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Bendamustine skin reactions",
      "Prolonged myelosuppression",
      "Infection risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "375 mg/m²",
          "name": "Rituximab",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "90 mg/m²",
          "name": "Bendamustine",
          "route": "IV",
          "schedule": "Days 1-2"
        }
      ],
      "cycles": "6 cycles every 28 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Immunoglobulin levels",
      "Skin assessment"
    ],
    "doseModifications": {
      "infection": "Prophylaxis if hypogammaglobulinemia",
      "skin_reactions": "Discontinue bendamustine for severe reactions",
      "prolonged_cytopenias": "Dose reduction 25%"
    },
    "referenceList": [
      "NCCN Lymphoma Guidelines",
      "StiL Study",
      "BRIGHT Study"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "6",
      "administration_time": "2 days per cycle"
    },
    "preMedications": {
      "skin_monitoring": "Baseline assessment",
      "infection_prevention": "Monitor for signs",
      "rituximab_premedication": "Standard premedication protocol"
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "skin_care": "Moisturizers, avoid sun",
      "infection_prevention": "Hygiene measures"
    },
    "supportiveCare": {
      "skin_monitoring": "Weekly assessment first 2 cycles",
      "infection_prevention": "Monitor immunoglobulins",
      "prolonged_monitoring": "FBC recovery may be delayed"
    },
    "rescueAgents": {
      "severe_infection": "IV antibiotics, IVIG",
      "prolonged_cytopenias": "Extended monitoring",
      "severe_skin_reaction": "Discontinue bendamustine"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "Immunoglobulins",
        "Skin assessment"
      ],
      "each_cycle": [
        "FBC",
        "Skin assessment"
      ],
      "post_treatment": "Extended FBC monitoring"
    },
    "toxicityMonitoring": {
      "infection": "Temperature and WBC monitoring",
      "skin_toxicity": "Weekly assessment first 2 cycles",
      "prolonged_effects": "Extended follow-up"
    },
    "interactions": {
      "warfarin": "Enhanced effect",
      "live_vaccines": "Contraindicated"
    },
    "contraindications": [
      "Severe skin disease",
      "Active infection",
      "Previous severe bendamustine reaction"
    ],
    "version": "2.2",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c6eaf82f-6192-4c0b-804d-a9023e977e15",
    "code": "Dasatinib",
    "tumourGroup": "CML",
    "tumourSupergroup": "CML",
    "treatmentIntent": "Curative",
    "summary": "Second-generation TKI for CML resistant or intolerant to imatinib with improved potency.",
    "eligibility": {
      "summary": [
        "CML resistant to imatinib",
        "Philadelphia chromosome positive"
      ],
      "criteria": {
        "QTc": "< 450ms",
        "BCR_ABL": "Positive",
        "Imatinib": "Resistant or intolerant"
      }
    },
    "precautions": [
      "Pleural effusions",
      "Myelosuppression",
      "QT prolongation"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "100mg daily",
          "name": "Dasatinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "BCR-ABL quantitative PCR",
      "ECG",
      "Chest X-ray"
    ],
    "doseModifications": {
      "QT_prolongation": "Electrolyte correction",
      "myelosuppression": "Dose interruption",
      "pleural_effusion": "Diuretics, dose reduction"
    },
    "referenceList": [
      "NCCN CML Guidelines",
      "DASISION Study",
      "ELN Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Indefinite",
      "administration_time": "Once daily with or without food"
    },
    "preMedications": {
      "cardiac_monitoring": "Baseline ECG",
      "pulmonary_monitoring": "Baseline chest X-ray",
      "electrolyte_monitoring": "Mg, K, Ca"
    },
    "postMedications": {
      "nausea": "Take with food",
      "fluid_retention": "Monitor weight",
      "pleural_effusion": "Diuretics, thoracentesis if severe"
    },
    "supportiveCare": {
      "cardiac_monitoring": "ECG every 3 months",
      "pleural_monitoring": "Regular chest X-rays",
      "molecular_monitoring": "BCR-ABL every 3 months"
    },
    "rescueAgents": {
      "cardiac_arrhythmia": "Cardiology referral",
      "severe_myelosuppression": "Treatment interruption",
      "severe_pleural_effusion": "Thoracentesis, dose reduction"
    },
    "monitoring": {
      "monthly": "FBC",
      "baseline": [
        "FBC",
        "BCR-ABL",
        "ECG",
        "CXR"
      ],
      "every_3_months": [
        "BCR-ABL",
        "ECG",
        "CXR"
      ]
    },
    "toxicityMonitoring": {
      "cardiac_effects": "ECG monitoring",
      "pleural_effusion": "Serial chest X-rays",
      "molecular_response": "BCR-ABL monitoring"
    },
    "interactions": {
      "warfarin": "Monitor INR",
      "acid_reducing_agents": "Take dasatinib 2 hours before or after"
    },
    "contraindications": [
      "Severe cardiac disease",
      "Active pleural disease",
      "Pregnancy"
    ],
    "version": "1.4",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d7eaf82f-6192-4c0b-804d-a9023e977e16",
    "code": "Nilotinib",
    "tumourGroup": "CML",
    "tumourSupergroup": "CML",
    "treatmentIntent": "Curative",
    "summary": "Second-generation TKI for CML with excellent molecular responses and specific cardiovascular monitoring.",
    "eligibility": {
      "summary": [
        "CML resistant to imatinib",
        "Newly diagnosed CML"
      ],
      "criteria": {
        "QTc": "< 450ms",
        "BCR_ABL": "Positive",
        "No_significant_cardiac_disease": "Required"
      }
    },
    "precautions": [
      "QT prolongation",
      "Cardiovascular events",
      "Hepatotoxicity"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "400mg BD",
          "name": "Nilotinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "BCR-ABL quantitative PCR",
      "ECG",
      "Liver function tests",
      "Lipid profile"
    ],
    "doseModifications": {
      "hepatotoxicity": "Hold if ALT >5x ULN",
      "QT_prolongation": "Hold if QTc >480ms",
      "cardiovascular_events": "Cardiology referral"
    },
    "referenceList": [
      "NCCN CML Guidelines",
      "ENESTnd Study",
      "ELN Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Indefinite",
      "administration_time": "Twice daily on empty stomach"
    },
    "preMedications": {
      "patient_education": "Take on empty stomach",
      "cardiac_monitoring": "Baseline ECG and lipids",
      "hepatic_monitoring": "Baseline LFTs"
    },
    "postMedications": {
      "nausea": "Manage timing with meals",
      "hepatotoxicity": "Avoid hepatotoxins",
      "cardiovascular_protection": "Lipid management"
    },
    "supportiveCare": {
      "liver_monitoring": "LFTs monthly initially",
      "cardiac_monitoring": "ECG and lipids every 3 months",
      "molecular_monitoring": "BCR-ABL every 3 months"
    },
    "rescueAgents": {
      "cardiovascular_events": "Cardiology management",
      "severe_hepatotoxicity": "Permanent discontinuation",
      "severe_QT_prolongation": "Discontinue, electrolyte correction"
    },
    "monitoring": {
      "monthly": "LFTs first 3 months",
      "baseline": [
        "FBC",
        "BCR-ABL",
        "ECG",
        "LFTs",
        "Lipids"
      ],
      "every_3_months": [
        "BCR-ABL",
        "ECG",
        "Lipids"
      ]
    },
    "toxicityMonitoring": {
      "QT_monitoring": "Regular ECG monitoring",
      "molecular_response": "BCR-ABL levels",
      "cardiovascular_risk": "Lipid and cardiovascular assessment"
    },
    "interactions": {
      "warfarin": "Monitor INR closely",
      "proton_pump_inhibitors": "Separate dosing by 2 hours"
    },
    "contraindications": [
      "Long QT syndrome",
      "Significant cardiac disease",
      "Severe liver disease"
    ],
    "version": "1.6",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e8eaf82f-6192-4c0b-804d-a9023e977e17",
    "code": "Hydroxyurea",
    "tumourGroup": "CML",
    "tumourSupergroup": "CML",
    "treatmentIntent": "Palliative",
    "summary": "Oral cytoreductive agent for CML when TKI therapy not suitable or as bridge therapy.",
    "eligibility": {
      "summary": [
        "CML cytoreduction",
        "Bridge therapy"
      ],
      "criteria": {
        "TKI_unsuitable": "Contraindicated or intolerant",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Skin hyperpigmentation",
      "Leg ulcers"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "15-30 mg/kg daily",
          "name": "Hydroxyurea",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous with dose adjustments"
    },
    "tests": [
      "Full blood count",
      "WBC differential",
      "Skin examination",
      "Renal function"
    ],
    "doseModifications": {
      "skin_ulcers": "Dose reduction or discontinuation",
      "myelosuppression": "Reduce dose if WBC <4.0",
      "renal_impairment": "Dose reduction"
    },
    "referenceList": [
      "NCCN CML Guidelines",
      "Historical Studies"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until better option available",
      "administration_time": "Daily oral"
    },
    "preMedications": {
      "dose_titration": "Based on WBC response",
      "baseline_assessment": "WBC count and skin examination"
    },
    "postMedications": {
      "nausea": "Take with food",
      "leg_care": "Regular inspection",
      "skin_care": "Moisturizers, avoid trauma"
    },
    "supportiveCare": {
      "hydration": "Adequate fluid intake",
      "WBC_monitoring": "Weekly initially then monthly",
      "skin_monitoring": "Regular examination"
    },
    "rescueAgents": {
      "leg_ulcers": "Wound care, discontinue if severe",
      "severe_anemia": "Transfusion support",
      "severe_myelosuppression": "Temporary discontinuation"
    },
    "monitoring": {
      "monthly": "FBC and clinical assessment",
      "baseline": [
        "FBC",
        "U&E",
        "Skin exam"
      ],
      "weekly_initially": "FBC"
    },
    "toxicityMonitoring": {
      "WBC_response": "Dose titration",
      "skin_toxicity": "Regular examination",
      "myelosuppression": "Weekly FBC monitoring initially"
    },
    "interactions": {
      "warfarin": "Monitor INR",
      "live_vaccines": "Avoid during treatment"
    },
    "contraindications": [
      "Severe myelosuppression",
      "Active leg ulcers",
      "Pregnancy"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f9eaf82f-6192-4c0b-804d-a9023e977e18",
    "code": "Rituximab-Chlorambucil",
    "tumourGroup": "Lymphoma",
    "tumourSupergroup": "Lymphoma",
    "treatmentIntent": "Palliative",
    "summary": "Gentle immunochemotherapy for elderly patients with CLL or indolent lymphomas.",
    "eligibility": {
      "summary": [
        "CLL in elderly",
        "Indolent lymphomas"
      ],
      "criteria": {
        "Age": "> 65 years",
        "CD20": "Positive",
        "ECOG": "0-3"
      }
    },
    "precautions": [
      "Chlorambucil myelosuppression",
      "Rituximab infusion reactions",
      "Infection risk in elderly"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "375 mg/m²",
          "name": "Rituximab",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "0.5 mg/kg",
          "name": "Chlorambucil",
          "route": "PO",
          "schedule": "Days 1-28"
        }
      ],
      "cycles": "6 cycles every 28 days"
    },
    "tests": [
      "Full blood count",
      "Immunoglobulin levels",
      "Performance status",
      "Infection assessment"
    ],
    "doseModifications": {
      "infection": "Prophylaxis if hypogammaglobulinemia",
      "myelosuppression": "Reduce chlorambucil dose 25%",
      "infusion_reactions": "Slow rituximab rate"
    },
    "referenceList": [
      "NCCN CLL Guidelines",
      "CLL8 Study"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "6",
      "administration_time": "Monthly rituximab + daily oral"
    },
    "preMedications": {
      "geriatric_assessment": "Baseline evaluation",
      "infection_monitoring": "Regular assessment",
      "rituximab_premedication": "Standard protocol"
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "fatigue": "Energy conservation",
      "infection_prevention": "Hygiene measures"
    },
    "supportiveCare": {
      "elderly_support": "Comprehensive geriatric care",
      "infection_prevention": "Monitor for signs",
      "immunoglobulin_monitoring": "Regular levels"
    },
    "rescueAgents": {
      "severe_infection": "IV antibiotics, IVIG",
      "infusion_reactions": "Discontinue rituximab",
      "severe_myelosuppression": "Dose reduction"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "Immunoglobulins",
        "Geriatric assessment"
      ],
      "each_cycle": [
        "FBC",
        "Infection assessment"
      ],
      "post_treatment": "Immunoglobulin monitoring"
    },
    "toxicityMonitoring": {
      "infection": "Clinical monitoring",
      "myelosuppression": "Monthly FBC",
      "infusion_reactions": "During rituximab"
    },
    "interactions": {
      "warfarin": "Enhanced effect",
      "live_vaccines": "Contraindicated"
    },
    "contraindications": [
      "Active infection",
      "Severe myelosuppression",
      "Previous severe rituximab reaction"
    ],
    "version": "1.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a0faf82f-6192-4c0b-804d-a9023e977e19",
    "code": "Fludarabine-Cyclophosphamide-Rituximab",
    "tumourGroup": "Lymphoma",
    "tumourSupergroup": "Lymphoma",
    "treatmentIntent": "Curative",
    "summary": "FCR regimen for CLL with excellent response rates but significant immunosuppression.",
    "eligibility": {
      "summary": [
        "CLL first-line",
        "Younger patients"
      ],
      "criteria": {
        "Age": "< 65 years",
        "CD20": "Positive",
        "ECOG": "0-2"
      }
    },
    "precautions": [
      "Profound immunosuppression",
      "Autoimmune complications",
      "Secondary malignancies"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "25 mg/m²",
          "name": "Fludarabine",
          "route": "IV",
          "schedule": "Days 1-3"
        },
        {
          "dose": "250 mg/m²",
          "name": "Cyclophosphamide",
          "route": "IV",
          "schedule": "Days 1-3"
        },
        {
          "dose": "375 mg/m²",
          "name": "Rituximab",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "6 cycles every 28 days"
    },
    "tests": [
      "Full blood count",
      "Immunoglobulin levels",
      "DAT",
      "CMV serology",
      "Performance status"
    ],
    "doseModifications": {
      "infection": "Aggressive management",
      "autoimmune_hemolysis": "Hold fludarabine",
      "severe_immunosuppression": "PCP prophylaxis"
    },
    "referenceList": [
      "NCCN CLL Guidelines",
      "CLL8 Study",
      "GCLLSG Studies"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "6",
      "administration_time": "3 days per cycle"
    },
    "preMedications": {
      "CMV_monitoring": "Regular surveillance",
      "PCP_prophylaxis": "Co-trimoxazole throughout",
      "autoimmune_screening": "Baseline DAT"
    },
    "postMedications": {
      "infection_prevention": "Aggressive hygiene",
      "prolonged_monitoring": "Extended follow-up",
      "autoimmune_monitoring": "Watch for hemolysis"
    },
    "supportiveCare": {
      "infection_prevention": "PCP prophylaxis mandatory",
      "autoimmune_monitoring": "DAT monitoring",
      "immunoglobulin_monitoring": "Regular levels"
    },
    "rescueAgents": {
      "CMV_reactivation": "Antiviral therapy",
      "severe_infection": "IV antibiotics, IVIG",
      "autoimmune_hemolysis": "Steroids, discontinue fludarabine"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "Immunoglobulins",
        "DAT",
        "CMV"
      ],
      "long_term": "Extended immunoglobulin monitoring",
      "each_cycle": [
        "FBC",
        "DAT"
      ]
    },
    "toxicityMonitoring": {
      "infection": "Aggressive surveillance",
      "immunosuppression": "Long-term monitoring",
      "autoimmune_hemolysis": "DAT monitoring"
    },
    "interactions": {
      "live_vaccines": "Contraindicated long-term",
      "nephrotoxic_drugs": "Avoid if possible"
    },
    "contraindications": [
      "Active autoimmune disease",
      "Severe infection",
      "Previous fludarabine intolerance"
    ],
    "version": "2.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b1faf82f-6192-4c0b-804d-a9023e977e20",
    "code": "Ibrutinib",
    "tumourGroup": "Lymphoma",
    "tumourSupergroup": "Lymphoma",
    "treatmentIntent": "Palliative",
    "summary": "BTK inhibitor for CLL and mantle cell lymphoma with excellent efficacy and unique toxicity profile.",
    "eligibility": {
      "summary": [
        "CLL relapsed/refractory",
        "Mantle cell lymphoma"
      ],
      "criteria": {
        "BTK": "Wild-type",
        "CD20": "Positive",
        "No_bleeding_risk": "Required"
      }
    },
    "precautions": [
      "Bleeding risk",
      "Atrial fibrillation",
      "Hypertension"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "420mg daily",
          "name": "Ibrutinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Coagulation studies",
      "ECG",
      "Blood pressure"
    ],
    "doseModifications": {
      "bleeding": "Hold for major bleeding",
      "hypertension": "Antihypertensive therapy",
      "atrial_fibrillation": "Rate control, anticoagulation"
    },
    "referenceList": [
      "NCCN CLL Guidelines",
      "RESONATE Studies",
      "PCYC Studies"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily with water"
    },
    "preMedications": {
      "BP_monitoring": "Regular checks",
      "cardiac_monitoring": "Baseline ECG",
      "bleeding_assessment": "Baseline history"
    },
    "postMedications": {
      "hypertension": "ACE inhibitors preferred",
      "cardiac_monitoring": "Regular ECG",
      "bleeding_prevention": "Avoid antiplatelet agents"
    },
    "supportiveCare": {
      "BP_management": "Regular monitoring",
      "cardiac_monitoring": "ECG every 3 months",
      "bleeding_monitoring": "Regular assessment"
    },
    "rescueAgents": {
      "tumor_lysis": "Rare but monitor",
      "major_bleeding": "Discontinue, manage bleeding",
      "atrial_fibrillation": "Cardiology referral"
    },
    "monitoring": {
      "monthly": "FBC",
      "baseline": [
        "FBC",
        "Coags",
        "ECG",
        "BP"
      ],
      "every_3_months": "ECG, BP assessment"
    },
    "toxicityMonitoring": {
      "bleeding": "Clinical assessment",
      "cardiac_rhythm": "ECG monitoring",
      "tumor_response": "Lymph node assessment"
    },
    "interactions": {
      "warfarin": "Avoid if possible",
      "strong_CYP3A4_inhibitors": "Dose reduction"
    },
    "contraindications": [
      "Active bleeding",
      "Warfarin requirement",
      "Pregnancy"
    ],
    "version": "1.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c2faf82f-6192-4c0b-804d-a9023e977e21",
    "code": "Venetoclax",
    "tumourGroup": "Lymphoma",
    "tumourSupergroup": "Lymphoma",
    "treatmentIntent": "Palliative",
    "summary": "BCL-2 inhibitor for CLL with excellent efficacy but requiring careful tumor lysis syndrome prevention.",
    "eligibility": {
      "summary": [
        "CLL relapsed/refractory",
        "High BCL-2 expression"
      ],
      "criteria": {
        "BCL2": "High expression",
        "TLS_risk": "Assessed",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Tumor lysis syndrome",
      "Myelosuppression",
      "Infection risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "Ramp-up 20mg to 400mg daily",
          "name": "Venetoclax",
          "route": "PO",
          "schedule": "Continuous with dose escalation"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "LDH",
      "Uric acid",
      "Electrolytes",
      "TLS risk assessment"
    ],
    "doseModifications": {
      "TLS": "Mandatory prevention protocol",
      "infection": "Aggressive management",
      "myelosuppression": "Dose reduction or delay"
    },
    "referenceList": [
      "NCCN CLL Guidelines",
      "MURANO Study",
      "CLL14 Study"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Daily with food"
    },
    "preMedications": {
      "ramp_up": "Slow dose escalation",
      "TLS_prevention": "Allopurinol, hydration",
      "hospitalization": "For high TLS risk"
    },
    "postMedications": {
      "nausea": "Take with food",
      "TLS_monitoring": "Electrolytes, LDH",
      "infection_prevention": "Monitor WBC"
    },
    "supportiveCare": {
      "TLS_prevention": "Mandatory protocol",
      "dose_escalation": "Careful ramp-up",
      "infection_monitoring": "Regular assessment"
    },
    "rescueAgents": {
      "TLS": "Rasburicase, dialysis if severe",
      "infection": "IV antibiotics",
      "severe_neutropenia": "G-CSF, dose reduction"
    },
    "monitoring": {
      "monthly": "FBC and biochemistry",
      "ramp_up": "Frequent monitoring first month",
      "baseline": [
        "FBC",
        "LDH",
        "Uric acid",
        "U&E",
        "TLS risk"
      ]
    },
    "toxicityMonitoring": {
      "TLS": "Weekly monitoring during ramp-up",
      "tumor_response": "Lymph node assessment",
      "myelosuppression": "Regular FBC"
    },
    "interactions": {
      "warfarin": "Monitor INR",
      "strong_CYP3A4_inhibitors": "Dose reduction"
    },
    "contraindications": [
      "High TLS risk without prevention",
      "Severe infection",
      "Pregnancy"
    ],
    "version": "2.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d3faf82f-6192-4c0b-804d-a9023e977e22",
    "code": "Panitumumab-FOLFIRI",
    "tumourGroup": "Colorectal",
    "tumourSupergroup": "Colorectal",
    "treatmentIntent": "Palliative",
    "summary": "Anti-EGFR monoclonal antibody with FOLFIRI for RAS wild-type metastatic colorectal cancer.",
    "eligibility": {
      "summary": [
        "RAS wild-type metastatic CRC",
        "Second-line therapy"
      ],
      "criteria": {
        "BRAF": "Wild-type preferred",
        "ECOG": "0-2",
        "RAS_status": "Wild-type"
      }
    },
    "precautions": [
      "Panitumumab skin reactions",
      "Hypomagnesemia",
      "Pulmonary fibrosis rare"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "6 mg/kg",
          "name": "Panitumumab",
          "route": "IV",
          "schedule": "Every 2 weeks"
        },
        {
          "dose": "180 mg/m²",
          "name": "Irinotecan",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "400 mg/m²",
          "name": "Leucovorin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "400 mg/m² bolus + 2400 mg/m² infusion",
          "name": "5-Fluorouracil",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "Every 14 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Magnesium levels",
      "Skin assessment",
      "RAS/BRAF status"
    ],
    "doseModifications": {
      "skin_toxicity": "Dose reduction for grade 3+",
      "hypomagnesemia": "Magnesium supplementation",
      "pulmonary_symptoms": "Chest imaging"
    },
    "referenceList": [
      "NCCN Colorectal Guidelines",
      "PRIME Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "14 days",
      "total_cycles": "Until progression",
      "administration_time": "Biweekly panitumumab + FOLFIRI"
    },
    "preMedications": {
      "skin_care": "Moisturizers, sun protection",
      "magnesium_monitoring": "Baseline levels",
      "pulmonary_monitoring": "Baseline chest imaging"
    },
    "postMedications": {
      "diarrhea": "Loperamide protocol",
      "skin_care": "Topical antibiotics for infected rash",
      "paronychia": "Nail care"
    },
    "supportiveCare": {
      "sun_protection": "SPF 30+ sunscreen",
      "skin_monitoring": "Weekly assessment",
      "magnesium_replacement": "Oral or IV supplementation"
    },
    "rescueAgents": {
      "severe_diarrhea": "IV hydration",
      "pulmonary_fibrosis": "Discontinue permanently",
      "severe_skin_toxicity": "Dose reduction, dermatology referral"
    },
    "monitoring": {
      "weekly": "Skin assessment, Mg levels",
      "baseline": [
        "FBC",
        "LFTs",
        "Mg",
        "RAS/BRAF testing",
        "CXR"
      ],
      "each_cycle": "FBC, LFTs"
    },
    "toxicityMonitoring": {
      "skin_toxicity": "Weekly grading and management",
      "hypomagnesemia": "Regular magnesium levels",
      "pulmonary_toxicity": "Dyspnea assessment"
    },
    "interactions": {
      "warfarin": "Enhanced effect",
      "live_vaccines": "Contraindicated"
    },
    "contraindications": [
      "RAS mutant tumors",
      "Active pulmonary fibrosis",
      "Previous severe skin reaction"
    ],
    "version": "2.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e4faf82f-6192-4c0b-804d-a9023e977e23",
    "code": "Aflibercept-FOLFIRI",
    "tumourGroup": "Colorectal",
    "tumourSupergroup": "Colorectal",
    "treatmentIntent": "Palliative",
    "summary": "Anti-VEGF fusion protein with FOLFIRI for metastatic colorectal cancer after oxaliplatin failure.",
    "eligibility": {
      "summary": [
        "Metastatic CRC after oxaliplatin",
        "Second-line therapy"
      ],
      "criteria": {
        "ECOG": "0-2",
        "No_bleeding_risk": "Required",
        "Previous_oxaliplatin": "Required"
      }
    },
    "precautions": [
      "Aflibercept bleeding and thrombosis",
      "Hypertension",
      "Proteinuria"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "4 mg/kg",
          "name": "Aflibercept",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "180 mg/m²",
          "name": "Irinotecan",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "400 mg/m²",
          "name": "Leucovorin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "400 mg/m² bolus + 2400 mg/m² infusion",
          "name": "5-Fluorouracil",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "Every 14 days"
    },
    "tests": [
      "Full blood count",
      "Blood pressure",
      "Proteinuria",
      "Liver function tests"
    ],
    "doseModifications": {
      "bleeding": "Discontinue aflibercept permanently",
      "proteinuria": "Hold if >2g/24h",
      "hypertension": "Antihypertensive therapy"
    },
    "referenceList": [
      "NCCN Colorectal Guidelines",
      "VELOUR Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "14 days",
      "total_cycles": "Until progression",
      "administration_time": "Biweekly aflibercept + FOLFIRI"
    },
    "preMedications": {
      "BP_monitoring": "Baseline and regular checks",
      "bleeding_assessment": "History and examination",
      "proteinuria_monitoring": "Urine dipstick"
    },
    "postMedications": {
      "diarrhea": "Loperamide protocol",
      "neuropathy": "Gabapentin if present",
      "hypertension": "ACE inhibitors preferred"
    },
    "supportiveCare": {
      "BP_management": "Regular monitoring",
      "bleeding_prevention": "Avoid unnecessary procedures",
      "proteinuria_monitoring": "Regular assessment"
    },
    "rescueAgents": {
      "thrombosis": "Anticoagulation",
      "severe_bleeding": "Discontinue aflibercept permanently",
      "hypertensive_crisis": "IV antihypertensives"
    },
    "monitoring": {
      "monthly": "Proteinuria",
      "baseline": [
        "FBC",
        "LFTs",
        "BP",
        "Urine protein"
      ],
      "each_cycle": [
        "FBC",
        "LFTs",
        "BP",
        "Bleeding assessment"
      ]
    },
    "toxicityMonitoring": {
      "bleeding": "Clinical assessment each visit",
      "proteinuria": "Urine protein monitoring",
      "hypertension": "BP monitoring"
    },
    "interactions": {
      "aspirin": "Caution with bleeding risk",
      "warfarin": "Increased bleeding risk"
    },
    "contraindications": [
      "Active bleeding",
      "Uncontrolled hypertension",
      "Recent surgery <28 days"
    ],
    "version": "1.9",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f5faf82f-6192-4c0b-804d-a9023e977e24",
    "code": "Regorafenib",
    "tumourGroup": "Colorectal",
    "tumourSupergroup": "Colorectal",
    "treatmentIntent": "Palliative",
    "summary": "Multi-kinase inhibitor for refractory metastatic colorectal cancer with modest survival benefit.",
    "eligibility": {
      "summary": [
        "Refractory metastatic CRC",
        "Third-line therapy"
      ],
      "criteria": {
        "ECOG": "0-1",
        "Adequate_organ_function": "Required",
        "Previous_standard_therapy": "Required"
      }
    },
    "precautions": [
      "Hand-foot skin reaction",
      "Hepatotoxicity",
      "Hypertension"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "160mg daily",
          "name": "Regorafenib",
          "route": "PO",
          "schedule": "Days 1-21 of 28-day cycle"
        }
      ],
      "cycles": "Until progression or toxicity"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Blood pressure",
      "Hand-foot assessment"
    ],
    "doseModifications": {
      "HFSR": "Dose reduction for grade 2+",
      "hypertension": "Antihypertensive therapy",
      "hepatotoxicity": "Hold if ALT >5x ULN"
    },
    "referenceList": [
      "NCCN Colorectal Guidelines",
      "CORRECT Study",
      "CONCUR Study"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "3 weeks on, 1 week off"
    },
    "preMedications": {
      "skin_care": "Moisturizers, avoid friction",
      "BP_monitoring": "Regular checks",
      "hepatic_monitoring": "Baseline LFTs"
    },
    "postMedications": {
      "HFSR": "Urea cream, dose modification",
      "fatigue": "Energy conservation",
      "hypertension": "ACE inhibitors"
    },
    "supportiveCare": {
      "BP_management": "Regular monitoring",
      "skin_monitoring": "Regular foot inspection",
      "liver_protection": "Avoid hepatotoxins"
    },
    "rescueAgents": {
      "severe_HFSR": "Dose interruption, topical care",
      "uncontrolled_HTN": "Optimize therapy",
      "severe_hepatotoxicity": "Permanent discontinuation"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "BP",
        "Skin assessment"
      ],
      "each_cycle": "FBC, LFTs, BP, HFSR assessment",
      "weekly_first_2_cycles": "LFTs"
    },
    "toxicityMonitoring": {
      "HFSR": "Weekly assessment first 2 cycles",
      "hypertension": "BP monitoring",
      "hepatotoxicity": "Regular LFT monitoring"
    },
    "interactions": {
      "warfarin": "Monitor INR closely",
      "strong_CYP3A4_inducers": "May reduce efficacy"
    },
    "contraindications": [
      "Severe liver disease",
      "Uncontrolled hypertension",
      "ECOG ≥ 2"
    ],
    "version": "1.4",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d9faf82f-6192-4c0b-804d-a9023e977e28",
    "code": "Ribociclib-Letrozole",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Palliative",
    "summary": "Ribociclib-Letrozole is a NCCN Category 1 first-line regimen for hormone receptor-positive, HER2-negative metastatic breast cancer. This CDK4/6 inhibitor combination has demonstrated overall survival benefit in the MONALEESA trials.",
    "eligibility": {
      "summary": [
        "HR-positive, HER2-negative metastatic breast cancer",
        "Postmenopausal women or premenopausal with ovarian suppression",
        "First-line endocrine therapy"
      ],
      "criteria": {
        "Age": "18+ years",
        "ECOG": "0–2",
        "Other": "Adequate organ function, normal electrolytes",
        "Cardiac": "QTcF <450 msec, no significant cardiac disease",
        "Biomarkers": "ER+ and/or PR+, HER2-negative"
      },
      "nccn_category": "1",
      "line_of_therapy": "First-line",
      "treatment_setting": "Metastatic",
      "biomarker_requirements": {
        "ER": "Positive (≥1% by IHC)",
        "PR": "Any status",
        "HER2": "Negative (IHC 0-1+ or FISH negative)"
      }
    },
    "precautions": [
      "QT prolongation",
      "Myelosuppression",
      "Hepatotoxicity"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "600mg daily",
          "name": "Ribociclib",
          "route": "PO",
          "schedule": "Days 1-21"
        },
        {
          "dose": "2.5mg daily",
          "name": "Letrozole",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Every 28 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "ECG",
      "Electrolytes",
      "Estrogen receptor status"
    ],
    "doseModifications": {
      "neutropenia": "Hold for ANC <1.0, resume with dose reduction",
      "hepatotoxicity": "Hold for grade 3+ ALT/AST elevation",
      "dose_reductions": {
        "ribociclib_level_1": "600 mg → 400 mg daily",
        "ribociclib_level_2": "400 mg → 200 mg daily"
      },
      "qt_prolongation": "Hold if QTcF >480 msec, resume when <450 msec with dose reduction",
      "alternate_options": {
        "progression": "Fulvestrant + CDK4/6 inhibitor or chemotherapy",
        "qt_concerns": "Switch to palbociclib (no QT prolongation)",
        "hepatotoxicity": "Consider abemaciclib or different CDK4/6 inhibitor"
      }
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "MONALEESA Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "21 days on, 7 days off ribociclib + continuous letrozole"
    },
    "preMedications": {
      "cardiac_monitoring": "Baseline ECG and electrolytes",
      "hepatic_monitoring": "Baseline LFTs",
      "myelosuppression_monitoring": "Baseline FBC"
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "QT_monitoring": "Electrolyte correction",
      "infection_prevention": "Neutropenia precautions"
    },
    "supportiveCare": {
      "cardiac_monitoring": "ECG days 14 and 28 of cycle 1",
      "electrolyte_management": "Mg, K correction",
      "neutropenia_monitoring": "Weekly FBC first 2 cycles"
    },
    "rescueAgents": {
      "febrile_neutropenia": "G-CSF, antibiotics",
      "severe_hepatotoxicity": "Permanent discontinuation",
      "severe_QT_prolongation": "Discontinue, electrolyte correction"
    },
    "monitoring": {
      "cycle_1": "ECG days 14, 28",
      "baseline": [
        "FBC",
        "LFTs",
        "ECG",
        "Electrolytes",
        "ER status"
      ],
      "weekly_first_2_cycles": "FBC"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "CBC with differential",
        "ECG monitoring",
        "Liver function tests",
        "Electrolyte monitoring"
      ],
      "primary_toxicities": [
        "Neutropenia",
        "QT prolongation",
        "Hepatotoxicity",
        "Fatigue",
        "Nausea",
        "Diarrhea"
      ],
      "monitoring_schedule": {
        "cycle_1": [
          "CBC days 1, 15",
          "ECG day 14"
        ],
        "ongoing": [
          "Continue monitoring throughout treatment"
        ],
        "baseline": [
          "CBC",
          "LFTs",
          "ECG",
          "Electrolytes"
        ],
        "subsequent_cycles": [
          "CBC day 1",
          "ECG every 2 cycles",
          "LFTs monthly"
        ]
      }
    },
    "interactions": {
      "QT_prolonging_drugs": "Avoid concurrent use",
      "strong_CYP3A4_inhibitors": "Reduce ribociclib dose"
    },
    "contraindications": [
      "QTcF >450 msec or history of QT prolongation",
      "Pregnancy or breastfeeding",
      "Severe hepatic impairment",
      "Concurrent QT-prolonging medications",
      "Significant cardiac arrhythmias",
      "Uncorrected hypokalemia or hypomagnesemia"
    ],
    "version": "2.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e0faf82f-6192-4c0b-804d-a9023e977e29",
    "code": "Abemaciclib-Fulvestrant",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Palliative",
    "summary": "Abemaciclib-Fulvestrant is a NCCN Category 1 regimen for hormone receptor-positive, HER2-negative metastatic breast cancer after prior endocrine therapy. This combination is effective for endocrine-resistant disease.",
    "eligibility": {
      "summary": [
        "HR-positive, HER2-negative metastatic breast cancer",
        "Prior endocrine therapy",
        "Endocrine-resistant disease"
      ],
      "criteria": {
        "Age": "18+ years",
        "ECOG": "0–2",
        "Other": "Adequate organ function",
        "Biomarkers": "ER+ and/or PR+, HER2-negative",
        "Prior_therapy": "Prior endocrine therapy (AI or tamoxifen)"
      },
      "nccn_category": "1",
      "line_of_therapy": "Second-line or later",
      "treatment_setting": "Metastatic",
      "biomarker_requirements": {
        "ER": "Positive (≥1% by IHC)",
        "PR": "Any status",
        "HER2": "Negative (IHC 0-1+ or FISH negative)"
      }
    },
    "precautions": [
      "Diarrhea",
      "Myelosuppression",
      "Venous thromboembolism"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "150mg BD",
          "name": "Abemaciclib",
          "route": "PO",
          "schedule": "Continuous"
        },
        {
          "dose": "500mg",
          "name": "Fulvestrant",
          "route": "IM",
          "schedule": "Days 1, 15, 29, then monthly"
        }
      ],
      "cycles": "Every 28 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Estrogen receptor status",
      "Performance status"
    ],
    "doseModifications": {
      "diarrhea": "Hold for grade 3+ diarrhea, resume with dose reduction and antidiarrheals",
      "fulvestrant": "Standard 500 mg IM monthly, no dose modifications typically needed",
      "neutropenia": "Hold for grade 3+ neutropenia, resume with dose reduction",
      "other_toxicity": "Hold for grade 3+ non-hematologic toxicity",
      "dose_reductions": {
        "abemaciclib_level_1": "150 mg BID → 100 mg BID",
        "abemaciclib_level_2": "100 mg BID → 50 mg BID"
      },
      "alternate_options": {
        "neutropenia": "Consider growth factor support or alternative CDK4/6 inhibitor",
        "progression": "Consider chemotherapy or other targeted agents",
        "diarrhea_intolerance": "Switch to palbociclib or ribociclib + fulvestrant"
      }
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "MONARCH Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "Continuous abemaciclib + monthly fulvestrant"
    },
    "preMedications": {
      "VTE_assessment": "Risk factors",
      "diarrhea_prevention": "Patient education",
      "myelosuppression_monitoring": "Baseline FBC"
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "diarrhea": "Early loperamide intervention",
      "VTE_prevention": "Mobilization, hydration"
    },
    "supportiveCare": {
      "VTE_prevention": "Risk assessment",
      "diarrhea_management": "Aggressive early intervention",
      "neutropenia_monitoring": "Regular FBC"
    },
    "rescueAgents": {
      "VTE": "Anticoagulation therapy",
      "severe_diarrhea": "IV hydration, dose reduction",
      "febrile_neutropenia": "G-CSF, antibiotics"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "ER status",
        "VTE risk"
      ],
      "each_cycle": "FBC, diarrhea assessment",
      "weekly_first_month": "FBC"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "CBC with differential",
        "Diarrhea assessment and management",
        "Performance status assessment",
        "Symptom monitoring"
      ],
      "primary_toxicities": [
        "Diarrhea",
        "Neutropenia",
        "Fatigue",
        "Nausea",
        "Abdominal pain",
        "Alopecia"
      ],
      "monitoring_schedule": {
        "ongoing": [
          "Continue monitoring throughout treatment"
        ],
        "baseline": [
          "CBC",
          "Comprehensive metabolic panel",
          "Performance status"
        ],
        "first_2_cycles": [
          "CBC every 2 weeks",
          "Diarrhea monitoring"
        ],
        "subsequent_cycles": [
          "CBC monthly",
          "Toxicity assessment"
        ]
      }
    },
    "interactions": {
      "warfarin": "Monitor INR closely",
      "strong_CYP3A4_inhibitors": "Reduce abemaciclib dose"
    },
    "contraindications": [
      "Pregnancy or breastfeeding",
      "Known hypersensitivity to abemaciclib or fulvestrant",
      "Severe hepatic impairment",
      "Concurrent strong CYP3A inhibitors",
      "Severe diarrhea or inflammatory bowel disease"
    ],
    "version": "1.9",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b7faf82f-6192-4c0b-804d-a9023e977e26",
    "code": "Fulvestrant",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Palliative",
    "summary": "Fulvestrant is a NCCN Category 1 selective estrogen receptor degrader for hormone receptor-positive metastatic breast cancer after prior endocrine therapy. This injection provides effective second-line endocrine treatment.",
    "eligibility": {
      "summary": [
        "HR-positive, HER2-negative metastatic breast cancer",
        "Prior endocrine therapy failure",
        "Postmenopausal women"
      ],
      "criteria": {
        "Age": "18+ years (postmenopausal)",
        "ECOG": "0–2",
        "Other": "Adequate performance status, no visceral crisis",
        "Biomarkers": "ER+ and/or PR+, HER2-negative",
        "Prior_therapy": "Prior AI or tamoxifen with progression"
      },
      "nccn_category": "1",
      "line_of_therapy": "Second-line or later",
      "treatment_setting": "Metastatic",
      "biomarker_requirements": {
        "ER": "Positive (≥1% by IHC)",
        "PR": "Any status",
        "HER2": "Negative (IHC 0-1+ or FISH negative)"
      }
    },
    "precautions": [
      "Injection site reactions",
      "Vaginal bleeding",
      "Thromboembolic events"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "500mg",
          "name": "Fulvestrant",
          "route": "IM",
          "schedule": "Days 1, 15, 29, then monthly"
        }
      ],
      "cycles": "Monthly until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Estrogen receptor status",
      "Coagulation studies"
    ],
    "doseModifications": {
      "bleeding_risk": "Consider subcutaneous administration if available",
      "dose_reductions": {
        "standard": "500 mg IM monthly, no standard dose reductions"
      },
      "alternate_options": {
        "progression": "CDK4/6 inhibitor combination or chemotherapy",
        "visceral_crisis": "Consider chemotherapy for rapid disease control",
        "injection_intolerance": "Consider oral SERDs when available (elacestrant)"
      },
      "systemic_reactions": "Hold for severe reactions, resume with premedication",
      "injection_reactions": "Local measures, consider antihistamines, continue treatment"
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "CONFIRM Study",
      "FALCON Study"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "Monthly IM injection"
    },
    "preMedications": {
      "bleeding_monitoring": "Menstrual history",
      "injection_technique": "Deep IM, rotate sites",
      "thrombosis_assessment": "Risk factors"
    },
    "postMedications": {
      "bleeding_monitoring": "Report unusual bleeding",
      "injection_site_care": "Warm compress, massage",
      "thrombosis_prevention": "Mobilization"
    },
    "supportiveCare": {
      "bleeding_evaluation": "Gynecological support",
      "thrombosis_prevention": "Risk assessment",
      "injection_site_management": "Proper technique"
    },
    "rescueAgents": {
      "thrombosis": "Anticoagulation therapy",
      "severe_bleeding": "Gynecological evaluation",
      "severe_injection_reaction": "Topical treatments, antihistamines"
    },
    "monitoring": {
      "monthly": "Clinical assessment",
      "baseline": [
        "FBC",
        "LFTs",
        "ER status",
        "Coagulation"
      ],
      "every_3_months": "FBC, LFTs"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "Injection site assessment",
        "Symptom monitoring",
        "Performance status evaluation",
        "Quality of life assessment"
      ],
      "primary_toxicities": [
        "Injection site reactions",
        "Hot flashes",
        "Fatigue",
        "Nausea",
        "Arthralgia",
        "Headache"
      ],
      "monitoring_schedule": {
        "monthly": [
          "Injection site check",
          "Toxicity assessment"
        ],
        "ongoing": [
          "Continue until progression or intolerance"
        ],
        "baseline": [
          "Performance status",
          "Symptom assessment"
        ],
        "every_3_months": [
          "Imaging for response assessment"
        ]
      }
    },
    "interactions": {
      "warfarin": "Monitor INR closely",
      "hormonal_contraceptives": "Avoid concurrent use"
    },
    "contraindications": [
      "Pregnancy or breastfeeding",
      "Known hypersensitivity to fulvestrant",
      "Bleeding disorders (relative contraindication for IM injection)",
      "Anticoagulation therapy requiring dose adjustment",
      "Premenopausal status without ovarian suppression"
    ],
    "version": "1.2",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a2faf82f-6192-4c0b-804d-a9023e977e31",
    "code": "Radium-223",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "Alpha-emitting radiopharmaceutical for bone metastases in castration-resistant prostate cancer.",
    "eligibility": {
      "summary": [
        "mCRPC with bone metastases",
        "No visceral disease"
      ],
      "criteria": {
        "Adequate_marrow": "Required",
        "Bone_metastases": "Symptomatic",
        "No_visceral_disease": "Required"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Diarrhea",
      "Radiation safety"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "50 kBq/kg",
          "name": "Radium-223 dichloride",
          "route": "IV",
          "schedule": "Every 4 weeks"
        }
      ],
      "cycles": "6 injections total"
    },
    "tests": [
      "Full blood count",
      "PSA",
      "Bone scan",
      "Alkaline phosphatase"
    ],
    "doseModifications": {
      "diarrhea": "Supportive care",
      "myelosuppression": "Delay if ANC <1.0 or platelets <50k",
      "radiation_exposure": "Safety protocols"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "ALSYMPCA Study",
      "EMA Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "6",
      "administration_time": "Single IV injection"
    },
    "preMedications": {
      "pain_assessment": "Baseline scores",
      "radiation_safety": "Nuclear medicine protocols",
      "myelosuppression_monitoring": "Baseline FBC"
    },
    "postMedications": {
      "diarrhea": "Loperamide",
      "pain_management": "Analgesics as needed",
      "radiation_precautions": "Follow nuclear medicine guidelines"
    },
    "supportiveCare": {
      "pain_monitoring": "Regular assessment",
      "radiation_safety": "Nuclear medicine protocols",
      "myelosuppression_monitoring": "Regular FBC"
    },
    "rescueAgents": {
      "severe_diarrhea": "IV hydration",
      "radiation_incident": "Nuclear medicine protocols",
      "severe_myelosuppression": "Treatment delay or discontinuation"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "PSA",
        "Bone scan",
        "ALP"
      ],
      "each_cycle": "FBC before injection",
      "post_treatment": "Bone scan, PSA"
    },
    "toxicityMonitoring": {
      "bone_pain": "Regular assessment",
      "myelosuppression": "FBC before each injection",
      "radiation_safety": "Nuclear medicine monitoring"
    },
    "interactions": {
      "bisphosphonates": "Hold during treatment",
      "calcium_supplements": "Ensure adequate intake"
    },
    "contraindications": [
      "Visceral metastases",
      "Severe myelosuppression",
      "Pregnancy/nursing"
    ],
    "version": "1.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b3faf82f-6192-4c0b-804d-a9023e977e32",
    "code": "Lutetium-177-PSMA",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "Targeted radiopharmaceutical therapy for PSMA-positive metastatic castration-resistant prostate cancer.",
    "eligibility": {
      "summary": [
        "PSMA-positive mCRPC",
        "Post-taxane and novel hormonal"
      ],
      "criteria": {
        "PSMA_positive": "68Ga-PSMA PET positive",
        "Adequate_marrow": "Required",
        "Previous_therapy": "Taxane and novel hormonal agent"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Xerostomia",
      "Radiation safety"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "7.4 GBq",
          "name": "Lutetium-177-PSMA-617",
          "route": "IV",
          "schedule": "Every 6 weeks"
        }
      ],
      "cycles": "4-6 cycles total"
    },
    "tests": [
      "Full blood count",
      "PSA",
      "PSMA PET scan",
      "Salivary gland function"
    ],
    "doseModifications": {
      "xerostomia": "Salivary gland protection",
      "myelosuppression": "Delay if severe cytopenias",
      "radiation_exposure": "Safety protocols"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "VISION Study",
      "TheraP Study"
    ],
    "cycleInfo": {
      "cycle_length": "42 days",
      "total_cycles": "4-6",
      "administration_time": "Single IV infusion"
    },
    "preMedications": {
      "radiation_safety": "Nuclear medicine protocols",
      "salivary_protection": "Ice chips during infusion",
      "myelosuppression_monitoring": "Baseline FBC"
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "xerostomia": "Artificial saliva, pilocarpine",
      "radiation_precautions": "Follow nuclear medicine guidelines"
    },
    "supportiveCare": {
      "radiation_safety": "Nuclear medicine protocols",
      "salivary_monitoring": "Regular assessment",
      "myelosuppression_monitoring": "Regular FBC"
    },
    "rescueAgents": {
      "severe_xerostomia": "Pilocarpine, artificial saliva",
      "radiation_incident": "Nuclear medicine protocols",
      "severe_myelosuppression": "Treatment delay or discontinuation"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "PSA",
        "PSMA PET",
        "Salivary function"
      ],
      "each_cycle": "FBC before infusion",
      "post_treatment": "PSA, imaging"
    },
    "toxicityMonitoring": {
      "myelosuppression": "FBC before each cycle",
      "radiation_safety": "Nuclear medicine monitoring",
      "salivary_function": "Regular assessment"
    },
    "interactions": {
      "nephrotoxic_agents": "Avoid if possible",
      "somatostatin_analogs": "May reduce uptake"
    },
    "contraindications": [
      "PSMA-negative disease",
      "Severe myelosuppression",
      "Pregnancy/nursing"
    ],
    "version": "1.3",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c4faf82f-6192-4c0b-804d-a9023e977e33",
    "code": "Olaparib-Monotherapy",
    "tumourGroup": "Ovarian",
    "tumourSupergroup": "Ovarian",
    "treatmentIntent": "Curative",
    "summary": "PARP inhibitor for BRCA-mutated ovarian cancer maintenance or treatment setting.",
    "eligibility": {
      "summary": [
        "BRCA-mutated ovarian cancer",
        "Maintenance or treatment"
      ],
      "criteria": {
        "ECOG": "0-2",
        "BRCA_mutation": "Germline or somatic",
        "Platinum_sensitive": "Required for maintenance"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Fatigue",
      "Nausea and vomiting"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "300mg BD",
          "name": "Olaparib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "BRCA mutation status",
      "CA-125",
      "Performance status"
    ],
    "doseModifications": {
      "severe_fatigue": "Dose reduction",
      "myelosuppression": "Dose reduction or interruption",
      "persistent_nausea": "Antiemetics, dose modification"
    },
    "referenceList": [
      "NCCN Ovarian Guidelines",
      "SOLO Studies",
      "Study 19"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Twice daily oral"
    },
    "preMedications": {
      "nausea_prevention": "Antiemetics PRN",
      "fatigue_assessment": "Baseline ECOG",
      "myelosuppression_monitoring": "Baseline FBC"
    },
    "postMedications": {
      "nausea": "Take with food, antiemetics",
      "fatigue": "Energy conservation techniques",
      "myelosuppression": "Infection precautions"
    },
    "supportiveCare": {
      "tumor_monitoring": "CA-125 and imaging",
      "fatigue_management": "Dose modifications",
      "myelosuppression_monitoring": "Monthly FBC"
    },
    "rescueAgents": {
      "severe_fatigue": "Dose reduction",
      "persistent_vomiting": "IV hydration",
      "severe_myelosuppression": "Treatment interruption, G-CSF"
    },
    "monitoring": {
      "monthly": "FBC",
      "baseline": [
        "FBC",
        "BRCA status",
        "CA-125",
        "ECOG"
      ],
      "each_cycle": "CA-125, clinical assessment"
    },
    "toxicityMonitoring": {
      "fatigue": "Regular assessment",
      "tumor_response": "CA-125 and imaging",
      "myelosuppression": "Monthly FBC monitoring"
    },
    "interactions": {
      "vaccines": "Live vaccines contraindicated",
      "strong_CYP3A4_inhibitors": "Reduce olaparib dose"
    },
    "contraindications": [
      "BRCA wild-type (unless HRD positive)",
      "Severe myelosuppression",
      "Pregnancy"
    ],
    "version": "1.7",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d5faf82f-6192-4c0b-804d-a9023e977e34",
    "code": "Niraparib-Monotherapy",
    "tumourGroup": "Ovarian",
    "tumourSupergroup": "Ovarian",
    "treatmentIntent": "Curative",
    "summary": "PARP inhibitor for ovarian cancer maintenance regardless of BRCA status with individualized dosing.",
    "eligibility": {
      "summary": [
        "Ovarian cancer maintenance",
        "BRCA mutated or HRD positive"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Platinum_sensitive": "Required",
        "Complete_or_partial_response": "To platinum"
      }
    },
    "precautions": [
      "Thrombocytopenia",
      "Neutropenia",
      "Hypertension"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "200-300mg daily",
          "name": "Niraparib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Blood pressure",
      "HRD status",
      "CA-125"
    ],
    "doseModifications": {
      "neutropenia": "Dose reduction or interruption",
      "hypertension": "Antihypertensive therapy",
      "thrombocytopenia": "Dose reduction if platelets <100k"
    },
    "referenceList": [
      "NCCN Ovarian Guidelines",
      "NOVA Study",
      "PRIMA Study"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily oral"
    },
    "preMedications": {
      "BP_monitoring": "Baseline and regular checks",
      "individualized_dosing": "Based on weight and platelets",
      "myelosuppression_monitoring": "Weekly FBC first month"
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "hypertension": "ACE inhibitors preferred",
      "myelosuppression": "Monitor counts, dose adjust"
    },
    "supportiveCare": {
      "BP_management": "Regular monitoring",
      "tumor_monitoring": "CA-125 and imaging",
      "myelosuppression_monitoring": "Weekly FBC first month"
    },
    "rescueAgents": {
      "severe_neutropenia": "G-CSF, dose reduction",
      "hypertensive_crisis": "IV antihypertensives",
      "severe_thrombocytopenia": "Dose interruption, platelet transfusion"
    },
    "monitoring": {
      "monthly": "FBC, BP",
      "baseline": [
        "FBC",
        "BP",
        "HRD status",
        "CA-125"
      ],
      "weekly_first_month": "FBC"
    },
    "toxicityMonitoring": {
      "hypertension": "Regular BP monitoring",
      "tumor_response": "CA-125 and imaging",
      "myelosuppression": "Weekly FBC first month"
    },
    "interactions": {
      "antihypertensives": "Monitor BP closely",
      "strong_CYP3A4_inhibitors": "Monitor for increased toxicity"
    },
    "contraindications": [
      "Severe myelosuppression",
      "Uncontrolled hypertension",
      "Pregnancy"
    ],
    "version": "1.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e6faf82f-6192-4c0b-804d-a9023e977e35",
    "code": "Pembrolizumab-Carboplatin-Paclitaxel",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Curative",
    "summary": "Immunotherapy combined with chemotherapy for advanced NSCLC first-line treatment with improved survival.",
    "eligibility": {
      "summary": [
        "Advanced NSCLC",
        "First-line immunochemotherapy"
      ],
      "criteria": {
        "ECOG": "0-1",
        "PD-L1": "Any expression",
        "No_EGFR_ALK": "Wild-type required"
      }
    },
    "precautions": [
      "Enhanced immune-related adverse events",
      "Chemotherapy toxicity",
      "Pneumonitis risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "200mg",
          "name": "Pembrolizumab",
          "route": "IV",
          "schedule": "Every 3 weeks"
        },
        {
          "dose": "AUC 5-6",
          "name": "Carboplatin",
          "route": "IV",
          "schedule": "Day 1 cycles 1-4"
        },
        {
          "dose": "200 mg/m²",
          "name": "Paclitaxel",
          "route": "IV",
          "schedule": "Day 1 cycles 1-4"
        }
      ],
      "cycles": "4 cycles chemotherapy + pembrolizumab maintenance"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Thyroid function",
      "Chest imaging",
      "PD-L1 status"
    ],
    "doseModifications": {
      "irAEs": "Hold pembrolizumab grade 2+",
      "neuropathy": "Reduce paclitaxel 25%",
      "pneumonitis": "Permanent discontinuation pembrolizumab"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "KEYNOTE Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "4 + maintenance",
      "administration_time": "4-6 hours"
    },
    "preMedications": {
      "irAE_education": "Comprehensive patient counseling",
      "pneumonitis_monitoring": "Baseline chest imaging",
      "hypersensitivity_prevention": "Paclitaxel premedication"
    },
    "postMedications": {
      "neuropathy": "Gabapentin if symptomatic",
      "pneumonitis": "Report dyspnea immediately",
      "irAE_monitoring": "Weekly contact first 8 weeks"
    },
    "supportiveCare": {
      "irAE_monitoring": "Weekly contact first 12 weeks",
      "pulmonary_monitoring": "Serial chest imaging",
      "neuropathy_prevention": "Dose modifications"
    },
    "rescueAgents": {
      "pneumonitis": "High-dose steroids, permanent discontinuation",
      "grade_4_irAEs": "Permanent discontinuation, high-dose steroids",
      "severe_neuropathy": "Paclitaxel discontinuation"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "TFTs",
        "CXR",
        "PD-L1"
      ],
      "each_cycle": "FBC, LFTs, TFTs",
      "weekly_first_12_weeks": "irAE assessment"
    },
    "toxicityMonitoring": {
      "neuropathy": "Clinical grading",
      "pneumonitis": "Dyspnea assessment, chest imaging",
      "irAE_monitoring": "Weekly assessment first 12 weeks"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "immunosuppressants": "May reduce pembrolizumab efficacy"
    },
    "contraindications": [
      "EGFR/ALK positive",
      "Active autoimmune disease",
      "Organ transplant"
    ],
    "version": "2.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f7faf82f-6192-4c0b-804d-a9023e977e36",
    "code": "Alectinib",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Palliative",
    "summary": "Second-generation ALK inhibitor for ALK-rearranged NSCLC with excellent CNS activity and tolerability.",
    "eligibility": {
      "summary": [
        "ALK-rearranged NSCLC",
        "First or second-line"
      ],
      "criteria": {
        "ECOG": "0-2",
        "ALK_rearrangement": "Positive",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Elevated CPK",
      "Bradycardia",
      "Photosensitivity"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "600mg BD",
          "name": "Alectinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "CPK",
      "ECG",
      "ALK status"
    ],
    "doseModifications": {
      "bradycardia": "Monitor heart rate",
      "elevated_CPK": "Hold if >5x ULN",
      "photosensitivity": "Sun protection"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "ALEX Study",
      "J-ALEX Study"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Twice daily with food"
    },
    "preMedications": {
      "sun_protection": "Patient education",
      "muscle_monitoring": "Baseline CPK",
      "cardiac_monitoring": "Baseline ECG"
    },
    "postMedications": {
      "bradycardia": "Monitor heart rate",
      "muscle_pain": "Monitor for myalgia",
      "photosensitivity": "SPF 30+ sunscreen, protective clothing"
    },
    "supportiveCare": {
      "sun_protection": "Ongoing education",
      "muscle_monitoring": "CPK every 2 weeks first 3 months",
      "cardiac_monitoring": "ECG monthly"
    },
    "rescueAgents": {
      "severe_CPK_elevation": "Discontinue until normalized",
      "severe_photosensitivity": "Dose reduction",
      "symptomatic_bradycardia": "Cardiology referral"
    },
    "monitoring": {
      "monthly": "FBC, LFTs, ECG",
      "baseline": [
        "FBC",
        "LFTs",
        "CPK",
        "ECG",
        "ALK testing"
      ],
      "every_2_weeks_first_3_months": "CPK"
    },
    "toxicityMonitoring": {
      "tumor_response": "Regular imaging",
      "cardiac_effects": "Heart rate monitoring",
      "muscle_toxicity": "CPK monitoring, myalgia assessment"
    },
    "interactions": {
      "strong_CYP3A4_inducers": "May reduce efficacy",
      "bradycardia_medications": "Monitor heart rate"
    },
    "contraindications": [
      "ALK-negative tumors",
      "Severe bradycardia",
      "Pregnancy"
    ],
    "version": "1.4",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a8faf82f-6192-4c0b-804d-a9023e977e37",
    "code": "Ceritinib",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Palliative",
    "summary": "Second-generation ALK inhibitor for ALK-rearranged NSCLC with activity against crizotinib-resistant mutations.",
    "eligibility": {
      "summary": [
        "ALK-rearranged NSCLC",
        "Crizotinib-resistant"
      ],
      "criteria": {
        "ECOG": "0-2",
        "ALK_rearrangement": "Positive",
        "Previous_crizotinib": "Allowed"
      }
    },
    "precautions": [
      "Gastrointestinal toxicity",
      "Hepatotoxicity",
      "Hyperglycemia"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "450mg daily",
          "name": "Ceritinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Blood glucose",
      "Lipase",
      "ALK status"
    ],
    "doseModifications": {
      "GI_toxicity": "Dose reduction for grade 3+",
      "hyperglycemia": "Diabetes management",
      "hepatotoxicity": "Hold if ALT >5x ULN"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "ASCEND Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily on empty stomach"
    },
    "preMedications": {
      "GI_monitoring": "Baseline assessment",
      "hepatic_monitoring": "Baseline LFTs",
      "metabolic_monitoring": "Glucose, lipase"
    },
    "postMedications": {
      "GI_toxicity": "Take on empty stomach, antiemetics",
      "hyperglycemia": "Monitor blood sugar",
      "hepatotoxicity": "Avoid hepatotoxins"
    },
    "supportiveCare": {
      "GI_monitoring": "Weekly assessment first month",
      "liver_monitoring": "LFTs every 2 weeks first 2 months",
      "metabolic_monitoring": "Regular glucose, lipase"
    },
    "rescueAgents": {
      "severe_GI_toxicity": "Dose reduction, supportive care",
      "severe_hyperglycemia": "Insulin therapy",
      "severe_hepatotoxicity": "Permanent discontinuation"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "Glucose",
        "Lipase",
        "ALK testing"
      ],
      "weekly_first_month": "GI assessment",
      "every_2_weeks_first_2_months": "LFTs"
    },
    "toxicityMonitoring": {
      "metabolic": "Glucose and lipase monitoring",
      "GI_toxicity": "Weekly assessment first month",
      "hepatotoxicity": "LFT monitoring"
    },
    "interactions": {
      "proton_pump_inhibitors": "May reduce absorption",
      "strong_CYP3A4_inhibitors": "Reduce ceritinib dose"
    },
    "contraindications": [
      "ALK-negative tumors",
      "Severe liver disease",
      "Severe GI disease"
    ],
    "version": "1.6",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b9faf82f-6192-4c0b-804d-a9023e977e38",
    "code": "Lorlatinib",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Palliative",
    "summary": "Third-generation ALK inhibitor for ALK-rearranged NSCLC with excellent CNS penetration and activity against resistance mutations.",
    "eligibility": {
      "summary": [
        "ALK-rearranged NSCLC",
        "Previous ALK inhibitor failure"
      ],
      "criteria": {
        "ECOG": "0-2",
        "ALK_rearrangement": "Positive",
        "Previous_ALK_inhibitor": "Crizotinib or second-generation"
      }
    },
    "precautions": [
      "CNS effects",
      "Hyperlipidemia",
      "Edema"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "100mg daily",
          "name": "Lorlatinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Lipid profile",
      "Neurological assessment",
      "ALK status"
    ],
    "doseModifications": {
      "edema": "Diuretics if symptomatic",
      "CNS_effects": "Dose reduction for cognitive effects",
      "hyperlipidemia": "Lipid-lowering therapy"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "CROWN Study",
      "B7461001 Study"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily with or without food"
    },
    "preMedications": {
      "edema_assessment": "Baseline weight",
      "lipid_monitoring": "Baseline lipid profile",
      "neurological_monitoring": "Baseline cognitive assessment"
    },
    "postMedications": {
      "edema": "Monitor weight, diuretics",
      "CNS_effects": "Monitor mood and cognition",
      "hyperlipidemia": "Dietary modification, statins"
    },
    "supportiveCare": {
      "edema_monitoring": "Weekly weight first month",
      "lipid_monitoring": "Lipid profile monthly first 3 months",
      "neurological_monitoring": "Monthly cognitive assessment"
    },
    "rescueAgents": {
      "severe_edema": "Diuretics, dose reduction",
      "severe_CNS_effects": "Dose reduction or discontinuation",
      "severe_hyperlipidemia": "Aggressive lipid-lowering therapy"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "Lipids",
        "Cognitive assessment",
        "ALK testing"
      ],
      "weekly_first_month": "Weight",
      "monthly_first_3_months": "Lipids, cognitive assessment"
    },
    "toxicityMonitoring": {
      "edema": "Weight monitoring",
      "CNS_effects": "Monthly cognitive and mood assessment",
      "hyperlipidemia": "Regular lipid monitoring"
    },
    "interactions": {
      "statin_interactions": "Monitor for myopathy",
      "strong_CYP3A4_inducers": "May reduce efficacy"
    },
    "contraindications": [
      "ALK-negative tumors",
      "Severe psychiatric disease",
      "Pregnancy"
    ],
    "version": "1.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c0faf82f-6192-4c0b-804d-a9023e977e39",
    "code": "Brigatinib",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Palliative",
    "summary": "Second-generation ALK inhibitor for ALK-rearranged NSCLC with unique safety profile requiring dose escalation.",
    "eligibility": {
      "summary": [
        "ALK-rearranged NSCLC",
        "Crizotinib-resistant"
      ],
      "criteria": {
        "ECOG": "0-2",
        "ALK_rearrangement": "Positive",
        "Previous_crizotinib": "Allowed"
      }
    },
    "precautions": [
      "Pneumonitis",
      "Hypertension",
      "CPK elevation"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "90mg daily x 7 days, then 180mg daily",
          "name": "Brigatinib",
          "route": "PO",
          "schedule": "Continuous with dose escalation"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Blood pressure",
      "CPK",
      "Chest imaging"
    ],
    "doseModifications": {
      "pneumonitis": "Permanent discontinuation grade 3+",
      "hypertension": "Antihypertensive therapy",
      "CPK_elevation": "Hold if >5x ULN"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "ALTA Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily with food"
    },
    "preMedications": {
      "BP_monitoring": "Baseline and regular checks",
      "muscle_monitoring": "Baseline CPK",
      "pulmonary_monitoring": "Baseline chest imaging"
    },
    "postMedications": {
      "muscle_pain": "Monitor for myalgia",
      "pneumonitis": "Report dyspnea immediately",
      "hypertension": "ACE inhibitors preferred"
    },
    "supportiveCare": {
      "BP_monitoring": "Weekly first month",
      "muscle_monitoring": "CPK every 2 weeks first 3 months",
      "pulmonary_monitoring": "Weekly assessment first month"
    },
    "rescueAgents": {
      "pneumonitis": "Discontinue permanently, high-dose steroids",
      "severe_hypertension": "IV antihypertensives",
      "severe_CPK_elevation": "Discontinue until normalized"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "BP",
        "CPK",
        "CXR"
      ],
      "weekly_first_month": "Pulmonary and BP assessment",
      "every_2_weeks_first_3_months": "CPK"
    },
    "toxicityMonitoring": {
      "pneumonitis": "Weekly assessment first month",
      "hypertension": "BP monitoring",
      "muscle_toxicity": "CPK monitoring"
    },
    "interactions": {
      "CYP3A4_inducers": "May reduce efficacy",
      "strong_CYP3A4_inhibitors": "Reduce brigatinib dose"
    },
    "contraindications": [
      "ALK-negative tumors",
      "Active pneumonitis",
      "Severe hypertension"
    ],
    "version": "1.7",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d1faf82f-6192-4c0b-804d-a9023e977e40",
    "code": "Afatinib",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Palliative",
    "summary": "Irreversible EGFR inhibitor for EGFR-mutated NSCLC with activity against uncommon mutations.",
    "eligibility": {
      "summary": [
        "EGFR-mutated NSCLC",
        "Uncommon EGFR mutations"
      ],
      "criteria": {
        "ECOG": "0-2",
        "EGFR_mutation": "Exon 19 del, L858R, or uncommon",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Severe diarrhea",
      "Skin toxicity",
      "Paronychia"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "40mg daily",
          "name": "Afatinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "EGFR mutation status",
      "Skin assessment"
    ],
    "doseModifications": {
      "diarrhea": "Dose reduction for grade 2+",
      "paronychia": "Topical antibiotics, dose modification",
      "skin_toxicity": "Dose reduction for grade 3+"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "LUX-Lung Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily on empty stomach"
    },
    "preMedications": {
      "skin_care": "Moisturizers, sun protection",
      "GI_monitoring": "Baseline assessment",
      "diarrhea_prevention": "Patient education"
    },
    "postMedications": {
      "diarrhea": "Early loperamide intervention",
      "skin_care": "Topical antibiotics for infected lesions",
      "paronychia": "Nail care, antibiotics"
    },
    "supportiveCare": {
      "nail_care": "Regular inspection",
      "skin_monitoring": "Weekly assessment first month",
      "diarrhea_management": "Aggressive early intervention"
    },
    "rescueAgents": {
      "severe_diarrhea": "IV hydration, dose reduction",
      "severe_paronychia": "Systemic antibiotics",
      "severe_skin_toxicity": "Dermatology referral"
    },
    "monitoring": {
      "monthly": "FBC, LFTs",
      "baseline": [
        "FBC",
        "LFTs",
        "EGFR testing",
        "Skin assessment"
      ],
      "weekly_first_month": "Skin and GI assessment"
    },
    "toxicityMonitoring": {
      "diarrhea": "Daily assessment first month",
      "paronychia": "Regular nail examination",
      "skin_toxicity": "Weekly grading first month"
    },
    "interactions": {
      "warfarin": "Monitor INR",
      "acid_reducing_agents": "Take afatinib 3 hours after"
    },
    "contraindications": [
      "EGFR wild-type",
      "Severe diarrhea",
      "Severe skin disease"
    ],
    "version": "1.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e2faf82f-6192-4c0b-804d-a9023e977e41",
    "code": "Dacomitinib",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Palliative",
    "summary": "Second-generation irreversible EGFR inhibitor for EGFR-mutated NSCLC with survival benefit.",
    "eligibility": {
      "summary": [
        "EGFR-mutated NSCLC",
        "First-line therapy"
      ],
      "criteria": {
        "ECOG": "0-1",
        "EGFR_mutation": "Exon 19 deletion or L858R",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Severe diarrhea",
      "Skin and nail toxicity",
      "ILD risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "45mg daily",
          "name": "Dacomitinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "EGFR mutation status",
      "Chest imaging"
    ],
    "doseModifications": {
      "ILD": "Permanent discontinuation",
      "diarrhea": "Dose reduction for grade 2+",
      "skin_toxicity": "Dose reduction for grade 3+"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "ARCHER 1050 Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily with food"
    },
    "preMedications": {
      "skin_care": "Moisturizers, sun protection",
      "GI_monitoring": "Baseline assessment",
      "ILD_monitoring": "Baseline chest imaging"
    },
    "postMedications": {
      "diarrhea": "Early antidiarrheal intervention",
      "skin_care": "Topical treatments for rash",
      "ILD_symptoms": "Report dyspnea immediately"
    },
    "supportiveCare": {
      "skin_monitoring": "Weekly assessment first month",
      "diarrhea_management": "Aggressive early management",
      "pulmonary_monitoring": "Serial chest imaging"
    },
    "rescueAgents": {
      "ILD": "Discontinue permanently, steroids",
      "severe_diarrhea": "IV hydration, dose reduction",
      "severe_skin_toxicity": "Dermatology referral"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "EGFR testing",
        "CXR"
      ],
      "every_3_months": "CXR",
      "weekly_first_month": "GI and skin assessment"
    },
    "toxicityMonitoring": {
      "ILD": "Dyspnea assessment, chest imaging",
      "diarrhea": "Daily assessment first month",
      "skin_toxicity": "Weekly grading"
    },
    "interactions": {
      "proton_pump_inhibitors": "Take dacomitinib with food",
      "strong_CYP2D6_inhibitors": "Monitor for increased toxicity"
    },
    "contraindications": [
      "EGFR wild-type",
      "Active ILD",
      "Severe GI disease"
    ],
    "version": "1.3",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f3faf82f-6192-4c0b-804d-a9023e977e42",
    "code": "Gefitinib",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Palliative",
    "summary": "First-generation EGFR inhibitor for EGFR-mutated NSCLC with favorable toxicity profile.",
    "eligibility": {
      "summary": [
        "EGFR-mutated NSCLC",
        "First-line or second-line"
      ],
      "criteria": {
        "ECOG": "0-3",
        "EGFR_mutation": "Activating mutations",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Skin rash",
      "Diarrhea",
      "ILD rare but serious"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "250mg daily",
          "name": "Gefitinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "EGFR mutation status",
      "Chest imaging"
    ],
    "doseModifications": {
      "ILD": "Permanent discontinuation",
      "diarrhea": "Dose reduction",
      "skin_toxicity": "Dose interruption for grade 3+"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "IPASS Study",
      "NEJ002 Study"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily with or without food"
    },
    "preMedications": {
      "skin_care": "Moisturizers, sun protection",
      "GI_monitoring": "Baseline assessment",
      "ILD_monitoring": "Baseline chest imaging"
    },
    "postMedications": {
      "diarrhea": "Loperamide",
      "skin_care": "Topical antibiotics for infected rash",
      "ILD_symptoms": "Report dyspnea immediately"
    },
    "supportiveCare": {
      "GI_monitoring": "Regular assessment",
      "skin_monitoring": "Weekly assessment first month",
      "pulmonary_monitoring": "Serial chest imaging"
    },
    "rescueAgents": {
      "ILD": "Discontinue permanently, steroids",
      "severe_diarrhea": "IV hydration",
      "severe_skin_toxicity": "Dose interruption, dermatology referral"
    },
    "monitoring": {
      "monthly": "FBC, LFTs",
      "baseline": [
        "FBC",
        "LFTs",
        "EGFR testing",
        "CXR"
      ],
      "weekly_first_month": "Skin assessment"
    },
    "toxicityMonitoring": {
      "ILD": "Dyspnea assessment",
      "skin_toxicity": "Weekly grading first month",
      "tumor_response": "Regular imaging"
    },
    "interactions": {
      "warfarin": "Monitor INR closely",
      "proton_pump_inhibitors": "May reduce absorption"
    },
    "contraindications": [
      "EGFR wild-type",
      "Active ILD",
      "Pregnancy"
    ],
    "version": "1.2",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a4faf82f-6192-4c0b-804d-a9023e977e43",
    "code": "Trabectedin",
    "tumourGroup": "Sarcoma",
    "tumourSupergroup": "Sarcoma",
    "treatmentIntent": "Palliative",
    "summary": "Marine-derived alkaloid for advanced soft tissue sarcoma after anthracycline failure.",
    "eligibility": {
      "summary": [
        "Advanced soft tissue sarcoma",
        "Post-anthracycline"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Previous_anthracycline": "Required",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Hepatotoxicity",
      "Myelosuppression",
      "Capillary leak syndrome"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "1.5 mg/m²",
          "name": "Trabectedin",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "Every 21 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Albumin",
      "Performance status"
    ],
    "doseModifications": {
      "capillary_leak": "Monitor albumin, edema",
      "hepatotoxicity": "Hold if ALT >2.5x ULN",
      "myelosuppression": "Dose reduction 25%"
    },
    "referenceList": [
      "NCCN Sarcoma Guidelines",
      "ET743 Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "24-hour infusion"
    },
    "preMedications": {
      "central_line": "Required for administration",
      "hepatic_monitoring": "Weekly LFTs first 2 cycles",
      "capillary_leak_monitoring": "Baseline albumin"
    },
    "postMedications": {
      "edema": "Monitor weight, albumin",
      "hepatotoxicity": "Avoid hepatotoxins",
      "myelosuppression": "Infection precautions"
    },
    "supportiveCare": {
      "hepatic_protection": "Weekly LFTs first 2 cycles",
      "capillary_leak_monitoring": "Albumin, weight",
      "myelosuppression_monitoring": "Weekly FBC"
    },
    "rescueAgents": {
      "capillary_leak": "IV albumin, diuretics",
      "febrile_neutropenia": "G-CSF, antibiotics",
      "severe_hepatotoxicity": "Permanent discontinuation"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "Albumin",
        "ECOG"
      ],
      "each_cycle": "FBC, LFTs, albumin",
      "weekly_first_2_cycles": "FBC, LFTs"
    },
    "toxicityMonitoring": {
      "capillary_leak": "Albumin and weight monitoring",
      "hepatotoxicity": "Weekly LFT monitoring first 2 cycles",
      "myelosuppression": "Weekly FBC"
    },
    "interactions": {
      "phenytoin": "May reduce efficacy",
      "strong_CYP3A4_inhibitors": "Avoid concurrent use"
    },
    "contraindications": [
      "Severe liver disease",
      "Severe myelosuppression",
      "Pregnancy"
    ],
    "version": "1.9",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b5faf82f-6192-4c0b-804d-a9023e977e44",
    "code": "Pazopanib",
    "tumourGroup": "Sarcoma",
    "tumourSupergroup": "Sarcoma",
    "treatmentIntent": "Palliative",
    "summary": "Multi-kinase inhibitor for advanced soft tissue sarcoma with anti-angiogenic activity.",
    "eligibility": {
      "summary": [
        "Advanced soft tissue sarcoma",
        "GIST after imatinib failure"
      ],
      "criteria": {
        "ECOG": "0-2",
        "No_brain_metastases": "Or treated and stable",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Hepatotoxicity",
      "Hypertension",
      "Diarrhea"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "800mg daily",
          "name": "Pazopanib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Blood pressure",
      "Thyroid function"
    ],
    "doseModifications": {
      "diarrhea": "Dose reduction",
      "hypertension": "Antihypertensive therapy",
      "hepatotoxicity": "Hold if ALT >3x ULN"
    },
    "referenceList": [
      "NCCN Sarcoma Guidelines",
      "PALETTE Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily on empty stomach"
    },
    "preMedications": {
      "BP_monitoring": "Regular checks",
      "GI_monitoring": "Baseline assessment",
      "hepatic_monitoring": "Weekly LFTs first month"
    },
    "postMedications": {
      "diarrhea": "Loperamide, hydration",
      "hypertension": "ACE inhibitors preferred",
      "hepatotoxicity": "Avoid hepatotoxins"
    },
    "supportiveCare": {
      "GI_support": "Antidiarrheal agents",
      "BP_management": "Regular monitoring",
      "liver_protection": "Weekly LFTs first month"
    },
    "rescueAgents": {
      "severe_diarrhea": "IV hydration, dose reduction",
      "hypertensive_crisis": "IV antihypertensives",
      "severe_hepatotoxicity": "Permanent discontinuation"
    },
    "monitoring": {
      "monthly": "FBC, LFTs, BP",
      "baseline": [
        "FBC",
        "LFTs",
        "BP",
        "TFTs"
      ],
      "weekly_first_month": "LFTs"
    },
    "toxicityMonitoring": {
      "hypertension": "BP monitoring",
      "hepatotoxicity": "Weekly LFT monitoring first month",
      "tumor_response": "Regular imaging"
    },
    "interactions": {
      "proton_pump_inhibitors": "Take pazopanib without food",
      "strong_CYP3A4_inhibitors": "Reduce pazopanib dose"
    },
    "contraindications": [
      "Severe liver disease",
      "Uncontrolled hypertension",
      "Recent GI bleeding"
    ],
    "version": "1.6",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c6faf82f-6192-4c0b-804d-a9023e977e45",
    "code": "Olaratumab-Doxorubicin",
    "tumourGroup": "Sarcoma",
    "tumourSupergroup": "Sarcoma",
    "treatmentIntent": "Curative",
    "summary": "Anti-PDGFR-alpha monoclonal antibody with doxorubicin for advanced soft tissue sarcoma.",
    "eligibility": {
      "summary": [
        "Advanced soft tissue sarcoma",
        "First-line treatment"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Histology": "Not GIST, Ewing, or chondrosarcoma",
        "Normal_cardiac_function": "Required"
      }
    },
    "precautions": [
      "Olaratumab infusion reactions",
      "Doxorubicin cardiotoxicity",
      "Myelosuppression"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "15 mg/kg",
          "name": "Olaratumab",
          "route": "IV",
          "schedule": "Days 1 and 8"
        },
        {
          "dose": "75 mg/m²",
          "name": "Doxorubicin",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "8 cycles then olaratumab maintenance"
    },
    "tests": [
      "Full blood count",
      "LVEF assessment",
      "Liver function tests",
      "Performance status"
    ],
    "doseModifications": {
      "neutropenia": "G-CSF support",
      "cardiotoxicity": "Monitor LVEF every 3 cycles",
      "infusion_reactions": "Slow olaratumab rate"
    },
    "referenceList": [
      "NCCN Sarcoma Guidelines",
      "ANNOUNCE Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "8 + maintenance",
      "administration_time": "2 days per cycle"
    },
    "preMedications": {
      "antiemetic": "Standard protocol",
      "cardiac_monitoring": "Baseline LVEF",
      "infusion_monitoring": "Slow first infusion"
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "cardiotoxicity": "Monitor for symptoms",
      "infusion_reactions": "Stop infusion, supportive care"
    },
    "supportiveCare": {
      "growth_factors": "G-CSF if indicated",
      "cardiac_protection": "LVEF every 3 cycles",
      "infusion_management": "Premedication if reactions"
    },
    "rescueAgents": {
      "cardiotoxicity": "Cardio-oncology referral",
      "febrile_neutropenia": "G-CSF, antibiotics",
      "severe_infusion_reaction": "Discontinue olaratumab"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LVEF",
        "LFTs",
        "ECOG"
      ],
      "each_cycle": "FBC, infusion reaction assessment",
      "every_3_cycles": "LVEF"
    },
    "toxicityMonitoring": {
      "cardiotoxicity": "Serial LVEF monitoring",
      "myelosuppression": "Weekly FBC",
      "infusion_reactions": "During olaratumab infusion"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "live_vaccines": "Contraindicated"
    },
    "contraindications": [
      "Severe cardiac dysfunction",
      "Previous severe infusion reaction",
      "Pregnancy"
    ],
    "version": "2.3",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d7faf82f-6192-4c0b-804d-a9023e977e46",
    "code": "Eribulin",
    "tumourGroup": "Sarcoma",
    "tumourSupergroup": "Sarcoma",
    "treatmentIntent": "Palliative",
    "summary": "Microtubule inhibitor for advanced liposarcoma and leiomyosarcoma with unique mechanism of action.",
    "eligibility": {
      "summary": [
        "Liposarcoma and leiomyosarcoma",
        "Second-line or later"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Histology": "Liposarcoma or leiomyosarcoma",
        "Previous_anthracycline": "Required"
      }
    },
    "precautions": [
      "Peripheral neuropathy",
      "Myelosuppression",
      "QT prolongation"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "1.4 mg/m²",
          "name": "Eribulin",
          "route": "IV",
          "schedule": "Days 1 and 8"
        }
      ],
      "cycles": "Every 21 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "ECG",
      "Neuropathy assessment"
    ],
    "doseModifications": {
      "neuropathy": "Dose reduction for grade 3+",
      "neutropenia": "Dose delay if ANC <1.0",
      "QT_prolongation": "Hold if QTc >500ms"
    },
    "referenceList": [
      "NCCN Sarcoma Guidelines",
      "Study 309",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "2-5 minutes IV push"
    },
    "preMedications": {
      "cardiac_monitoring": "Baseline ECG",
      "neuropathy_monitoring": "Baseline assessment",
      "electrolyte_monitoring": "Mg, K, Ca"
    },
    "postMedications": {
      "neuropathy": "Gabapentin if symptomatic",
      "QT_monitoring": "Electrolyte correction",
      "myelosuppression": "Infection precautions"
    },
    "supportiveCare": {
      "cardiac_monitoring": "ECG every 3 cycles",
      "neuropathy_prevention": "Dose modifications",
      "electrolyte_management": "Regular monitoring"
    },
    "rescueAgents": {
      "severe_neuropathy": "Dose reduction or discontinuation",
      "febrile_neutropenia": "G-CSF, antibiotics",
      "severe_QT_prolongation": "Electrolyte correction, discontinue"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "ECG",
        "Neuropathy score",
        "Electrolytes"
      ],
      "each_cycle": "FBC, neuropathy assessment",
      "every_3_cycles": "ECG"
    },
    "toxicityMonitoring": {
      "neuropathy": "Clinical grading each cycle",
      "QT_monitoring": "ECG every 3 cycles",
      "myelosuppression": "Weekly FBC"
    },
    "interactions": {
      "QT_prolonging_drugs": "Avoid concurrent use",
      "strong_CYP3A4_inhibitors": "Monitor for increased toxicity"
    },
    "contraindications": [
      "Long QT syndrome",
      "Severe neuropathy",
      "Severe myelosuppression"
    ],
    "version": "1.7",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e8faf82f-6192-4c0b-804d-a9023e977e47",
    "code": "Ifosfamide-Doxorubicin",
    "tumourGroup": "Sarcoma",
    "tumourSupergroup": "Sarcoma",
    "treatmentIntent": "Curative",
    "summary": "High-dose ifosfamide with doxorubicin for high-grade sarcomas requiring intensive therapy.",
    "eligibility": {
      "summary": [
        "High-grade soft tissue sarcoma",
        "Neoadjuvant or metastatic"
      ],
      "criteria": {
        "Age": "16-65 years",
        "ECOG": "0-1",
        "Normal_cardiac_and_renal_function": "Required"
      }
    },
    "precautions": [
      "Ifosfamide hemorrhagic cystitis",
      "Doxorubicin cardiotoxicity",
      "CNS toxicity"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "3 g/m²/day",
          "name": "Ifosfamide",
          "route": "IV",
          "schedule": "Days 1-3"
        },
        {
          "dose": "25 mg/m²/day",
          "name": "Doxorubicin",
          "route": "IV",
          "schedule": "Days 1-3"
        },
        {
          "dose": "3 g/m²/day",
          "name": "Mesna",
          "route": "IV",
          "schedule": "Days 1-3"
        }
      ],
      "cycles": "4-6 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "LVEF assessment",
      "Renal function",
      "Urinalysis",
      "Neurological assessment"
    ],
    "doseModifications": {
      "CNS_toxicity": "Neurological monitoring",
      "cardiotoxicity": "Monitor LVEF every 2 cycles",
      "hemorrhagic_cystitis": "Ensure adequate mesna"
    },
    "referenceList": [
      "NCCN Sarcoma Guidelines",
      "High-dose Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "4-6",
      "administration_time": "3 days continuous infusion"
    },
    "preMedications": {
      "CNS_monitoring": "Baseline neurological exam",
      "bladder_protection": "Continuous mesna",
      "cardiac_protection": "Baseline LVEF"
    },
    "postMedications": {
      "CNS_effects": "Report confusion immediately",
      "bladder_care": "Adequate hydration, frequent voiding",
      "cardiotoxicity": "Monitor for symptoms"
    },
    "supportiveCare": {
      "bladder_protection": "Continuous mesna infusion",
      "cardiac_monitoring": "LVEF every 2 cycles",
      "neurological_monitoring": "Daily assessment during treatment"
    },
    "rescueAgents": {
      "CNS_toxicity": "Discontinue ifosfamide",
      "cardiotoxicity": "Cardio-oncology referral",
      "hemorrhagic_cystitis": "Bladder irrigation, cystoscopy"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LVEF",
        "U&E",
        "Urinalysis",
        "Neuro exam"
      ],
      "every_2_cycles": "LVEF",
      "daily_during_cycles": "Urinalysis, neuro assessment"
    },
    "toxicityMonitoring": {
      "urotoxicity": "Daily urinalysis during cycles",
      "CNS_toxicity": "Daily neurological assessment",
      "cardiotoxicity": "Serial LVEF monitoring"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "phenytoin": "May affect ifosfamide metabolism"
    },
    "contraindications": [
      "Severe cardiac dysfunction",
      "Severe renal impairment",
      "Active CNS disease"
    ],
    "version": "2.7",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f9faf82f-6192-4c0b-804d-a9023e977e48",
    "code": "Imatinib-GIST",
    "tumourGroup": "GIST",
    "tumourSupergroup": "GIST",
    "treatmentIntent": "Palliative",
    "summary": "First-line tyrosine kinase inhibitor for gastrointestinal stromal tumors with KIT or PDGFRA mutations.",
    "eligibility": {
      "summary": [
        "GIST with KIT mutation",
        "Advanced or metastatic"
      ],
      "criteria": {
        "ECOG": "0-2",
        "KIT_mutation": "Positive",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Fluid retention and edema",
      "Hepatotoxicity",
      "Cytopenias"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "400mg daily",
          "name": "Imatinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "KIT mutation status",
      "Performance status"
    ],
    "doseModifications": {
      "cytopenias": "Dose reduction or interruption",
      "hepatotoxicity": "Hold if ALT >5x ULN",
      "fluid_retention": "Diuretics if symptomatic"
    },
    "referenceList": [
      "NCCN GIST Guidelines",
      "B2222 Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily with food"
    },
    "preMedications": {
      "fluid_monitoring": "Daily weights",
      "hepatic_monitoring": "LFTs monthly",
      "monitoring_schedule": "Monthly FBC first 3 months"
    },
    "postMedications": {
      "edema": "Monitor weight, diuretics",
      "nausea": "Take with food",
      "muscle_cramps": "Tonic water, magnesium"
    },
    "supportiveCare": {
      "fluid_management": "Daily weights",
      "liver_protection": "Avoid hepatotoxins",
      "response_monitoring": "CT every 3 months"
    },
    "rescueAgents": {
      "heart_failure": "Cardiology referral",
      "severe_cytopenias": "Treatment interruption",
      "severe_hepatotoxicity": "Discontinue permanently"
    },
    "monitoring": {
      "monthly": "FBC, LFTs",
      "baseline": [
        "FBC",
        "LFTs",
        "KIT testing",
        "ECOG"
      ],
      "every_3_months": "CT abdomen/pelvis"
    },
    "toxicityMonitoring": {
      "hepatotoxicity": "LFT monitoring",
      "tumor_response": "CT every 3 months",
      "fluid_retention": "Weight monitoring"
    },
    "interactions": {
      "warfarin": "Monitor INR closely",
      "CYP3A4_inducers": "May reduce efficacy"
    },
    "contraindications": [
      "KIT wild-type",
      "Severe liver disease",
      "Pregnancy"
    ],
    "version": "1.2",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a1aaaa2f-6192-4c0b-804d-a9023e977e49",
    "code": "Sunitinib-GIST",
    "tumourGroup": "GIST",
    "tumourSupergroup": "GIST",
    "treatmentIntent": "Palliative",
    "summary": "Second-line multi-kinase inhibitor for GIST after imatinib resistance or intolerance.",
    "eligibility": {
      "summary": [
        "GIST after imatinib failure",
        "KIT exon 9 mutations"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Previous_imatinib": "Required",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Hand-foot syndrome",
      "Diarrhea",
      "Hypertension and cardiac dysfunction"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "50mg daily",
          "name": "Sunitinib",
          "route": "PO",
          "schedule": "4 weeks on, 2 weeks off"
        }
      ],
      "cycles": "6-week cycles until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "LVEF assessment",
      "Blood pressure",
      "Thyroid function"
    ],
    "doseModifications": {
      "hypertension": "Antihypertensive therapy",
      "hand_foot_syndrome": "Dose reduction or interruption",
      "cardiac_dysfunction": "LVEF monitoring"
    },
    "referenceList": [
      "NCCN GIST Guidelines",
      "A6181004 Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "42 days",
      "total_cycles": "Until progression",
      "administration_time": "4 weeks on, 2 weeks off"
    },
    "preMedications": {
      "skin_care": "Moisturizers, sun protection",
      "BP_monitoring": "Regular checks",
      "cardiac_monitoring": "Baseline LVEF"
    },
    "postMedications": {
      "diarrhea": "Loperamide",
      "hypertension": "ACE inhibitors",
      "hand_foot_syndrome": "Urea cream, dose modification"
    },
    "supportiveCare": {
      "BP_management": "Antihypertensives",
      "skin_monitoring": "Regular inspection",
      "cardiac_protection": "LVEF monitoring"
    },
    "rescueAgents": {
      "severe_HFS": "Topical treatments, dose interruption",
      "uncontrolled_HTN": "Optimize antihypertensives",
      "cardiac_dysfunction": "Cardio-oncology referral"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "LVEF",
        "BP",
        "TFTs"
      ],
      "each_cycle": "FBC, LFTs, BP",
      "every_3_cycles": "LVEF, CT"
    },
    "toxicityMonitoring": {
      "tumor_response": "CT every 3 cycles",
      "cardiac_function": "Serial LVEF",
      "hand_foot_syndrome": "CTCAE grading"
    },
    "interactions": {
      "warfarin": "Monitor INR",
      "strong_CYP3A4_inhibitors": "Reduce sunitinib dose"
    },
    "contraindications": [
      "Severe cardiac disease",
      "Uncontrolled hypertension",
      "Pregnancy"
    ],
    "version": "1.4",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b2bbbb2f-6192-4c0b-804d-a9023e977e50",
    "code": "Regorafenib-GIST",
    "tumourGroup": "GIST",
    "tumourSupergroup": "GIST",
    "treatmentIntent": "Palliative",
    "summary": "Third-line multi-kinase inhibitor for GIST after imatinib and sunitinib failure.",
    "eligibility": {
      "summary": [
        "GIST after imatinib and sunitinib",
        "Third-line therapy"
      ],
      "criteria": {
        "ECOG": "0-1",
        "Adequate_organ_function": "Required",
        "Previous_imatinib_and_sunitinib": "Required"
      }
    },
    "precautions": [
      "Hand-foot skin reaction",
      "Hepatotoxicity",
      "Hypertension"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "160mg daily",
          "name": "Regorafenib",
          "route": "PO",
          "schedule": "Days 1-21 of 28-day cycle"
        }
      ],
      "cycles": "Until progression or toxicity"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Blood pressure",
      "Hand-foot assessment"
    ],
    "doseModifications": {
      "HFSR": "Dose reduction for grade 2+",
      "hypertension": "Antihypertensive therapy",
      "hepatotoxicity": "Hold if ALT >5x ULN"
    },
    "referenceList": [
      "NCCN GIST Guidelines",
      "GRID Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "3 weeks on, 1 week off"
    },
    "preMedications": {
      "skin_care": "Moisturizers, avoid friction",
      "BP_monitoring": "Regular checks",
      "hepatic_monitoring": "Baseline LFTs"
    },
    "postMedications": {
      "HFSR": "Urea cream, dose modification",
      "fatigue": "Energy conservation",
      "hypertension": "ACE inhibitors"
    },
    "supportiveCare": {
      "BP_management": "Regular monitoring",
      "skin_monitoring": "Regular foot inspection",
      "liver_protection": "Avoid hepatotoxins"
    },
    "rescueAgents": {
      "severe_HFSR": "Dose interruption, topical care",
      "uncontrolled_HTN": "Optimize therapy",
      "severe_hepatotoxicity": "Permanent discontinuation"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "BP",
        "Skin assessment"
      ],
      "each_cycle": "FBC, LFTs, BP, HFSR assessment",
      "weekly_first_2_cycles": "LFTs"
    },
    "toxicityMonitoring": {
      "HFSR": "Weekly assessment first 2 cycles",
      "hepatotoxicity": "Regular LFT monitoring",
      "tumor_response": "CT every 2 cycles"
    },
    "interactions": {
      "warfarin": "Monitor INR closely",
      "strong_CYP3A4_inducers": "May reduce efficacy"
    },
    "contraindications": [
      "Severe liver disease",
      "Uncontrolled hypertension",
      "ECOG ≥ 2"
    ],
    "version": "1.3",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c3cccc2f-6192-4c0b-804d-a9023e977e51",
    "code": "Ripretinib",
    "tumourGroup": "GIST",
    "tumourSupergroup": "GIST",
    "treatmentIntent": "Palliative",
    "summary": "Fourth-line switch-control kinase inhibitor for GIST after multiple prior therapies.",
    "eligibility": {
      "summary": [
        "GIST after 3 prior therapies",
        "Fourth-line treatment"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Adequate_organ_function": "Required",
        "Previous_imatinib_sunitinib_regorafenib": "Required"
      }
    },
    "precautions": [
      "Alopecia",
      "Myalgia",
      "Abdominal pain"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "150mg daily",
          "name": "Ripretinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Performance status",
      "Muscle assessment"
    ],
    "doseModifications": {
      "myalgia": "Analgesics, dose reduction if severe",
      "abdominal_pain": "Symptomatic management",
      "hepatotoxicity": "Hold if ALT >3x ULN"
    },
    "referenceList": [
      "NCCN GIST Guidelines",
      "INVICTUS Study",
      "FDA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily with or without food"
    },
    "preMedications": {
      "GI_monitoring": "Baseline symptoms",
      "muscle_monitoring": "Baseline assessment",
      "hepatic_monitoring": "Baseline LFTs"
    },
    "postMedications": {
      "myalgia": "Analgesics, physical therapy",
      "alopecia": "Hair care support",
      "abdominal_pain": "Antispasmodics"
    },
    "supportiveCare": {
      "GI_monitoring": "Symptom assessment",
      "liver_monitoring": "LFTs monthly",
      "muscle_monitoring": "Regular assessment"
    },
    "rescueAgents": {
      "severe_myalgia": "Dose reduction, physical therapy",
      "severe_abdominal_pain": "Imaging, dose modification",
      "severe_hepatotoxicity": "Permanent discontinuation"
    },
    "monitoring": {
      "monthly": "FBC, LFTs",
      "baseline": [
        "FBC",
        "LFTs",
        "Muscle assessment",
        "ECOG"
      ],
      "each_cycle": "Muscle and GI assessment"
    },
    "toxicityMonitoring": {
      "myalgia": "Clinical assessment",
      "hepatotoxicity": "LFT monitoring",
      "tumor_response": "CT every 2 months"
    },
    "interactions": {
      "acid_reducing_agents": "No significant interaction",
      "strong_CYP3A4_inducers": "May reduce efficacy"
    },
    "contraindications": [
      "Severe liver disease",
      "Severe muscle disease",
      "Pregnancy"
    ],
    "version": "1.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d4dddd2f-6192-4c0b-804d-a9023e977e52",
    "code": "Avapritinib",
    "tumourGroup": "GIST",
    "tumourSupergroup": "GIST",
    "treatmentIntent": "Palliative",
    "summary": "Selective KIT and PDGFRA inhibitor for GIST with exon 18 PDGFRA mutations.",
    "eligibility": {
      "summary": [
        "GIST with PDGFRA exon 18 mutations",
        "Targeted therapy"
      ],
      "criteria": {
        "ECOG": "0-2",
        "PDGFRA_exon_18": "D842V or other mutations",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Cognitive effects",
      "Periorbital edema",
      "Nausea and vomiting"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "300mg daily",
          "name": "Avapritinib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "PDGFRA mutation status",
      "Cognitive assessment"
    ],
    "doseModifications": {
      "nausea": "Antiemetics, dose modification",
      "cognitive_effects": "Dose reduction for grade 2+",
      "periorbital_edema": "Diuretics if symptomatic"
    },
    "referenceList": [
      "NCCN GIST Guidelines",
      "NAVIGATOR Study",
      "VOYAGER Study"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily with food"
    },
    "preMedications": {
      "GI_monitoring": "Baseline symptoms",
      "edema_monitoring": "Baseline examination",
      "cognitive_monitoring": "Baseline assessment"
    },
    "postMedications": {
      "edema": "Elevation, diuretics",
      "nausea": "Take with food, antiemetics",
      "cognitive_effects": "Monitor memory and concentration"
    },
    "supportiveCare": {
      "GI_monitoring": "Symptom assessment",
      "edema_monitoring": "Clinical examination",
      "cognitive_monitoring": "Regular assessment"
    },
    "rescueAgents": {
      "severe_edema": "Diuretics, dose modification",
      "persistent_vomiting": "IV hydration",
      "severe_cognitive_effects": "Dose reduction or discontinuation"
    },
    "monitoring": {
      "monthly": "FBC, LFTs, cognitive assessment",
      "baseline": [
        "FBC",
        "LFTs",
        "PDGFRA testing",
        "Cognitive assessment"
      ],
      "each_cycle": "Edema and GI assessment"
    },
    "toxicityMonitoring": {
      "edema": "Clinical monitoring",
      "tumor_response": "CT every 2 months",
      "cognitive_effects": "Regular cognitive assessment"
    },
    "interactions": {
      "acid_reducing_agents": "Take with food",
      "strong_CYP3A4_inhibitors": "Reduce avapritinib dose"
    },
    "contraindications": [
      "PDGFRA wild-type",
      "Severe cognitive impairment",
      "Pregnancy"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e5eeee2f-6192-4c0b-804d-a9023e977e53",
    "code": "Bevacizumab-Paclitaxel-Ovarian",
    "tumourGroup": "Ovarian",
    "tumourSupergroup": "Ovarian",
    "treatmentIntent": "Curative",
    "summary": "Anti-VEGF therapy with chemotherapy for advanced ovarian cancer with improved progression-free survival.",
    "eligibility": {
      "summary": [
        "Advanced ovarian cancer",
        "First-line with bevacizumab"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Stage": "IIIC-IV",
        "No_bleeding_risk": "Required"
      }
    },
    "precautions": [
      "Bevacizumab bleeding and bowel perforation",
      "Hypertension",
      "Proteinuria"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "15 mg/kg",
          "name": "Bevacizumab",
          "route": "IV",
          "schedule": "Every 3 weeks"
        },
        {
          "dose": "175 mg/m²",
          "name": "Paclitaxel",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "AUC 5-6",
          "name": "Carboplatin",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "6 cycles + bevacizumab maintenance"
    },
    "tests": [
      "Full blood count",
      "Blood pressure",
      "Proteinuria",
      "CA-125",
      "Performance status"
    ],
    "doseModifications": {
      "bleeding": "Discontinue bevacizumab permanently",
      "hypertension": "Antihypertensive therapy",
      "bowel_perforation": "Emergency surgery"
    },
    "referenceList": [
      "NCCN Ovarian Guidelines",
      "GOG-218 Study",
      "ICON7 Study"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "6 + maintenance",
      "administration_time": "4-6 hours"
    },
    "preMedications": {
      "BP_monitoring": "Baseline and regular checks",
      "bowel_assessment": "Baseline imaging",
      "bleeding_assessment": "History and examination"
    },
    "postMedications": {
      "neuropathy": "Gabapentin for paclitaxel",
      "proteinuria": "Monitor urine protein",
      "hypertension": "ACE inhibitors preferred"
    },
    "supportiveCare": {
      "BP_management": "Regular monitoring",
      "bowel_monitoring": "Clinical assessment",
      "bleeding_prevention": "Avoid unnecessary procedures"
    },
    "rescueAgents": {
      "severe_bleeding": "Discontinue bevacizumab permanently",
      "bowel_perforation": "Emergency surgery",
      "hypertensive_crisis": "IV antihypertensives"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "CA-125",
        "BP",
        "Urine protein"
      ],
      "each_cycle": [
        "FBC",
        "CA-125",
        "BP",
        "Bleeding assessment"
      ],
      "maintenance": "Bevacizumab alone"
    },
    "toxicityMonitoring": {
      "bleeding": "Clinical assessment each visit",
      "hypertension": "BP monitoring",
      "bowel_perforation": "Abdominal pain monitoring"
    },
    "interactions": {
      "aspirin": "Caution with bleeding risk",
      "warfarin": "Increased bleeding risk"
    },
    "contraindications": [
      "Active bleeding",
      "Bowel obstruction",
      "Recent surgery <28 days"
    ],
    "version": "2.3",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f6ffff2f-6192-4c0b-804d-a9023e977e54",
    "code": "Rucaparib-Maintenance",
    "tumourGroup": "Ovarian",
    "tumourSupergroup": "Ovarian",
    "treatmentIntent": "Curative",
    "summary": "PARP inhibitor maintenance therapy for platinum-sensitive recurrent ovarian cancer.",
    "eligibility": {
      "summary": [
        "Platinum-sensitive recurrent ovarian cancer",
        "Maintenance therapy"
      ],
      "criteria": {
        "ECOG": "0-2",
        "BRCA_status": "Any",
        "Platinum_response": "Complete or partial"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Nausea and vomiting",
      "Fatigue"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "600mg BD",
          "name": "Rucaparib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "BRCA mutation status",
      "CA-125",
      "Liver function tests"
    ],
    "doseModifications": {
      "severe_fatigue": "Dose reduction",
      "myelosuppression": "Dose reduction or interruption",
      "persistent_nausea": "Antiemetics, dose modification"
    },
    "referenceList": [
      "NCCN Ovarian Guidelines",
      "ARIEL3 Study",
      "RUBRACA Studies"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Twice daily oral"
    },
    "preMedications": {
      "nausea_prevention": "Antiemetics PRN",
      "fatigue_assessment": "Baseline ECOG",
      "myelosuppression_monitoring": "Weekly FBC first month"
    },
    "postMedications": {
      "nausea": "Take with food, antiemetics",
      "fatigue": "Energy conservation techniques",
      "myelosuppression": "Infection precautions"
    },
    "supportiveCare": {
      "tumor_monitoring": "CA-125 and imaging",
      "fatigue_management": "Dose modifications",
      "myelosuppression_monitoring": "Weekly FBC first month"
    },
    "rescueAgents": {
      "severe_fatigue": "Dose reduction",
      "persistent_vomiting": "IV hydration",
      "severe_myelosuppression": "Treatment interruption"
    },
    "monitoring": {
      "monthly": "FBC, CA-125",
      "baseline": [
        "FBC",
        "BRCA status",
        "CA-125",
        "LFTs"
      ],
      "weekly_first_month": "FBC"
    },
    "toxicityMonitoring": {
      "fatigue": "Regular assessment",
      "tumor_response": "CA-125 and imaging",
      "myelosuppression": "Weekly FBC first month"
    },
    "interactions": {
      "acid_reducing_agents": "Take with food",
      "strong_CYP3A4_inhibitors": "Monitor for increased toxicity"
    },
    "contraindications": [
      "Severe myelosuppression",
      "Pregnancy",
      "Breastfeeding"
    ],
    "version": "1.6",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a7aaaa2f-6192-4c0b-804d-a9023e977e55",
    "code": "Durvalumab-Maintenance",
    "tumourGroup": "Lung",
    "tumourSupergroup": "Lung",
    "treatmentIntent": "Curative",
    "summary": "Anti-PD-L1 immunotherapy maintenance for unresectable stage III NSCLC after chemoradiotherapy.",
    "eligibility": {
      "summary": [
        "Unresectable stage III NSCLC",
        "Post-chemoradiotherapy maintenance"
      ],
      "criteria": {
        "ECOG": "0-1",
        "PD-L1": "Any expression",
        "No_progression": "After chemoRT"
      }
    },
    "precautions": [
      "Immune-related adverse events",
      "Pneumonitis",
      "Endocrinopathies"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "10 mg/kg",
          "name": "Durvalumab",
          "route": "IV",
          "schedule": "Every 2 weeks"
        }
      ],
      "cycles": "Until progression or 12 months"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Thyroid function",
      "Chest imaging"
    ],
    "doseModifications": {
      "irAEs": "Steroids for grade 2+",
      "pneumonitis": "Permanent discontinuation grade 3+",
      "endocrinopathy": "Hormone replacement"
    },
    "referenceList": [
      "NCCN NSCLC Guidelines",
      "PACIFIC Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "14 days",
      "total_cycles": "Up to 12 months",
      "administration_time": "60 minutes"
    },
    "preMedications": {
      "irAE_education": "Comprehensive patient counseling",
      "endocrine_monitoring": "Baseline TFTs",
      "pneumonitis_monitoring": "Baseline chest imaging"
    },
    "postMedications": {
      "pneumonitis": "Report dyspnea immediately",
      "irAE_management": "Early steroid intervention",
      "endocrine_effects": "Monitor symptoms"
    },
    "supportiveCare": {
      "irAE_monitoring": "Weekly contact first 8 weeks",
      "endocrine_support": "Hormone replacement",
      "pneumonitis_prevention": "Serial chest imaging"
    },
    "rescueAgents": {
      "pneumonitis": "High-dose steroids, permanent discontinuation",
      "severe_irAEs": "High-dose steroids",
      "endocrinopathy": "Hormone replacement therapy"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "TFTs",
        "CXR"
      ],
      "each_cycle": "FBC, LFTs, TFTs",
      "weekly_first_8_weeks": "irAE assessment"
    },
    "toxicityMonitoring": {
      "endocrine": "Hormone levels",
      "pneumonitis": "Dyspnea assessment, chest imaging",
      "irAE_monitoring": "Weekly assessment first 8 weeks"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "immunosuppressants": "May reduce efficacy but needed for irAEs"
    },
    "contraindications": [
      "Active autoimmune disease",
      "Organ transplant",
      "Active pneumonitis"
    ],
    "version": "1.9",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b8bbbb2f-6192-4c0b-804d-a9023e977e56",
    "code": "Atezolizumab-Nab-Paclitaxel",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Palliative",
    "summary": "Atezolizumab-Nab-Paclitaxel is a NCCN Category 1 regimen for PD-L1 positive metastatic triple-negative breast cancer in the first-line setting. This immunotherapy combination improves overall survival in selected patients.",
    "eligibility": {
      "summary": [
        "Metastatic triple-negative breast cancer",
        "PD-L1 positive by SP142 assay",
        "First-line metastatic treatment"
      ],
      "criteria": {
        "Age": "18+ years",
        "ECOG": "0–1",
        "Other": "No active autoimmune disease",
        "Biomarkers": "Triple-negative, PD-L1 positive (≥1% IC by SP142)",
        "Prior_therapy": "No prior chemotherapy for metastatic disease"
      },
      "nccn_category": "1",
      "line_of_therapy": "First-line",
      "treatment_setting": "Metastatic",
      "biomarker_requirements": {
        "ER": "Negative (<1% by IHC)",
        "PR": "Negative (<1% by IHC)",
        "HER2": "Negative (IHC 0-1+ or FISH negative)",
        "PD_L1": "Positive (≥1% immune cells by SP142 assay)"
      }
    },
    "precautions": [
      "Immune-related adverse events",
      "Nab-paclitaxel neuropathy",
      "Pneumonitis risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "840mg",
          "name": "Atezolizumab",
          "route": "IV",
          "schedule": "Every 2 weeks"
        },
        {
          "dose": "100 mg/m²",
          "name": "Nab-paclitaxel",
          "route": "IV",
          "schedule": "Days 1, 8, 15"
        }
      ],
      "cycles": "Until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Thyroid function",
      "PD-L1 status",
      "Neuropathy assessment"
    ],
    "doseModifications": {
      "hepatitis": "Permanently discontinue atezolizumab for grade 3+ hepatitis",
      "neuropathy": "Hold nab-paclitaxel for grade 3+ neuropathy",
      "pneumonitis": "Permanently discontinue atezolizumab for grade 2+ pneumonitis",
      "dose_reductions": {
        "nab_paclitaxel_level_1": "100 mg/m² → 80 mg/m²",
        "nab_paclitaxel_level_2": "80 mg/m² → 60 mg/m²"
      },
      "immune_toxicity": "Hold atezolizumab for grade 2+ immune-related AEs, treat with steroids",
      "alternate_options": {
        "neuropathy": "Switch to carboplatin or gemcitabine",
        "pd_l1_negative": "Consider chemotherapy alone or clinical trials",
        "immune_toxicity": "Continue nab-paclitaxel alone if atezolizumab discontinued"
      }
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "IMpassion130 Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "3 days per cycle"
    },
    "preMedications": {
      "irAE_education": "Comprehensive patient counseling",
      "neuropathy_monitoring": "Baseline assessment",
      "pneumonitis_monitoring": "Baseline chest imaging"
    },
    "postMedications": {
      "neuropathy": "Gabapentin if symptomatic",
      "pneumonitis": "Report dyspnea immediately",
      "irAE_management": "Early steroid intervention"
    },
    "supportiveCare": {
      "irAE_monitoring": "Weekly contact first 8 weeks",
      "pulmonary_monitoring": "Serial chest imaging",
      "neuropathy_prevention": "Dose modifications"
    },
    "rescueAgents": {
      "pneumonitis": "High-dose steroids, permanent discontinuation",
      "grade_4_irAEs": "Permanent discontinuation, high-dose steroids",
      "severe_neuropathy": "Nab-paclitaxel discontinuation"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "TFTs",
        "PD-L1",
        "Neuropathy score"
      ],
      "each_cycle": "FBC, LFTs, TFTs, neuropathy",
      "weekly_first_8_weeks": "irAE assessment"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "CBC with differential",
        "Liver function tests",
        "Thyroid function tests",
        "Chest imaging",
        "Neurological assessment"
      ],
      "primary_toxicities": [
        "Immune-related adverse events",
        "Peripheral neuropathy",
        "Myelosuppression",
        "Infusion reactions",
        "Pneumonitis",
        "Hepatitis"
      ],
      "monitoring_schedule": {
        "ongoing": [
          "Monitor for delayed immune toxicities up to 1 year post-treatment"
        ],
        "baseline": [
          "CBC",
          "LFTs",
          "TSH",
          "Chest CT",
          "Autoimmune screening"
        ],
        "every_6_weeks": [
          "Thyroid function",
          "Chest imaging"
        ],
        "before_each_cycle": [
          "CBC",
          "LFTs",
          "Performance status",
          "Immune toxicity assessment"
        ]
      }
    },
    "interactions": {
      "CYP2C8_substrates": "Monitor closely",
      "immunosuppressants": "May reduce atezolizumab efficacy"
    },
    "contraindications": [
      "Active autoimmune disease requiring systemic immunosuppression",
      "Known hypersensitivity to atezolizumab or nab-paclitaxel",
      "Pregnancy or breastfeeding",
      "Active pneumonitis or ILD",
      "Severe hepatic impairment",
      "Live vaccine within 30 days"
    ],
    "version": "2.4",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a3aaaa2f-6192-4c0b-804d-a9023e977e61",
    "code": "Cetuximab-Irinotecan",
    "tumourGroup": "Colorectal",
    "tumourSupergroup": "Colorectal",
    "treatmentIntent": "Palliative",
    "summary": "Anti-EGFR therapy with irinotecan for RAS wild-type metastatic colorectal cancer after 5-FU failure.",
    "eligibility": {
      "summary": [
        "RAS wild-type metastatic CRC",
        "Irinotecan-based second-line"
      ],
      "criteria": {
        "ECOG": "0-2",
        "RAS_status": "Wild-type",
        "Previous_5FU": "Required"
      }
    },
    "precautions": [
      "Cetuximab skin reactions",
      "Irinotecan diarrhea",
      "Hypomagnesemia"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "400 mg/m² loading, then 250 mg/m²",
          "name": "Cetuximab",
          "route": "IV",
          "schedule": "Weekly"
        },
        {
          "dose": "180 mg/m²",
          "name": "Irinotecan",
          "route": "IV",
          "schedule": "Every 2 weeks"
        }
      ],
      "cycles": "Until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Magnesium levels",
      "RAS/BRAF status"
    ],
    "doseModifications": {
      "diarrhea": "Loperamide protocol",
      "skin_toxicity": "Dose reduction for grade 3+",
      "hypomagnesemia": "Magnesium supplementation"
    },
    "referenceList": [
      "NCCN Colorectal Guidelines",
      "EPIC Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "14 days",
      "total_cycles": "Until progression",
      "administration_time": "Weekly cetuximab + biweekly irinotecan"
    },
    "preMedications": {
      "skin_care": "Moisturizers, sun protection",
      "diarrhea_education": "Early intervention protocol",
      "cetuximab_premedication": "Standard antihistamine protocol"
    },
    "postMedications": {
      "diarrhea": "Aggressive loperamide use",
      "skin_care": "Antibiotics for infected rash",
      "paronychia": "Nail care, topical antibiotics"
    },
    "supportiveCare": {
      "skin_monitoring": "Weekly assessment",
      "diarrhea_management": "Early intervention",
      "magnesium_replacement": "Regular supplementation"
    },
    "rescueAgents": {
      "severe_diarrhea": "IV hydration",
      "severe_skin_toxicity": "Dermatology referral",
      "severe_infusion_reaction": "Discontinue cetuximab"
    },
    "monitoring": {
      "weekly": "Skin assessment, Mg levels",
      "baseline": [
        "FBC",
        "LFTs",
        "Mg",
        "RAS testing"
      ],
      "each_cycle": "FBC, LFTs"
    },
    "toxicityMonitoring": {
      "diarrhea": "Frequency monitoring",
      "skin_toxicity": "Weekly grading and photography",
      "hypomagnesemia": "Regular magnesium levels"
    },
    "interactions": {
      "warfarin": "Enhanced effect",
      "UGT1A1_polymorphisms": "Consider genotyping"
    },
    "contraindications": [
      "RAS mutant tumors",
      "Previous severe skin reaction",
      "Chronic diarrhea"
    ],
    "version": "1.7",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f2ffff2f-6192-4c0b-804d-a9023e977e60",
    "code": "Tucatinib-Trastuzumab-Capecitabine",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Palliative",
    "summary": "Tucatinib-Trastuzumab-Capecitabine is a NCCN Category 1 regimen for HER2-positive metastatic breast cancer after prior anti-HER2 therapy. This oral HER2 tyrosine kinase inhibitor combination shows excellent CNS activity and overcomes trastuzumab resistance.",
    "eligibility": {
      "summary": [
        "HER2-positive metastatic breast cancer",
        "Prior trastuzumab and taxane therapy",
        "Brain metastases allowed"
      ],
      "criteria": {
        "Age": "18+ years",
        "CNS": "Brain metastases allowed and specifically studied",
        "ECOG": "0–2",
        "Biomarkers": "HER2-positive (IHC 3+ or FISH amplified)",
        "Prior_therapy": "Prior trastuzumab and taxane (adjuvant or metastatic)"
      },
      "nccn_category": "1",
      "line_of_therapy": "Second-line or later",
      "treatment_setting": "Metastatic",
      "biomarker_requirements": {
        "HER2": "Positive (IHC 3+ or FISH amplified, HER2/CEP17 ratio ≥2.0)",
        "ER_PR": "Any status"
      }
    },
    "precautions": [
      "Diarrhea",
      "Hepatotoxicity",
      "Hand-foot syndrome"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "300mg BD",
          "name": "Tucatinib",
          "route": "PO",
          "schedule": "Continuous"
        },
        {
          "dose": "6 mg/kg",
          "name": "Trastuzumab",
          "route": "IV",
          "schedule": "Every 3 weeks"
        },
        {
          "dose": "1000 mg/m² BD",
          "name": "Capecitabine",
          "route": "PO",
          "schedule": "Days 1-14"
        }
      ],
      "cycles": "Every 21 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "HER2 status",
      "Brain imaging"
    ],
    "doseModifications": {
      "diarrhea": "Hold for grade 3+ diarrhea, resume with dose reduction and antidiarrheals",
      "lvef_decline": "Hold trastuzumab for LVEF drop >10% or <45%",
      "hepatotoxicity": "Hold for grade 3+ ALT/AST elevation, may require permanent discontinuation",
      "dose_reductions": {
        "tucatinib_level_1": "300 mg BID → 250 mg BID",
        "tucatinib_level_2": "250 mg BID → 200 mg BID",
        "capecitabine_level_1": "2000 mg/m² daily → 1500 mg/m² daily"
      },
      "alternate_options": {
        "hepatotoxicity": "Switch to other HER2-targeted combinations",
        "cns_progression": "Consider stereotactic radiosurgery with continued systemic therapy",
        "severe_diarrhea": "Consider T-DM1 or trastuzumab deruxtecan"
      },
      "hand_foot_syndrome": "Hold for grade 2+ HFS, resume with dose reduction"
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "HER2CLIMB Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "Continuous tucatinib + 3-weekly trastuzumab + 14-day capecitabine"
    },
    "preMedications": {
      "GI_monitoring": "Baseline assessment",
      "CNS_monitoring": "Baseline brain MRI",
      "hepatic_monitoring": "Weekly LFTs first month"
    },
    "postMedications": {
      "diarrhea": "Early loperamide intervention",
      "hand_foot_care": "Urea cream, avoid friction",
      "hepatotoxicity": "Avoid hepatotoxins"
    },
    "supportiveCare": {
      "CNS_monitoring": "Regular brain imaging",
      "liver_protection": "Weekly LFTs first month",
      "diarrhea_management": "Aggressive early intervention"
    },
    "rescueAgents": {
      "severe_HFS": "Treatment interruption",
      "severe_diarrhea": "IV hydration, dose reduction",
      "severe_hepatotoxicity": "Permanent discontinuation"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "HER2 status",
        "Brain MRI"
      ],
      "each_cycle": "FBC, LFTs, GI assessment",
      "weekly_first_month": "LFTs"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "Diarrhea assessment and management",
        "Skin examination for HFS",
        "Liver function tests",
        "ECHO or MUGA scan",
        "CNS imaging"
      ],
      "primary_toxicities": [
        "Diarrhea",
        "Hand-foot syndrome",
        "Nausea",
        "Fatigue",
        "Hepatotoxicity",
        "Left ventricular dysfunction"
      ],
      "monitoring_schedule": {
        "baseline": [
          "LFTs",
          "LVEF assessment",
          "CBC",
          "CNS imaging if indicated"
        ],
        "every_3_months": [
          "LVEF assessment",
          "CNS imaging for brain mets patients"
        ],
        "before_each_cycle": [
          "LFTs",
          "CBC",
          "Performance status"
        ],
        "weekly_first_cycle": [
          "Toxicity assessment",
          "Diarrhea monitoring"
        ]
      }
    },
    "interactions": {
      "warfarin": "Monitor INR closely",
      "strong_CYP3A4_inhibitors": "Reduce tucatinib dose"
    },
    "contraindications": [
      "Known hypersensitivity to tucatinib, trastuzumab, or capecitabine",
      "Pregnancy or breastfeeding",
      "Severe hepatic impairment",
      "Dihydropyrimidine dehydrogenase deficiency",
      "Concurrent warfarin therapy",
      "Severe heart failure (LVEF <40%)"
    ],
    "version": "2.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e1eeee2f-6192-4c0b-804d-a9023e977e59",
    "code": "Alpelisib-Fulvestrant",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Palliative",
    "summary": "Alpelisib-Fulvestrant is a NCCN Category 1 regimen for PIK3CA-mutated, hormone receptor-positive metastatic breast cancer after prior endocrine therapy. This PI3K inhibitor combination targets specific molecular alterations.",
    "eligibility": {
      "summary": [
        "HR-positive, HER2-negative metastatic breast cancer",
        "PIK3CA mutation detected",
        "Prior endocrine therapy"
      ],
      "criteria": {
        "Age": "18+ years",
        "ECOG": "0–2",
        "Other": "Adequate glucose control, no diabetes complications",
        "Biomarkers": "ER+ and/or PR+, HER2-negative, PIK3CA mutation",
        "Prior_therapy": "Prior endocrine therapy progression"
      },
      "nccn_category": "1",
      "line_of_therapy": "Second-line or later",
      "treatment_setting": "Metastatic",
      "biomarker_requirements": {
        "ER": "Positive (≥1% by IHC)",
        "HER2": "Negative (IHC 0-1+ or FISH negative)",
        "PIK3CA": "Mutation detected by FDA-approved assay"
      }
    },
    "precautions": [
      "Hyperglycemia",
      "Diarrhea",
      "Rash"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "300mg daily",
          "name": "Alpelisib",
          "route": "PO",
          "schedule": "Continuous"
        },
        {
          "dose": "500mg",
          "name": "Fulvestrant",
          "route": "IM",
          "schedule": "Days 1, 15, 29, then monthly"
        }
      ],
      "cycles": "Until progression"
    },
    "tests": [
      "Full blood count",
      "Blood glucose",
      "HbA1c",
      "PIK3CA mutation status"
    ],
    "doseModifications": {
      "rash": "Hold for grade 3+ rash, treat with topical steroids",
      "diarrhea": "Hold for grade 3+ diarrhea, aggressive antidiarrheal management",
      "hyperglycemia": "Hold for glucose >500 mg/dL, resume with antidiabetic management",
      "dose_reductions": {
        "alpelisib_level_1": "300 mg daily → 250 mg daily",
        "alpelisib_level_2": "250 mg daily → 200 mg daily"
      },
      "alternate_options": {
        "progression": "Chemotherapy or clinical trials",
        "severe_rash": "Dermatology consultation, possible permanent discontinuation",
        "diabetes_intolerance": "Consider other targeted agents or CDK4/6 inhibitors"
      }
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "SOLAR-1 Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "Daily oral + monthly IM"
    },
    "preMedications": {
      "GI_monitoring": "Baseline assessment",
      "skin_monitoring": "Baseline examination",
      "metabolic_monitoring": "Baseline glucose, HbA1c"
    },
    "postMedications": {
      "rash": "Moisturizers, topical steroids",
      "diarrhea": "Early loperamide intervention",
      "hyperglycemia": "Dietary modification, metformin"
    },
    "supportiveCare": {
      "skin_monitoring": "Regular assessment",
      "glucose_monitoring": "Weekly first month",
      "diarrhea_management": "Aggressive early intervention"
    },
    "rescueAgents": {
      "severe_rash": "Dermatology referral",
      "severe_diarrhea": "IV hydration, dose reduction",
      "severe_hyperglycemia": "Insulin therapy, dose reduction"
    },
    "monitoring": {
      "monthly": "Glucose, HbA1c",
      "baseline": [
        "FBC",
        "Glucose",
        "HbA1c",
        "PIK3CA testing"
      ],
      "weekly_first_month": "Glucose"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "Glucose monitoring",
        "HbA1c testing",
        "Skin examination",
        "Diarrhea assessment"
      ],
      "primary_toxicities": [
        "Hyperglycemia",
        "Diarrhea",
        "Rash",
        "Nausea",
        "Fatigue",
        "Stomatitis"
      ],
      "monitoring_schedule": {
        "monthly": [
          "HbA1c",
          "Glucose trends"
        ],
        "baseline": [
          "Fasting glucose",
          "HbA1c",
          "PIK3CA mutation testing"
        ],
        "before_each_cycle": [
          "Glucose",
          "Performance status",
          "Toxicity assessment"
        ],
        "weekly_first_month": [
          "Glucose monitoring"
        ]
      }
    },
    "interactions": {
      "diabetes_medications": "Monitor glucose closely",
      "strong_CYP3A4_inhibitors": "Reduce alpelisib dose"
    },
    "contraindications": [
      "Uncontrolled diabetes (HbA1c >8%)",
      "History of severe ketoacidosis",
      "Known hypersensitivity to alpelisib or fulvestrant",
      "Pregnancy or breastfeeding",
      "Severe hepatic impairment",
      "Stevens-Johnson syndrome history"
    ],
    "version": "1.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b4bbbb2f-6192-4c0b-804d-a9023e977e62",
    "code": "Trifluridine-Tipiracil",
    "tumourGroup": "Colorectal",
    "tumourSupergroup": "Colorectal",
    "treatmentIntent": "Palliative",
    "summary": "Oral nucleoside antimetabolite for refractory metastatic colorectal cancer after standard therapies.",
    "eligibility": {
      "summary": [
        "Refractory metastatic CRC",
        "Third-line or later"
      ],
      "criteria": {
        "ECOG": "0-1",
        "Adequate_organ_function": "Required",
        "Previous_standard_therapy": "5-FU, oxaliplatin, irinotecan"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Nausea and vomiting",
      "Fatigue"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "35 mg/m² BD",
          "name": "Trifluridine/tipiracil",
          "route": "PO",
          "schedule": "Days 1-5 and 8-12"
        }
      ],
      "cycles": "Every 28 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Performance status",
      "Renal function"
    ],
    "doseModifications": {
      "neutropenia": "Dose reduction for grade 3+",
      "severe_fatigue": "Dose reduction",
      "thrombocytopenia": "Hold if platelets <75k"
    },
    "referenceList": [
      "NCCN Colorectal Guidelines",
      "RECOURSE Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "10 days per cycle"
    },
    "preMedications": {
      "antiemetic": "Ondansetron PRN",
      "fatigue_assessment": "Baseline ECOG",
      "myelosuppression_monitoring": "Baseline FBC"
    },
    "postMedications": {
      "nausea": "Take with food",
      "fatigue": "Energy conservation",
      "myelosuppression": "Infection precautions"
    },
    "supportiveCare": {
      "fatigue_management": "Dose modifications",
      "infection_prevention": "Hygiene measures",
      "neutropenia_monitoring": "Weekly FBC"
    },
    "rescueAgents": {
      "severe_fatigue": "Treatment delay",
      "febrile_neutropenia": "G-CSF, antibiotics",
      "severe_thrombocytopenia": "Platelet transfusion"
    },
    "monitoring": {
      "weekly": "FBC",
      "baseline": [
        "FBC",
        "LFTs",
        "U&E",
        "ECOG"
      ],
      "each_cycle": "FBC, clinical assessment"
    },
    "toxicityMonitoring": {
      "fatigue": "Regular assessment",
      "tumor_response": "CT every 2 cycles",
      "myelosuppression": "Weekly FBC monitoring"
    },
    "interactions": {
      "warfarin": "Monitor INR closely",
      "live_vaccines": "Contraindicated"
    },
    "contraindications": [
      "Severe myelosuppression",
      "ECOG ≥ 2",
      "Active infection"
    ],
    "version": "1.2",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c5cccc2f-6192-4c0b-804d-a9023e977e63",
    "code": "Mitomycin-5FU",
    "tumourGroup": "Anal",
    "tumourSupergroup": "Anal",
    "treatmentIntent": "Curative",
    "summary": "Concurrent chemoradiotherapy for squamous cell carcinoma of the anal canal with curative intent.",
    "eligibility": {
      "summary": [
        "Squamous cell carcinoma of anal canal",
        "Concurrent chemoradiotherapy"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Stage": "T2-4 or N+",
        "Histology": "Squamous cell carcinoma"
      }
    },
    "precautions": [
      "Severe mucositis and dermatitis",
      "Myelosuppression",
      "Late bowel toxicity"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "10 mg/m²",
          "name": "Mitomycin C",
          "route": "IV",
          "schedule": "Days 1 and 29"
        },
        {
          "dose": "1000 mg/m²/day",
          "name": "5-Fluorouracil",
          "route": "IV",
          "schedule": "Days 1-4 and 29-32"
        }
      ],
      "cycles": "2 cycles with concurrent radiotherapy"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Performance status",
      "Anal examination"
    ],
    "doseModifications": {
      "renal_toxicity": "Monitor creatinine",
      "myelosuppression": "G-CSF support",
      "severe_mucositis": "Treatment break"
    },
    "referenceList": [
      "NCCN Anal Cancer Guidelines",
      "RTOG Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "2",
      "administration_time": "Concurrent with radiotherapy"
    },
    "preMedications": {
      "skin_care": "Barrier creams",
      "mucositis_prevention": "Intensive oral care",
      "myelosuppression_monitoring": "Weekly FBC"
    },
    "postMedications": {
      "diarrhea": "Loperamide, hydration",
      "mucositis": "Magic mouthwash, soft diet",
      "skin_care": "Barrier creams, sitz baths"
    },
    "supportiveCare": {
      "mucositis_care": "Intensive oral hygiene",
      "skin_protection": "Barrier creams during RT",
      "nutritional_support": "Dietitian involvement"
    },
    "rescueAgents": {
      "severe_mucositis": "Treatment break, IV nutrition",
      "febrile_neutropenia": "G-CSF, antibiotics",
      "severe_skin_reaction": "Treatment break"
    },
    "monitoring": {
      "weekly": "FBC, mucositis assessment",
      "baseline": [
        "FBC",
        "U&E",
        "Anal exam",
        "HIV status"
      ],
      "post_treatment": "Response assessment"
    },
    "toxicityMonitoring": {
      "mucositis": "Daily assessment during RT",
      "anal_response": "Post-treatment biopsy",
      "skin_toxicity": "Daily assessment"
    },
    "interactions": {
      "warfarin": "Enhanced effect",
      "nephrotoxic_drugs": "Avoid during mitomycin"
    },
    "contraindications": [
      "Severe renal impairment",
      "Previous pelvic radiotherapy",
      "Active infection"
    ],
    "version": "2.4",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d6dddd2f-6192-4c0b-804d-a9023e977e64",
    "code": "Carboplatin-5FU-Head-Neck",
    "tumourGroup": "Head-Neck",
    "tumourSupergroup": "Head-Neck",
    "treatmentIntent": "Curative",
    "summary": "Concurrent chemoradiotherapy for head and neck squamous cell carcinoma when cisplatin contraindicated.",
    "eligibility": {
      "summary": [
        "HNSCC concurrent chemoRT",
        "Cisplatin contraindicated"
      ],
      "criteria": {
        "Stage": "III-IV",
        "Histology": "Squamous cell carcinoma",
        "Cisplatin_contraindicated": "Renal impairment or hearing loss"
      }
    },
    "precautions": [
      "Carboplatin thrombocytopenia",
      "5-FU mucositis",
      "Enhanced radiation toxicity"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "AUC 1.5",
          "name": "Carboplatin",
          "route": "IV",
          "schedule": "Weekly"
        },
        {
          "dose": "600 mg/m²/day",
          "name": "5-Fluorouracil",
          "route": "IV",
          "schedule": "Days 1-4, weeks 1 and 6"
        }
      ],
      "cycles": "Concurrent with radiotherapy"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Nutritional status",
      "Performance status"
    ],
    "doseModifications": {
      "severe_mucositis": "Treatment break",
      "thrombocytopenia": "Hold if platelets <75k",
      "renal_deterioration": "Dose adjustment"
    },
    "referenceList": [
      "NCCN Head-Neck Guidelines",
      "Alternative Protocols"
    ],
    "cycleInfo": {
      "cycle_length": "Weekly carboplatin",
      "total_cycles": "6-7 weeks",
      "administration_time": "Concurrent with RT"
    },
    "preMedications": {
      "PEG_consideration": "Early evaluation",
      "mucositis_prevention": "Intensive oral care",
      "nutritional_assessment": "Baseline dietitian"
    },
    "postMedications": {
      "mucositis": "Magic mouthwash, PEG feeding",
      "thrombocytopenia": "Platelet monitoring",
      "nutritional_support": "PEG tube use"
    },
    "supportiveCare": {
      "mucositis_care": "Intensive protocol",
      "nutritional_support": "PEG tube if severe mucositis",
      "platelet_monitoring": "Weekly FBC"
    },
    "rescueAgents": {
      "aspiration": "Immediate PEG",
      "severe_mucositis": "Treatment break, PEG feeding",
      "severe_thrombocytopenia": "Platelet transfusion"
    },
    "monitoring": {
      "weekly": "FBC, mucositis assessment",
      "baseline": [
        "FBC",
        "U&E",
        "Nutritional assessment",
        "Swallowing study"
      ],
      "post_treatment": "Response evaluation"
    },
    "toxicityMonitoring": {
      "mucositis": "Daily assessment during RT",
      "swallowing": "Weekly assessment",
      "thrombocytopenia": "Weekly platelet monitoring"
    },
    "interactions": {
      "warfarin": "Enhanced effect",
      "nephrotoxic_drugs": "Monitor renal function"
    },
    "contraindications": [
      "Severe renal impairment",
      "Severe malnutrition",
      "Active bleeding"
    ],
    "version": "2.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e7eeee2f-6192-4c0b-804d-a9023e977e65",
    "code": "Cetuximab-Radiotherapy",
    "tumourGroup": "Head-Neck",
    "tumourSupergroup": "Head-Neck",
    "treatmentIntent": "Curative",
    "summary": "Anti-EGFR therapy with radiotherapy for head and neck squamous cell carcinoma when chemotherapy contraindicated.",
    "eligibility": {
      "summary": [
        "HNSCC with radiotherapy",
        "Chemotherapy contraindicated"
      ],
      "criteria": {
        "ECOG": "0-3",
        "Histology": "Squamous cell carcinoma",
        "Chemotherapy_contraindicated": "Poor performance status or comorbidities"
      }
    },
    "precautions": [
      "Cetuximab skin reactions",
      "Infusion reactions",
      "Enhanced radiation dermatitis"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "400 mg/m² loading, then 250 mg/m²",
          "name": "Cetuximab",
          "route": "IV",
          "schedule": "Weekly during radiotherapy"
        }
      ],
      "cycles": "7-8 weeks concurrent with RT"
    },
    "tests": [
      "Full blood count",
      "Magnesium levels",
      "Performance status",
      "Skin assessment"
    ],
    "doseModifications": {
      "skin_toxicity": "Dose reduction for grade 3+",
      "hypomagnesemia": "Magnesium supplementation",
      "infusion_reactions": "Premedication protocol"
    },
    "referenceList": [
      "NCCN Head-Neck Guidelines",
      "Bonner Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Weekly",
      "total_cycles": "7-8 weeks",
      "administration_time": "Concurrent with radiotherapy"
    },
    "preMedications": {
      "skin_care": "Moisturizers, sun protection",
      "magnesium_monitoring": "Baseline levels",
      "cetuximab_premedication": "Standard antihistamine protocol"
    },
    "postMedications": {
      "skin_care": "Antibiotics for infected rash",
      "hypomagnesemia": "Oral magnesium",
      "radiation_dermatitis": "Enhanced skin care"
    },
    "supportiveCare": {
      "skin_monitoring": "Weekly assessment",
      "magnesium_replacement": "Regular supplementation",
      "radiation_enhancement": "Enhanced skin care"
    },
    "rescueAgents": {
      "severe_dermatitis": "Treatment break",
      "severe_skin_toxicity": "Treatment break, dermatology referral",
      "severe_infusion_reaction": "Discontinue cetuximab"
    },
    "monitoring": {
      "weekly": "Skin assessment, Mg levels",
      "baseline": [
        "FBC",
        "Mg",
        "Skin assessment",
        "ECOG"
      ],
      "post_treatment": "Response evaluation"
    },
    "toxicityMonitoring": {
      "skin_toxicity": "Weekly grading during RT",
      "infusion_reactions": "During cetuximab infusion",
      "radiation_enhancement": "Enhanced monitoring"
    },
    "interactions": {
      "warfarin": "Monitor INR",
      "live_vaccines": "Contraindicated"
    },
    "contraindications": [
      "Previous severe skin reaction",
      "Active skin infection",
      "Severe hypomagnesemia"
    ],
    "version": "1.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f8ffff2f-6192-4c0b-804d-a9023e977e66",
    "code": "Pembrolizumab-Head-Neck",
    "tumourGroup": "Head-Neck",
    "tumourSupergroup": "Head-Neck",
    "treatmentIntent": "Palliative",
    "summary": "Anti-PD-1 immunotherapy for recurrent or metastatic head and neck squamous cell carcinoma.",
    "eligibility": {
      "summary": [
        "Recurrent/metastatic HNSCC",
        "First-line or second-line"
      ],
      "criteria": {
        "ECOG": "0-2",
        "PD-L1": "CPS ≥1 for first-line",
        "No_autoimmune_disease": "Required"
      }
    },
    "precautions": [
      "Immune-related adverse events",
      "Pneumonitis",
      "Thyroid dysfunction"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "200mg",
          "name": "Pembrolizumab",
          "route": "IV",
          "schedule": "Every 3 weeks"
        }
      ],
      "cycles": "Until progression or toxicity"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Thyroid function",
      "PD-L1 status"
    ],
    "doseModifications": {
      "irAEs": "Hold pembrolizumab grade 2+",
      "pneumonitis": "Permanent discontinuation grade 3+",
      "thyroid_dysfunction": "Hormone replacement"
    },
    "referenceList": [
      "NCCN Head-Neck Guidelines",
      "KEYNOTE Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "30 minutes"
    },
    "preMedications": {
      "irAE_education": "Comprehensive patient counseling",
      "thyroid_monitoring": "Baseline TFTs",
      "pneumonitis_monitoring": "Baseline chest imaging"
    },
    "postMedications": {
      "pneumonitis": "Report dyspnea immediately",
      "irAE_management": "Early steroid intervention",
      "thyroid_effects": "Monitor symptoms"
    },
    "supportiveCare": {
      "irAE_monitoring": "Weekly contact first 8 weeks",
      "thyroid_support": "Hormone replacement",
      "pneumonitis_prevention": "Serial chest imaging"
    },
    "rescueAgents": {
      "pneumonitis": "High-dose steroids, permanent discontinuation",
      "grade_4_irAEs": "Permanent discontinuation, high-dose steroids",
      "severe_thyroiditis": "Hormone replacement"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "TFTs",
        "PD-L1",
        "CXR"
      ],
      "each_cycle": "FBC, LFTs, TFTs",
      "weekly_first_8_weeks": "irAE assessment"
    },
    "toxicityMonitoring": {
      "thyroid": "Hormone levels",
      "pneumonitis": "Dyspnea assessment",
      "irAE_monitoring": "Weekly assessment first 8 weeks"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "immunosuppressants": "May reduce efficacy but needed for irAEs"
    },
    "contraindications": [
      "Active autoimmune disease",
      "Organ transplant",
      "Active pneumonitis"
    ],
    "version": "1.7",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a9aaaa2f-6192-4c0b-804d-a9023e977e67",
    "code": "Nivolumab-Head-Neck",
    "tumourGroup": "Head-Neck",
    "tumourSupergroup": "Head-Neck",
    "treatmentIntent": "Palliative",
    "summary": "Anti-PD-1 immunotherapy for platinum-refractory recurrent or metastatic head and neck cancer.",
    "eligibility": {
      "summary": [
        "Platinum-refractory HNSCC",
        "Second-line therapy"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Previous_platinum": "Required",
        "No_autoimmune_disease": "Required"
      }
    },
    "precautions": [
      "Immune-related adverse events",
      "Pneumonitis",
      "Colitis"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "240mg",
          "name": "Nivolumab",
          "route": "IV",
          "schedule": "Every 2 weeks"
        }
      ],
      "cycles": "Until progression or toxicity"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Thyroid function",
      "Chest imaging"
    ],
    "doseModifications": {
      "irAEs": "Hold nivolumab grade 2+",
      "colitis": "Steroids grade 2+",
      "pneumonitis": "Permanent discontinuation grade 3+"
    },
    "referenceList": [
      "NCCN Head-Neck Guidelines",
      "CheckMate Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "14 days",
      "total_cycles": "Until progression",
      "administration_time": "30 minutes"
    },
    "preMedications": {
      "irAE_education": "Comprehensive patient counseling",
      "colitis_monitoring": "Baseline stool assessment",
      "pneumonitis_monitoring": "Baseline chest imaging"
    },
    "postMedications": {
      "colitis": "Monitor stool frequency",
      "pneumonitis": "Report dyspnea immediately",
      "irAE_management": "Early steroid intervention"
    },
    "supportiveCare": {
      "irAE_monitoring": "Weekly contact first 8 weeks",
      "colitis_management": "Steroid protocol",
      "pneumonitis_prevention": "Serial chest imaging"
    },
    "rescueAgents": {
      "pneumonitis": "High-dose steroids, permanent discontinuation",
      "grade_4_irAEs": "Permanent discontinuation, high-dose steroids",
      "severe_colitis": "Infliximab if steroid-refractory"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "TFTs",
        "CXR",
        "Stool assessment"
      ],
      "each_cycle": "FBC, LFTs, TFTs",
      "weekly_first_8_weeks": "irAE assessment"
    },
    "toxicityMonitoring": {
      "colitis": "Stool frequency monitoring",
      "pneumonitis": "Dyspnea assessment, chest imaging",
      "irAE_monitoring": "Weekly assessment first 8 weeks"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "immunosuppressants": "May reduce efficacy but needed for irAEs"
    },
    "contraindications": [
      "Active autoimmune disease",
      "Organ transplant",
      "Active pneumonitis"
    ],
    "version": "1.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b0bbbb2f-6192-4c0b-804d-a9023e977e68",
    "code": "Methotrexate-Head-Neck",
    "tumourGroup": "Head-Neck",
    "tumourSupergroup": "Head-Neck",
    "treatmentIntent": "Palliative",
    "summary": "Single-agent methotrexate for recurrent or metastatic head and neck cancer when combination therapy not suitable.",
    "eligibility": {
      "summary": [
        "Recurrent/metastatic HNSCC",
        "Palliative single agent"
      ],
      "criteria": {
        "CrCl": "> 30 mL/min",
        "ECOG": "0-3",
        "Previous_therapy": "Platinum-based"
      }
    },
    "precautions": [
      "Methotrexate mucositis",
      "Myelosuppression",
      "Renal toxicity"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "40 mg/m²",
          "name": "Methotrexate",
          "route": "IV",
          "schedule": "Weekly"
        }
      ],
      "cycles": "Until progression"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Liver function tests",
      "Folate levels"
    ],
    "doseModifications": {
      "mucositis": "Reduce dose 25% for grade 2+",
      "renal_toxicity": "Reduce dose if CrCl <50",
      "myelosuppression": "Hold if ANC <1.0"
    },
    "referenceList": [
      "NCCN Head-Neck Guidelines",
      "Historical Studies"
    ],
    "cycleInfo": {
      "cycle_length": "Weekly",
      "total_cycles": "Until progression",
      "administration_time": "IV push"
    },
    "preMedications": {
      "hydration": "Adequate fluid intake",
      "mucositis_prevention": "Oral care protocol",
      "folate_supplementation": "Folic acid 5mg daily"
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "mucositis": "Magic mouthwash, soft diet",
      "myelosuppression": "Infection precautions"
    },
    "supportiveCare": {
      "mucositis_care": "Intensive oral hygiene",
      "renal_protection": "Adequate hydration",
      "folate_monitoring": "Regular levels"
    },
    "rescueAgents": {
      "renal_toxicity": "Dose reduction",
      "severe_mucositis": "Treatment delay, IV nutrition",
      "severe_myelosuppression": "G-CSF support"
    },
    "monitoring": {
      "weekly": "FBC, mucositis assessment",
      "monthly": "U&E, LFTs",
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "Folate",
        "CrCl"
      ]
    },
    "toxicityMonitoring": {
      "mucositis": "Weekly oral examination",
      "renal_function": "Regular creatinine",
      "myelosuppression": "Weekly FBC"
    },
    "interactions": {
      "warfarin": "Enhanced effect",
      "trimethoprim": "Folate antagonism"
    },
    "contraindications": [
      "Severe renal impairment",
      "Active mucositis",
      "Folate deficiency"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c1cccc2f-6192-4c0b-804d-a9023e977e69",
    "code": "Bortezomib-Melphalan-Prednisolone",
    "tumourGroup": "Myeloma",
    "tumourSupergroup": "Myeloma",
    "treatmentIntent": "Curative",
    "summary": "VMP regimen for newly diagnosed multiple myeloma in transplant-ineligible patients with excellent response rates.",
    "eligibility": {
      "summary": [
        "Newly diagnosed myeloma",
        "Transplant ineligible"
      ],
      "criteria": {
        "Age": "> 65 years or transplant ineligible",
        "ECOG": "0-3",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Bortezomib peripheral neuropathy",
      "Melphalan myelosuppression",
      "Herpes zoster risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "1.3 mg/m²",
          "name": "Bortezomib",
          "route": "SC",
          "schedule": "Days 1, 4, 8, 11, 22, 25, 29, 32"
        },
        {
          "dose": "9 mg/m²",
          "name": "Melphalan",
          "route": "PO",
          "schedule": "Days 1-4"
        },
        {
          "dose": "60mg/m²",
          "name": "Prednisolone",
          "route": "PO",
          "schedule": "Days 1-4"
        }
      ],
      "cycles": "9 cycles"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Paraprotein levels",
      "Neuropathy assessment"
    ],
    "doseModifications": {
      "neuropathy": "Reduce bortezomib dose or change to weekly",
      "herpes_zoster": "Antiviral prophylaxis",
      "myelosuppression": "G-CSF support if indicated"
    },
    "referenceList": [
      "NCCN Myeloma Guidelines",
      "VISTA Study",
      "IMWG Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "42 days cycles 1-4, then 35 days",
      "total_cycles": "9",
      "administration_time": "Variable schedule"
    },
    "preMedications": {
      "herpes_prophylaxis": "Aciclovir 400mg BD",
      "neuropathy_monitoring": "Baseline assessment",
      "myelosuppression_monitoring": "Weekly FBC first 2 cycles"
    },
    "postMedications": {
      "neuropathy": "Gabapentin if symptomatic",
      "myelosuppression": "Monitor counts",
      "infection_prevention": "Herpes prophylaxis"
    },
    "supportiveCare": {
      "infection_prevention": "Antiviral prophylaxis",
      "neuropathy_prevention": "Dose modifications",
      "myelosuppression_monitoring": "Regular FBC"
    },
    "rescueAgents": {
      "herpes_zoster": "Antiviral treatment",
      "severe_neuropathy": "Dose reduction, neurology referral",
      "severe_myelosuppression": "G-CSF support"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "Paraprotein",
        "Neuropathy score"
      ],
      "each_cycle": "FBC, paraprotein, neuropathy",
      "weekly_first_2_cycles": "FBC"
    },
    "toxicityMonitoring": {
      "response": "Paraprotein levels",
      "neuropathy": "Clinical neuropathy score",
      "myelosuppression": "Weekly FBC first 2 cycles"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "antiviral_prophylaxis": "Aciclovir recommended"
    },
    "contraindications": [
      "Severe neuropathy",
      "Active infection",
      "Pregnancy"
    ],
    "version": "2.3",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d2dddd2f-6192-4c0b-804d-a9023e977e70",
    "code": "Carfilzomib-Lenalidomide-Dex",
    "tumourGroup": "Myeloma",
    "tumourSupergroup": "Myeloma",
    "treatmentIntent": "Curative",
    "summary": "KRd regimen for newly diagnosed multiple myeloma with improved efficacy over bortezomib-based therapy.",
    "eligibility": {
      "summary": [
        "Newly diagnosed myeloma",
        "Transplant eligible or ineligible"
      ],
      "criteria": {
        "Age": "18+ years",
        "CrCl": "> 30 mL/min",
        "ECOG": "0-2"
      }
    },
    "precautions": [
      "Carfilzomib cardiotoxicity",
      "Lenalidomide thrombosis",
      "Tumor lysis syndrome"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "20/27 mg/m²",
          "name": "Carfilzomib",
          "route": "IV",
          "schedule": "Days 1, 2, 8, 9, 15, 16"
        },
        {
          "dose": "25mg",
          "name": "Lenalidomide",
          "route": "PO",
          "schedule": "Days 1-21"
        },
        {
          "dose": "40mg",
          "name": "Dexamethasone",
          "route": "PO",
          "schedule": "Days 1, 8, 15, 22"
        }
      ],
      "cycles": "Until progression"
    },
    "tests": [
      "Full blood count",
      "LVEF assessment",
      "Renal function",
      "Paraprotein levels"
    ],
    "doseModifications": {
      "TLS": "Hydration, allopurinol",
      "thrombosis": "Aspirin prophylaxis",
      "cardiotoxicity": "Monitor LVEF, reduce dose if drops"
    },
    "referenceList": [
      "NCCN Myeloma Guidelines",
      "ASPIRE Study",
      "IMWG Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "30-minute infusion"
    },
    "preMedications": {
      "TLS_prevention": "Hydration, allopurinol",
      "cardiac_monitoring": "Baseline LVEF",
      "thromboprophylaxis": "Aspirin 75mg daily"
    },
    "postMedications": {
      "TLS_monitoring": "LDH, uric acid",
      "cardiotoxicity": "Monitor for dyspnea",
      "thrombosis_prevention": "Mobilization"
    },
    "supportiveCare": {
      "TLS_prevention": "Hydration protocol",
      "cardiac_protection": "LVEF every 4 cycles",
      "thrombosis_prevention": "Risk assessment"
    },
    "rescueAgents": {
      "TLS": "Rasburicase if severe",
      "thrombosis": "Anticoagulation",
      "cardiotoxicity": "Cardio-oncology referral"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LVEF",
        "U&E",
        "Paraprotein"
      ],
      "each_cycle": "FBC, paraprotein",
      "every_4_cycles": "LVEF"
    },
    "toxicityMonitoring": {
      "TLS": "LDH and uric acid monitoring",
      "thrombosis": "Clinical assessment",
      "cardiotoxicity": "LVEF monitoring"
    },
    "interactions": {
      "thromboprophylaxis": "Aspirin or LMWH",
      "strong_CYP3A4_inhibitors": "Monitor closely"
    },
    "contraindications": [
      "Severe heart failure",
      "Active thrombosis without anticoagulation",
      "Pregnancy"
    ],
    "version": "2.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e3eeee2f-6192-4c0b-804d-a9023e977e71",
    "code": "Daratumumab-VMP",
    "tumourGroup": "Myeloma",
    "tumourSupergroup": "Myeloma",
    "treatmentIntent": "Curative",
    "summary": "Anti-CD38 monoclonal antibody with VMP for newly diagnosed multiple myeloma transplant-ineligible patients.",
    "eligibility": {
      "summary": [
        "Newly diagnosed myeloma",
        "Transplant ineligible"
      ],
      "criteria": {
        "Age": "> 65 years or transplant ineligible",
        "CD38": "Positive",
        "ECOG": "0-3"
      }
    },
    "precautions": [
      "Daratumumab infusion reactions",
      "Prolonged cytopenias",
      "Infection risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "16 mg/kg",
          "name": "Daratumumab",
          "route": "IV",
          "schedule": "Weekly cycles 1-6, then biweekly"
        },
        {
          "dose": "1.3 mg/m²",
          "name": "Bortezomib",
          "route": "SC",
          "schedule": "Days 1, 4, 8, 11"
        },
        {
          "dose": "9 mg/m²",
          "name": "Melphalan",
          "route": "PO",
          "schedule": "Days 1-4"
        },
        {
          "dose": "60mg/m²",
          "name": "Prednisolone",
          "route": "PO",
          "schedule": "Days 1-4"
        }
      ],
      "cycles": "9 cycles"
    },
    "tests": [
      "Full blood count",
      "Immunoglobulin levels",
      "Paraprotein levels",
      "CD38 expression"
    ],
    "doseModifications": {
      "infection": "Prophylaxis if hypogammaglobulinemia",
      "infusion_reactions": "Premedication protocol",
      "prolonged_cytopenias": "Extended monitoring"
    },
    "referenceList": [
      "NCCN Myeloma Guidelines",
      "ALCYONE Study",
      "IMWG Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "42 days cycles 1-4, then 35 days",
      "total_cycles": "9",
      "administration_time": "3-7 hours first infusion"
    },
    "preMedications": {
      "infusion_monitoring": "Vital signs every 30 minutes",
      "infection_monitoring": "Regular assessment",
      "daratumumab_premedication": "Corticosteroids, antihistamines, paracetamol"
    },
    "postMedications": {
      "infusion_reactions": "Stop infusion, supportive care",
      "infection_prevention": "Monitor for signs",
      "prolonged_monitoring": "Extended FBC monitoring"
    },
    "supportiveCare": {
      "infusion_management": "Premedication protocol",
      "infection_prevention": "Monitor immunoglobulins",
      "prolonged_monitoring": "Extended follow-up"
    },
    "rescueAgents": {
      "severe_infection": "IV antibiotics, IVIG",
      "prolonged_cytopenias": "Extended monitoring",
      "severe_infusion_reaction": "Discontinue daratumumab"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "Paraprotein",
        "Immunoglobulins",
        "CD38"
      ],
      "each_cycle": "FBC, paraprotein",
      "post_treatment": "Extended monitoring"
    },
    "toxicityMonitoring": {
      "response": "Paraprotein monitoring",
      "infection": "Regular clinical assessment",
      "infusion_reactions": "During daratumumab infusion"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "herpes_prophylaxis": "Antiviral recommended"
    },
    "contraindications": [
      "Active infection",
      "Previous severe infusion reaction",
      "Pregnancy"
    ],
    "version": "2.7",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f4ffff2f-6192-4c0b-804d-a9023e977e72",
    "code": "Pomalidomide-Dexamethasone",
    "tumourGroup": "Myeloma",
    "tumourSupergroup": "Myeloma",
    "treatmentIntent": "Palliative",
    "summary": "Third-generation immunomodulatory drug with dexamethasone for relapsed/refractory multiple myeloma.",
    "eligibility": {
      "summary": [
        "Relapsed/refractory myeloma",
        "≥2 prior therapies"
      ],
      "criteria": {
        "ANC": "> 0.5",
        "ECOG": "0-2",
        "Previous_lenalidomide_and_proteasome_inhibitor": "Required"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Thrombosis risk",
      "Infection risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "4mg daily",
          "name": "Pomalidomide",
          "route": "PO",
          "schedule": "Days 1-21"
        },
        {
          "dose": "40mg",
          "name": "Dexamethasone",
          "route": "PO",
          "schedule": "Days 1, 8, 15, 22"
        }
      ],
      "cycles": "Every 28 days"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Paraprotein levels",
      "Performance status"
    ],
    "doseModifications": {
      "infection": "Monitor closely",
      "thrombosis": "Prophylaxis if high risk",
      "myelosuppression": "Dose reduction for grade 3+"
    },
    "referenceList": [
      "NCCN Myeloma Guidelines",
      "MM-003 Study",
      "IMWG Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "21 days pomalidomide + dexamethasone"
    },
    "preMedications": {
      "thromboprophylaxis": "Risk assessment",
      "infection_monitoring": "Regular assessment",
      "myelosuppression_monitoring": "Weekly FBC first 8 weeks"
    },
    "postMedications": {
      "myelosuppression": "Monitor counts closely",
      "infection_prevention": "Monitor for signs",
      "thrombosis_prevention": "Aspirin or LMWH"
    },
    "supportiveCare": {
      "infection_prevention": "Regular assessment",
      "thrombosis_prevention": "Risk-based prophylaxis",
      "neutropenia_monitoring": "Weekly FBC first 8 weeks"
    },
    "rescueAgents": {
      "thrombosis": "Anticoagulation therapy",
      "severe_infection": "IV antibiotics",
      "severe_neutropenia": "G-CSF support"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "Paraprotein",
        "ECOG"
      ],
      "each_cycle": "FBC, paraprotein",
      "weekly_first_8_weeks": "FBC"
    },
    "toxicityMonitoring": {
      "response": "Paraprotein levels",
      "thrombosis": "Clinical assessment",
      "myelosuppression": "Weekly FBC first 8 weeks"
    },
    "interactions": {
      "thromboprophylaxis": "Aspirin or LMWH",
      "strong_CYP3A4_inhibitors": "Monitor closely"
    },
    "contraindications": [
      "Severe myelosuppression",
      "Active thrombosis",
      "Pregnancy"
    ],
    "version": "1.9",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a5aaaa2f-6192-4c0b-804d-a9023e977e73",
    "code": "Elotuzumab-Lenalidomide-Dex",
    "tumourGroup": "Myeloma",
    "tumourSupergroup": "Myeloma",
    "treatmentIntent": "Palliative",
    "summary": "Anti-SLAMF7 monoclonal antibody with lenalidomide and dexamethasone for relapsed/refractory myeloma.",
    "eligibility": {
      "summary": [
        "Relapsed/refractory myeloma",
        "1-3 prior therapies"
      ],
      "criteria": {
        "ECOG": "0-2",
        "SLAMF7": "Positive",
        "Previous_therapy": "1-3 lines"
      }
    },
    "precautions": [
      "Elotuzumab infusion reactions",
      "Lenalidomide thrombosis",
      "Infection risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "10 mg/kg cycles 1-2, then 20 mg/kg",
          "name": "Elotuzumab",
          "route": "IV",
          "schedule": "Days 1, 8, 15, 22 cycles 1-2, then days 1, 15"
        },
        {
          "dose": "25mg",
          "name": "Lenalidomide",
          "route": "PO",
          "schedule": "Days 1-21"
        },
        {
          "dose": "28mg/40mg",
          "name": "Dexamethasone",
          "route": "PO/IV",
          "schedule": "Days 1, 8, 15, 22"
        }
      ],
      "cycles": "Every 28 days"
    },
    "tests": [
      "Full blood count",
      "Paraprotein levels",
      "SLAMF7 expression",
      "Performance status"
    ],
    "doseModifications": {
      "infection": "Monitor for signs",
      "thrombosis": "Aspirin prophylaxis",
      "infusion_reactions": "Premedication protocol"
    },
    "referenceList": [
      "NCCN Myeloma Guidelines",
      "ELOQUENT-2 Study",
      "IMWG Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "2-5 hours"
    },
    "preMedications": {
      "thromboprophylaxis": "Aspirin 75mg daily",
      "infusion_monitoring": "Vital signs monitoring",
      "elotuzumab_premedication": "Dexamethasone, antihistamines, paracetamol"
    },
    "postMedications": {
      "infusion_reactions": "Stop infusion if severe",
      "infection_prevention": "Monitor for signs",
      "thrombosis_prevention": "Mobilization"
    },
    "supportiveCare": {
      "infusion_management": "Premedication protocol",
      "infection_prevention": "Regular monitoring",
      "thrombosis_prevention": "Risk-based prophylaxis"
    },
    "rescueAgents": {
      "thrombosis": "Anticoagulation therapy",
      "severe_infection": "IV antibiotics",
      "severe_infusion_reaction": "Discontinue elotuzumab"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "Paraprotein",
        "SLAMF7",
        "ECOG"
      ],
      "infusion": "Vital signs monitoring",
      "each_cycle": "FBC, paraprotein"
    },
    "toxicityMonitoring": {
      "response": "Paraprotein monitoring",
      "thrombosis": "Clinical assessment",
      "infusion_reactions": "During elotuzumab infusion"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "thromboprophylaxis": "Aspirin or LMWH"
    },
    "contraindications": [
      "Previous severe infusion reaction",
      "Active thrombosis",
      "Pregnancy"
    ],
    "version": "2.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b6bbbb2f-6192-4c0b-804d-a9023e977e74",
    "code": "Ixazomib-Lenalidomide-Dex",
    "tumourGroup": "Myeloma",
    "tumourSupergroup": "Myeloma",
    "treatmentIntent": "Palliative",
    "summary": "Oral proteasome inhibitor with lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.",
    "eligibility": {
      "summary": [
        "Relapsed/refractory myeloma",
        "1-3 prior therapies"
      ],
      "criteria": {
        "CrCl": "> 30 mL/min",
        "ECOG": "0-2",
        "Previous_therapy": "1-3 lines"
      }
    },
    "precautions": [
      "Peripheral neuropathy",
      "Thrombocytopenia",
      "Gastrointestinal toxicity"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "4mg",
          "name": "Ixazomib",
          "route": "PO",
          "schedule": "Days 1, 8, 15"
        },
        {
          "dose": "25mg",
          "name": "Lenalidomide",
          "route": "PO",
          "schedule": "Days 1-21"
        },
        {
          "dose": "40mg",
          "name": "Dexamethasone",
          "route": "PO",
          "schedule": "Days 1, 8, 15, 22"
        }
      ],
      "cycles": "Every 28 days"
    },
    "tests": [
      "Full blood count",
      "Paraprotein levels",
      "Neuropathy assessment",
      "Performance status"
    ],
    "doseModifications": {
      "neuropathy": "Dose reduction for grade 2+",
      "GI_toxicity": "Dose reduction",
      "thrombocytopenia": "Hold if platelets <30k"
    },
    "referenceList": [
      "NCCN Myeloma Guidelines",
      "TOURMALINE Studies",
      "IMWG Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "All oral therapy"
    },
    "preMedications": {
      "GI_monitoring": "Baseline symptoms",
      "neuropathy_monitoring": "Baseline assessment",
      "thrombocytopenia_monitoring": "Weekly FBC first 3 cycles"
    },
    "postMedications": {
      "GI_effects": "Take on empty stomach",
      "neuropathy": "Gabapentin if symptomatic",
      "thrombocytopenia": "Monitor counts"
    },
    "supportiveCare": {
      "GI_management": "Supportive care",
      "platelet_monitoring": "Weekly FBC first 3 cycles",
      "neuropathy_prevention": "Dose modifications"
    },
    "rescueAgents": {
      "severe_GI": "Dose modification",
      "severe_neuropathy": "Dose reduction or discontinuation",
      "severe_thrombocytopenia": "Platelet transfusion"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "Paraprotein",
        "Neuropathy score",
        "ECOG"
      ],
      "each_cycle": "FBC, paraprotein, neuropathy",
      "weekly_first_3_cycles": "FBC"
    },
    "toxicityMonitoring": {
      "response": "Paraprotein levels",
      "neuropathy": "Clinical grading each cycle",
      "thrombocytopenia": "Weekly platelet monitoring first 3 cycles"
    },
    "interactions": {
      "acid_reducing_agents": "Take ixazomib 1 hour before",
      "strong_CYP3A4_inducers": "May reduce efficacy"
    },
    "contraindications": [
      "Severe neuropathy",
      "Severe thrombocytopenia",
      "Pregnancy"
    ],
    "version": "1.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c7cccc2f-6192-4c0b-804d-a9023e977e75",
    "code": "Selinexor-Dexamethasone",
    "tumourGroup": "Myeloma",
    "tumourSupergroup": "Myeloma",
    "treatmentIntent": "Palliative",
    "summary": "Selective nuclear export inhibitor with dexamethasone for heavily pretreated relapsed/refractory myeloma.",
    "eligibility": {
      "summary": [
        "Heavily pretreated myeloma",
        "≥4 prior therapies"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Platelet_count": "> 50k",
        "Previous_therapies": "≥4 lines including PI, IMiD, anti-CD38"
      }
    },
    "precautions": [
      "Severe nausea and vomiting",
      "Thrombocytopenia",
      "Hyponatremia"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "80mg",
          "name": "Selinexor",
          "route": "PO",
          "schedule": "Days 1 and 3 weekly"
        },
        {
          "dose": "20mg",
          "name": "Dexamethasone",
          "route": "PO",
          "schedule": "Days 1 and 3 weekly"
        }
      ],
      "cycles": "Weekly until progression"
    },
    "tests": [
      "Full blood count",
      "Electrolytes",
      "Paraprotein levels",
      "Weight monitoring"
    ],
    "doseModifications": {
      "nausea": "Aggressive antiemetics, dose reduction",
      "hyponatremia": "Sodium monitoring",
      "thrombocytopenia": "Hold if platelets <50k"
    },
    "referenceList": [
      "NCCN Myeloma Guidelines",
      "STORM Study",
      "FDA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "Weekly",
      "total_cycles": "Until progression",
      "administration_time": "Twice weekly oral"
    },
    "preMedications": {
      "weight_monitoring": "Baseline weight",
      "antiemetic_protocol": "5-HT3 antagonists, NK1 antagonists",
      "electrolyte_monitoring": "Baseline Na, K"
    },
    "postMedications": {
      "nausea": "Aggressive antiemetic support",
      "hyponatremia": "Monitor electrolytes",
      "thrombocytopenia": "Monitor counts"
    },
    "supportiveCare": {
      "nausea_management": "Comprehensive antiemetic protocol",
      "weight_monitoring": "Weekly weights",
      "electrolyte_monitoring": "Regular Na monitoring"
    },
    "rescueAgents": {
      "severe_nausea": "IV antiemetics, dose reduction",
      "severe_hyponatremia": "IV saline",
      "severe_thrombocytopenia": "Platelet transfusion"
    },
    "monitoring": {
      "weekly": "FBC, electrolytes, weight",
      "baseline": [
        "FBC",
        "Electrolytes",
        "Paraprotein",
        "Weight"
      ],
      "each_cycle": "Paraprotein"
    },
    "toxicityMonitoring": {
      "nausea": "Daily assessment",
      "hyponatremia": "Weekly sodium levels",
      "thrombocytopenia": "Twice weekly platelet counts"
    },
    "interactions": {
      "P-gp_inhibitors": "Monitor for increased toxicity",
      "strong_CYP3A4_inhibitors": "Reduce selinexor dose"
    },
    "contraindications": [
      "Severe nausea/vomiting",
      "Severe thrombocytopenia",
      "Pregnancy"
    ],
    "version": "1.2",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d8dddd2f-6192-4c0b-804d-a9023e977e76",
    "code": "Belantamab-Mafodotin",
    "tumourGroup": "Myeloma",
    "tumourSupergroup": "Myeloma",
    "treatmentIntent": "Palliative",
    "summary": "Anti-BCMA antibody-drug conjugate for relapsed/refractory multiple myeloma with unique ocular toxicity.",
    "eligibility": {
      "summary": [
        "Relapsed/refractory myeloma",
        "≥4 prior therapies"
      ],
      "criteria": {
        "BCMA": "Positive",
        "ECOG": "0-2",
        "Previous_therapies": "≥4 lines"
      }
    },
    "precautions": [
      "Keratopathy and vision changes",
      "Thrombocytopenia",
      "Infusion reactions"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "2.5 mg/kg",
          "name": "Belantamab mafodotin",
          "route": "IV",
          "schedule": "Every 3 weeks"
        }
      ],
      "cycles": "Until progression or toxicity"
    },
    "tests": [
      "Full blood count",
      "BCMA expression",
      "Ophthalmologic examination",
      "Performance status"
    ],
    "doseModifications": {
      "keratopathy": "Dose delay or reduction for grade 2+",
      "thrombocytopenia": "Hold if platelets <25k",
      "infusion_reactions": "Premedication protocol"
    },
    "referenceList": [
      "NCCN Myeloma Guidelines",
      "DREAMM Studies",
      "IMWG Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "30 minutes"
    },
    "preMedications": {
      "infusion_monitoring": "Vital signs",
      "ophthalmologic_monitoring": "Baseline eye exam",
      "thrombocytopenia_monitoring": "Baseline FBC"
    },
    "postMedications": {
      "keratopathy": "Preservative-free artificial tears",
      "thrombocytopenia": "Monitor counts",
      "infusion_reactions": "Premedication"
    },
    "supportiveCare": {
      "infusion_management": "Premedication protocol",
      "platelet_monitoring": "Weekly FBC",
      "ophthalmologic_monitoring": "Eye exam before each cycle"
    },
    "rescueAgents": {
      "severe_keratopathy": "Ophthalmology referral, treatment delay",
      "severe_thrombocytopenia": "Platelet transfusion",
      "severe_infusion_reaction": "Discontinue"
    },
    "monitoring": {
      "weekly": "FBC",
      "baseline": [
        "FBC",
        "BCMA",
        "Eye exam",
        "ECOG"
      ],
      "before_each_cycle": "Eye exam"
    },
    "toxicityMonitoring": {
      "keratopathy": "Ophthalmologic exam before each cycle",
      "thrombocytopenia": "Weekly platelet monitoring",
      "infusion_reactions": "During infusion"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "topical_corticosteroids": "May worsen keratopathy"
    },
    "contraindications": [
      "Severe keratopathy",
      "Severe thrombocytopenia",
      "Pregnancy"
    ],
    "version": "1.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e9eeee2f-6192-4c0b-804d-a9023e977e77",
    "code": "Melphalan-Flufenamide",
    "tumourGroup": "Myeloma",
    "tumourSupergroup": "Myeloma",
    "treatmentIntent": "Palliative",
    "summary": "Peptide-drug conjugate delivering melphalan selectively to myeloma cells for relapsed/refractory disease.",
    "eligibility": {
      "summary": [
        "Relapsed/refractory myeloma",
        "≥4 prior therapies"
      ],
      "criteria": {
        "ANC": "> 1.0",
        "ECOG": "0-2",
        "Previous_therapies": "≥4 lines including PI, IMiD, anti-CD38"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Thrombocytopenia",
      "Febrile neutropenia"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "40mg",
          "name": "Melphalan flufenamide",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "40mg",
          "name": "Dexamethasone",
          "route": "PO/IV",
          "schedule": "Days 1, 8, 15, 22"
        }
      ],
      "cycles": "Every 28 days"
    },
    "tests": [
      "Full blood count",
      "Paraprotein levels",
      "Performance status",
      "Infection assessment"
    ],
    "doseModifications": {
      "myelosuppression": "G-CSF support, dose reduction",
      "thrombocytopenia": "Hold if platelets <50k",
      "febrile_neutropenia": "Immediate antibiotics"
    },
    "referenceList": [
      "NCCN Myeloma Guidelines",
      "HORIZON Study",
      "EMA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "30 minutes"
    },
    "preMedications": {
      "G-CSF": "Primary prophylaxis",
      "infection_prevention": "Monitor for signs",
      "myelosuppression_monitoring": "Weekly FBC first 2 cycles"
    },
    "postMedications": {
      "myelosuppression": "G-CSF support",
      "thrombocytopenia": "Monitor counts",
      "infection_prevention": "Hygiene measures"
    },
    "supportiveCare": {
      "infection_prevention": "Prophylactic G-CSF",
      "neutropenia_monitoring": "Weekly FBC first 2 cycles",
      "thrombocytopenia_monitoring": "Regular platelet counts"
    },
    "rescueAgents": {
      "severe_infection": "IV antibiotics",
      "febrile_neutropenia": "G-CSF, broad-spectrum antibiotics",
      "severe_thrombocytopenia": "Platelet transfusion"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "Paraprotein",
        "ECOG",
        "Infection screen"
      ],
      "each_cycle": "FBC, paraprotein",
      "weekly_first_2_cycles": "FBC"
    },
    "toxicityMonitoring": {
      "response": "Paraprotein levels",
      "infection": "Clinical monitoring",
      "myelosuppression": "Weekly FBC first 2 cycles"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "nephrotoxic_drugs": "Monitor renal function"
    },
    "contraindications": [
      "Severe myelosuppression",
      "Active infection",
      "Pregnancy"
    ],
    "version": "1.3",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f0ffff2f-6192-4c0b-804d-a9023e977e78",
    "code": "Teclistamab",
    "tumourGroup": "Myeloma",
    "tumourSupergroup": "Myeloma",
    "treatmentIntent": "Palliative",
    "summary": "Bispecific T-cell engager targeting BCMA for heavily pretreated relapsed/refractory multiple myeloma.",
    "eligibility": {
      "summary": [
        "Heavily pretreated myeloma",
        "≥3 prior therapies"
      ],
      "criteria": {
        "BCMA": "Positive",
        "ECOG": "0-2",
        "Previous_therapies": "≥3 lines including PI, IMiD, anti-CD38"
      }
    },
    "precautions": [
      "Cytokine release syndrome",
      "Neurotoxicity",
      "Cytopenias"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "Step-up dosing: 0.06mg/kg, 0.3mg/kg, then 1.5mg/kg",
          "name": "Teclistamab",
          "route": "SC",
          "schedule": "Weekly"
        }
      ],
      "cycles": "Weekly until progression"
    },
    "tests": [
      "Full blood count",
      "BCMA expression",
      "Neurological assessment",
      "Cytokine levels"
    ],
    "doseModifications": {
      "CRS": "Tocilizumab, steroids for grade 2+",
      "cytopenias": "G-CSF, transfusions",
      "neurotoxicity": "Steroids, supportive care"
    },
    "referenceList": [
      "NCCN Myeloma Guidelines",
      "MajesTEC-1 Study",
      "FDA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "Weekly",
      "total_cycles": "Until progression",
      "administration_time": "Step-up dosing protocol"
    },
    "preMedications": {
      "CRS_monitoring": "Temperature, vital signs",
      "step_up_dosing": "Hospitalization for first doses",
      "neurotoxicity_monitoring": "Neurological assessment"
    },
    "postMedications": {
      "CRS": "Supportive care, tocilizumab if severe",
      "cytopenias": "Transfusion support",
      "neurotoxicity": "Neurological monitoring"
    },
    "supportiveCare": {
      "CRS_management": "Tocilizumab available",
      "cytopenia_support": "G-CSF, transfusions",
      "neurotoxicity_monitoring": "Regular assessment"
    },
    "rescueAgents": {
      "severe_CRS": "Tocilizumab, steroids, ICU care",
      "severe_cytopenias": "Transfusion support",
      "severe_neurotoxicity": "Steroids, neurology referral"
    },
    "monitoring": {
      "weekly": "FBC, neuro assessment",
      "baseline": [
        "FBC",
        "BCMA",
        "Neuro assessment",
        "Cytokines"
      ],
      "each_cycle": "Paraprotein"
    },
    "toxicityMonitoring": {
      "CRS": "Temperature monitoring, cytokine levels",
      "cytopenias": "Regular FBC",
      "neurotoxicity": "Neurological examination"
    },
    "interactions": {
      "tocilizumab": "Available for CRS management",
      "live_vaccines": "Contraindicated"
    },
    "contraindications": [
      "Active infection",
      "Severe cytopenias",
      "Pregnancy"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a1bbbb2f-6192-4c0b-804d-a9023e977e79",
    "code": "Ciltacabtagene-Autoleucel",
    "tumourGroup": "Myeloma",
    "tumourSupergroup": "Myeloma",
    "treatmentIntent": "Curative",
    "summary": "CAR-T cell therapy targeting BCMA for relapsed/refractory multiple myeloma with exceptional response rates.",
    "eligibility": {
      "summary": [
        "Relapsed/refractory myeloma",
        "≥3 prior therapies"
      ],
      "criteria": {
        "BCMA": "Positive",
        "ECOG": "0-2",
        "Previous_therapies": "≥3 lines including PI, IMiD, anti-CD38"
      }
    },
    "precautions": [
      "Cytokine release syndrome",
      "Neurotoxicity",
      "Prolonged cytopenias"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "0.5-1.0 x 10^6 CAR+ cells/kg",
          "name": "Ciltacabtagene autoleucel",
          "route": "IV",
          "schedule": "Single infusion"
        }
      ],
      "cycles": "Single treatment"
    },
    "tests": [
      "Full blood count",
      "BCMA expression",
      "Neurological assessment",
      "Cardiac function"
    ],
    "doseModifications": {
      "CRS": "Tocilizumab, steroids for grade 2+",
      "cytopenias": "Transfusions, G-CSF",
      "neurotoxicity": "Steroids, supportive care"
    },
    "referenceList": [
      "NCCN Myeloma Guidelines",
      "CARTITUDE Studies",
      "FDA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "Single infusion",
      "total_cycles": "1",
      "administration_time": "CAR-T manufacturing and infusion"
    },
    "preMedications": {
      "CRS_monitoring": "ICU-level care",
      "lymphodepletion": "Fludarabine and cyclophosphamide",
      "neurotoxicity_monitoring": "Neurological assessment"
    },
    "postMedications": {
      "CRS": "Supportive care, tocilizumab",
      "cytopenias": "Transfusion support",
      "neurotoxicity": "Neurological monitoring"
    },
    "supportiveCare": {
      "CRS_management": "Tocilizumab, steroids",
      "neurotoxicity_care": "ICU monitoring",
      "long_term_monitoring": "Extended follow-up"
    },
    "rescueAgents": {
      "severe_CRS": "Tocilizumab, steroids, ICU",
      "prolonged_cytopenias": "Long-term support",
      "severe_neurotoxicity": "Steroids, neurology"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "BCMA",
        "Neuro assessment",
        "Cardiac function"
      ],
      "long_term": "Extended monitoring",
      "daily_first_week": "FBC, neuro"
    },
    "toxicityMonitoring": {
      "CRS": "Daily monitoring first week",
      "cytopenias": "Long-term FBC monitoring",
      "neurotoxicity": "Neurological examination"
    },
    "interactions": {
      "live_vaccines": "Contraindicated long-term",
      "immunosuppression": "Monitor for infections"
    },
    "contraindications": [
      "Active infection",
      "Severe organ dysfunction",
      "Pregnancy"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b2cccc2f-6192-4c0b-804d-a9023e977e80",
    "code": "Idecabtagene-Vicleucel",
    "tumourGroup": "Myeloma",
    "tumourSupergroup": "Myeloma",
    "treatmentIntent": "Curative",
    "summary": "CAR-T cell therapy targeting BCMA for relapsed/refractory multiple myeloma with durable responses.",
    "eligibility": {
      "summary": [
        "Relapsed/refractory myeloma",
        "≥4 prior therapies"
      ],
      "criteria": {
        "BCMA": "Positive",
        "ECOG": "0-1",
        "Previous_therapies": "≥4 lines"
      }
    },
    "precautions": [
      "Cytokine release syndrome",
      "Neurotoxicity",
      "Secondary malignancies"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "150-450 x 10^6 CAR+ cells",
          "name": "Idecabtagene vicleucel",
          "route": "IV",
          "schedule": "Single infusion"
        }
      ],
      "cycles": "Single treatment"
    },
    "tests": [
      "Full blood count",
      "BCMA expression",
      "Neurological assessment",
      "Paraprotein levels"
    ],
    "doseModifications": {
      "CRS": "Tocilizumab, steroids for grade 2+",
      "cytopenias": "Transfusions",
      "neurotoxicity": "Steroids, supportive care"
    },
    "referenceList": [
      "NCCN Myeloma Guidelines",
      "KarMMa Study",
      "FDA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "Single infusion",
      "total_cycles": "1",
      "administration_time": "CAR-T manufacturing and infusion"
    },
    "preMedications": {
      "apheresis": "T-cell collection",
      "CRS_monitoring": "ICU-level care",
      "lymphodepletion": "Fludarabine and cyclophosphamide"
    },
    "postMedications": {
      "CRS": "Supportive care, tocilizumab",
      "neurotoxicity": "Neurological monitoring",
      "infection_prevention": "Monitor closely"
    },
    "supportiveCare": {
      "CRS_management": "Tocilizumab available",
      "neurotoxicity_care": "Specialized monitoring",
      "infection_prevention": "Prophylaxis"
    },
    "rescueAgents": {
      "infections": "Broad-spectrum antibiotics",
      "severe_CRS": "Tocilizumab, steroids, ICU care",
      "severe_neurotoxicity": "Steroids, neurology referral"
    },
    "monitoring": {
      "monthly": "Paraprotein",
      "baseline": [
        "FBC",
        "BCMA",
        "Neuro assessment",
        "Paraprotein"
      ],
      "daily_first_week": "FBC, neuro"
    },
    "toxicityMonitoring": {
      "CRS": "Daily monitoring first week",
      "response": "Paraprotein levels",
      "neurotoxicity": "Neurological examination"
    },
    "interactions": {
      "live_vaccines": "Contraindicated permanently",
      "secondary_malignancies": "Long-term surveillance"
    },
    "contraindications": [
      "Active infection",
      "Secondary malignancy",
      "Pregnancy"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c3dddd2f-6192-4c0b-804d-a9023e977e81",
    "code": "Cisplatin-Gemcitabine-Ovarian",
    "tumourGroup": "Ovarian",
    "tumourSupergroup": "Ovarian",
    "treatmentIntent": "Curative",
    "summary": "Alternative platinum-based therapy for ovarian cancer when carboplatin contraindicated due to hypersensitivity.",
    "eligibility": {
      "summary": [
        "Ovarian cancer",
        "Carboplatin hypersensitivity"
      ],
      "criteria": {
        "CrCl": "> 60 mL/min",
        "ECOG": "0-2",
        "Carboplatin_hypersensitivity": "Previous reaction"
      }
    },
    "precautions": [
      "Cisplatin nephrotoxicity and ototoxicity",
      "Gemcitabine thrombocytopenia",
      "Fluid retention"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "75 mg/m²",
          "name": "Cisplatin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "1250 mg/m²",
          "name": "Gemcitabine",
          "route": "IV",
          "schedule": "Days 1 and 8"
        }
      ],
      "cycles": "6 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Hearing assessment",
      "CA-125"
    ],
    "doseModifications": {
      "ototoxicity": "Audiometry if hearing loss",
      "nephrotoxicity": "Hold if creatinine >1.5x baseline",
      "thrombocytopenia": "Hold if platelets <75k"
    },
    "referenceList": [
      "NCCN Ovarian Guidelines",
      "Alternative Regimens",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "6",
      "administration_time": "2 days per cycle"
    },
    "preMedications": {
      "hydration": "Normal saline 1-2L with Mg/K supplementation",
      "antiemetic": "Ondansetron 8mg IV",
      "audiometry": "Baseline hearing assessment"
    },
    "postMedications": {
      "ototoxicity": "Report hearing changes",
      "nephrotoxicity": "Adequate hydration",
      "thrombocytopenia": "Monitor counts"
    },
    "supportiveCare": {
      "renal_protection": "Pre/post hydration",
      "platelet_monitoring": "Weekly FBC",
      "ototoxicity_monitoring": "Regular audiometry"
    },
    "rescueAgents": {
      "ototoxicity": "Hearing aids if permanent",
      "nephrotoxicity": "Discontinue cisplatin",
      "severe_thrombocytopenia": "Platelet transfusion"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "CA-125",
        "Audiometry",
        "CrCl"
      ],
      "each_cycle": [
        "FBC",
        "U&E",
        "CA-125"
      ],
      "every_2_cycles": "Audiometry"
    },
    "toxicityMonitoring": {
      "ototoxicity": "Audiometry every 2 cycles",
      "nephrotoxicity": "Creatinine monitoring",
      "thrombocytopenia": "Weekly platelet monitoring"
    },
    "interactions": {
      "loop_diuretics": "Increased ototoxicity",
      "aminoglycosides": "Increased nephrotoxicity"
    },
    "contraindications": [
      "Severe renal impairment",
      "Significant hearing loss",
      "Pregnancy"
    ],
    "version": "1.7",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d4eeee2f-6192-4c0b-804d-a9023e977e82",
    "code": "Topotecan-Weekly",
    "tumourGroup": "Ovarian",
    "tumourSupergroup": "Ovarian",
    "treatmentIntent": "Palliative",
    "summary": "Weekly topotecan for platinum-resistant recurrent ovarian cancer with improved tolerability profile.",
    "eligibility": {
      "summary": [
        "Platinum-resistant ovarian cancer",
        "Recurrent disease"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Platinum_free_interval": "< 6 months",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Diarrhea",
      "Alopecia"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "4 mg/m²",
          "name": "Topotecan",
          "route": "IV",
          "schedule": "Days 1, 8, 15"
        }
      ],
      "cycles": "Every 28 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "CA-125",
      "Performance status"
    ],
    "doseModifications": {
      "diarrhea": "Supportive care",
      "neutropenia": "Dose reduction 25% for grade 3+",
      "thrombocytopenia": "Hold if platelets <50k"
    },
    "referenceList": [
      "NCCN Ovarian Guidelines",
      "Weekly Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "3 days per cycle"
    },
    "preMedications": {
      "antiemetic": "Ondansetron 8mg IV",
      "alopecia_counseling": "Hair loss expected",
      "myelosuppression_monitoring": "Weekly FBC"
    },
    "postMedications": {
      "alopecia": "Scalp cooling if available",
      "diarrhea": "Loperamide",
      "myelosuppression": "Infection precautions"
    },
    "supportiveCare": {
      "tumor_monitoring": "CA-125 every 2 cycles",
      "infection_prevention": "Hygiene measures",
      "neutropenia_monitoring": "Weekly FBC"
    },
    "rescueAgents": {
      "severe_diarrhea": "IV hydration",
      "febrile_neutropenia": "G-CSF, antibiotics",
      "severe_thrombocytopenia": "Platelet transfusion"
    },
    "monitoring": {
      "weekly": "FBC",
      "baseline": [
        "FBC",
        "LFTs",
        "CA-125",
        "ECOG"
      ],
      "every_2_cycles": "CA-125"
    },
    "toxicityMonitoring": {
      "diarrhea": "Frequency monitoring",
      "tumor_response": "CA-125 every 2 cycles",
      "myelosuppression": "Weekly FBC monitoring"
    },
    "interactions": {
      "phenytoin": "May reduce efficacy",
      "live_vaccines": "Contraindicated"
    },
    "contraindications": [
      "Severe myelosuppression",
      "Active infection",
      "Pregnancy"
    ],
    "version": "1.4",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e5ffff2f-6192-4c0b-804d-a9023e977e83",
    "code": "Liposomal-Doxorubicin",
    "tumourGroup": "Ovarian",
    "tumourSupergroup": "Ovarian",
    "treatmentIntent": "Palliative",
    "summary": "Pegylated liposomal doxorubicin for platinum-resistant recurrent ovarian cancer with reduced cardiotoxicity.",
    "eligibility": {
      "summary": [
        "Platinum-resistant ovarian cancer",
        "Recurrent disease"
      ],
      "criteria": {
        "ECOG": "0-2",
        "LVEF": "> 50%",
        "Platinum_free_interval": "< 6 months"
      }
    },
    "precautions": [
      "Hand-foot syndrome",
      "Mucositis",
      "Infusion reactions"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "40 mg/m²",
          "name": "Pegylated liposomal doxorubicin",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "Every 28 days"
    },
    "tests": [
      "Full blood count",
      "LVEF assessment",
      "CA-125",
      "Hand-foot assessment"
    ],
    "doseModifications": {
      "mucositis": "Dose delay",
      "hand_foot_syndrome": "Dose reduction 25% for grade 2+",
      "cardiac_dysfunction": "LVEF monitoring"
    },
    "referenceList": [
      "NCCN Ovarian Guidelines",
      "CALYPSO Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "1 hour"
    },
    "preMedications": {
      "skin_care": "Moisturizers, avoid friction",
      "cardiac_monitoring": "Baseline LVEF",
      "infusion_monitoring": "Slow initial rate"
    },
    "postMedications": {
      "mucositis": "Oral care",
      "hand_foot_syndrome": "Urea cream, dose modification",
      "infusion_reactions": "Premedication"
    },
    "supportiveCare": {
      "skin_monitoring": "Regular foot inspection",
      "cardiac_protection": "LVEF every 4 cycles",
      "mucositis_prevention": "Oral hygiene"
    },
    "rescueAgents": {
      "severe_mucositis": "Treatment delay",
      "cardiac_dysfunction": "Cardio-oncology referral",
      "severe_hand_foot_syndrome": "Dose interruption, topical care"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LVEF",
        "CA-125",
        "Skin assessment"
      ],
      "each_cycle": "FBC, CA-125, skin assessment",
      "every_4_cycles": "LVEF"
    },
    "toxicityMonitoring": {
      "tumor_response": "CA-125 levels",
      "cardiac_function": "Serial LVEF monitoring",
      "hand_foot_syndrome": "CTCAE grading"
    },
    "interactions": {
      "dexrazoxane": "For cardioprotection if needed",
      "live_vaccines": "Contraindicated"
    },
    "contraindications": [
      "Severe cardiac dysfunction",
      "Severe hand-foot syndrome",
      "Pregnancy"
    ],
    "version": "1.6",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f6aaaa2f-6192-4c0b-804d-a9023e977e84",
    "code": "Paclitaxel-Weekly-Ovarian",
    "tumourGroup": "Ovarian",
    "tumourSupergroup": "Ovarian",
    "treatmentIntent": "Palliative",
    "summary": "Weekly paclitaxel for platinum-resistant recurrent ovarian cancer with improved neuropathy profile.",
    "eligibility": {
      "summary": [
        "Platinum-resistant ovarian cancer",
        "Weekly schedule"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Previous_taxane": "Allowed",
        "Platinum_free_interval": "< 6 months"
      }
    },
    "precautions": [
      "Peripheral neuropathy",
      "Hypersensitivity reactions",
      "Myelosuppression"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "80 mg/m²",
          "name": "Paclitaxel",
          "route": "IV",
          "schedule": "Days 1, 8, 15"
        }
      ],
      "cycles": "Every 28 days"
    },
    "tests": [
      "Full blood count",
      "CA-125",
      "Neuropathy assessment",
      "Performance status"
    ],
    "doseModifications": {
      "neuropathy": "Dose reduction 25% for grade 2+",
      "neutropenia": "Hold if ANC <1.0",
      "hypersensitivity": "Premedication protocol"
    },
    "referenceList": [
      "NCCN Ovarian Guidelines",
      "Weekly Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "3 days per cycle"
    },
    "preMedications": {
      "antiemetic": "Ondansetron 8mg IV",
      "neuropathy_monitoring": "Baseline assessment",
      "hypersensitivity_prevention": "Dexamethasone, antihistamines"
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "neuropathy": "Gabapentin if symptomatic",
      "hypersensitivity": "Monitor during infusion"
    },
    "supportiveCare": {
      "tumor_monitoring": "CA-125 every 2 cycles",
      "neuropathy_prevention": "Weekly assessment",
      "hypersensitivity_management": "Premedication protocol"
    },
    "rescueAgents": {
      "severe_neuropathy": "Dose reduction or discontinuation",
      "febrile_neutropenia": "G-CSF, antibiotics",
      "severe_hypersensitivity": "Discontinue paclitaxel"
    },
    "monitoring": {
      "weekly": "Neuropathy assessment",
      "baseline": [
        "FBC",
        "CA-125",
        "Neuropathy score",
        "ECOG"
      ],
      "every_2_cycles": "CA-125"
    },
    "toxicityMonitoring": {
      "neuropathy": "Weekly clinical grading",
      "tumor_response": "CA-125 every 2 cycles",
      "hypersensitivity": "During paclitaxel infusion"
    },
    "interactions": {
      "warfarin": "Enhanced effect",
      "CYP2C8_inhibitors": "Monitor for increased toxicity"
    },
    "contraindications": [
      "Severe neuropathy",
      "Previous severe hypersensitivity",
      "Pregnancy"
    ],
    "version": "1.3",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a7bbbb2f-6192-4c0b-804d-a9023e977e85",
    "code": "Mirvetuximab-Soravtansine",
    "tumourGroup": "Ovarian",
    "tumourSupergroup": "Ovarian",
    "treatmentIntent": "Palliative",
    "summary": "Antibody-drug conjugate targeting folate receptor alpha for platinum-resistant ovarian cancer.",
    "eligibility": {
      "summary": [
        "Platinum-resistant ovarian cancer",
        "Folate receptor alpha positive"
      ],
      "criteria": {
        "ECOG": "0-1",
        "FRα": "Medium or high expression",
        "Platinum_free_interval": "< 6 months"
      }
    },
    "precautions": [
      "Ocular toxicity",
      "Peripheral neuropathy",
      "Pneumonitis"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "6 mg/kg",
          "name": "Mirvetuximab soravtansine",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "Every 21 days"
    },
    "tests": [
      "Full blood count",
      "FRα expression",
      "Ophthalmologic examination",
      "Chest imaging"
    ],
    "doseModifications": {
      "neuropathy": "Dose reduction 25%",
      "pneumonitis": "Permanent discontinuation",
      "ocular_toxicity": "Dose reduction for grade 2+"
    },
    "referenceList": [
      "NCCN Ovarian Guidelines",
      "SORAYA Study",
      "FDA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "60 minutes"
    },
    "preMedications": {
      "neuropathy_monitoring": "Baseline assessment",
      "pneumonitis_monitoring": "Baseline chest imaging",
      "ophthalmologic_monitoring": "Baseline eye exam"
    },
    "postMedications": {
      "neuropathy": "Gabapentin if symptomatic",
      "pneumonitis": "Report dyspnea immediately",
      "ocular_toxicity": "Artificial tears, ophthalmology referral"
    },
    "supportiveCare": {
      "pulmonary_monitoring": "Serial chest imaging",
      "neuropathy_prevention": "Dose modifications",
      "ophthalmologic_monitoring": "Eye exam before each cycle"
    },
    "rescueAgents": {
      "pneumonitis": "Discontinue permanently, steroids",
      "severe_neuropathy": "Dose reduction",
      "severe_ocular_toxicity": "Ophthalmology referral, treatment delay"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "FRα",
        "Eye exam",
        "CXR"
      ],
      "each_cycle": "FBC, neuropathy assessment",
      "before_each_cycle": "Eye exam"
    },
    "toxicityMonitoring": {
      "neuropathy": "Clinical grading",
      "pneumonitis": "Dyspnea assessment",
      "ocular_toxicity": "Ophthalmologic exam before each cycle"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "folate_supplements": "May reduce efficacy"
    },
    "contraindications": [
      "FRα negative",
      "Severe ocular disease",
      "Active pneumonitis"
    ],
    "version": "1.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b8cccc2f-6192-4c0b-804d-a9023e977e86",
    "code": "Anastrozole",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Curative",
    "summary": "Anastrozole is a NCCN Category 1 aromatase inhibitor for hormone receptor-positive breast cancer in postmenopausal women. Alternative to letrozole with similar efficacy profile.",
    "eligibility": {
      "nccn_category": "1",
      "line_of_therapy": "First-line or adjuvant",
      "treatment_setting": "Adjuvant or metastatic",
      "biomarker_requirements": {
        "ER": "Positive (≥1% by IHC)",
        "HER2": "Any status"
      }
    },
    "precautions": [
      "Bone loss and fractures",
      "Arthralgia",
      "Hot flashes"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "1mg daily",
          "name": "Anastrozole",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "5 years adjuvant or until progression"
    },
    "tests": [
      "Bone density scan",
      "Liver function tests",
      "Estrogen receptor status",
      "Lipid profile"
    ],
    "doseModifications": {
      "bone_loss": "Bisphosphonates, calcium/vitamin D",
      "arthralgia": "Analgesics, dose modification",
      "hot_flashes": "Symptomatic management"
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "ATAC Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "5 years or until progression",
      "administration_time": "Once daily oral"
    },
    "preMedications": {
      "bone_monitoring": "Baseline DEXA scan",
      "arthralgia_assessment": "Joint symptoms",
      "cardiovascular_monitoring": "Lipid profile"
    },
    "postMedications": {
      "arthralgia": "NSAIDs, physical therapy",
      "bone_health": "Calcium 1200mg, vitamin D 800IU daily",
      "hot_flashes": "Lifestyle modifications"
    },
    "supportiveCare": {
      "joint_care": "Exercise, physiotherapy",
      "bone_protection": "Bisphosphonates if osteoporosis",
      "cardiovascular_monitoring": "Regular lipids"
    },
    "rescueAgents": {
      "severe_bone_loss": "Bisphosphonates, endocrine referral",
      "severe_arthralgia": "Switch to tamoxifen",
      "cardiovascular_events": "Cardiology referral"
    },
    "monitoring": {
      "annually": "DEXA scan",
      "baseline": [
        "DEXA",
        "LFTs",
        "ER status",
        "Lipids"
      ],
      "every_6_months": "Lipids"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "DEXA scan",
        "Joint assessment"
      ],
      "primary_toxicities": [
        "Bone loss",
        "Arthralgia",
        "Hot flashes"
      ]
    },
    "interactions": {
      "warfarin": "Monitor INR",
      "estrogen_supplements": "Contraindicated"
    },
    "contraindications": [
      "Premenopausal status",
      "Pregnancy",
      "Known hypersensitivity"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d0eeee2f-6192-4c0b-804d-a9023e977e88",
    "code": "Exemestane",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Curative",
    "summary": "Exemestane is a NCCN Category 1 steroidal aromatase inhibitor for hormone receptor-positive breast cancer in postmenopausal women. Alternative AI with different side effect profile.",
    "eligibility": {
      "nccn_category": "1",
      "line_of_therapy": "First-line or adjuvant",
      "treatment_setting": "Adjuvant or metastatic",
      "biomarker_requirements": {
        "ER": "Positive (≥1% by IHC)",
        "HER2": "Any status"
      }
    },
    "precautions": [
      "Bone loss",
      "Hot flashes",
      "Arthralgia"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "25mg daily",
          "name": "Exemestane",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Until progression"
    },
    "tests": [
      "Bone density scan",
      "Liver function tests",
      "Estrogen receptor status",
      "Performance status"
    ],
    "doseModifications": {
      "bone_loss": "Bisphosphonates, calcium/vitamin D",
      "arthralgia": "Analgesics",
      "hot_flashes": "Lifestyle modifications"
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "IES Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily after food"
    },
    "preMedications": {
      "bone_monitoring": "Baseline DEXA scan",
      "liver_monitoring": "Baseline LFTs",
      "menopausal_symptoms": "Assessment"
    },
    "postMedications": {
      "arthralgia": "NSAIDs, exercise",
      "bone_health": "Calcium and vitamin D",
      "hot_flashes": "Non-hormonal management"
    },
    "supportiveCare": {
      "joint_care": "Physical therapy",
      "bone_protection": "Bisphosphonates if osteoporosis",
      "symptom_management": "Supportive care"
    },
    "rescueAgents": {
      "severe_bone_loss": "Bisphosphonates, specialist referral",
      "disease_progression": "Second-line therapy",
      "intolerable_symptoms": "Consider tamoxifen"
    },
    "monitoring": {
      "annually": "DEXA scan",
      "baseline": [
        "DEXA",
        "LFTs",
        "ER status"
      ],
      "every_6_months": "Clinical assessment"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "DEXA scan",
        "Joint assessment"
      ],
      "primary_toxicities": [
        "Bone loss",
        "Arthralgia",
        "Hot flashes"
      ]
    },
    "interactions": {
      "estrogen_supplements": "Contraindicated",
      "strong_CYP3A4_inducers": "May reduce efficacy"
    },
    "contraindications": [
      "Premenopausal status",
      "Pregnancy",
      "Known hypersensitivity"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a3bbbb2f-6192-4c0b-804d-a9023e977e91",
    "code": "Leuprolide",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "LHRH agonist for advanced prostate cancer providing castrate levels of testosterone.",
    "eligibility": {
      "summary": [
        "Advanced prostate cancer",
        "Androgen deprivation therapy"
      ],
      "criteria": {
        "ECOG": "0-4",
        "Testosterone": "Any level",
        "Metastatic_or_locally_advanced": "Required"
      }
    },
    "precautions": [
      "Tumor flare",
      "Hot flashes",
      "Bone loss"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "22.5mg",
          "name": "Leuprolide",
          "route": "IM",
          "schedule": "Every 3 months"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "PSA",
      "Testosterone",
      "Bone density scan",
      "Liver function tests"
    ],
    "doseModifications": {
      "bone_loss": "Bisphosphonates",
      "hot_flashes": "Symptomatic management",
      "tumor_flare": "Antiandrogen cover first month"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "LNCaP Studies",
      "EAU Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "84 days",
      "total_cycles": "Until progression",
      "administration_time": "Quarterly IM injection"
    },
    "preMedications": {
      "bone_monitoring": "Baseline DEXA",
      "tumor_flare_prevention": "Bicalutamide 50mg daily first month",
      "cardiovascular_assessment": "Baseline ECG"
    },
    "postMedications": {
      "bone_health": "Exercise, calcium/vitamin D",
      "hot_flashes": "Lifestyle modifications, fans",
      "cardiovascular_monitoring": "Regular assessment"
    },
    "supportiveCare": {
      "PSA_monitoring": "Every 3 months",
      "bone_protection": "Bisphosphonates if osteoporosis",
      "cardiovascular_monitoring": "Regular ECG"
    },
    "rescueAgents": {
      "tumor_flare": "Antiandrogen, steroids if severe",
      "severe_bone_loss": "Denosumab or bisphosphonates",
      "cardiovascular_events": "Cardiology referral"
    },
    "monitoring": {
      "annually": "DEXA scan",
      "baseline": [
        "PSA",
        "Testosterone",
        "DEXA",
        "ECG"
      ],
      "every_3_months": "PSA, testosterone"
    },
    "toxicityMonitoring": {
      "castration": "Testosterone <1.7 nmol/L",
      "bone_health": "Annual DEXA scan",
      "PSA_response": "PSA levels every 3 months"
    },
    "interactions": {
      "antiandrogens": "Use for tumor flare prevention",
      "5-alpha_reductase_inhibitors": "No interaction"
    },
    "contraindications": [
      "Pregnancy in partner",
      "Severe osteoporosis",
      "Recent MI"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b4cccc2f-6192-4c0b-804d-a9023e977e92",
    "code": "Bicalutamide",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "Non-steroidal antiandrogen for advanced prostate cancer as monotherapy or with LHRH agonist.",
    "eligibility": {
      "summary": [
        "Advanced prostate cancer",
        "Antiandrogen therapy"
      ],
      "criteria": {
        "PSA": "Any level",
        "Testosterone": "Normal or castrate",
        "Locally_advanced_or_metastatic": "Required"
      }
    },
    "precautions": [
      "Hepatotoxicity",
      "Gynecomastia",
      "Hot flashes"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "50mg daily",
          "name": "Bicalutamide",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "PSA",
      "Liver function tests",
      "Testosterone",
      "Performance status"
    ],
    "doseModifications": {
      "hot_flashes": "Symptomatic management",
      "gynecomastia": "Breast irradiation or tamoxifen",
      "hepatotoxicity": "Hold if ALT >3x ULN"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "EPC Study",
      "EAU Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily oral"
    },
    "preMedications": {
      "PSA_monitoring": "Monthly initially",
      "hepatic_monitoring": "Weekly LFTs first 3 months",
      "gynecomastia_prevention": "Consider prophylactic breast irradiation"
    },
    "postMedications": {
      "hot_flashes": "Lifestyle modifications",
      "gynecomastia": "Supportive bras if symptomatic",
      "hepatotoxicity": "Avoid alcohol and hepatotoxins"
    },
    "supportiveCare": {
      "PSA_monitoring": "Regular assessment",
      "liver_protection": "Regular LFTs",
      "gynecomastia_management": "Cosmetic support"
    },
    "rescueAgents": {
      "PSA_progression": "Add LHRH agonist",
      "severe_gynecomastia": "Surgical consultation",
      "severe_hepatotoxicity": "Permanent discontinuation"
    },
    "monitoring": {
      "monthly": "PSA",
      "baseline": [
        "PSA",
        "LFTs",
        "Testosterone"
      ],
      "weekly_first_3_months": "LFTs"
    },
    "toxicityMonitoring": {
      "PSA_response": "Monthly PSA levels",
      "gynecomastia": "Clinical examination",
      "hepatotoxicity": "Weekly LFTs first 3 months"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "CYP3A4_inducers": "May reduce efficacy"
    },
    "contraindications": [
      "Severe liver disease",
      "Women",
      "Known hypersensitivity"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c5dddd2f-6192-4c0b-804d-a9023e977e93",
    "code": "Flutamide",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "Non-steroidal antiandrogen for advanced prostate cancer with hepatotoxicity monitoring required.",
    "eligibility": {
      "summary": [
        "Advanced prostate cancer",
        "Antiandrogen therapy"
      ],
      "criteria": {
        "ECOG": "0-3",
        "Normal_liver_function": "Required",
        "Metastatic_or_locally_advanced": "Required"
      }
    },
    "precautions": [
      "Severe hepatotoxicity",
      "Diarrhea",
      "Gynecomastia"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "250mg TDS",
          "name": "Flutamide",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "PSA",
      "Liver function tests",
      "Testosterone",
      "Stool assessment"
    ],
    "doseModifications": {
      "diarrhea": "Symptomatic management",
      "gynecomastia": "Supportive care",
      "hepatotoxicity": "Discontinue if ALT >2x ULN"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "Historical Studies",
      "EAU Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Three times daily oral"
    },
    "preMedications": {
      "GI_monitoring": "Baseline bowel habits",
      "PSA_monitoring": "Monthly initially",
      "hepatic_monitoring": "Weekly LFTs first month"
    },
    "postMedications": {
      "diarrhea": "Loperamide, dietary modification",
      "gynecomastia": "Supportive garments",
      "hepatotoxicity": "Strict LFT monitoring"
    },
    "supportiveCare": {
      "GI_management": "Dietary counseling",
      "PSA_monitoring": "Regular assessment",
      "liver_protection": "Frequent LFT monitoring"
    },
    "rescueAgents": {
      "PSA_progression": "Switch antiandrogen",
      "severe_diarrhea": "IV hydration",
      "severe_hepatotoxicity": "Immediate discontinuation"
    },
    "monitoring": {
      "monthly": "PSA, LFTs",
      "baseline": [
        "PSA",
        "LFTs",
        "Testosterone"
      ],
      "weekly_first_month": "LFTs"
    },
    "toxicityMonitoring": {
      "diarrhea": "Frequency monitoring",
      "PSA_response": "Monthly levels",
      "hepatotoxicity": "Weekly LFTs first month, then monthly"
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "hepatotoxic_drugs": "Avoid concurrent use"
    },
    "contraindications": [
      "Severe liver disease",
      "Women",
      "Pregnancy in partner"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d6eeee2f-6192-4c0b-804d-a9023e977e94",
    "code": "Degarelix",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "GnRH antagonist for advanced prostate cancer providing immediate testosterone suppression without flare.",
    "eligibility": {
      "summary": [
        "Advanced prostate cancer",
        "Immediate castration required"
      ],
      "criteria": {
        "ECOG": "0-4",
        "Cardiovascular_risk": "High risk patients",
        "Metastatic_or_locally_advanced": "Required"
      }
    },
    "precautions": [
      "Injection site reactions",
      "Hot flashes",
      "QT prolongation"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "240mg loading, then 80mg monthly",
          "name": "Degarelix",
          "route": "SC",
          "schedule": "Monthly"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "PSA",
      "Testosterone",
      "ECG",
      "Injection site assessment"
    ],
    "doseModifications": {
      "hot_flashes": "Symptomatic management",
      "QT_prolongation": "ECG monitoring",
      "injection_reactions": "Rotate sites, topical treatment"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "CS21 Study",
      "EAU Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "Monthly SC injection"
    },
    "preMedications": {
      "cardiac_monitoring": "Baseline ECG",
      "injection_technique": "Proper SC technique",
      "testosterone_monitoring": "Baseline levels"
    },
    "postMedications": {
      "hot_flashes": "Lifestyle modifications",
      "cardiac_monitoring": "Regular ECG if high risk",
      "injection_reactions": "Ice, topical treatments"
    },
    "supportiveCare": {
      "cardiac_monitoring": "ECG if QT risk",
      "testosterone_monitoring": "Monthly initially",
      "injection_site_management": "Rotation, proper technique"
    },
    "rescueAgents": {
      "cardiovascular_events": "Immediate assessment",
      "severe_injection_reaction": "Switch to LHRH agonist",
      "significant_QT_prolongation": "Cardiology referral"
    },
    "monitoring": {
      "monthly": "PSA, testosterone",
      "baseline": [
        "PSA",
        "Testosterone",
        "ECG"
      ],
      "every_6_months": "ECG if indicated"
    },
    "toxicityMonitoring": {
      "cardiac": "ECG monitoring if risk factors",
      "injection_site": "Site assessment each visit",
      "testosterone_suppression": "Monthly levels initially"
    },
    "interactions": {
      "QT_prolonging_drugs": "Monitor closely",
      "class_III_antiarrhythmics": "Avoid if possible"
    },
    "contraindications": [
      "Long QT syndrome",
      "Severe injection site reactions",
      "Pregnancy in partner"
    ],
    "version": "1.2",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e7ffff2f-6192-4c0b-804d-a9023e977e95",
    "code": "Darolutamide",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "Androgen receptor antagonist for non-metastatic castration-resistant prostate cancer with metastasis-free survival benefit.",
    "eligibility": {
      "summary": [
        "Non-metastatic CRPC",
        "High PSA doubling time"
      ],
      "criteria": {
        "PSA_doubling_time": "≤10 months",
        "Non_metastatic_CRPC": "Required",
        "Castrate_testosterone": "< 1.7 nmol/L"
      }
    },
    "precautions": [
      "Fatigue",
      "Fractures",
      "Rash"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "600mg BD",
          "name": "Darolutamide",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression or metastases"
    },
    "tests": [
      "PSA",
      "Testosterone",
      "Bone scan",
      "CT scan",
      "Performance status"
    ],
    "doseModifications": {
      "rash": "Topical treatments",
      "fatigue": "Dose reduction if severe",
      "fractures": "Bone health optimization"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "ARAMIS Study",
      "EAU Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until metastases or progression",
      "administration_time": "Twice daily with food"
    },
    "preMedications": {
      "bone_monitoring": "Baseline bone scan",
      "fatigue_assessment": "Baseline ECOG",
      "imaging_surveillance": "CT/bone scan every 4 months"
    },
    "postMedications": {
      "rash": "Moisturizers, topical steroids",
      "fatigue": "Energy conservation techniques",
      "bone_health": "Calcium, vitamin D, exercise"
    },
    "supportiveCare": {
      "bone_protection": "Bisphosphonates if indicated",
      "fatigue_management": "Dose modifications",
      "metastasis_surveillance": "Regular imaging"
    },
    "rescueAgents": {
      "severe_fatigue": "Dose reduction or interruption",
      "metastatic_progression": "Systemic therapy",
      "pathological_fractures": "Orthopedic referral"
    },
    "monitoring": {
      "baseline": [
        "PSA",
        "Testosterone",
        "Bone scan",
        "CT"
      ],
      "every_8_weeks": "PSA initially",
      "every_4_months": "PSA, imaging"
    },
    "toxicityMonitoring": {
      "fracture_risk": "Clinical assessment",
      "PSA_monitoring": "Every 8 weeks initially",
      "metastasis_surveillance": "CT and bone scan every 4 months"
    },
    "interactions": {
      "warfarin": "Monitor INR",
      "strong_CYP3A4_inducers": "May reduce efficacy"
    },
    "contraindications": [
      "Metastatic disease",
      "Severe fatigue",
      "Pregnancy"
    ],
    "version": "1.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f8aaaa2f-6192-4c0b-804d-a9023e977e96",
    "code": "Apalutamide",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "Androgen receptor antagonist for non-metastatic CRPC and metastatic hormone-sensitive prostate cancer.",
    "eligibility": {
      "summary": [
        "Non-metastatic CRPC or mHSPC",
        "High-risk disease"
      ],
      "criteria": {
        "ECOG": "0-1",
        "CRPC_or_mHSPC": "Required",
        "High_risk_features": "Present"
      }
    },
    "precautions": [
      "Seizure risk",
      "Falls",
      "Fractures"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "240mg daily",
          "name": "Apalutamide",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "PSA",
      "Testosterone",
      "Neurological assessment",
      "Fall risk assessment",
      "Bone scan"
    ],
    "doseModifications": {
      "falls": "Fall prevention strategies",
      "seizure": "Permanent discontinuation",
      "fractures": "Bone health optimization"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "SPARTAN and TITAN Studies",
      "EAU Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily with or without food"
    },
    "preMedications": {
      "bone_monitoring": "Baseline bone scan",
      "fall_risk_assessment": "Baseline evaluation",
      "neurological_monitoring": "Baseline assessment"
    },
    "postMedications": {
      "bone_health": "Exercise, calcium, vitamin D",
      "fall_prevention": "Home safety assessment",
      "seizure_prevention": "Avoid seizure precipitants"
    },
    "supportiveCare": {
      "bone_protection": "Bisphosphonates if indicated",
      "fall_prevention": "Ongoing evaluation",
      "neurological_monitoring": "Regular assessment"
    },
    "rescueAgents": {
      "seizure": "Discontinue permanently, neurology referral",
      "serious_fall": "Orthopedic assessment",
      "pathological_fracture": "Immediate orthopedic care"
    },
    "monitoring": {
      "monthly": "PSA",
      "baseline": [
        "PSA",
        "Testosterone",
        "Neuro assessment",
        "Fall risk",
        "Bone scan"
      ],
      "every_4_months": "Imaging"
    },
    "toxicityMonitoring": {
      "fall_risk": "Regular evaluation",
      "PSA_response": "Monthly monitoring",
      "seizure_monitoring": "Neurological assessment"
    },
    "interactions": {
      "strong_CYP3A4_inducers": "May reduce efficacy",
      "seizure_threshold_lowering_drugs": "Avoid if possible"
    },
    "contraindications": [
      "History of seizures",
      "High fall risk",
      "Pregnancy"
    ],
    "version": "1.3",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a9bbbb2f-6192-4c0b-804d-a9023e977e97",
    "code": "Finasteride",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Prevention",
    "summary": "5-alpha reductase inhibitor for benign prostatic hyperplasia and prostate cancer risk reduction.",
    "eligibility": {
      "summary": [
        "BPH",
        "Prostate cancer risk reduction"
      ],
      "criteria": {
        "Age": "> 50 years",
        "No_known_prostate_cancer": "Required",
        "Elevated_PSA_or_BPH_symptoms": "Present"
      }
    },
    "precautions": [
      "Sexual dysfunction",
      "Gynecomastia",
      "Depression"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "5mg daily",
          "name": "Finasteride",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Long-term use"
    },
    "tests": [
      "PSA",
      "Prostate examination",
      "Sexual function assessment",
      "Mood assessment"
    ],
    "doseModifications": {
      "depression": "Psychiatric evaluation",
      "gynecomastia": "Observation, discontinue if severe",
      "sexual_dysfunction": "Counseling, dose reduction"
    },
    "referenceList": [
      "AUA Guidelines",
      "PCPT Study",
      "EAU Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Long-term",
      "administration_time": "Once daily"
    },
    "preMedications": {
      "PSA_monitoring": "Baseline and regular monitoring",
      "mood_monitoring": "Regular assessment",
      "sexual_function_assessment": "Baseline evaluation"
    },
    "postMedications": {
      "gynecomastia": "Monitor for changes",
      "mood_changes": "Report depression symptoms",
      "sexual_dysfunction": "Counseling available"
    },
    "supportiveCare": {
      "PSA_monitoring": "Adjust for 50% reduction on finasteride",
      "mood_monitoring": "Depression screening",
      "sexual_function_monitoring": "Regular assessment"
    },
    "rescueAgents": {
      "severe_depression": "Psychiatric referral",
      "prostate_cancer_diagnosis": "Immediate urological referral",
      "severe_sexual_dysfunction": "Discontinue finasteride"
    },
    "monitoring": {
      "annually": "Prostate exam",
      "baseline": [
        "PSA",
        "Prostate exam",
        "Sexual function",
        "Mood"
      ],
      "every_6_months": "PSA"
    },
    "toxicityMonitoring": {
      "prostate_exam": "Annual DRE",
      "PSA_monitoring": "Every 6 months (adjust for 50% reduction)",
      "sexual_function": "Annual assessment"
    },
    "interactions": {
      "warfarin": "No significant interaction",
      "alpha_blockers": "Synergistic effect for BPH"
    },
    "contraindications": [
      "Known prostate cancer",
      "Women",
      "Pregnancy"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b0cccc2f-6192-4c0b-804d-a9023e977e98",
    "code": "Dutasteride",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Prevention",
    "summary": "Dual 5-alpha reductase inhibitor for BPH and prostate cancer risk reduction with enhanced efficacy.",
    "eligibility": {
      "summary": [
        "BPH",
        "Prostate cancer risk reduction"
      ],
      "criteria": {
        "Age": "> 50 years",
        "No_known_prostate_cancer": "Required",
        "BPH_symptoms_or_risk_factors": "Present"
      }
    },
    "precautions": [
      "Sexual dysfunction",
      "Gynecomastia",
      "Heart failure"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "0.5mg daily",
          "name": "Dutasteride",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Long-term use"
    },
    "tests": [
      "PSA",
      "Prostate examination",
      "Sexual function assessment",
      "Cardiac assessment"
    ],
    "doseModifications": {
      "gynecomastia": "Monitor, discontinue if severe",
      "heart_failure": "Cardiac evaluation",
      "sexual_dysfunction": "Counseling, consider discontinuation"
    },
    "referenceList": [
      "AUA Guidelines",
      "REDUCE Study",
      "EAU Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Long-term",
      "administration_time": "Once daily"
    },
    "preMedications": {
      "PSA_monitoring": "Baseline and regular monitoring",
      "cardiac_assessment": "Baseline if risk factors",
      "sexual_function_assessment": "Baseline evaluation"
    },
    "postMedications": {
      "gynecomastia": "Monitor for development",
      "cardiac_symptoms": "Report immediately",
      "sexual_dysfunction": "Counseling and support"
    },
    "supportiveCare": {
      "PSA_monitoring": "Adjust for 50% reduction",
      "cardiac_monitoring": "If risk factors present",
      "sexual_function_monitoring": "Regular assessment"
    },
    "rescueAgents": {
      "heart_failure": "Cardiology referral",
      "prostate_cancer_diagnosis": "Immediate urological referral",
      "severe_sexual_dysfunction": "Discontinue dutasteride"
    },
    "monitoring": {
      "annually": "Prostate exam",
      "baseline": [
        "PSA",
        "Prostate exam",
        "Sexual function",
        "Cardiac assessment"
      ],
      "every_6_months": "PSA"
    },
    "toxicityMonitoring": {
      "cardiac": "Monitor if risk factors",
      "PSA_monitoring": "Every 6 months (adjust for 50% reduction)",
      "sexual_function": "Annual assessment"
    },
    "interactions": {
      "alpha_blockers": "Synergistic for BPH",
      "CYP3A4_inhibitors": "May increase levels"
    },
    "contraindications": [
      "Known prostate cancer",
      "Women",
      "Severe heart failure"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c1dddd2f-6192-4c0b-804d-a9023e977e99",
    "code": "Enzalutamide-CRPC",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "Androgen receptor antagonist for metastatic castration-resistant prostate cancer with survival benefit.",
    "eligibility": {
      "summary": [
        "Metastatic CRPC",
        "Pre or post-chemotherapy"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Metastatic_CRPC": "Required",
        "Castrate_testosterone": "< 1.7 nmol/L"
      }
    },
    "precautions": [
      "Seizure risk",
      "Fatigue",
      "Falls"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "160mg daily",
          "name": "Enzalutamide",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "PSA",
      "Testosterone",
      "Neurological assessment",
      "Fall risk assessment",
      "Liver function tests"
    ],
    "doseModifications": {
      "falls": "Fall prevention measures",
      "fatigue": "Dose reduction if severe",
      "seizure": "Permanent discontinuation"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "AFFIRM and PREVAIL Studies",
      "EAU Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily with or without food"
    },
    "preMedications": {
      "hepatic_monitoring": "Baseline LFTs",
      "fall_risk_assessment": "Baseline evaluation",
      "neurological_monitoring": "Baseline assessment"
    },
    "postMedications": {
      "fall_prevention": "Home safety",
      "fatigue_management": "Energy conservation",
      "seizure_prevention": "Avoid precipitants"
    },
    "supportiveCare": {
      "fall_prevention": "Ongoing evaluation",
      "hepatic_monitoring": "Regular LFTs",
      "neurological_monitoring": "Regular assessment"
    },
    "rescueAgents": {
      "seizure": "Discontinue permanently",
      "serious_fall": "Orthopedic assessment",
      "hepatotoxicity": "Dose modification"
    },
    "monitoring": {
      "monthly": "PSA",
      "baseline": [
        "PSA",
        "Testosterone",
        "Neuro assessment",
        "LFTs"
      ],
      "every_3_months": "LFTs"
    },
    "toxicityMonitoring": {
      "hepatic": "LFT monitoring",
      "fall_risk": "Regular evaluation",
      "seizure_monitoring": "Neurological assessment"
    },
    "interactions": {
      "strong_CYP2C8_inducers": "May reduce efficacy",
      "seizure_threshold_lowering_drugs": "Avoid"
    },
    "contraindications": [
      "History of seizures",
      "Severe hepatic impairment",
      "Pregnancy"
    ],
    "version": "1.4",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d2eeee2f-6192-4c0b-804d-a9023e977100",
    "code": "Abiraterone-Pred",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "CYP17 inhibitor with prednisolone for metastatic castration-resistant prostate cancer.",
    "eligibility": {
      "summary": [
        "Metastatic CRPC",
        "Pre or post-chemotherapy"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Metastatic_CRPC": "Required",
        "Castrate_testosterone": "< 1.7 nmol/L"
      }
    },
    "precautions": [
      "Mineralocorticoid excess",
      "Hepatotoxicity",
      "Cardiac toxicity"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "1000mg daily",
          "name": "Abiraterone acetate",
          "route": "PO",
          "schedule": "Continuous"
        },
        {
          "dose": "5mg BD",
          "name": "Prednisolone",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "PSA",
      "Liver function tests",
      "Potassium",
      "Blood pressure",
      "LVEF"
    ],
    "doseModifications": {
      "hypokalemia": "Potassium supplementation",
      "hypertension": "Antihypertensive therapy",
      "hepatotoxicity": "Dose reduction or interruption"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "COU-AA Studies",
      "EAU Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Abiraterone on empty stomach"
    },
    "preMedications": {
      "cardiac_monitoring": "Baseline BP and LVEF",
      "hepatic_monitoring": "Weekly LFTs first 3 months",
      "electrolyte_monitoring": "Baseline K+"
    },
    "postMedications": {
      "hypokalemia": "K+ supplementation",
      "hypertension": "Monitor BP regularly",
      "hepatotoxicity": "Avoid hepatotoxins"
    },
    "supportiveCare": {
      "liver_protection": "Regular LFT monitoring",
      "cardiac_monitoring": "BP and LVEF",
      "electrolyte_monitoring": "Regular K+ monitoring"
    },
    "rescueAgents": {
      "severe_hypokalemia": "IV potassium",
      "severe_hypertension": "Antihypertensive therapy",
      "severe_hepatotoxicity": "Permanent discontinuation"
    },
    "monitoring": {
      "monthly": "PSA, K+, BP",
      "baseline": [
        "PSA",
        "LFTs",
        "K+",
        "BP",
        "LVEF"
      ],
      "weekly_first_3_months": "LFTs"
    },
    "toxicityMonitoring": {
      "cardiac": "BP monitoring",
      "electrolytes": "K+ monitoring",
      "hepatotoxicity": "Weekly LFTs first 3 months"
    },
    "interactions": {
      "strong_CYP3A4_inducers": "May reduce abiraterone efficacy",
      "potassium_sparing_diuretics": "Monitor K+ closely"
    },
    "contraindications": [
      "Severe hepatic impairment",
      "Uncontrolled hypertension",
      "Severe heart failure"
    ],
    "version": "1.6",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e3ffff2f-6192-4c0b-804d-a9023e977101",
    "code": "Radium-223-Bone",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "Alpha-particle emitting radiopharmaceutical for bone metastases in castration-resistant prostate cancer.",
    "eligibility": {
      "summary": [
        "CRPC with bone metastases",
        "No visceral metastases"
      ],
      "criteria": {
        "Symptomatic": "Bone pain",
        "Bone_metastases_only": "Required",
        "No_visceral_metastases": "Required"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Diarrhea",
      "Bone marrow toxicity"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "55 kBq/kg (1.49 microcurie/kg)",
          "name": "Radium-223 dichloride",
          "route": "IV",
          "schedule": "Every 4 weeks"
        }
      ],
      "cycles": "6 injections"
    },
    "tests": [
      "Full blood count",
      "Bone scan",
      "CT scan",
      "Performance status"
    ],
    "doseModifications": {
      "diarrhea": "Supportive care",
      "myelosuppression": "Hold if severe cytopenias",
      "bone_marrow_failure": "Discontinue treatment"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "ALSYMPCA Study",
      "EAU Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "6",
      "administration_time": "Slow IV injection"
    },
    "preMedications": {
      "hydration": "Adequate fluid intake",
      "radiation_safety": "Nuclear medicine protocols",
      "myelosuppression_monitoring": "Weekly FBC"
    },
    "postMedications": {
      "diarrhea": "Loperamide, hydration",
      "myelosuppression": "Infection precautions",
      "radiation_safety": "Follow nuclear medicine protocols"
    },
    "supportiveCare": {
      "radiation_safety": "Nuclear medicine follow-up",
      "symptom_monitoring": "Pain assessment",
      "myelosuppression_monitoring": "Weekly FBC"
    },
    "rescueAgents": {
      "severe_diarrhea": "IV hydration",
      "radiation_exposure": "Nuclear medicine consultation",
      "severe_myelosuppression": "Treatment delay or discontinuation"
    },
    "monitoring": {
      "weekly": "FBC",
      "baseline": [
        "FBC",
        "Bone scan",
        "CT chest/abdomen/pelvis"
      ],
      "before_each_injection": "FBC"
    },
    "toxicityMonitoring": {
      "pain_response": "Regular assessment",
      "myelosuppression": "Weekly FBC monitoring",
      "radiation_safety": "Nuclear medicine protocols"
    },
    "interactions": {
      "chemotherapy": "Contraindicated concurrently",
      "other_radiopharmaceuticals": "Avoid concurrent use"
    },
    "contraindications": [
      "Visceral metastases",
      "Severe myelosuppression",
      "Imminent spinal cord compression"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f4aaaa2f-6192-4c0b-804d-a9023e977102",
    "code": "Sipuleucel-T-Immunotherapy",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "Autologous cellular immunotherapy for asymptomatic or minimally symptomatic metastatic CRPC.",
    "eligibility": {
      "summary": [
        "Asymptomatic metastatic CRPC",
        "Immunotherapy"
      ],
      "criteria": {
        "Metastatic_CRPC": "Required",
        "Good_performance_status": "ECOG 0-1",
        "Asymptomatic_or_minimally_symptomatic": "Required"
      }
    },
    "precautions": [
      "Infusion reactions",
      "Chills",
      "Fatigue"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "Minimum 50 million autologous CD54+ cells",
          "name": "Sipuleucel-T",
          "route": "IV",
          "schedule": "Weeks 0, 2, 4"
        }
      ],
      "cycles": "3 infusions total"
    },
    "tests": [
      "Full blood count",
      "Performance status",
      "Leukapheresis feasibility",
      "Cardiac assessment"
    ],
    "doseModifications": {
      "chills": "Supportive care",
      "fatigue": "Symptomatic management",
      "infusion_reactions": "Premedication, slow infusion"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "IMPACT Study",
      "FDA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "2 weeks",
      "total_cycles": "3",
      "administration_time": "Leukapheresis + 3 infusions"
    },
    "preMedications": {
      "leukapheresis": "Central venous access",
      "premedication": "Acetaminophen and antihistamine",
      "infusion_monitoring": "Vital signs monitoring"
    },
    "postMedications": {
      "chills": "Supportive care",
      "fatigue": "Rest periods",
      "infusion_reactions": "Monitor during infusion"
    },
    "supportiveCare": {
      "immune_monitoring": "Immune response assessment",
      "infusion_monitoring": "Vital signs during infusion",
      "leukapheresis_monitoring": "Blood counts"
    },
    "rescueAgents": {
      "severe_fatigue": "Supportive care",
      "inadequate_cell_yield": "Repeat leukapheresis",
      "severe_infusion_reaction": "Slow or stop infusion"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "ECOG",
        "Cardiac assessment"
      ],
      "post_infusion": "Monitoring for reactions",
      "before_each_infusion": "Vital signs"
    },
    "toxicityMonitoring": {
      "immune_response": "Laboratory assessment",
      "clinical_response": "PSA and imaging",
      "infusion_reactions": "During and post-infusion monitoring"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "immunosuppressive_drugs": "May reduce efficacy"
    },
    "contraindications": [
      "Symptomatic disease",
      "Visceral metastases",
      "Immunocompromised state"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a5bbbb2f-6192-4c0b-804d-a9023e977103",
    "code": "Lu-177-PSMA-617",
    "tumourGroup": "Prostate",
    "tumourSupergroup": "Prostate",
    "treatmentIntent": "Palliative",
    "summary": "Radioligand therapy targeting PSMA for heavily pretreated metastatic castration-resistant prostate cancer.",
    "eligibility": {
      "summary": [
        "Heavily pretreated mCRPC",
        "PSMA-positive disease"
      ],
      "criteria": {
        "ECOG": "0-2",
        "PSMA_positive": "Required on imaging",
        "Previous_chemotherapy_and_ARAT": "Required"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Xerostomia",
      "Renal toxicity"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "7.4 GBq (200 mCi)",
          "name": "Lutetium-177-PSMA-617",
          "route": "IV",
          "schedule": "Every 6 weeks"
        }
      ],
      "cycles": "Up to 6 cycles"
    },
    "tests": [
      "Full blood count",
      "PSMA PET scan",
      "Renal function",
      "Salivary gland function"
    ],
    "doseModifications": {
      "xerostomia": "Supportive care",
      "renal_toxicity": "Dose reduction",
      "myelosuppression": "Hold if severe cytopenias"
    },
    "referenceList": [
      "NCCN Prostate Guidelines",
      "VISION Study",
      "EMA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "42 days",
      "total_cycles": "Up to 6",
      "administration_time": "Slow IV infusion"
    },
    "preMedications": {
      "radiation_safety": "Nuclear medicine protocols",
      "renal_protection": "Adequate hydration",
      "myelosuppression_monitoring": "Baseline FBC"
    },
    "postMedications": {
      "xerostomia": "Artificial saliva, frequent hydration",
      "myelosuppression": "Infection precautions",
      "radiation_safety": "Nuclear medicine guidelines"
    },
    "supportiveCare": {
      "radiation_safety": "Nuclear medicine follow-up",
      "renal_protection": "Hydration protocols",
      "myelosuppression_monitoring": "Regular FBC"
    },
    "rescueAgents": {
      "renal_toxicity": "Nephrology referral",
      "severe_xerostomia": "Salivary stimulants",
      "severe_myelosuppression": "Treatment delay"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "PSMA PET",
        "U&E",
        "Salivary function"
      ],
      "post_treatment": "Extended monitoring",
      "before_each_cycle": "FBC, U&E"
    },
    "toxicityMonitoring": {
      "renal_function": "Creatinine monitoring",
      "myelosuppression": "Regular FBC monitoring",
      "radiation_safety": "Nuclear medicine protocols"
    },
    "interactions": {
      "radiotherapy": "Coordinate timing",
      "nephrotoxic_drugs": "Avoid concurrent use"
    },
    "contraindications": [
      "PSMA negative",
      "Severe myelosuppression",
      "Severe renal impairment"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b6cccc2f-6192-4c0b-804d-a9023e977104",
    "code": "Olaparib-BRCA",
    "tumourGroup": "Ovarian",
    "tumourSupergroup": "Ovarian",
    "treatmentIntent": "Palliative",
    "summary": "PARP inhibitor for BRCA-mutated ovarian cancer with excellent response rates in platinum-sensitive disease.",
    "eligibility": {
      "summary": [
        "BRCA-mutated ovarian cancer",
        "Platinum-sensitive recurrence"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Platinum_sensitivity": "Required",
        "BRCA1_or_BRCA2_mutation": "Required"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Fatigue",
      "Secondary malignancies"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "300mg BD",
          "name": "Olaparib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Until progression"
    },
    "tests": [
      "Full blood count",
      "BRCA mutation status",
      "CA-125",
      "Performance status"
    ],
    "doseModifications": {
      "fatigue": "Dose modification",
      "myelosuppression": "Dose reduction for grade 3+",
      "secondary_malignancy": "Long-term monitoring"
    },
    "referenceList": [
      "NCCN Ovarian Guidelines",
      "SOLO Studies",
      "EMA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Twice daily oral"
    },
    "preMedications": {
      "BRCA_testing": "Confirmed mutation",
      "fatigue_assessment": "Baseline ECOG",
      "myelosuppression_monitoring": "Weekly FBC first month"
    },
    "postMedications": {
      "nausea": "Antiemetics PRN",
      "fatigue": "Energy conservation",
      "myelosuppression": "Infection precautions"
    },
    "supportiveCare": {
      "tumor_monitoring": "CA-125 every 3 months",
      "fatigue_management": "Dose modifications",
      "neutropenia_monitoring": "Regular FBC"
    },
    "rescueAgents": {
      "severe_fatigue": "Dose reduction",
      "severe_neutropenia": "G-CSF support",
      "secondary_malignancy": "Oncology referral"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "BRCA status",
        "CA-125",
        "ECOG"
      ],
      "every_3_months": "CA-125",
      "weekly_first_month": "FBC"
    },
    "toxicityMonitoring": {
      "fatigue": "ECOG assessment",
      "myelosuppression": "Regular FBC monitoring",
      "secondary_malignancy": "Clinical surveillance"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "strong_CYP3A4_inhibitors": "Reduce olaparib dose"
    },
    "contraindications": [
      "BRCA wild-type",
      "Severe myelosuppression",
      "Pregnancy"
    ],
    "version": "1.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c7dddd2f-6192-4c0b-804d-a9023e977105",
    "code": "Niraparib-Maintenance",
    "tumourGroup": "Ovarian",
    "tumourSupergroup": "Ovarian",
    "treatmentIntent": "Curative",
    "summary": "PARP inhibitor maintenance therapy for newly diagnosed advanced ovarian cancer regardless of BRCA status.",
    "eligibility": {
      "summary": [
        "Newly diagnosed advanced ovarian cancer",
        "Post-platinum response"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Response_to_platinum": "Complete or partial",
        "Advanced_ovarian_cancer": "Stage III-IV"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Hypertension",
      "Fatigue"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "200-300mg daily",
          "name": "Niraparib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Until progression"
    },
    "tests": [
      "Full blood count",
      "Blood pressure",
      "CA-125",
      "Homologous recombination status"
    ],
    "doseModifications": {
      "fatigue": "Dose modification",
      "hypertension": "Antihypertensive therapy",
      "myelosuppression": "Dose reduction or interruption"
    },
    "referenceList": [
      "NCCN Ovarian Guidelines",
      "PRIMA Study",
      "FDA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Once daily oral"
    },
    "preMedications": {
      "BP_monitoring": "Baseline and regular",
      "weight_monitoring": "Baseline weight",
      "myelosuppression_monitoring": "Weekly FBC first 2 months"
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "hypertension": "BP monitoring",
      "myelosuppression": "Infection precautions"
    },
    "supportiveCare": {
      "BP_monitoring": "Regular assessment",
      "tumor_monitoring": "CA-125 every 3 months",
      "neutropenia_monitoring": "Weekly FBC first 2 months"
    },
    "rescueAgents": {
      "severe_fatigue": "Dose interruption",
      "severe_neutropenia": "Dose reduction or G-CSF",
      "severe_hypertension": "Antihypertensive therapy"
    },
    "monitoring": {
      "monthly": "BP",
      "baseline": [
        "FBC",
        "BP",
        "CA-125",
        "HRD status",
        "Weight"
      ],
      "weekly_first_2_months": "FBC"
    },
    "toxicityMonitoring": {
      "fatigue": "Regular assessment",
      "hypertension": "BP monitoring",
      "myelosuppression": "Weekly FBC first 2 months"
    },
    "interactions": {
      "antihypertensives": "Monitor BP closely",
      "strong_CYP3A4_inducers": "May reduce efficacy"
    },
    "contraindications": [
      "Severe myelosuppression",
      "Uncontrolled hypertension",
      "Pregnancy"
    ],
    "version": "1.3",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d8eeee2f-6192-4c0b-804d-a9023e977106",
    "code": "Rucaparib-Recurrent",
    "tumourGroup": "Ovarian",
    "tumourSupergroup": "Ovarian",
    "treatmentIntent": "Palliative",
    "summary": "PARP inhibitor for recurrent ovarian cancer with BRCA mutation or homologous recombination deficiency.",
    "eligibility": {
      "summary": [
        "Recurrent ovarian cancer",
        "BRCA mutation or HRD"
      ],
      "criteria": {
        "ECOG": "0-2",
        "BRCA_mutation_or_HRD": "Required",
        "Previous_platinum_therapy": "≥2 lines"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Elevated creatinine",
      "Liver enzyme elevation"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "600mg BD",
          "name": "Rucaparib",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Until progression"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Liver function tests",
      "BRCA/HRD status"
    ],
    "doseModifications": {
      "elevated_ALT": "Dose modification",
      "myelosuppression": "Dose reduction for grade 3+",
      "elevated_creatinine": "Monitor renal function"
    },
    "referenceList": [
      "NCCN Ovarian Guidelines",
      "ARIEL Studies",
      "EMA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Twice daily oral"
    },
    "preMedications": {
      "renal_monitoring": "Baseline creatinine",
      "hepatic_monitoring": "Baseline LFTs",
      "myelosuppression_monitoring": "Weekly FBC first 2 months"
    },
    "postMedications": {
      "myelosuppression": "Infection precautions",
      "renal_monitoring": "Regular creatinine",
      "hepatic_monitoring": "Avoid hepatotoxins"
    },
    "supportiveCare": {
      "renal_protection": "Adequate hydration",
      "hepatic_monitoring": "Regular LFTs",
      "neutropenia_monitoring": "Weekly FBC first 2 months"
    },
    "rescueAgents": {
      "hepatotoxicity": "Dose interruption",
      "renal_impairment": "Dose modification",
      "severe_neutropenia": "Dose reduction or G-CSF"
    },
    "monitoring": {
      "monthly": "U&E, LFTs",
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "BRCA/HRD status"
      ],
      "weekly_first_2_months": "FBC"
    },
    "toxicityMonitoring": {
      "hepatic": "LFT monitoring",
      "renal_function": "Creatinine monitoring",
      "myelosuppression": "Weekly FBC first 2 months"
    },
    "interactions": {
      "nephrotoxic_drugs": "Monitor creatinine",
      "strong_CYP3A4_inducers": "May reduce efficacy"
    },
    "contraindications": [
      "BRCA/HRD negative",
      "Severe renal impairment",
      "Pregnancy"
    ],
    "version": "1.2",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e9ffff2f-6192-4c0b-804d-a9023e977107",
    "code": "Bevacizumab-Maintenance-Ovarian",
    "tumourGroup": "Ovarian",
    "tumourSupergroup": "Ovarian",
    "treatmentIntent": "Curative",
    "summary": "Anti-VEGF monoclonal antibody maintenance therapy for newly diagnosed advanced ovarian cancer.",
    "eligibility": {
      "summary": [
        "Newly diagnosed advanced ovarian cancer",
        "High-risk features"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Response_to_chemotherapy": "Complete or partial",
        "Stage_III_with_residual_disease_or_Stage_IV": "Required"
      }
    },
    "precautions": [
      "Hypertension",
      "Proteinuria",
      "Bleeding risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "15 mg/kg",
          "name": "Bevacizumab",
          "route": "IV",
          "schedule": "Every 3 weeks"
        }
      ],
      "cycles": "Up to 22 cycles total"
    },
    "tests": [
      "Blood pressure",
      "Urinalysis",
      "Full blood count",
      "LVEF assessment"
    ],
    "doseModifications": {
      "bleeding": "Discontinue bevacizumab",
      "proteinuria": "Hold if ≥2g/24h",
      "hypertension": "Antihypertensive therapy"
    },
    "referenceList": [
      "NCCN Ovarian Guidelines",
      "ICON7 and GOG-218 Studies",
      "EMA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Up to 22",
      "administration_time": "30-90 minutes"
    },
    "preMedications": {
      "BP_monitoring": "Baseline and regular",
      "bleeding_assessment": "Clinical evaluation",
      "proteinuria_monitoring": "Baseline urinalysis"
    },
    "postMedications": {
      "bleeding": "Report any unusual bleeding",
      "proteinuria": "Report foamy urine",
      "hypertension": "Monitor BP regularly"
    },
    "supportiveCare": {
      "BP_monitoring": "Regular assessment",
      "bleeding_monitoring": "Clinical assessment",
      "proteinuria_monitoring": "Urinalysis each cycle"
    },
    "rescueAgents": {
      "major_bleeding": "Permanent discontinuation",
      "severe_hypertension": "Antihypertensive therapy, hold bevacizumab",
      "significant_proteinuria": "Hold bevacizumab"
    },
    "monitoring": {
      "baseline": [
        "BP",
        "Urinalysis",
        "FBC",
        "LVEF"
      ],
      "each_cycle": "BP, urinalysis",
      "every_3_cycles": "FBC"
    },
    "toxicityMonitoring": {
      "bleeding": "Clinical assessment",
      "proteinuria": "Urinalysis each cycle",
      "hypertension": "BP monitoring each cycle"
    },
    "interactions": {
      "anticoagulants": "Increased bleeding risk",
      "antihypertensives": "Monitor BP closely"
    },
    "contraindications": [
      "Uncontrolled hypertension",
      "Significant proteinuria",
      "Recent major surgery"
    ],
    "version": "1.4",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f0aaaa2f-6192-4c0b-804d-a9023e977108",
    "code": "Dostarlimab-Endometrial",
    "tumourGroup": "Endometrial",
    "tumourSupergroup": "Endometrial",
    "treatmentIntent": "Palliative",
    "summary": "Anti-PD-1 immunotherapy for mismatch repair deficient or microsatellite instability-high endometrial cancer.",
    "eligibility": {
      "summary": [
        "dMMR/MSI-H endometrial cancer",
        "Advanced or recurrent"
      ],
      "criteria": {
        "ECOG": "0-2",
        "dMMR_or_MSI_H": "Required",
        "Advanced_or_recurrent": "Required"
      }
    },
    "precautions": [
      "Immune-related adverse events",
      "Pneumonitis",
      "Thyroid dysfunction"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "500mg",
          "name": "Dostarlimab",
          "route": "IV",
          "schedule": "Every 3 weeks for 4 cycles, then 1000mg every 6 weeks"
        }
      ],
      "cycles": "Until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Thyroid function",
      "MMR/MSI status"
    ],
    "doseModifications": {
      "irAEs": "Hold dostarlimab grade 2+",
      "pneumonitis": "Permanent discontinuation grade 3+",
      "thyroid_dysfunction": "Hormone replacement"
    },
    "referenceList": [
      "NCCN Endometrial Guidelines",
      "GARNET Study",
      "FDA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "21 days initial, then 42 days",
      "total_cycles": "Until progression",
      "administration_time": "30 minutes"
    },
    "preMedications": {
      "irAE_education": "Comprehensive patient counseling",
      "thyroid_monitoring": "Baseline TFTs",
      "pneumonitis_monitoring": "Baseline chest imaging"
    },
    "postMedications": {
      "pneumonitis": "Report dyspnea immediately",
      "irAE_management": "Early steroid intervention",
      "thyroid_effects": "Monitor symptoms"
    },
    "supportiveCare": {
      "irAE_monitoring": "Weekly contact first 8 weeks",
      "thyroid_support": "Hormone replacement",
      "pneumonitis_prevention": "Serial chest imaging"
    },
    "rescueAgents": {
      "pneumonitis": "High-dose steroids, permanent discontinuation",
      "grade_4_irAEs": "Permanent discontinuation, high-dose steroids",
      "severe_thyroiditis": "Hormone replacement"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "TFTs",
        "MMR/MSI",
        "CXR"
      ],
      "each_cycle": "FBC, LFTs, TFTs",
      "weekly_first_8_weeks": "irAE assessment"
    },
    "toxicityMonitoring": {
      "thyroid": "Hormone levels",
      "pneumonitis": "Dyspnea assessment",
      "irAE_monitoring": "Weekly assessment first 8 weeks"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "immunosuppressants": "May reduce efficacy but needed for irAEs"
    },
    "contraindications": [
      "dMMR/MSI negative",
      "Active autoimmune disease",
      "Pregnancy"
    ],
    "version": "1.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a1bbbb2f-6192-4c0b-804d-a9023e977109",
    "code": "Lenvatinib-Pembrolizumab-Endometrial",
    "tumourGroup": "Endometrial",
    "tumourSupergroup": "Endometrial",
    "treatmentIntent": "Palliative",
    "summary": "Multi-kinase inhibitor with anti-PD-1 therapy for advanced endometrial cancer regardless of MMR status.",
    "eligibility": {
      "summary": [
        "Advanced endometrial cancer",
        "Not MSI-H/dMMR"
      ],
      "criteria": {
        "ECOG": "0-1",
        "Advanced_or_recurrent": "Required",
        "Previous_platinum_therapy": "Required"
      }
    },
    "precautions": [
      "Hypertension",
      "Proteinuria",
      "Hand-foot syndrome",
      "Immune-related adverse events"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "20mg daily",
          "name": "Lenvatinib",
          "route": "PO",
          "schedule": "Continuous"
        },
        {
          "dose": "200mg",
          "name": "Pembrolizumab",
          "route": "IV",
          "schedule": "Every 3 weeks"
        }
      ],
      "cycles": "Until progression"
    },
    "tests": [
      "Blood pressure",
      "Urinalysis",
      "Thyroid function",
      "Full blood count"
    ],
    "doseModifications": {
      "irAEs": "Steroid therapy",
      "proteinuria": "Hold if ≥2g/24h",
      "hypertension": "Antihypertensive therapy",
      "hand_foot_syndrome": "Dose reduction"
    },
    "referenceList": [
      "NCCN Endometrial Guidelines",
      "Study 309/KEYNOTE-775",
      "FDA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "Daily lenvatinib + pembrolizumab every 3 weeks"
    },
    "preMedications": {
      "BP_monitoring": "Baseline and weekly first month",
      "thyroid_monitoring": "Baseline TFTs",
      "proteinuria_monitoring": "Baseline urinalysis"
    },
    "postMedications": {
      "irAEs": "Report symptoms immediately",
      "proteinuria": "Report foamy urine",
      "hypertension": "Monitor BP regularly",
      "hand_foot_syndrome": "Moisturizers"
    },
    "supportiveCare": {
      "BP_monitoring": "Weekly first month, then regular",
      "irAE_monitoring": "Weekly first 8 weeks",
      "thyroid_monitoring": "Regular TFTs",
      "proteinuria_monitoring": "Each cycle"
    },
    "rescueAgents": {
      "severe_irAEs": "Steroids, hold pembrolizumab",
      "severe_hypertension": "Hold lenvatinib, antihypertensive therapy",
      "significant_proteinuria": "Hold lenvatinib",
      "severe_hand_foot_syndrome": "Dose reduction"
    },
    "monitoring": {
      "baseline": [
        "BP",
        "Urinalysis",
        "TFTs",
        "FBC"
      ],
      "each_cycle": "BP, urinalysis, TFTs",
      "weekly_first_month": "BP"
    },
    "toxicityMonitoring": {
      "irAEs": "Regular assessment",
      "thyroid": "TFT monitoring",
      "proteinuria": "Urinalysis each cycle",
      "hypertension": "Weekly BP first month"
    },
    "interactions": {
      "antihypertensives": "Monitor BP closely",
      "immunosuppressants": "May reduce pembrolizumab efficacy"
    },
    "contraindications": [
      "Uncontrolled hypertension",
      "Significant proteinuria",
      "Active autoimmune disease"
    ],
    "version": "1.2",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b2cccc2f-6192-4c0b-804d-a9023e977110",
    "code": "Carboplatin-Paclitaxel-Endometrial",
    "tumourGroup": "Endometrial",
    "tumourSupergroup": "Endometrial",
    "treatmentIntent": "Curative",
    "summary": "Standard platinum-taxane combination for advanced or recurrent endometrial cancer with excellent response rates.",
    "eligibility": {
      "summary": [
        "Advanced endometrial cancer",
        "First-line therapy"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Advanced_or_recurrent": "Required",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Carboplatin hypersensitivity",
      "Paclitaxel neuropathy",
      "Myelosuppression"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "AUC 5",
          "name": "Carboplatin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "175 mg/m²",
          "name": "Paclitaxel",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "6 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "CA-125",
      "Neuropathy assessment"
    ],
    "doseModifications": {
      "neuropathy": "Dose reduction 25%",
      "neutropenia": "G-CSF support",
      "hypersensitivity": "Premedication protocol"
    },
    "referenceList": [
      "NCCN Endometrial Guidelines",
      "GOG-209 Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "6",
      "administration_time": "Day 1 infusions"
    },
    "preMedications": {
      "antiemetic": "Ondansetron 8mg IV",
      "neuropathy_monitoring": "Baseline assessment",
      "hypersensitivity_prevention": "Dexamethasone, antihistamines"
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "neuropathy": "Gabapentin if symptomatic",
      "hypersensitivity": "Monitor during infusion"
    },
    "supportiveCare": {
      "tumor_monitoring": "CA-125 every 2 cycles",
      "neuropathy_prevention": "Weekly assessment",
      "hypersensitivity_management": "Premedication protocol"
    },
    "rescueAgents": {
      "severe_neuropathy": "Dose reduction or discontinuation",
      "febrile_neutropenia": "G-CSF, antibiotics",
      "severe_hypersensitivity": "Switch to cisplatin"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "CA-125",
        "Neuropathy score"
      ],
      "each_cycle": "FBC",
      "every_2_cycles": "CA-125"
    },
    "toxicityMonitoring": {
      "neuropathy": "Weekly clinical grading",
      "tumor_response": "CA-125 every 2 cycles",
      "hypersensitivity": "During carboplatin infusion"
    },
    "interactions": {
      "warfarin": "Enhanced effect",
      "CYP2C8_inhibitors": "Monitor for increased paclitaxel toxicity"
    },
    "contraindications": [
      "Previous severe hypersensitivity",
      "Severe neuropathy",
      "Pregnancy"
    ],
    "version": "1.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c3dddd2f-6192-4c0b-804d-a9023e977111",
    "code": "Doxorubicin-Cisplatin-Endometrial",
    "tumourGroup": "Endometrial",
    "tumourSupergroup": "Endometrial",
    "treatmentIntent": "Curative",
    "summary": "Anthracycline-platinum combination for high-risk endometrial cancer with superior efficacy in serous histology.",
    "eligibility": {
      "summary": [
        "High-risk endometrial cancer",
        "Serous or clear cell histology"
      ],
      "criteria": {
        "ECOG": "0-2",
        "LVEF": "> 50%",
        "High_risk_histology": "Serous, clear cell, or grade 3"
      }
    },
    "precautions": [
      "Doxorubicin cardiotoxicity",
      "Cisplatin nephrotoxicity",
      "Myelosuppression"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "60 mg/m²",
          "name": "Doxorubicin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "50 mg/m²",
          "name": "Cisplatin",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "6 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "LVEF assessment",
      "Renal function",
      "Hearing assessment"
    ],
    "doseModifications": {
      "ototoxicity": "Audiometry",
      "cardiotoxicity": "LVEF monitoring, dexrazoxane",
      "nephrotoxicity": "Adequate hydration"
    },
    "referenceList": [
      "NCCN Endometrial Guidelines",
      "GOG-177 Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "6",
      "administration_time": "Day 1 infusions"
    },
    "preMedications": {
      "hydration": "Normal saline 1-2L with Mg/K",
      "antiemetic": "Ondansetron 8mg IV",
      "cardiac_monitoring": "Baseline LVEF"
    },
    "postMedications": {
      "ototoxicity": "Report hearing changes",
      "cardiotoxicity": "Monitor for dyspnea",
      "nephrotoxicity": "Adequate hydration"
    },
    "supportiveCare": {
      "renal_protection": "Pre/post hydration",
      "cardiac_protection": "LVEF every 2 cycles",
      "ototoxicity_monitoring": "Audiometry every 2 cycles"
    },
    "rescueAgents": {
      "cardiotoxicity": "Discontinue doxorubicin, cardio-oncology referral",
      "nephrotoxicity": "Discontinue cisplatin",
      "severe_ototoxicity": "Switch to carboplatin"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LVEF",
        "U&E",
        "Audiometry"
      ],
      "each_cycle": "FBC, U&E",
      "every_2_cycles": "LVEF, audiometry"
    },
    "toxicityMonitoring": {
      "ototoxicity": "Audiometry every 2 cycles",
      "cardiotoxicity": "LVEF monitoring every 2 cycles",
      "nephrotoxicity": "Creatinine monitoring"
    },
    "interactions": {
      "trastuzumab": "Increased cardiotoxicity risk",
      "aminoglycosides": "Increased nephrotoxicity"
    },
    "contraindications": [
      "Severe cardiac dysfunction",
      "Severe renal impairment",
      "Pregnancy"
    ],
    "version": "2.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d4eeee2f-6192-4c0b-804d-a9023e977112",
    "code": "Paclitaxel-Carboplatin-Cervical",
    "tumourGroup": "Cervical",
    "tumourSupergroup": "Cervical",
    "treatmentIntent": "Curative",
    "summary": "Standard platinum-taxane combination with radiotherapy for locally advanced cervical cancer.",
    "eligibility": {
      "summary": [
        "Locally advanced cervical cancer",
        "Concurrent chemoradiotherapy"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Stage_IB2_to_IVA": "Required",
        "Adequate_organ_function": "Required"
      }
    },
    "precautions": [
      "Radiosensitization",
      "Peripheral neuropathy",
      "Myelosuppression"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "40-50 mg/m²",
          "name": "Paclitaxel",
          "route": "IV",
          "schedule": "Weekly"
        },
        {
          "dose": "AUC 2",
          "name": "Carboplatin",
          "route": "IV",
          "schedule": "Weekly"
        }
      ],
      "cycles": "5-6 weeks concurrent with RT"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Neuropathy assessment",
      "Performance status"
    ],
    "doseModifications": {
      "neuropathy": "Dose reduction 25%",
      "neutropenia": "Hold if ANC <1.0",
      "radiation_enhancement": "Enhanced monitoring"
    },
    "referenceList": [
      "NCCN Cervical Guidelines",
      "NRG Oncology Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Weekly",
      "total_cycles": "5-6 weeks",
      "administration_time": "Concurrent with radiotherapy"
    },
    "preMedications": {
      "antiemetic": "Ondansetron 8mg IV",
      "radiation_planning": "Coordinate with radiation oncology",
      "neuropathy_monitoring": "Baseline assessment"
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "neuropathy": "Gabapentin if symptomatic",
      "radiation_dermatitis": "Enhanced skin care"
    },
    "supportiveCare": {
      "tumor_monitoring": "Weekly assessment",
      "neuropathy_prevention": "Weekly assessment",
      "radiation_enhancement": "Enhanced skin monitoring"
    },
    "rescueAgents": {
      "severe_neuropathy": "Dose reduction or discontinuation",
      "radiation_toxicity": "Treatment break",
      "severe_neutropenia": "Treatment break"
    },
    "monitoring": {
      "weekly": "FBC, neuropathy assessment",
      "baseline": [
        "FBC",
        "U&E",
        "Neuropathy score",
        "ECOG"
      ],
      "during_RT": "Enhanced monitoring"
    },
    "toxicityMonitoring": {
      "neuropathy": "Weekly clinical grading during treatment",
      "myelosuppression": "Weekly FBC",
      "radiation_toxicity": "Enhanced monitoring"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "radiation_therapy": "Enhanced toxicity expected"
    },
    "contraindications": [
      "Severe neuropathy",
      "Active infection",
      "Pregnancy"
    ],
    "version": "1.9",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e5ffff2f-6192-4c0b-804d-a9023e977113",
    "code": "Cisplatin-Concurrent-RT-Cervical",
    "tumourGroup": "Cervical",
    "tumourSupergroup": "Cervical",
    "treatmentIntent": "Curative",
    "summary": "Cisplatin with concurrent radiotherapy for locally advanced cervical cancer - gold standard treatment.",
    "eligibility": {
      "summary": [
        "Locally advanced cervical cancer",
        "Concurrent chemoradiotherapy"
      ],
      "criteria": {
        "CrCl": "> 60 mL/min",
        "ECOG": "0-2",
        "Stage_IB2_to_IVA": "Required"
      }
    },
    "precautions": [
      "Cisplatin nephrotoxicity",
      "Enhanced radiation toxicity",
      "Ototoxicity"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "40 mg/m²",
          "name": "Cisplatin",
          "route": "IV",
          "schedule": "Weekly"
        }
      ],
      "cycles": "5-6 weeks concurrent with RT"
    },
    "tests": [
      "Full blood count",
      "Renal function",
      "Hearing assessment",
      "Performance status"
    ],
    "doseModifications": {
      "ototoxicity": "Audiometry monitoring",
      "nephrotoxicity": "Hold if creatinine >1.5x baseline",
      "radiation_enhancement": "Enhanced monitoring"
    },
    "referenceList": [
      "NCCN Cervical Guidelines",
      "NCI Alert",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Weekly",
      "total_cycles": "5-6 weeks",
      "administration_time": "Concurrent with radiotherapy"
    },
    "preMedications": {
      "hydration": "Normal saline 1-2L with Mg/K supplementation",
      "audiometry": "Baseline hearing assessment",
      "radiation_planning": "Coordinate timing"
    },
    "postMedications": {
      "ototoxicity": "Report hearing changes",
      "nephrotoxicity": "Adequate hydration",
      "radiation_dermatitis": "Enhanced skin care"
    },
    "supportiveCare": {
      "renal_protection": "Pre/post hydration weekly",
      "radiation_enhancement": "Enhanced monitoring",
      "ototoxicity_monitoring": "Weekly audiometry"
    },
    "rescueAgents": {
      "ototoxicity": "Switch to carboplatin",
      "nephrotoxicity": "Discontinue cisplatin",
      "severe_radiation_toxicity": "Treatment break"
    },
    "monitoring": {
      "weekly": "FBC, U&E, audiometry",
      "baseline": [
        "FBC",
        "U&E",
        "Audiometry",
        "CrCl"
      ],
      "during_RT": "Enhanced monitoring"
    },
    "toxicityMonitoring": {
      "ototoxicity": "Weekly audiometry",
      "nephrotoxicity": "Weekly creatinine monitoring",
      "radiation_toxicity": "Enhanced assessment"
    },
    "interactions": {
      "loop_diuretics": "Increased ototoxicity",
      "aminoglycosides": "Increased nephrotoxicity"
    },
    "contraindications": [
      "Severe renal impairment",
      "Significant hearing loss",
      "Pregnancy"
    ],
    "version": "2.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f6aaaa2f-6192-4c0b-804d-a9023e977114",
    "code": "Bevacizumab-Paclitaxel-Cervical",
    "tumourGroup": "Cervical",
    "tumourSupergroup": "Cervical",
    "treatmentIntent": "Palliative",
    "summary": "Anti-VEGF therapy with paclitaxel for recurrent or metastatic cervical cancer with survival benefit.",
    "eligibility": {
      "summary": [
        "Recurrent or metastatic cervical cancer",
        "Previously treated"
      ],
      "criteria": {
        "ECOG": "0-2",
        "Recurrent_or_metastatic": "Required",
        "Previous_platinum_therapy": "Required"
      }
    },
    "precautions": [
      "Bevacizumab bleeding risk",
      "Fistula formation",
      "Hypertension"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "15 mg/kg",
          "name": "Bevacizumab",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "80 mg/m²",
          "name": "Paclitaxel",
          "route": "IV",
          "schedule": "Days 1, 8, 15"
        }
      ],
      "cycles": "Every 28 days"
    },
    "tests": [
      "Full blood count",
      "Blood pressure",
      "Urinalysis",
      "Fistula assessment"
    ],
    "doseModifications": {
      "fistula": "Permanent discontinuation",
      "bleeding": "Discontinue bevacizumab",
      "hypertension": "Antihypertensive therapy"
    },
    "referenceList": [
      "NCCN Cervical Guidelines",
      "GOG-240 Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "3 days per cycle"
    },
    "preMedications": {
      "BP_monitoring": "Baseline and regular",
      "fistula_monitoring": "Pelvic examination",
      "bleeding_assessment": "Clinical evaluation"
    },
    "postMedications": {
      "fistula": "Report pelvic pain or discharge",
      "bleeding": "Report any unusual bleeding",
      "hypertension": "Monitor BP regularly"
    },
    "supportiveCare": {
      "BP_monitoring": "Each cycle",
      "fistula_monitoring": "Regular pelvic exams",
      "bleeding_monitoring": "Clinical assessment each cycle"
    },
    "rescueAgents": {
      "major_bleeding": "Permanent bevacizumab discontinuation",
      "fistula_formation": "Immediate discontinuation",
      "severe_hypertension": "Antihypertensive therapy"
    },
    "monitoring": {
      "weekly": "Neuropathy assessment",
      "baseline": [
        "FBC",
        "BP",
        "Urinalysis",
        "Pelvic exam"
      ],
      "each_cycle": "FBC, BP, pelvic exam"
    },
    "toxicityMonitoring": {
      "fistula": "Pelvic examination",
      "bleeding": "Clinical assessment each cycle",
      "hypertension": "BP monitoring"
    },
    "interactions": {
      "anticoagulants": "Increased bleeding risk",
      "antihypertensives": "Monitor BP closely"
    },
    "contraindications": [
      "Recent major bleeding",
      "Fistula formation risk",
      "Uncontrolled hypertension"
    ],
    "version": "1.7",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a7bbbb2f-6192-4c0b-804d-a9023e977115",
    "code": "Pembrolizumab-Cervical",
    "tumourGroup": "Cervical",
    "tumourSupergroup": "Cervical",
    "treatmentIntent": "Palliative",
    "summary": "Anti-PD-1 immunotherapy for recurrent or metastatic cervical cancer with PD-L1 expression.",
    "eligibility": {
      "summary": [
        "Recurrent or metastatic cervical cancer",
        "PD-L1 positive"
      ],
      "criteria": {
        "ECOG": "0-2",
        "PD_L1_CPS": "≥1",
        "Previous_platinum_therapy": "Required"
      }
    },
    "precautions": [
      "Immune-related adverse events",
      "Pneumonitis",
      "Thyroid dysfunction"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "200mg",
          "name": "Pembrolizumab",
          "route": "IV",
          "schedule": "Every 3 weeks"
        }
      ],
      "cycles": "Until progression or toxicity"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Thyroid function",
      "PD-L1 status"
    ],
    "doseModifications": {
      "irAEs": "Hold pembrolizumab grade 2+",
      "pneumonitis": "Permanent discontinuation grade 3+",
      "thyroid_dysfunction": "Hormone replacement"
    },
    "referenceList": [
      "NCCN Cervical Guidelines",
      "KEYNOTE Studies",
      "FDA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "30 minutes"
    },
    "preMedications": {
      "irAE_education": "Comprehensive patient counseling",
      "thyroid_monitoring": "Baseline TFTs",
      "pneumonitis_monitoring": "Baseline chest imaging"
    },
    "postMedications": {
      "pneumonitis": "Report dyspnea immediately",
      "irAE_management": "Early steroid intervention",
      "thyroid_effects": "Monitor symptoms"
    },
    "supportiveCare": {
      "irAE_monitoring": "Weekly contact first 8 weeks",
      "thyroid_support": "Hormone replacement",
      "pneumonitis_prevention": "Serial chest imaging"
    },
    "rescueAgents": {
      "pneumonitis": "High-dose steroids, permanent discontinuation",
      "grade_4_irAEs": "Permanent discontinuation, high-dose steroids",
      "severe_thyroiditis": "Hormone replacement"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "TFTs",
        "PD-L1",
        "CXR"
      ],
      "each_cycle": "FBC, LFTs, TFTs",
      "weekly_first_8_weeks": "irAE assessment"
    },
    "toxicityMonitoring": {
      "thyroid": "Hormone levels",
      "pneumonitis": "Dyspnea assessment",
      "irAE_monitoring": "Weekly assessment first 8 weeks"
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "immunosuppressants": "May reduce efficacy but needed for irAEs"
    },
    "contraindications": [
      "PD-L1 negative",
      "Active autoimmune disease",
      "Pregnancy"
    ],
    "version": "1.4",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "00eaf82f-6192-4c0b-804d-a9023e977d56",
    "code": "AC-T",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Curative",
    "summary": "AC-T is a standard curative regimen for early-stage breast cancer, administered sequentially as AC followed by Paclitaxel. This is a Category 1 NCCN recommendation for HER2-negative breast cancer in the adjuvant setting.",
    "eligibility": {
      "summary": [
        "Early-stage or locally advanced breast cancer",
        "HER2-negative disease",
        "ER-positive or triple-negative subtypes"
      ],
      "criteria": {
        "Age": "18–70 years",
        "ECOG": "0–2",
        "Other": "No active infections or uncontrolled comorbidities",
        "Cardiac": "LVEF ≥50% or within institutional normal limits",
        "Biomarkers": "HER2-negative (IHC 0-1+ or FISH negative)"
      },
      "nccn_category": "1",
      "line_of_therapy": "Adjuvant",
      "treatment_setting": "Early-stage",
      "biomarker_requirements": {
        "HER2": "Negative (IHC 0-1+ or FISH negative)",
        "ER_PR": "Any status (works for both ER+ and TNBC)"
      }
    },
    "precautions": [
      "Anthracyclines carry cumulative cardiotoxicity risk — LVEF must be monitored",
      "Paclitaxel requires steroid and antihistamine premedication to prevent hypersensitivity",
      "Myelosuppression is common during AC — counsel on neutropenic precautions",
      "Monitor for peripheral neuropathy during paclitaxel phase",
      "Assess cardiac function before each cycle if borderline LVEF",
      "Consider growth factor support for high-risk patients"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "60 mg/m²",
          "name": "Doxorubicin (Adriamycin)",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "600 mg/m²",
          "name": "Cyclophosphamide",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "4 cycles of AC every 21 days, followed by",
      "subsequent_treatment": {
        "drugs": [
          {
            "dose": "175 mg/m²",
            "name": "Paclitaxel",
            "route": "IV",
            "schedule": "Day 1"
          }
        ],
        "cycles": "4 cycles every 21 days or 12 weekly doses"
      }
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Renal function tests",
      "LVEF assessment (ECHO or MUGA)"
    ],
    "doseModifications": {
      "neuropathy": "Discontinue paclitaxel if grade 3+ neuropathy persists",
      "neutropenia": "Hold treatment if ANC <1.0, resume with growth factor support",
      "cardiotoxicity": "Discontinue if LVEF drops >10% from baseline or <50%",
      "dose_reductions": {
        "level_1": "25% dose reduction for grade 3 toxicity",
        "level_2": "50% dose reduction for recurrent grade 3 or grade 4 toxicity"
      },
      "thrombocytopenia": "Hold treatment if platelets <100,000",
      "alternate_options": {
        "neuropathy_concerns": "Consider dose-dense AC q2weeks x 4 without taxane",
        "paclitaxel_intolerance": "Switch to docetaxel 75 mg/m² q3weeks x 4",
        "anthracycline_contraindication": "Consider TC (docetaxel + cyclophosphamide) x 4"
      }
    },
    "referenceList": [
      "NCCN Breast Cancer Guidelines",
      "ASCO Clinical Practice Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "8 (4 AC + 4 Paclitaxel)",
      "administration_time": "AC: 2-3 hours, Paclitaxel: 3-4 hours"
    },
    "preMedications": {
      "ac_phase": [
        "Dexamethasone 8mg PO",
        "Ondansetron 8mg IV",
        "Lorazepam 1mg PO"
      ],
      "paclitaxel_phase": [
        "Dexamethasone 20mg IV",
        "Diphenhydramine 50mg IV",
        "Ranitidine 50mg IV"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron 8mg TDS PRN",
      "mucositis": "Magic mouthwash PRN",
      "constipation": "Docusate 100mg BD"
    },
    "supportiveCare": {
      "growth_factors": "Pegfilgrastim 6mg SC day +2 if indicated",
      "cardiac_monitoring": "LVEF assessment every 3 months",
      "neuropathy_assessment": "Before each paclitaxel cycle"
    },
    "rescueAgents": {
      "anaphylaxis": "Epinephrine 1:1000, 0.3-0.5mL IM",
      "severe_neuropathy": "Gabapentin 300mg TDS",
      "febrile_neutropenia": "Immediate broad-spectrum antibiotics"
    },
    "monitoring": {
      "weekly": [
        "FBC during AC phase"
      ],
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "LVEF"
      ],
      "before_each_cycle": [
        "FBC",
        "U&E",
        "LFTs",
        "Performance status"
      ]
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "CBC with differential",
        "ECHO or MUGA scan",
        "Neurological assessment",
        "Symptom assessment",
        "Vital signs during infusion"
      ],
      "primary_toxicities": [
        "Myelosuppression",
        "Cardiotoxicity",
        "Peripheral neuropathy",
        "Alopecia",
        "Nausea/vomiting",
        "Hypersensitivity reactions"
      ],
      "monitoring_schedule": {
        "baseline": [
          "CBC",
          "Comprehensive metabolic panel",
          "LVEF assessment",
          "Neurologic exam"
        ],
        "post_treatment": [
          "LVEF assessment 3-6 months post completion"
        ],
        "during_treatment": [
          "Cardiac monitoring every 3 months",
          "Neuropathy assessment before each paclitaxel"
        ],
        "before_each_cycle": [
          "CBC",
          "Basic metabolic panel",
          "Performance status",
          "Toxicity assessment"
        ]
      }
    },
    "interactions": {
      "warfarin": "Monitor INR closely",
      "paclitaxel": "CYP3A4 inhibitors may increase toxicity",
      "anthracyclines": "Avoid live vaccines"
    },
    "contraindications": [
      "Severe heart failure (LVEF <40%)",
      "Active severe infection",
      "Pregnancy or breastfeeding",
      "Known hypersensitivity to anthracyclines, taxanes, or excipients",
      "Prior cumulative anthracycline dose >300 mg/m² doxorubicin equivalent",
      "Severe hepatic impairment (bilirubin >3x ULN)",
      "Severe renal impairment (CrCl <30 mL/min)",
      "Active cardiac arrhythmias requiring medication"
    ],
    "version": "2.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "33eaf82f-6192-4c0b-804d-a9023e977d59",
    "code": "TCH",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Curative",
    "summary": "TCH (Docetaxel, Carboplatin, Trastuzumab) is a NCCN Category 1 regimen for HER2-positive early-stage breast cancer. This anthracycline-free approach provides excellent efficacy while avoiding cardiotoxicity associated with doxorubicin-trastuzumab combinations.",
    "eligibility": {
      "summary": [
        "Early-stage HER2-positive breast cancer",
        "Alternative to anthracycline-containing regimens",
        "Preferred for patients with cardiac risk factors"
      ],
      "criteria": {
        "Age": "18+ years",
        "ECOG": "0–2",
        "Other": "No active infections, adequate organ function",
        "Cardiac": "LVEF ≥50% or within institutional normal limits",
        "Biomarkers": "HER2-positive (IHC 3+ or FISH amplified)"
      },
      "nccn_category": "1",
      "line_of_therapy": "Adjuvant",
      "treatment_setting": "Early-stage",
      "biomarker_requirements": {
        "HER2": "Positive (IHC 3+ or FISH amplified, HER2/CEP17 ratio ≥2.0)",
        "ER_PR": "Any status"
      }
    },
    "precautions": [
      "Trastuzumab cardiotoxicity monitoring required",
      "Docetaxel hypersensitivity potential",
      "Carboplatin allergic reactions"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "75 mg/m²",
          "name": "Docetaxel",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "AUC 6",
          "name": "Carboplatin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "8 mg/kg loading, then 6 mg/kg",
          "name": "Trastuzumab",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "6 cycles every 21 days, then trastuzumab continues"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "LVEF assessment",
      "Renal function"
    ],
    "doseModifications": {
      "neuropathy": "Reduce docetaxel by 25% for grade 2, hold for grade 3+",
      "neutropenia": "Hold treatment if ANC <1.5, resume with growth factor support",
      "cardiotoxicity": "Hold trastuzumab if LVEF drops >10% from baseline or <50%, resume when recovered",
      "dose_reductions": {
        "carboplatin": "Reduce AUC by 25% for persistent toxicity",
        "docetaxel_level_1": "75 mg/m² → 60 mg/m²",
        "docetaxel_level_2": "60 mg/m² → 45 mg/m²"
      },
      "hypersensitivity": "Premedicate with steroids, antihistamines; discontinue for severe reactions",
      "alternate_options": {
        "cardiac_concerns": "Monitor more frequently, consider cardio-oncology consultation",
        "docetaxel_intolerance": "Switch to paclitaxel 80 mg/m² weekly x 12",
        "carboplatin_intolerance": "Consider AC-TH (doxorubicin/cyclophosphamide → taxane/trastuzumab)"
      }
    },
    "referenceList": [
      "NCCN Breast Cancer Guidelines",
      "ASCO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "6 + maintenance",
      "administration_time": "5-6 hours"
    },
    "preMedications": {
      "antiemetic": [
        "Ondansetron 8mg IV"
      ],
      "hypersensitivity_prevention": [
        "Dexamethasone 8mg PO x3 days",
        "Diphenhydramine 50mg IV",
        "Ranitidine 50mg IV"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron 8mg TDS PRN",
      "mucositis": "Magic mouthwash PRN",
      "neuropathy": "Gabapentin if symptomatic"
    },
    "supportiveCare": {
      "skin_care": "Moisturizers for hand-foot syndrome",
      "growth_factors": "G-CSF if febrile neutropenia",
      "cardiac_monitoring": "LVEF every 3 cycles"
    },
    "rescueAgents": {
      "hypersensitivity": "Epinephrine, steroids, antihistamines",
      "cardiac_dysfunction": "ACE inhibitors, beta-blockers",
      "febrile_neutropenia": "Broad-spectrum antibiotics"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "LVEF",
        "HER2 status"
      ],
      "every_3_cycles": [
        "LVEF assessment"
      ],
      "before_each_cycle": [
        "FBC",
        "U&E",
        "LFTs",
        "Clinical assessment"
      ]
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "CBC with differential",
        "ECHO or MUGA scan",
        "Neurological assessment",
        "Infusion reaction monitoring",
        "Weight and edema assessment"
      ],
      "primary_toxicities": [
        "Myelosuppression",
        "Cardiotoxicity (trastuzumab-related)",
        "Peripheral neuropathy",
        "Hypersensitivity reactions",
        "Fluid retention",
        "Alopecia"
      ],
      "monitoring_schedule": {
        "baseline": [
          "CBC",
          "Comprehensive metabolic panel",
          "LVEF assessment",
          "HER2 testing confirmation"
        ],
        "post_treatment": [
          "LVEF assessment at completion and 6 months post-treatment"
        ],
        "during_treatment": [
          "LVEF assessment every 3 months",
          "Weekly CBC during cycle 1"
        ],
        "before_each_cycle": [
          "CBC",
          "Basic metabolic panel",
          "Performance status",
          "Cardiac symptoms assessment"
        ]
      }
    },
    "interactions": {
      "warfarin": "Monitor INR closely",
      "anthracyclines": "Avoid concurrent use"
    },
    "contraindications": [
      "Severe heart failure (LVEF <40%)",
      "Active severe infection",
      "Pregnancy or breastfeeding",
      "Known hypersensitivity to trastuzumab, docetaxel, or carboplatin",
      "Severe hepatic impairment (bilirubin >3x ULN)",
      "Severe renal impairment (CrCl <30 mL/min)",
      "Uncontrolled cardiac arrhythmias",
      "Recent myocardial infarction (<6 months)"
    ],
    "version": "1.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "88eaf82f-6192-4c0b-804d-a9023e977d64",
    "code": "CMF",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Curative",
    "summary": "CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) is a well-established NCCN Category 1 regimen for early-stage breast cancer. This anthracycline-free approach is particularly suitable for patients with cardiac contraindications or lower-risk disease.",
    "eligibility": {
      "summary": [
        "Early-stage breast cancer",
        "Alternative to anthracycline-based regimens",
        "Suitable for older patients or those with cardiac comorbidities"
      ],
      "criteria": {
        "Age": "18+ years (often preferred for >65 years)",
        "ECOG": "0–2",
        "Other": "Adequate renal and hepatic function",
        "Cardiac": "Any LVEF (cardiac-sparing regimen)",
        "Biomarkers": "HER2-negative preferred"
      },
      "nccn_category": "1",
      "line_of_therapy": "Adjuvant",
      "treatment_setting": "Early-stage",
      "biomarker_requirements": {
        "HER2": "Negative preferred",
        "ER_PR": "Any status (particularly effective in ER-positive disease)"
      }
    },
    "precautions": [
      "Methotrexate mucositis and pneumonitis",
      "Cyclophosphamide hemorrhagic cystitis",
      "5-FU mucositis"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "600 mg/m²",
          "name": "Cyclophosphamide",
          "route": "IV",
          "schedule": "Days 1 and 8"
        },
        {
          "dose": "40 mg/m²",
          "name": "Methotrexate",
          "route": "IV",
          "schedule": "Days 1 and 8"
        },
        {
          "dose": "600 mg/m²",
          "name": "5-Fluorouracil",
          "route": "IV",
          "schedule": "Days 1 and 8"
        }
      ],
      "cycles": "6 cycles every 28 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Renal function",
      "Chest X-ray"
    ],
    "doseModifications": {
      "mucositis": "Hold for grade 3+ mucositis, resume with 25% dose reduction",
      "hepatotoxicity": "Monitor LFTs, reduce methotrexate by 50% if ALT/AST >3x ULN",
      "renal_toxicity": "Adjust methotrexate based on creatinine clearance",
      "dose_reductions": {
        "level_1": "25% reduction in all drugs",
        "level_2": "50% reduction in all drugs"
      },
      "myelosuppression": "Hold if ANC <1.5 or platelets <100,000, reduce doses by 25% for grade 3+ toxicity",
      "alternate_options": {
        "hepatotoxicity": "Substitute methotrexate with docetaxel (switch to TC regimen)",
        "elderly_patients": "Consider dose reduction to 75% of standard doses upfront",
        "mucositis_intolerance": "Consider oral CMF regimen with lower 5-FU doses"
      }
    },
    "referenceList": [
      "NCCN Guidelines",
      "ESMO Guidelines",
      "Early Breast Cancer Trialists Collaborative Group"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "6",
      "administration_time": "2-3 hours"
    },
    "preMedications": {
      "hydration": [
        "Normal saline 500ml pre/post"
      ],
      "antiemetic": [
        "Ondansetron 8mg IV"
      ]
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "cystitis": "Increased fluid intake",
      "mucositis": "Oral care, folate supplementation"
    },
    "supportiveCare": {
      "bladder_protection": "Adequate hydration",
      "infection_prevention": "Monitor WBC",
      "folate_supplementation": "Folic acid 5mg daily"
    },
    "rescueAgents": {
      "pneumonitis": "Steroids, stop MTX",
      "severe_mucositis": "IV hydration",
      "hemorrhagic_cystitis": "Bladder irrigation"
    },
    "monitoring": {
      "weekly": [
        "FBC"
      ],
      "baseline": [
        "FBC",
        "U&E",
        "LFTs",
        "CXR"
      ],
      "each_cycle": [
        "U&E",
        "LFTs",
        "Clinical assessment"
      ]
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "CBC with differential",
        "Liver function tests",
        "Renal function tests",
        "Oral examination",
        "Pulmonary function if indicated"
      ],
      "primary_toxicities": [
        "Myelosuppression",
        "Mucositis",
        "Nausea/vomiting",
        "Alopecia",
        "Hepatotoxicity (methotrexate)",
        "Pulmonary toxicity (rare)"
      ],
      "monitoring_schedule": {
        "baseline": [
          "CBC",
          "Comprehensive metabolic panel",
          "LFTs",
          "Creatinine clearance"
        ],
        "post_treatment": [
          "Follow-up CBC and chemistry panel 4-6 weeks post-completion"
        ],
        "during_treatment": [
          "Weekly CBC for first 2 cycles",
          "Oral cavity assessment"
        ],
        "before_each_cycle": [
          "CBC",
          "LFTs",
          "Creatinine",
          "Performance status"
        ]
      }
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "trimethoprim": "Folate antagonism"
    },
    "contraindications": [
      "Severe hepatic impairment (bilirubin >3x ULN)",
      "Severe renal impairment (CrCl <30 mL/min)",
      "Active severe infection",
      "Pregnancy or breastfeeding",
      "Known hypersensitivity to study drugs",
      "Severe mucositis or active peptic ulcer disease",
      "Immunodeficiency syndromes",
      "Active pulmonary disease (relative contraindication)"
    ],
    "version": "1.5",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "b3daf82f-6192-4c0b-804d-a9023e977e02",
    "code": "Trastuzumab-Pertuzumab-Docetaxel",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Curative",
    "summary": "Trastuzumab-Pertuzumab-Docetaxel (THP) is the NCCN Category 1 standard first-line regimen for HER2-positive metastatic breast cancer. This dual HER2 blockade with chemotherapy provides superior efficacy compared to single-agent HER2 targeting.",
    "eligibility": {
      "summary": [
        "HER2-positive metastatic breast cancer",
        "First-line treatment",
        "No prior anti-HER2 therapy in metastatic setting"
      ],
      "criteria": {
        "Age": "18+ years",
        "ECOG": "0–2",
        "Other": "Adequate organ function, life expectancy >3 months",
        "Cardiac": "LVEF ≥50% or within institutional normal limits",
        "Biomarkers": "HER2-positive (IHC 3+ or FISH amplified)"
      },
      "nccn_category": "1",
      "line_of_therapy": "First-line",
      "treatment_setting": "Metastatic",
      "biomarker_requirements": {
        "HER2": "Positive (IHC 3+ or FISH amplified, HER2/CEP17 ratio ≥2.0)",
        "ER_PR": "Any status"
      }
    },
    "precautions": [
      "Dual HER2 blockade cardiotoxicity",
      "Docetaxel hypersensitivity",
      "Diarrhea with pertuzumab"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "8 mg/kg loading, then 6 mg/kg",
          "name": "Trastuzumab",
          "route": "IV",
          "schedule": "Every 3 weeks"
        },
        {
          "dose": "840mg loading, then 420mg",
          "name": "Pertuzumab",
          "route": "IV",
          "schedule": "Every 3 weeks"
        },
        {
          "dose": "75 mg/m²",
          "name": "Docetaxel",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "Until progression"
    },
    "tests": [
      "Full blood count",
      "LVEF assessment",
      "HER2 status",
      "Liver function tests"
    ],
    "doseModifications": {
      "diarrhea": "Manage with antidiarrheals, hold pertuzumab for grade 3+ diarrhea",
      "neuropathy": "Reduce or discontinue docetaxel for grade 2+, continue HER2 agents",
      "neutropenia": "Hold chemotherapy if ANC <1.0, continue HER2 agents with growth factor support",
      "cardiotoxicity": "Hold HER2-targeted agents if LVEF drops >10% or <50%, resume when recovered",
      "dose_reductions": {
        "docetaxel_level_1": "75 mg/m² → 60 mg/m²",
        "docetaxel_level_2": "60 mg/m² → 45 mg/m²"
      },
      "alternate_options": {
        "cardiac_toxicity": "Hold HER2 agents, resume when LVEF recovers, consider cardio-oncology",
        "docetaxel_intolerance": "Switch to paclitaxel 80 mg/m² weekly or carboplatin AUC 6",
        "progression_on_therapy": "Continue HER2 agents with different chemotherapy backbone"
      }
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "CLEOPATRA Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "4-6 hours"
    },
    "preMedications": {
      "cardiac_monitoring": "Baseline LVEF",
      "infusion_monitoring": "First cycle closely monitored",
      "docetaxel_premedication": "Dexamethasone 8mg PO x3 days"
    },
    "postMedications": {
      "diarrhea": "Early loperamide intervention",
      "mucositis": "Oral care",
      "neuropathy": "Gabapentin if symptomatic"
    },
    "supportiveCare": {
      "GI_support": "Antidiarrheal agents",
      "cardiac_protection": "LVEF every 3 cycles",
      "neuropathy_prevention": "Dose modifications"
    },
    "rescueAgents": {
      "severe_diarrhea": "IV hydration, electrolytes",
      "severe_neuropathy": "Docetaxel dose reduction",
      "cardiac_dysfunction": "Hold HER2 agents, cardio-oncology"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "LVEF",
        "HER2 status"
      ],
      "each_cycle": [
        "FBC",
        "LFTs",
        "Diarrhea assessment"
      ],
      "every_3_cycles": "LVEF"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "ECHO or MUGA scan",
        "CBC with differential",
        "Neurological assessment",
        "Diarrhea assessment and management",
        "Infusion reaction monitoring"
      ],
      "primary_toxicities": [
        "Cardiotoxicity (trastuzumab/pertuzumab)",
        "Myelosuppression",
        "Peripheral neuropathy",
        "Diarrhea (pertuzumab-specific)",
        "Hypersensitivity reactions",
        "Fluid retention"
      ],
      "monitoring_schedule": {
        "ongoing": [
          "Continue HER2-targeted therapy until progression"
        ],
        "baseline": [
          "LVEF assessment",
          "CBC",
          "Comprehensive metabolic panel",
          "Performance status"
        ],
        "during_treatment": [
          "LVEF assessment every 3 months",
          "Weekly CBC for first 2 cycles"
        ],
        "before_each_cycle": [
          "CBC",
          "Basic metabolic panel",
          "Cardiac symptoms",
          "Toxicity assessment"
        ]
      }
    },
    "interactions": {
      "warfarin": "Monitor INR",
      "anthracyclines": "Avoid concurrent use"
    },
    "contraindications": [
      "Severe heart failure (LVEF <40%)",
      "Known hypersensitivity to trastuzumab, pertuzumab, or docetaxel",
      "Pregnancy or breastfeeding",
      "Severe hepatic impairment",
      "Active severe infection",
      "Uncontrolled cardiac arrhythmias",
      "Recent myocardial infarction (<6 months)"
    ],
    "version": "2.6",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c8faf82f-6192-4c0b-804d-a9023e977e27",
    "code": "Palbociclib-Letrozole",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Palliative",
    "summary": "Palbociclib-Letrozole is a NCCN Category 1 first-line regimen for hormone receptor-positive, HER2-negative metastatic breast cancer in postmenopausal women. This CDK4/6 inhibitor combination significantly improves progression-free survival.",
    "eligibility": {
      "summary": [
        "HR-positive, HER2-negative metastatic breast cancer",
        "Postmenopausal women or premenopausal with ovarian suppression",
        "First-line endocrine therapy"
      ],
      "criteria": {
        "Age": "18+ years (postmenopausal preferred)",
        "ECOG": "0–2",
        "Other": "Adequate organ function, no visceral crisis",
        "Biomarkers": "ER+ and/or PR+, HER2-negative",
        "Menopausal": "Postmenopausal or with ovarian suppression"
      },
      "nccn_category": "1",
      "line_of_therapy": "First-line",
      "treatment_setting": "Metastatic",
      "biomarker_requirements": {
        "ER": "Positive (≥1% by IHC)",
        "PR": "Any status",
        "HER2": "Negative (IHC 0-1+ or FISH negative)"
      }
    },
    "precautions": [
      "Myelosuppression",
      "Fatigue",
      "Pulmonary embolism risk"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "125mg daily",
          "name": "Palbociclib",
          "route": "PO",
          "schedule": "Days 1-21"
        },
        {
          "dose": "2.5mg daily",
          "name": "Letrozole",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Every 28 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Estrogen receptor status",
      "Performance status"
    ],
    "doseModifications": {
      "letrozole": "Standard 2.5 mg daily, no dose reductions typically needed",
      "neutropenia": "Hold for ANC <1.0, resume with dose reduction for grade 3+ neutropenia",
      "other_toxicity": "Hold for grade 3+ non-hematologic toxicity, resume with dose reduction",
      "dose_reductions": {
        "palbociclib_level_1": "125 mg → 100 mg daily",
        "palbociclib_level_2": "100 mg → 75 mg daily"
      },
      "alternate_options": {
        "progression": "Consider fulvestrant + CDK4/6 inhibitor or chemotherapy",
        "letrozole_intolerance": "Switch to anastrozole 1 mg daily or exemestane 25 mg daily",
        "palbociclib_intolerance": "Switch to ribociclib 600 mg daily or abemaciclib 150 mg BID"
      }
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "PALOMA Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "Until progression",
      "administration_time": "21 days on, 7 days off palbociclib + continuous letrozole"
    },
    "preMedications": {
      "fatigue_assessment": "Baseline ECOG",
      "thrombosis_assessment": "Risk factors",
      "myelosuppression_monitoring": "Baseline FBC"
    },
    "postMedications": {
      "fatigue": "Energy conservation techniques",
      "infection_prevention": "Neutropenia precautions",
      "thrombosis_prevention": "Mobilization"
    },
    "supportiveCare": {
      "fatigue_management": "Dose modifications",
      "thrombosis_prevention": "Risk assessment",
      "neutropenia_monitoring": "Weekly FBC first 2 cycles"
    },
    "rescueAgents": {
      "severe_fatigue": "Dose reduction",
      "pulmonary_embolism": "Anticoagulation",
      "febrile_neutropenia": "G-CSF, antibiotics"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "ER status",
        "ECOG"
      ],
      "each_cycle": "FBC, clinical assessment",
      "weekly_first_2_cycles": "FBC"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "CBC with differential",
        "Performance status assessment",
        "Symptom monitoring",
        "Quality of life assessment"
      ],
      "primary_toxicities": [
        "Neutropenia",
        "Fatigue",
        "Nausea",
        "Diarrhea",
        "Alopecia",
        "Stomatitis"
      ],
      "monitoring_schedule": {
        "cycle_1": [
          "CBC on days 1, 15"
        ],
        "ongoing": [
          "Monthly CBC, toxicity assessment every 3 months"
        ],
        "baseline": [
          "CBC",
          "Comprehensive metabolic panel",
          "Performance status"
        ],
        "subsequent_cycles": [
          "CBC day 1 of each cycle"
        ]
      }
    },
    "interactions": {
      "warfarin": "Monitor INR",
      "strong_CYP3A4_inhibitors": "Reduce palbociclib dose"
    },
    "contraindications": [
      "Pregnancy or breastfeeding",
      "Known hypersensitivity to palbociclib or letrozole",
      "Severe hepatic impairment",
      "Premenopausal status without ovarian suppression",
      "Visceral crisis requiring immediate cytoreduction",
      "Concurrent strong CYP3A inhibitors"
    ],
    "version": "1.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a4eaf82f-6192-4c0b-804d-a9023e977e13",
    "code": "Doxorubicin-Cyclophosphamide",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Curative",
    "summary": "Doxorubicin-Cyclophosphamide (AC) is a NCCN Category 1 regimen for early-stage breast cancer when taxanes are contraindicated or by patient preference. This anthracycline-based doublet provides excellent efficacy with shorter treatment duration.",
    "eligibility": {
      "summary": [
        "Early-stage breast cancer",
        "Taxane contraindication or intolerance",
        "Patient preference for shorter regimen"
      ],
      "criteria": {
        "Age": "18–75 years",
        "ECOG": "0–2",
        "Other": "Adequate organ function, no peripheral neuropathy concerns",
        "Cardiac": "LVEF ≥50% or within institutional normal limits",
        "Biomarkers": "HER2-negative"
      },
      "nccn_category": "1",
      "line_of_therapy": "Adjuvant",
      "treatment_setting": "Early-stage",
      "biomarker_requirements": {
        "HER2": "Negative",
        "ER_PR": "Any status"
      }
    },
    "precautions": [
      "Doxorubicin cardiotoxicity",
      "Cyclophosphamide hemorrhagic cystitis",
      "Myelosuppression"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "60 mg/m²",
          "name": "Doxorubicin",
          "route": "IV",
          "schedule": "Day 1"
        },
        {
          "dose": "600 mg/m²",
          "name": "Cyclophosphamide",
          "route": "IV",
          "schedule": "Day 1"
        }
      ],
      "cycles": "4 cycles every 21 days"
    },
    "tests": [
      "Full blood count",
      "LVEF assessment",
      "Liver function tests",
      "Renal function"
    ],
    "doseModifications": {
      "mucositis": "Hold for grade 3+ mucositis, resume with dose reduction",
      "neutropenia": "Hold treatment if ANC <1.0, resume with growth factor support",
      "cardiotoxicity": "Discontinue if LVEF drops >10% from baseline or <50%",
      "dose_reductions": {
        "level_1": "25% dose reduction for grade 3+ toxicity",
        "level_2": "50% dose reduction for recurrent grade 3+ toxicity"
      },
      "thrombocytopenia": "Hold if platelets <100,000",
      "alternate_options": {
        "severe_nausea": "Enhanced antiemetic regimen with NK1 antagonists",
        "cardiac_concerns": "Consider CMF or TC regimen",
        "patient_preference": "Discuss AC-T for potentially better outcomes"
      }
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "NSABP Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "4",
      "administration_time": "2-3 hours"
    },
    "preMedications": {
      "hydration": "Adequate fluid intake",
      "antiemetic": "Ondansetron 8mg IV, dexamethasone 8mg IV",
      "cardiac_protection": "Consider dexrazoxane if high cumulative dose"
    },
    "postMedications": {
      "nausea": "Ondansetron PRN",
      "alopecia": "Scalp cooling if available",
      "mucositis": "Oral care"
    },
    "supportiveCare": {
      "bladder_protection": "Adequate hydration",
      "cardiac_monitoring": "LVEF every 2 cycles",
      "infection_prevention": "Neutropenia precautions"
    },
    "rescueAgents": {
      "cardiotoxicity": "Cardio-oncology referral",
      "febrile_neutropenia": "G-CSF, antibiotics",
      "hemorrhagic_cystitis": "Bladder irrigation"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LVEF",
        "LFTs",
        "U&E"
      ],
      "each_cycle": [
        "FBC",
        "Clinical assessment"
      ],
      "every_2_cycles": "LVEF"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "CBC with differential",
        "ECHO or MUGA scan",
        "Symptom assessment",
        "Performance status evaluation"
      ],
      "primary_toxicities": [
        "Myelosuppression",
        "Cardiotoxicity",
        "Nausea/vomiting",
        "Alopecia",
        "Mucositis",
        "Secondary malignancies (rare)"
      ],
      "monitoring_schedule": {
        "baseline": [
          "CBC",
          "Comprehensive metabolic panel",
          "LVEF assessment"
        ],
        "post_treatment": [
          "LVEF assessment 3-6 months post completion"
        ],
        "during_treatment": [
          "LVEF assessment every 2 cycles"
        ],
        "before_each_cycle": [
          "CBC",
          "Basic metabolic panel",
          "Performance status"
        ]
      }
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "phenytoin": "Monitor levels"
    },
    "contraindications": [
      "Severe heart failure (LVEF <40%)",
      "Prior cumulative anthracycline dose >240 mg/m² doxorubicin equivalent",
      "Active severe infection",
      "Pregnancy or breastfeeding",
      "Known hypersensitivity to anthracyclines",
      "Severe hepatic impairment",
      "Uncontrolled cardiac arrhythmias"
    ],
    "version": "1.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "a6faf82f-6192-4c0b-804d-a9023e977e25",
    "code": "Lapatinib-Capecitabine",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Palliative",
    "summary": "Lapatinib-Capecitabine is a NCCN Category 1 regimen for HER2-positive metastatic breast cancer after trastuzumab failure. This dual HER2/EGFR inhibition with oral chemotherapy provides an effective salvage option.",
    "eligibility": {
      "summary": [
        "HER2-positive metastatic breast cancer",
        "Prior trastuzumab therapy",
        "Progression on or after trastuzumab"
      ],
      "criteria": {
        "Age": "18+ years",
        "ECOG": "0–2",
        "Other": "Adequate organ function, able to swallow oral medications",
        "Cardiac": "LVEF ≥50% (lapatinib less cardiotoxic than trastuzumab)",
        "Biomarkers": "HER2-positive (IHC 3+ or FISH amplified)"
      },
      "nccn_category": "1",
      "line_of_therapy": "Second-line or later",
      "treatment_setting": "Metastatic",
      "biomarker_requirements": {
        "HER2": "Positive (IHC 3+ or FISH amplified)",
        "ER_PR": "Any status"
      }
    },
    "precautions": [
      "Lapatinib diarrhea",
      "Hepatotoxicity",
      "Capecitabine hand-foot syndrome"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "1250mg daily",
          "name": "Lapatinib",
          "route": "PO",
          "schedule": "Continuous"
        },
        {
          "dose": "2000 mg/m² daily",
          "name": "Capecitabine",
          "route": "PO",
          "schedule": "Days 1-14"
        }
      ],
      "cycles": "Every 21 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "LVEF assessment",
      "Hand-foot assessment"
    ],
    "doseModifications": {
      "rash": "Hold for grade 3+ rash, treat with topical steroids",
      "diarrhea": "Hold for grade 3+ diarrhea, resume with dose reduction and antidiarrheals",
      "hepatotoxicity": "Hold for grade 3+ ALT/AST elevation",
      "dose_reductions": {
        "lapatinib_level_1": "1250 mg daily → 1000 mg daily",
        "lapatinib_level_2": "1000 mg daily → 750 mg daily",
        "capecitabine_level_1": "2000 mg/m² daily → 1500 mg/m² daily",
        "capecitabine_level_2": "1500 mg/m² daily → 1000 mg/m² daily"
      },
      "alternate_options": {
        "progression": "Consider trastuzumab deruxtecan or neratinib-based regimens",
        "severe_diarrhea": "Consider T-DM1 or other HER2-targeted agents",
        "hand_foot_syndrome": "Switch capecitabine to different chemotherapy backbone"
      },
      "hand_foot_syndrome": "Hold for grade 2+ HFS, resume with dose reduction"
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "EGF100151 Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "Continuous lapatinib + 14 days capecitabine"
    },
    "preMedications": {
      "GI_monitoring": "Baseline assessment",
      "cardiac_monitoring": "Baseline LVEF",
      "hepatic_monitoring": "Baseline LFTs"
    },
    "postMedications": {
      "nausea": "Take with food",
      "diarrhea": "Early loperamide intervention",
      "hand_foot_care": "Urea cream, avoid friction"
    },
    "supportiveCare": {
      "skin_monitoring": "Daily foot inspection",
      "liver_monitoring": "Regular LFTs",
      "diarrhea_management": "Aggressive early intervention"
    },
    "rescueAgents": {
      "severe_HFS": "Treatment interruption",
      "severe_diarrhea": "IV hydration, dose reduction",
      "severe_hepatotoxicity": "Permanent discontinuation"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "LVEF"
      ],
      "each_cycle": "FBC, LFTs, LVEF if indicated, HFS assessment",
      "weekly_first_month": "LFTs"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "Diarrhea assessment and management",
        "Skin examination",
        "Liver function tests",
        "ECG monitoring if indicated"
      ],
      "primary_toxicities": [
        "Diarrhea",
        "Hand-foot syndrome",
        "Rash",
        "Fatigue",
        "Hepatotoxicity",
        "QT prolongation (rare)"
      ],
      "monitoring_schedule": {
        "ongoing": [
          "Continue monitoring throughout treatment"
        ],
        "baseline": [
          "LFTs",
          "CBC",
          "Performance status",
          "Skin assessment"
        ],
        "subsequent_cycles": [
          "LFTs monthly",
          "Toxicity assessment every 2 weeks"
        ],
        "weekly_first_cycle": [
          "Toxicity assessment",
          "Diarrhea monitoring"
        ]
      }
    },
    "interactions": {
      "warfarin": "Monitor INR closely",
      "acid_reducing_agents": "Take lapatinib 1 hour before food"
    },
    "contraindications": [
      "Pregnancy or breastfeeding",
      "Known hypersensitivity to lapatinib or capecitabine",
      "Severe hepatic impairment",
      "Severe renal impairment (CrCl <30 mL/min)",
      "Dihydropyrimidine dehydrogenase deficiency",
      "Concurrent warfarin therapy"
    ],
    "version": "1.7",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "d0dddd2f-6192-4c0b-804d-a9023e977e58",
    "code": "Trastuzumab-Deruxtecan",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Palliative",
    "summary": "Trastuzumab-Deruxtecan (T-DXd) is a NCCN Category 1 HER2-directed antibody-drug conjugate for HER2-positive metastatic breast cancer after prior anti-HER2 therapy. This agent shows remarkable efficacy even in HER2-low expressing tumors.",
    "eligibility": {
      "summary": [
        "HER2-positive metastatic breast cancer",
        "Prior anti-HER2 therapy",
        "Also active in HER2-low disease"
      ],
      "criteria": {
        "Age": "18+ years",
        "ECOG": "0–1",
        "Other": "Adequate organ function, no severe comorbidities",
        "Pulmonary": "No active ILD or pneumonitis",
        "Biomarkers": "HER2-positive (IHC 3+ or FISH amplified) or HER2-low (IHC 1+ or 2+/FISH negative)"
      },
      "nccn_category": "1",
      "line_of_therapy": "Second-line or later",
      "treatment_setting": "Metastatic",
      "biomarker_requirements": {
        "HER2": "Positive (IHC 3+ or FISH amplified) or Low (IHC 1-2+/FISH negative)",
        "ER_PR": "Any status"
      }
    },
    "precautions": [
      "Interstitial lung disease",
      "Left ventricular dysfunction",
      "Nausea and fatigue"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "5.4 mg/kg",
          "name": "Trastuzumab deruxtecan",
          "route": "IV",
          "schedule": "Every 3 weeks"
        }
      ],
      "cycles": "Until progression or toxicity"
    },
    "tests": [
      "Full blood count",
      "LVEF assessment",
      "Chest imaging",
      "HER2 status"
    ],
    "doseModifications": {
      "neutropenia": "Hold for grade 3+ neutropenia, resume with growth factor support",
      "lvef_decline": "Hold for LVEF drop >10% or <45%, resume when recovered",
      "dose_reductions": {
        "level_1": "5.4 mg/kg → 4.4 mg/kg",
        "level_2": "4.4 mg/kg → 3.2 mg/kg"
      },
      "ild_pneumonitis": "Permanently discontinue for grade 2+ ILD",
      "alternate_options": {
        "progression": "Consider tucatinib-based regimens or clinical trials",
        "ild_development": "Consider other HER2-targeted agents (tucatinib combinations)",
        "cardiac_toxicity": "Hold and reassess, consider cardio-oncology consultation"
      }
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "DESTINY-Breast Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "90 minutes"
    },
    "preMedications": {
      "cardiac_monitoring": "Baseline LVEF",
      "antiemetic_protocol": "Comprehensive premedication",
      "pulmonary_monitoring": "Baseline chest imaging"
    },
    "postMedications": {
      "nausea": "Aggressive antiemetic support",
      "ILD_symptoms": "Report dyspnea immediately",
      "cardiac_effects": "Monitor for symptoms"
    },
    "supportiveCare": {
      "cardiac_protection": "LVEF every 3 cycles",
      "pulmonary_monitoring": "Serial chest imaging",
      "antiemetic_optimization": "Prophylactic regimen"
    },
    "rescueAgents": {
      "ILD": "Discontinue permanently, high-dose steroids",
      "severe_nausea": "IV antiemetics, dose delay",
      "cardiac_dysfunction": "Cardio-oncology referral"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LVEF",
        "CXR",
        "HER2 status"
      ],
      "each_cycle": "FBC, pulmonary assessment",
      "every_3_cycles": "LVEF, CXR"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "Chest CT scan",
        "CBC with differential",
        "ECHO or MUGA scan",
        "Pulmonary function assessment",
        "Symptom monitoring"
      ],
      "primary_toxicities": [
        "Interstitial lung disease",
        "Myelosuppression",
        "Nausea/vomiting",
        "Fatigue",
        "Alopecia",
        "Left ventricular dysfunction"
      ],
      "monitoring_schedule": {
        "ongoing": [
          "Immediate evaluation for respiratory symptoms"
        ],
        "baseline": [
          "Chest CT",
          "LVEF assessment",
          "CBC",
          "Pulmonary symptoms"
        ],
        "every_2_cycles": [
          "Chest imaging for ILD screening"
        ],
        "before_each_cycle": [
          "CBC",
          "Pulmonary symptoms",
          "Performance status"
        ]
      }
    },
    "interactions": {
      "live_vaccines": "Contraindicated",
      "strong_CYP3A4_inhibitors": "Monitor for increased toxicity"
    },
    "contraindications": [
      "Active interstitial lung disease or pneumonitis",
      "Severe pulmonary impairment",
      "Known hypersensitivity to trastuzumab deruxtecan",
      "Pregnancy or breastfeeding",
      "Severe heart failure (LVEF <40%)",
      "History of severe ILD"
    ],
    "version": "2.1",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c9cccc2f-6192-4c0b-804d-a9023e977e57",
    "code": "Sacituzumab-Govitecan",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Palliative",
    "summary": "Sacituzumab-Govitecan is a NCCN Category 1 TROP-2 directed antibody-drug conjugate for metastatic triple-negative breast cancer after prior chemotherapy. This agent provides significant survival benefit in heavily pretreated patients.",
    "eligibility": {
      "summary": [
        "Metastatic triple-negative breast cancer",
        "Prior chemotherapy in metastatic setting",
        "TROP-2 expression (typically positive)"
      ],
      "criteria": {
        "Age": "18+ years",
        "ECOG": "0–1",
        "Other": "Adequate organ function, UGT1A1 genotyping recommended",
        "Biomarkers": "Triple-negative (ER <1%, PR <1%, HER2-negative)",
        "Prior_therapy": "At least 2 prior chemotherapies for metastatic disease"
      },
      "nccn_category": "1",
      "line_of_therapy": "Second-line or later",
      "treatment_setting": "Metastatic",
      "biomarker_requirements": {
        "ER": "Negative (<1% by IHC)",
        "PR": "Negative (<1% by IHC)",
        "HER2": "Negative (IHC 0-1+ or FISH negative)",
        "TROP2": "Positive (typically expressed in >90% of TNBC)"
      }
    },
    "precautions": [
      "Severe diarrhea",
      "Neutropenia",
      "Nausea and vomiting"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "10 mg/kg",
          "name": "Sacituzumab govitecan",
          "route": "IV",
          "schedule": "Days 1 and 8"
        }
      ],
      "cycles": "Every 21 days"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "UGT1A1 genotyping",
      "Performance status"
    ],
    "doseModifications": {
      "diarrhea": "Hold for grade 3+ diarrhea, aggressive antidiarrheal management",
      "neutropenia": "Hold for ANC <1500, resume with dose reduction for grade 3+ neutropenia",
      "dose_reductions": {
        "level_1": "10 mg/kg → 7.5 mg/kg",
        "level_2": "7.5 mg/kg → 5 mg/kg"
      },
      "ugt1a1_variants": "Reduce dose by one level for UGT1A1*28 homozygotes",
      "alternate_options": {
        "progression": "Consider clinical trials or other ADCs if available",
        "severe_neutropenia": "Growth factor support, consider dose reduction",
        "diarrhea_intolerance": "Aggressive supportive care, dose modification"
      }
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "ASCENT Study",
      "FDA Approval"
    ],
    "cycleInfo": {
      "cycle_length": "21 days",
      "total_cycles": "Until progression",
      "administration_time": "2 days per cycle"
    },
    "preMedications": {
      "GI_monitoring": "Baseline assessment",
      "UGT1A1_testing": "Baseline genotyping",
      "myelosuppression_monitoring": "Weekly FBC first 2 cycles"
    },
    "postMedications": {
      "nausea": "Aggressive antiemetics",
      "diarrhea": "Early loperamide intervention",
      "neutropenia": "G-CSF support"
    },
    "supportiveCare": {
      "antiemetic_protocol": "Comprehensive coverage",
      "diarrhea_management": "Aggressive early intervention",
      "neutropenia_monitoring": "Weekly FBC first 2 cycles"
    },
    "rescueAgents": {
      "severe_nausea": "IV antiemetics",
      "severe_diarrhea": "IV hydration, dose reduction",
      "febrile_neutropenia": "G-CSF, antibiotics"
    },
    "monitoring": {
      "baseline": [
        "FBC",
        "LFTs",
        "UGT1A1",
        "ECOG"
      ],
      "each_cycle": "FBC, diarrhea assessment",
      "weekly_first_2_cycles": "FBC"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "CBC with differential",
        "UGT1A1 genotyping",
        "Diarrhea management",
        "Performance status assessment"
      ],
      "primary_toxicities": [
        "Neutropenia",
        "Diarrhea",
        "Nausea/vomiting",
        "Fatigue",
        "Alopecia",
        "Rash"
      ],
      "monitoring_schedule": {
        "weekly": [
          "CBC for first 2 cycles"
        ],
        "ongoing": [
          "Continue monitoring throughout treatment"
        ],
        "baseline": [
          "CBC",
          "UGT1A1 testing",
          "Comprehensive metabolic panel"
        ],
        "before_each_cycle": [
          "CBC",
          "Performance status",
          "Toxicity assessment"
        ]
      }
    },
    "interactions": {
      "UGT1A1_inhibitors": "Monitor for increased toxicity",
      "strong_CYP3A4_inhibitors": "Monitor closely"
    },
    "contraindications": [
      "Known hypersensitivity to sacituzumab govitecan",
      "Pregnancy or breastfeeding",
      "Severe neutropenia (ANC <1000)",
      "UGT1A1*28 homozygosity (relative contraindication - requires dose reduction)",
      "Active severe infection",
      "Severe hepatic impairment"
    ],
    "version": "1.8",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "e1ffff2f-6192-4c0b-804d-a9023e977e89",
    "code": "Tamoxifen",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Curative",
    "summary": "Tamoxifen is a NCCN Category 1 selective estrogen receptor modulator for hormone receptor-positive breast cancer in pre/postmenopausal women. This oral endocrine therapy is used in adjuvant and metastatic settings.",
    "eligibility": {
      "summary": [
        "HR-positive breast cancer",
        "Adjuvant or metastatic treatment",
        "Pre/postmenopausal women"
      ],
      "criteria": {
        "Age": "18+ years",
        "ECOG": "0–2",
        "Other": "No contraindications to estrogen modulation",
        "Biomarkers": "ER+ and/or PR+",
        "Thrombotic_risk": "No active thromboembolism"
      },
      "nccn_category": "1",
      "line_of_therapy": "First-line or adjuvant",
      "treatment_setting": "Adjuvant or metastatic",
      "biomarker_requirements": {
        "ER": "Positive (≥1% by IHC)",
        "PR": "Any status",
        "HER2": "Any status"
      }
    },
    "precautions": [
      "Thromboembolic events",
      "Endometrial cancer risk",
      "Hot flashes"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "20mg daily",
          "name": "Tamoxifen",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "5-10 years"
    },
    "tests": [
      "Liver function tests",
      "Endometrial assessment",
      "Coagulation studies",
      "Estrogen receptor status"
    ],
    "doseModifications": {
      "standard_dose": "20 mg daily, no routine dose modifications",
      "alternate_options": {
        "premenopausal": "Consider ovarian suppression + AI",
        "thrombosis_risk": "Consider aromatase inhibitors in postmenopausal women",
        "tolerance_issues": "Switch to different SERM or AI"
      }
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "ATLAS Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "5-10 years",
      "administration_time": "Once daily oral"
    },
    "preMedications": {
      "liver_monitoring": "Baseline LFTs",
      "thrombosis_assessment": "Risk factors",
      "endometrial_monitoring": "Baseline pelvic exam"
    },
    "postMedications": {
      "hot_flashes": "Lifestyle modifications",
      "thrombosis_prevention": "Mobilization, avoid prolonged immobility",
      "endometrial_monitoring": "Report abnormal bleeding"
    },
    "supportiveCare": {
      "liver_protection": "Regular LFTs",
      "thrombosis_prevention": "Risk assessment",
      "endometrial_monitoring": "Annual gynecological exam"
    },
    "rescueAgents": {
      "thrombosis": "Anticoagulation, consider discontinuation",
      "endometrial_cancer": "Urgent gynecological referral",
      "severe_liver_dysfunction": "Discontinue tamoxifen"
    },
    "monitoring": {
      "annually": "Pelvic exam",
      "baseline": [
        "LFTs",
        "Pelvic exam",
        "ER status",
        "Coagulation"
      ],
      "every_6_months": "LFTs"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "Gynecologic examination",
        "Thrombosis assessment",
        "Mood evaluation"
      ],
      "primary_toxicities": [
        "Hot flashes",
        "Vaginal discharge",
        "Thromboembolism",
        "Endometrial cancer",
        "Mood changes"
      ],
      "monitoring_schedule": {
        "ongoing": [
          "Monitor for thrombotic symptoms"
        ],
        "annually": [
          "Gynecologic exam",
          "Endometrial assessment if indicated"
        ],
        "baseline": [
          "Gynecologic exam",
          "Thrombosis history"
        ]
      }
    },
    "interactions": {
      "warfarin": "Enhanced anticoagulation",
      "CYP2D6_inhibitors": "May reduce efficacy"
    },
    "contraindications": [
      "Active thromboembolism",
      "Pregnancy or breastfeeding",
      "Known hypersensitivity",
      "High-risk endometrial pathology"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "c9dddd2f-6192-4c0b-804d-a9023e977e87",
    "code": "Letrozole",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Curative",
    "summary": "Letrozole is a NCCN Category 1 aromatase inhibitor for hormone receptor-positive breast cancer in postmenopausal women. This oral endocrine therapy is used in adjuvant and metastatic settings.",
    "eligibility": {
      "summary": [
        "HR-positive breast cancer",
        "Postmenopausal women",
        "Adjuvant or metastatic treatment"
      ],
      "criteria": {
        "Age": "18+ years (postmenopausal)",
        "Bone": "Adequate bone health assessment",
        "ECOG": "0–2",
        "Biomarkers": "ER+ and/or PR+",
        "Menopausal": "Postmenopausal status confirmed"
      },
      "nccn_category": "1",
      "line_of_therapy": "First-line or adjuvant",
      "treatment_setting": "Adjuvant or metastatic",
      "biomarker_requirements": {
        "ER": "Positive (≥1% by IHC)",
        "PR": "Any status",
        "HER2": "Any status"
      }
    },
    "precautions": [
      "Bone loss and fractures",
      "Arthralgia",
      "Fatigue"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "2.5mg daily",
          "name": "Letrozole",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "5 years adjuvant or until progression"
    },
    "tests": [
      "Bone density scan",
      "Liver function tests",
      "Estrogen receptor status",
      "Cholesterol levels"
    ],
    "doseModifications": {
      "standard_dose": "2.5 mg daily, no routine dose modifications",
      "alternate_options": {
        "bone_loss": "Add bisphosphonates or denosumab",
        "arthralgia": "Switch to different AI or tamoxifen",
        "intolerance": "Consider anastrozole or exemestane"
      }
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "BIG 1-98 Study",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "5 years or until progression",
      "administration_time": "Once daily oral"
    },
    "preMedications": {
      "bone_monitoring": "Baseline DEXA scan",
      "liver_monitoring": "Baseline LFTs",
      "arthralgia_assessment": "Joint symptoms"
    },
    "postMedications": {
      "fatigue": "Energy conservation",
      "arthralgia": "Exercise, NSAIDs",
      "bone_health": "Calcium and vitamin D supplementation"
    },
    "supportiveCare": {
      "joint_care": "Physical therapy",
      "bone_protection": "Bisphosphonates if indicated",
      "fatigue_management": "Lifestyle modifications"
    },
    "rescueAgents": {
      "severe_fatigue": "Dose interruption",
      "severe_bone_loss": "Bisphosphonates, specialist referral",
      "severe_arthralgia": "Switch AI or tamoxifen"
    },
    "monitoring": {
      "annually": "DEXA scan",
      "baseline": [
        "DEXA",
        "LFTs",
        "ER status",
        "Cholesterol"
      ],
      "every_6_months": "LFTs, cholesterol"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "DEXA scan",
        "Lipid profile",
        "Joint assessment"
      ],
      "primary_toxicities": [
        "Bone loss",
        "Arthralgia",
        "Hot flashes",
        "Fatigue",
        "Hypercholesterolemia"
      ],
      "monitoring_schedule": {
        "ongoing": [
          "Bone health management"
        ],
        "annually": [
          "DEXA scan",
          "Lipid monitoring"
        ],
        "baseline": [
          "DEXA scan",
          "Lipid profile"
        ]
      }
    },
    "interactions": {
      "warfarin": "Monitor INR",
      "estrogen_supplements": "Contraindicated"
    },
    "contraindications": [
      "Premenopausal status",
      "Pregnancy or breastfeeding",
      "Known hypersensitivity",
      "Severe hepatic impairment"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f1faf82f-6192-4c0b-804d-a9023e977e30",
    "code": "Everolimus-Exemestane",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Palliative",
    "summary": "Everolimus-Exemestane is a NCCN Category 1 mTOR inhibitor combination for hormone receptor-positive metastatic breast cancer after prior AI failure.",
    "eligibility": {
      "nccn_category": "1",
      "line_of_therapy": "Second-line or later",
      "treatment_setting": "Metastatic",
      "biomarker_requirements": {
        "ER": "Positive (≥1% by IHC)",
        "HER2": "Negative"
      }
    },
    "precautions": [
      "Everolimus pneumonitis",
      "Mucositis",
      "Hyperglycemia"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "10mg daily",
          "name": "Everolimus",
          "route": "PO",
          "schedule": "Continuous"
        },
        {
          "dose": "25mg daily",
          "name": "Exemestane",
          "route": "PO",
          "schedule": "Continuous"
        }
      ],
      "cycles": "Continuous until progression"
    },
    "tests": [
      "Full blood count",
      "Liver function tests",
      "Chest imaging",
      "Blood glucose",
      "Lipid profile"
    ],
    "doseModifications": {
      "mucositis": "Dose reduction",
      "pneumonitis": "Hold everolimus, steroids if grade 2+",
      "hyperglycemia": "Diabetes management"
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "BOLERO Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "Continuous",
      "total_cycles": "Until progression",
      "administration_time": "Daily oral therapy"
    },
    "preMedications": {
      "metabolic_monitoring": "Glucose and lipids",
      "mucositis_prevention": "Oral care protocol",
      "pulmonary_monitoring": "Baseline chest imaging"
    },
    "postMedications": {
      "mucositis": "Magic mouthwash, soft diet",
      "pneumonitis": "Report dyspnea immediately",
      "hyperglycemia": "Monitor blood sugar"
    },
    "supportiveCare": {
      "mucositis_care": "Intensive oral hygiene",
      "metabolic_monitoring": "Regular glucose and lipids",
      "pulmonary_monitoring": "Serial chest imaging"
    },
    "rescueAgents": {
      "pneumonitis": "Discontinue everolimus, high-dose steroids",
      "severe_mucositis": "Treatment interruption",
      "severe_hyperglycemia": "Insulin therapy"
    },
    "monitoring": {
      "monthly": "FBC, LFTs, glucose",
      "baseline": [
        "FBC",
        "LFTs",
        "CXR",
        "Glucose",
        "Lipids"
      ],
      "every_3_months": "CXR"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "Chest CT",
        "Glucose monitoring"
      ],
      "primary_toxicities": [
        "Pneumonitis",
        "Stomatitis",
        "Hyperglycemia"
      ]
    },
    "interactions": {
      "ACE_inhibitors": "Monitor for angioedema",
      "strong_CYP3A4_inhibitors": "Reduce everolimus dose"
    },
    "contraindications": [
      "Active pneumonitis",
      "Severe immunosuppression",
      "Live vaccines"
    ],
    "version": "1.6",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  },
  {
    "id": "f2aaaa2f-6192-4c0b-804d-a9023e977e90",
    "code": "Goserelin",
    "tumourGroup": "Breast",
    "tumourSupergroup": "Breast",
    "treatmentIntent": "Curative",
    "summary": "Goserelin is a NCCN Category 1 GnRH agonist for ovarian suppression in premenopausal women with hormone receptor-positive breast cancer.",
    "eligibility": {
      "nccn_category": "1",
      "line_of_therapy": "Adjuvant or first-line",
      "treatment_setting": "Adjuvant or metastatic",
      "biomarker_requirements": {
        "ER": "Positive (≥1% by IHC)",
        "HER2": "Any status"
      }
    },
    "precautions": [
      "Menopausal symptoms",
      "Bone loss",
      "Mood changes"
    ],
    "treatment": {
      "drugs": [
        {
          "dose": "3.6mg",
          "name": "Goserelin",
          "route": "SC",
          "schedule": "Every 28 days"
        }
      ],
      "cycles": "2-5 years with endocrine therapy"
    },
    "tests": [
      "Estradiol levels",
      "Bone density scan",
      "LH/FSH levels",
      "Mood assessment"
    ],
    "doseModifications": {
      "bone_loss": "Bisphosphonates",
      "mood_changes": "Psychological support",
      "inadequate_suppression": "Check injection technique"
    },
    "referenceList": [
      "NCCN Breast Guidelines",
      "SOFT/TEXT Studies",
      "ESMO Guidelines"
    ],
    "cycleInfo": {
      "cycle_length": "28 days",
      "total_cycles": "2-5 years",
      "administration_time": "Monthly SC injection"
    },
    "preMedications": {
      "bone_monitoring": "Baseline DEXA scan",
      "mood_assessment": "Baseline evaluation",
      "hormonal_monitoring": "Estradiol levels"
    },
    "postMedications": {
      "bone_health": "Calcium, vitamin D",
      "mood_support": "Counseling available",
      "menopausal_symptoms": "HRT contraindicated, lifestyle modifications"
    },
    "supportiveCare": {
      "bone_protection": "Bisphosphonates if osteoporosis",
      "mood_monitoring": "Regular assessment",
      "hormonal_monitoring": "Estradiol suppression"
    },
    "rescueAgents": {
      "severe_bone_loss": "Bisphosphonates, endocrine referral",
      "severe_mood_changes": "Psychiatric referral",
      "inadequate_suppression": "Alternative LHRH agonist"
    },
    "monitoring": {
      "annually": "DEXA scan",
      "baseline": [
        "Estradiol",
        "DEXA",
        "LH/FSH",
        "Mood assessment"
      ],
      "every_3_months": "Estradiol"
    },
    "toxicityMonitoring": {
      "monitoring_tools": [
        "DEXA scan",
        "Mood assessment"
      ],
      "primary_toxicities": [
        "Hot flashes",
        "Bone loss",
        "Mood changes"
      ]
    },
    "interactions": {
      "estrogen_supplements": "Contraindicated",
      "bone_protecting_agents": "Consider if osteoporosis"
    },
    "contraindications": [
      "Pregnancy",
      "Postmenopausal status",
      "Known hypersensitivity"
    ],
    "version": "1.0",
    "status": "active",
    "createdBy": null,
    "updatedBy": null,
    "createdAt": "2024-01-15T10:30:00.000Z",
    "updatedAt": "2024-01-15T10:30:00.000Z",
    "lastReviewed": "2024-01-15T10:30:00.000Z"
  }
]